{
    "14e55d50-c012-4f32-afc5-6f5f7a030667": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00328783",
        "Statement": "the primary trial documents a comprehensive list of adverse events",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "fef5aedb-21c0-4130-b8a3-cb1df5017c7a"
        ]
    },
    "ea57b54d-1912-4d9f-bcf7-7f423aed195b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572727",
        "Secondary_id": "NCT00328783",
        "Statement": "in the primary clinical trial, patients receive paclitaxel at a higher dosage than those in the secondary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "3ba42f68-a643-4d10-afd0-cbb358d05a6f"
        ]
    },
    "6c337426-cff6-4f2c-acab-e7bf15f09cc2": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01830933",
        "Statement": "the primary trial and the secondary trial report the same types of adverse events. non-neoplastic chronic respiratory system disorder is a non-neoplastic longstanding disorder of the respiratory system.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "c7a953b0-ac96-4e0a-9c1d-98cf8af2861d"
        ]
    },
    "141798cc-9851-4bdf-b8a9-ce688db34e72": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Statement": "ongoing flucytosine treatments are not permitted for participants of the primary trial. extrahepatic biliary atresia is a congenital disorder characterized by blockage or absence of the extrahepatic bile ducts.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "f10f3b84-e039-4a02-a98b-86d149d9a16f"
        ]
    },
    "fdbb037a-8084-4267-9143-f989d26726ab": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "all the primary trial patients had a minimum of 300% decrease in the sum of the longest diameter of target lesions",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "985bc5a0-bc21-447f-92f1-150e23ede3f5"
        ]
    },
    "47f4c385-4dd8-4b6e-a365-bb2fac258ab9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00915603",
        "Statement": "in cohort 1 of the primary clinical trial, the least progression-free survival (pfs) was less than 7 months, while in cohort 2, the minimum was slightly more than 7 months.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "0cef8c8e-7986-46c7-a597-c5733a9899c0"
        ]
    },
    "d31f179f-1253-44c8-8fc6-167f7b3d41db": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572727",
        "Secondary_id": "NCT00328783",
        "Statement": "the intake of paclitaxel for patients in the primary clinical trial is set higher than for patients that are in the secondary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "3ba42f68-a643-4d10-afd0-cbb358d05a6f"
        ]
    },
    "76236597-7a5e-4042-b1c4-ddd5a4aa57e7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02915744",
        "Statement": "the collection of overall survival metrics of patients isn't part of the protocol for both the primary and secondary clinical trials",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "dc4c57b0-8c75-494e-81b0-3528df85ebff"
        ]
    },
    "64ab5bcd-229a-4aac-8d01-609e514400d7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00374322",
        "Statement": "the patient cohorts in the primary clinical trial only received therapeutic interventions",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "c40fdf91-9f81-454a-bba9-ec5c950cef6e"
        ]
    },
    "f0271e34-7791-441b-ad94-a8e2e7f1f909": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01644890",
        "Statement": "cohort 1 of the primary clinical trial had an average pfs record",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "8c6314f7-34f5-42a7-ba66-b95d050a6315"
        ]
    },
    "572c52ba-9518-4b72-9a32-a08604808764": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00357110",
        "Statement": "the primary clinical trial reported 6 losses in cohort 1 and 7 in cohort 2.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "f114846e-79d8-4712-add0-bb34b65d418f"
        ]
    },
    "11073b50-f135-48a1-a8ac-333375a49c14": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02186015",
        "Statement": "children are allowed to participate in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "a805f174-2707-4302-a195-05153ea8523e"
        ]
    },
    "ec5ca1ce-8399-4213-9f44-53e55b7352db": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Secondary_id": "NCT00325234",
        "Statement": "child needs help playing with other children is a question about whether a child needed or needs help playing with other children. There are more cases of Holocraneal cephale and Catheter - related infections in the primary trial than in the secondary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "9c033072-5f94-4d79-af47-126d531f0d6e"
        ]
    },
    "95f5af8f-1590-4254-bd9f-885b6720b7b5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Statement": "Patients must have a Life expectancy of at least 1 year to enroll in the primary trial. usual severity hair loss is a question about the usual severity of an individual's hair loss.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "618a3ae1-b22c-4c35-86a6-190c1b5b5d21"
        ]
    },
    "96237d2a-e7f5-4582-b1a9-1dfb233b980d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00915603",
        "Statement": "at least 5 participants of the primary trial, at least one from each cohort, had a progression-free survival of 15.8 months",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "47ba01d6-edc7-4acb-ab49-b0e86f4eeaf7"
        ]
    },
    "41a49fe6-55b7-4f89-bc8c-b0107350a79a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Statement": "neither of the cohorts in the primary trial are required to undergo surgery or receive any oral medication as part of the intervention. physical object property is a characteristic of a physical object.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "63a0a9fc-80b9-450f-b2c6-7aee37ce26a9"
        ]
    },
    "764bd30d-89e3-45d5-b385-95b63322a043": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00333775",
        "Statement": "both the primary trial cohorts receive identical doses of Docetaxel . statistics filenote is a notation regarding the decisions, and/or clarification of any information pertaining to the statistics used in a clinical trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "9bcc31df-c1f6-4785-9235-f673213acf3a"
        ]
    },
    "7bd16537-caf9-4749-bb7d-bdc5207a5ac2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00606931",
        "Statement": "There is no adverse events section in the primary trial. coxen score 7 is a score of 7 on the coxen sensitivity scale.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "21611c2a-e6eb-4012-a209-9b6781e1f260"
        ]
    },
    "3de38124-1362-45d3-8ee3-ea39c1331315": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00572728",
        "Statement": "the primary clinical trial requires patients to be either bedbound or severely disabled to be eligible.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "62be4676-099f-4c42-8029-773af8fde6f7"
        ]
    },
    "78ac8091-0f1b-44d1-a760-71bfdc2d46ff": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Statement": "none of the participants in the first group of the primary clinical trial reported any negative side effects.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "8e91e404-086e-4063-8d54-83d1b8ebd969"
        ]
    },
    "33726f21-bdaa-48a2-a431-c61a84511f7c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00593346",
        "Statement": "primary clinical trial provides data on the objective response rate (orr) of its patient cohort",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "88668508-dfd4-4a39-91cd-cf1654a6dfc4"
        ]
    },
    "f364bafe-7930-4aae-8ca5-8494d115fe6a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00572728",
        "Statement": "participation in the primary clinical trial requires patients to be in good health with no physical or mobility impairments",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "62be4676-099f-4c42-8029-773af8fde6f7"
        ]
    },
    "fdc0dbd2-c722-4b99-be3c-602046ef53d2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Secondary_id": "NCT03098550",
        "Statement": "all participants of the primary clinical trial are only diagnosed with stage 4 hematologic or lymphatic malignancies, there is a requirement for a specifically staged cancer for entry to the secondary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "07042b0f-d422-49c3-8d53-81319927a4b3"
        ]
    },
    "8d01a287-19f8-4403-8b1d-eb40b70f3254": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00328783",
        "Statement": "the primary clinical trial's adverse events section reports the occurrence rates of just five different aes.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "97fd111c-6969-43ab-93af-b3dff09960e5"
        ]
    },
    "699fe4af-e23b-4d8d-b9e8-aa8a722d5a22": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "all patients involved in the primary clinical trial experienced at least a 50% reduction in the sum of the longest diameter of target lesions",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "985bc5a0-bc21-447f-92f1-150e23ede3f5"
        ]
    },
    "3b28a747-dad6-4b2f-bdf0-c7678b3b0506": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01224678",
        "Secondary_id": "NCT01042535",
        "Statement": "the secondary clinical trial had a higher incidence of eye disorders, abdominal pain, febrile neutropenia and anemia compared to the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "b8322b23-a4f6-4cba-9761-be826b509de7"
        ]
    },
    "7901f050-9868-48c7-b64b-e3f7c7856ed9": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Secondary_id": "NCT03098550",
        "Statement": "all participants of the primary clinical trial are verified to have stage 1 metastatic prostate cancer, whereas stage 4 colorectal cancer is a requirement for involvement in the secondary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "7f3fe97e-68ee-470f-b06e-21cdddb67aa8"
        ]
    },
    "ffb356e8-2d61-4f1d-9ab9-978c7a723172": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00612560",
        "Secondary_id": "NCT01216176",
        "Statement": "while anastrazole in pill form is given to every participant in the primary clinical trial, it is not used in the secondary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "e9fd065c-342c-4dfb-9c1c-a4c0c44d0acd"
        ]
    },
    "a898a914-758e-4531-875e-7c21b4bd1a66": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01125566",
        "Statement": "an ecog score exceeding 2 is a prerequisite for inclusion in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "b2cdbcb8-de26-4a44-8a94-dd68c13f7e41"
        ]
    },
    "57cecfab-a127-4cce-9bc0-e4fe035e4ca1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Statement": "for entry into the primary clinical trial, individuals must already be receiving flucytosine treatments continuously for at least a 6-month period.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "565d7982-aa9a-4c01-987c-1d67bc9c212d"
        ]
    },
    "045ad91e-44fa-42cc-ac22-a7aab26a9009": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00240071",
        "Statement": "the primary trial participants are administered Avastin, Bevacizumab and radiotherapy as part of the intervention",
        "Label": "Contradiction"
    },
    "63b1ee39-fe0e-4ee2-b80b-123356bfc3a2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Statement": "continuous flucytosine treatment is considered incompatible for primary clinical trial participants",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "f10f3b84-e039-4a02-a98b-86d149d9a16f"
        ]
    },
    "da65ff08-5187-43e3-9036-5f9453ea36af": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "the principal adverse event identified in the primary clinical trial was febrile neutropenia, affecting a large portion of the trial participants",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "614d7ade-0fa7-4d77-bc19-1d3a2f2f48c2"
        ]
    },
    "dbdb4be1-04c7-4ffe-bcbd-6de8ca84c231": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00425854",
        "Secondary_id": "NCT01224678",
        "Statement": "patients with an exceptionally high ejection fraction can participate in the primary clinical trial but are ineligible for the secondary clinical trial unless they are over 65 years old ",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "d1b7105d-0b7d-4b10-92a7-d63243ff0629"
        ]
    },
    "2ba9023e-a5a3-4f89-8157-d80cde72de54": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01416389",
        "Statement": "the primary clinical trial documents the variations in the tumor dimensions for individuals in its cohorts.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "7cde9a22-a91f-4feb-892d-7cbd35f96a27"
        ]
    },
    "a0c68f97-9bed-45da-8600-2f7d3d579fac": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01581619",
        "Secondary_id": "NCT00106002",
        "Statement": "the findings of the primary clinical trial and the secondary clinical trial are not comparable",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "0a6d1b4c-244e-44e2-a229-62e4cbdfa979"
        ]
    },
    "00c0d4a6-2223-4cc7-ad9f-f5366f5705bb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00374322",
        "Statement": "no cohort in the primary clinical trial was exposed to a placebo intervention",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "c40fdf91-9f81-454a-bba9-ec5c950cef6e"
        ]
    },
    "751ef33b-0f7c-4aa3-8636-d82f12cfa7e6": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03012477",
        "Secondary_id": "NCT02419807",
        "Statement": "the results from both the primary and secondary clinical trials are reported in percentages, however, they employ different units of evaluation.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "0e609fad-9a28-4fb6-90b6-32a731e3b02c"
        ]
    },
    "05978a8b-e549-48e5-b2ae-3b6927908feb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02186015",
        "Statement": "history of trauma in chief complaint is a traumatic event preceded the chief complaint. adults and children can take part in the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "2825d63b-8f22-4fb8-829f-9567845251c6"
        ]
    },
    "70677d5f-7022-404c-8410-d1f89366d92f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00856492",
        "Secondary_id": "NCT00009945",
        "Statement": "the secondary trial and the primary trial both measure the pCR and tumor diameter of their patient cohorts.",
        "Label": "Contradiction"
    },
    "7edeb40b-8d5d-4956-9532-587e83f6f0f4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Statement": "the primary clinical trial accepts only those patients that have previously experienced endocrine therapy for breast cancer",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "6d621974-c719-46df-8a50-d94e49583e33"
        ]
    },
    "83583af0-1c00-42f8-8a93-100685bea8aa": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "presence of hot flashes for approximately 4 weeks prior to study registration is required for all patients that want to participate in the primary trial, but not necessary for entry to the secondary trial.",
        "Label": "Entailment",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "31105b43-832b-48bc-a78d-ee90c155ca44"
        ]
    },
    "1b5a2128-4e50-4dc7-bba8-16d458bc5256": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01998906",
        "Statement": "the primary clinical trial allows participants to complete only 10 cycles, each lasting 2 weeks.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "43ce26e5-03fa-4e9d-b0eb-6ea356295753"
        ]
    },
    "fa0f5d56-6ddb-4909-b55f-45f383ec9590": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00915603",
        "Statement": "the shortest PFS in cohort 1 of the primary trial was under 7 months, in cohort 2 the shortest was just over 7 months. protein energy malnutrition is a nutritional deficit that is caused by inadequate protein or calorie intake.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "0cef8c8e-7986-46c7-a597-c5733a9899c0"
        ]
    },
    "a368c0e8-9e89-426f-b4e5-69f9de48f5c2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042938",
        "Statement": "the primary clinical trial discloses severity of dermatitis in radiation treatment site for both the curcumin c3 complex group and the placebo group, revealing no disparity in the findings from these two groups",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "e62f5a3f-0091-4980-9822-db8f4dc2502a"
        ]
    },
    "9d8b26d6-d574-4717-88b6-77458bc683f3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00733408",
        "Statement": "Syncope was the most common adverse event recorded in the primary trial",
        "Label": "Contradiction"
    },
    "47deae13-17f0-40ce-a6ce-95223bd676c8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00127933",
        "Statement": "eliane, a woman of 56 years, and elizabeth, a 32-year-old woman, both possess the suitability to participate in the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "f0273b8c-460d-46fe-9c52-8ff4b08e439b"
        ]
    },
    "87acd09b-52a8-4bb5-b45a-528a6908ecd6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01224678",
        "Secondary_id": "NCT01042535",
        "Statement": "how itchy is a question about how itchy an individual was. There were more cases of mental health disorders, PLEUROPERICARDITIS, ATRIAL THROMBOSIS  and Anemia in the secondary trial than in the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "57b2ae97-0d1d-4d5d-bc4b-109e8e5acb32"
        ]
    },
    "6bf5ee31-7b3c-4606-9383-7a86c27457e3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "patients who wish to join the primary clinical trial are expected to have hot flashes for at least 30 days before study registration. this requirement does not apply to those entering the secondary clinical trial.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "31105b43-832b-48bc-a78d-ee90c155ca44"
        ]
    },
    "0cd8b018-fb42-464e-9047-742e8ed15eb3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02915744",
        "Statement": "the secondary trial and the primary trial do not record the same metrics in their results section. tsc2 gene rearrangement is a molecular abnormality indicating rearrangement of the tsc2 gene.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "dd2f3c3d-fa95-4fca-a3f0-795fd4f3abf1"
        ]
    },
    "c316ffaf-91f3-47c1-a7d9-b8ba2346e3bb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00093795",
        "Statement": "the majority of participants in cohort 1 and 2 of the primary trial suffered some kind of disease Recurrence, Contralateral Breast Cancer, Second Primary Cancer, Death From Any Cause Prior to Recurrence or Second Primary Cancer. atrial ablation is a invasive therapeutic procedure to destroy the tissue in the cardiac atria that is the source of an arrhythmia.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "0ea29bd5-20be-40ea-8ad7-705d283d1d48"
        ]
    },
    "65f541a6-ef9e-46b3-a17e-ea8f9768e2be": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT02340221",
        "Statement": "the primary trial and the secondary trial measure the Percent Change in Net Influx Constant (Ki) by FLT PET in their patient cohorts. can deal with whatever comes my way is a question about whether an individual is able to deal with whatever comes their way.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "49ba06b2-576d-4db2-80b6-51673416f2ba"
        ]
    },
    "839fd2a0-24d0-417f-9c37-7fb960860547": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00240071",
        "Statement": "participants in the primary clinical trial are administered a single type of medication throughout the study period.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "82a3e542-f784-44d7-90f6-34d7e969283c"
        ]
    },
    "17f9cd4d-fced-4e62-9ddd-51a8f59b3751": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01011946",
        "Secondary_id": "NCT00066573",
        "Statement": "the primary trial participants are administered oral and topical medication, whereas the secondary trial patients only receive treatment orally. standard deviation of cell density is a measure of the range of values in a set of values that describe the cell density.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "8ddf8b88-6e06-4c71-9e28-45f73a637af0"
        ]
    },
    "6c4d4bc4-9e8e-4ad0-bf0b-279292b7c74c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "the primary trial intervention protocol lasts a total of 2 weeks",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "236780db-9e59-4dc9-8da0-e786287011cf"
        ]
    },
    "c09fa61c-967a-40ae-96b0-c87b7cde237b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02679755",
        "Statement": "None of the individual Aes recorded in the primary trial affect more than 10% of the population.",
        "Label": "Entailment"
    },
    "ff29cd7d-fb7d-4afc-9b0a-38dc6ddcc067": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02658734",
        "Statement": "in the primary clinical trial, the majority of patients encountered grade 1 adverse events, and the least frequent severity noted was grade 4.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "878c09e7-3fd9-404e-921e-5b549e9578fb"
        ]
    },
    "452b60fb-8243-407a-b047-59ee7a26c49b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Statement": "in the primary clinical trial, only 6 out of 67 patients in the first cohort experienced adverse events",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "29b2fa29-5a76-4877-95bb-1a8de7973d33"
        ]
    },
    "1645f343-bb82-4128-b3ec-99b8537b70cb": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01042535",
        "Statement": "ocular vascular disorder is a non-neoplastic disorder that is caused by pathologic changes in the ocular vasculature. The least common adverse event in the primary trial was Constipation .",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "16c29502-4683-4087-9410-ff1b786556f5"
        ]
    },
    "715a0a0e-b767-43a8-ba69-a766616e18c4": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00856492",
        "Secondary_id": "NCT00009945",
        "Statement": "neither the primary clinical trial nor the secondary clinical trial measures the pcr of their respective patient cohorts.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "42d1fcd3-8faa-4065-bbba-42cc90ab67fb"
        ]
    },
    "bd72a83b-c520-4666-ad7b-0d1710d6fc02": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00374322",
        "Statement": "a cohort of patients within the primary clinical trial was administered with a placebo intervention",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "c40fdf91-9f81-454a-bba9-ec5c950cef6e"
        ]
    },
    "586d8785-551f-4bde-a354-7475ccb45b59": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00733408",
        "Statement": "shoulder arthroscopy is a visualization of the shoulder joint via an arthroscope. Syncope was the most common adverse event recorded in the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "9d8b26d6-d574-4717-88b6-77458bc683f3"
        ]
    },
    "9ad5500f-66ad-43b6-93d3-50d660f23e56": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02915744",
        "Statement": "the same therapeutic intervention is applied to cohort 1 and 2 of the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "8e9611fc-89f8-44cb-af09-8d71a13ca082"
        ]
    },
    "c9f84c80-2f88-48de-a9cf-35468e45e83b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00263588",
        "Statement": "the primary clinical trial is open for patients diagnosed with types of cancer other than breast cancer.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "215a5c4a-d90c-4500-8284-0679ce311734"
        ]
    },
    "6cead4e7-6b19-4dc9-b63e-25358e67b374": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01596751",
        "Statement": "Breast cancer patients must have documented progressive disease to participate in the primary trial. respiratory system findings sequence number is an identifier that describes the relative position of respiratory system findings data within a series.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "bc2024fc-5b39-4fa6-badf-f034d6fe8bb8"
        ]
    },
    "97e36c06-65fd-43dc-8b87-d4c01ccefeee": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00066573",
        "Statement": "there is a 0.2% difference between the results from the two the primary trial cohorts",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "1adc970c-d433-44d0-aa09-d3834986f7a2"
        ]
    },
    "69708ca0-e7d2-420d-9de9-6d7d9bb0f0ae": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Statement": "primary clinical trial accepts applicants who are being treated with flucytosine",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "f10f3b84-e039-4a02-a98b-86d149d9a16f"
        ]
    },
    "54952d5f-6ccc-4979-96f1-9f7e4e469b98": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02658734",
        "Statement": "the majority of the patients in the primary clinical trial underwent a grade 5 adverse event, whereas grade 1 events were notably uncommon.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "40f699a1-fbc6-40de-8e80-85b28f71632f"
        ]
    },
    "bdc333ae-331c-4c80-9232-8363ad15a7a4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT00852930",
        "Statement": "the primary trial and the secondary trial do not record any cardiac or infection related adverse events, but they both record several instances of epilepsy. oct embedded indicator is an indicator that specifies whether a specimen or sample was embedded in optimal cutting temperature (oct) compound.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "c2217d42-e90c-4ffe-b084-e653b9ace4d5"
        ]
    },
    "10c9669a-38ea-4bf5-96f1-e8d8d9d79901": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "low-dose cyclophosphamide/vinorelbine regimen is a regimen consisting of low-dose cyclophosphamide and vinorelbine that can be used for the treatment of rhabdomyosarcoma. neither of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "75affd49-4905-4d43-9a5c-ef795281bac4"
        ]
    },
    "4b97a844-8d52-48bb-8eda-ca205268f016": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Statement": "Patients must have a Life expectancy of 75+ years to enroll in the primary trial",
        "Label": "Contradiction"
    },
    "cf2bcfb1-74c4-47cb-a659-80395064e8d3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT00852930",
        "Statement": "unit of electric flux density is a unit for measurement of vector-valued field that appears in maxwell's equations. the primary trial and the secondary trial do not record any cardiac or infection related adverse events.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "06f798d1-2956-4903-83e9-58a41fa425f7"
        ]
    },
    "14acd92d-56b5-4676-96e3-f3d1c86cfcf5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00428922",
        "Statement": "the primary clinical trial measures outcomes by the span of time a patient continues to live with the disease during and after undergoing treatment.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "3facad41-0221-42f8-834d-470e65c4aad5"
        ]
    },
    "6e194fa5-c672-4896-8c0b-ae90010b6671": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00915603",
        "Statement": "at least two participants in the primary clinical trial, one representative from each cohort, recorded a progression-free survival span of 10.8 months",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "47ba01d6-edc7-4acb-ab49-b0e86f4eeaf7"
        ]
    },
    "11adc400-d6f6-4185-8c65-21c5a4ef581f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "the primary clinical trial's intervention protocol has a total duration of 14 days",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "236780db-9e59-4dc9-8da0-e786287011cf"
        ]
    },
    "57576f8e-683a-4360-a1ca-8f54c3bf70f6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042938",
        "Statement": "skin cystic basal cell carcinoma is a basal cell carcinoma of the skin that is characterized by cyst formation. the primary trial reports the Severity of Dermatitis in Radiation Treatment Site for the Curcumin C3 Complex cohort and the placebo cohort, there is no difference in the results from these two cohorts.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "e62f5a3f-0091-4980-9822-db8f4dc2502a"
        ]
    },
    "35436508-ba9b-4a7c-b69d-37f2e12b56f4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02186015",
        "Statement": "both adults and children are eligible to participate in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "2825d63b-8f22-4fb8-829f-9567845251c6"
        ]
    },
    "8b91cab9-d858-45f3-bf8d-3d6fc55b4818": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02419807",
        "Statement": "The the primary trial results section reports two different measurements",
        "Label": "Entailment"
    },
    "ce8464bd-951e-44aa-97d9-10b917b055ce": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005879",
        "Statement": "there was a significantly higher percentage of patients with slipped disks in cohort 2 of the primary trial than in cohort 1",
        "Label": "Contradiction"
    },
    "f10f3b84-e039-4a02-a98b-86d149d9a16f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Statement": "ongoing flucytosine treatments are not permitted for participants of the primary trial",
        "Label": "Entailment"
    },
    "d4194e20-9607-49ab-a431-e132080be0f4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01307891",
        "Statement": "there were no cases of neutropenia in either cohort of the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "a9907a2e-254a-45ca-af50-3e44fd2f7af3"
        ]
    },
    "d7781ad6-a9a5-4262-a10c-5cfc7d1639d5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00477464",
        "Statement": "the primary clinical trial participants receive capecitabine more often than they receive lapatinib.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "a52b2d4f-0b06-4960-a9c3-88cb92df0980"
        ]
    },
    "8cda7f9c-e3fd-4e67-b2d1-306c797893b3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01416389",
        "Statement": "the alteration in the number of lesions for the involved patients is recorded in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "812bd63c-4bfb-49cb-8fa9-baa3f8f6dabe"
        ]
    },
    "2655c892-216e-4b96-a8f2-6f64403215c5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01905592",
        "Statement": "there were 4 types of Adverse events which did not affect any of the patients in cohort 1 of the primary trial",
        "Label": "Contradiction"
    },
    "2e90dac9-4aee-4438-adeb-0bc02dc4a384": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00063570",
        "Statement": "patients with a less harmless brain tumor or colon polyps may apply for participation in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "015dd869-db90-45a9-a951-9dc7dc2b2e01"
        ]
    },
    "61358ef0-09e6-4fc3-8f25-1b8606b36bdc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Statement": "there are no requirements for surgery or oral medicine as part of the intervention for any cohort in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "63a0a9fc-80b9-450f-b2c6-7aee37ce26a9"
        ]
    },
    "bd7f913b-5401-4768-aedc-d1b24bfbbb34": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00428922",
        "Statement": "rpl22 gene rearrangement is a molecular abnormality indicating rearrangement of the rpl22 gene. the outcome measurement of the primary trial is The length of time during and after the treatment that a patient survives with the disease .",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "3facad41-0221-42f8-834d-470e65c4aad5"
        ]
    },
    "2d51d176-fbd0-4fe6-aeed-b5d4baba5cdb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00593346",
        "Statement": "the primary trial does not report the PFS or objective response rate of its patient cohort, instead reporting the proportion of patients which experience dermatitis. cdisc adas-cog - word recall trial 1 subscore is alzheimer's disease assessment scale-cognitive cdisc version (adas-cog cdisc version) sub-score for word recall task trial 1.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "88668508-dfd4-4a39-91cd-cf1654a6dfc4"
        ]
    },
    "fb4e7d9b-2b1d-4c36-8f7d-bde95694fef3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00376597",
        "Statement": "organizations recommend stage 4 cancer patients for the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "b1dd7632-ed92-40a9-9293-bce68619c658"
        ]
    },
    "826c1c0b-e551-4636-93b0-0d7e774417fa": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00856492",
        "Secondary_id": "NCT00009945",
        "Statement": "the pcr of the patient cohorts is not measured in both the primary clinical trial and the secondary clinical trial.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "42d1fcd3-8faa-4065-bbba-42cc90ab67fb"
        ]
    },
    "94640d96-4700-4642-b982-aea75868398a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232505",
        "Statement": "a patient diagnosed with stage iii breast cancer through histological testing can participate in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "3cb71095-8e01-40dc-bbf5-eeffed55f354"
        ]
    },
    "37aed673-4bbd-4bae-b0d0-525861ba6798": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Secondary_id": "NCT00876395",
        "Statement": "running 110 yards or playing softball or baseball is a question about an individual's ability to run 110 yards or 100 meters or play softball or baseball. Diarrhoea is the most common adverse event in the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "eb1bfb08-eba0-4130-b328-00f56c0f84a6"
        ]
    },
    "72d27e5e-d3ac-4d55-836c-508dbccadc65": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Secondary_id": "NCT00274469",
        "Statement": "patients must be healthy, without any confirmed cancer diagnoses, to be eligible for the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "06fad978-1dc3-46f5-b45f-5ac6577f28b9"
        ]
    },
    "4ed79a10-5fc1-43fa-b77d-7e284b9d45a9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01118624",
        "Statement": "the primary trial participants recieve doses of Pralatrexate that are calculated based on bodyweight. cdkn2a protein variant is a variation in the amino acid sequence for a protein encoded by the cdkn2a gene.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "0ddb07ae-6e70-436d-8723-f609e59c57da"
        ]
    },
    "015dd869-db90-45a9-a951-9dc7dc2b2e01": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00063570",
        "Statement": "patients with a Malignant brain tumour or colon cancer diagnosis are eligible for the primary trial",
        "Label": "Contradiction"
    },
    "8369f1d0-2c09-452f-a86c-5569258f0dfb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02340221",
        "Statement": "urethral meatus stenosis is a narrowing of the opening of the urethra at the external meatus. Prior treatment with fulvestrant or with a phosphatidylinositol 3-kinase (PI3K) inhibitor will not prevent a patient from participating in the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "904061c0-14fa-4f13-9118-9a41e24fa8eb"
        ]
    },
    "469aae6a-a1ec-4049-9df6-797ecc38a29d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01125566",
        "Statement": "an eligibility criterion for the primary clinical trial is an ecog score below 3.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "b2cdbcb8-de26-4a44-8a94-dd68c13f7e41"
        ]
    },
    "576468bd-7016-4b54-835c-bda143b0fdcb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "candidates eligible for the primary clinical trial should be older than 18, have a karnofsky record above 80, and have satisfactory hepatic, renal, and cardiac functions and corresponding hematology levels.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "7c7418d2-32d7-4517-874b-eb3db24ea16a"
        ]
    },
    "45fd649b-58c5-4f67-b745-f2df4a7efa65": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Statement": "the primary clinical trial does not necessitate surgery as a component of the intervention for any of the cohorts.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "0a079cca-abde-42cf-9cec-a76e7a380e14"
        ]
    },
    "5843a7ec-fdd4-495a-bee4-f6f58beda8bf": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "presence of hot flashes for at least 40 years prior to study registration is required for all patients that want to participate in the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "a5baab2c-9c32-4301-a574-4ba5a0c2eb00"
        ]
    },
    "f8de3ff4-ecdf-4ac6-b691-e597a59fc96f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00503750",
        "Secondary_id": "NCT00005879",
        "Statement": "sound absorber device is a device or material designed to attenuate sound energy. The results from the secondary trial and the primary trial are non-comparable.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "dca4c9f7-bb2a-4f73-b390-93b7ced87c73"
        ]
    },
    "66a93ac6-4d2b-4a15-af93-1fb5ed6c7517": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572727",
        "Secondary_id": "NCT00328783",
        "Statement": "all patients in the primary trial receive lower doses of paclitaxel than patients in the secondary trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "3ba42f68-a643-4d10-afd0-cbb358d05a6f"
        ]
    },
    "cb00ee8e-6333-4f64-b168-5073c509bf7d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01998906",
        "Statement": "both cohorts of the primary trial undergo a total of 50 cycles, each lasting 1 week.",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "43ce26e5-03fa-4e9d-b0eb-6ea356295753"
        ]
    },
    "75a65913-5655-4377-b441-ecdd4dd75175": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00376597",
        "Statement": "Patients with stage 4 cancer are excluded from the primary trial",
        "Label": "Entailment"
    },
    "bdb4841f-3830-41dd-bcc7-64c0e45116f3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "persons having a t2 n2 m0 breast adenocarcinoma with positive nodes or a node negative breast adenocarcinoma with a tumor size of 1.5cm are accepted for the primary clinical trial.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "e6a4e9a6-56b8-4a30-9743-eb02688c090f"
        ]
    },
    "0dac0b34-c820-4354-b870-bfceca835823": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01416389",
        "Statement": "the adjustments in tumor size among its cohorts of patients are reported in the primary clinical trial.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "7cde9a22-a91f-4feb-892d-7cbd35f96a27"
        ]
    },
    "e77246b4-80a7-4b37-827c-90ed7083dc90": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Secondary_id": "NCT00274469",
        "Statement": "only male patients diagnosed with early stage prostate cancer may be accepted into the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "06fad978-1dc3-46f5-b45f-5ac6577f28b9"
        ]
    },
    "5c43271c-6b45-4c12-b8d0-e3a212d42de2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "clinical informaticist is an individual that designs, implements, evaluates and/or analyzes information technology in a healthcare or research setting. A patient with a node positive T2 N2 M0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of over 2cm.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "016943fa-57ea-4293-8131-03292ea1836c"
        ]
    },
    "24a380b1-1674-4a2f-a9f4-72502adb6379": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01929395",
        "Statement": "blood product collection is any process that harvests blood or blood products for clinical or manufacturing purposes. Patients must have a palpable carcinoma to be included in the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "24b85b44-b9e6-4c28-b3aa-1bd97102b7f1"
        ]
    },
    "d1b217ae-76f3-4ba6-958e-5b2558703ba4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01912612",
        "Statement": "several cases of congestive heart failure in the primary trial occurred in cohort 1, but none in cohort 2",
        "Label": "Contradiction"
    },
    "0ffa6ff4-8852-498d-b7f9-4f844b157f51": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00820170",
        "Secondary_id": "NCT00263588",
        "Statement": "the stipulations for inclusion and exclusion differ between the primary clinical trial and the secondary clinical trial.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "3a4003f6-ff1c-43d8-be48-f767266b2cf5"
        ]
    },
    "44a646fc-41d6-4ef3-b913-71ef26f245a6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00450723",
        "Statement": "The the primary trial intervention involves one drug taken orally and the secondary trial intervention is based on a medical procedure. beam hardening artifact is an artifact resulting from absorpsion of lower energy photons as the beam penetrates through a tissue.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "f0e845f9-8991-45b5-a520-51e934756f7a"
        ]
    },
    "85540b31-df4c-4850-907f-5ba51584eb4b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Secondary_id": "NCT00325234",
        "Statement": "the number of holocraneal cephale and catheter - related infections is equally distributed among the primary and secondary trials",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "9c033072-5f94-4d79-af47-126d531f0d6e"
        ]
    },
    "739c3d02-6fba-43c1-8c1b-e1e5ee83c044": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232505",
        "Statement": "mapk1 fusion positive is an indication that the expression of a mapk1 fusion has been detected in a sample. Patients with Histologically confirmed breast cancer stage I-IV are not eligible for the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "3cb71095-8e01-40dc-bbf5-eeffed55f354"
        ]
    },
    "996858ca-5ff0-4edb-940b-235900b5a859": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "only patients lacking radiographically verified brain metastases are suitable for the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "a9bb6de9-c6f8-4c99-81cd-f101cbaab387"
        ]
    },
    "9b13ccff-409c-4fa8-adfc-2c9030e551ad": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00754325",
        "Statement": "the number of patients who encountered disease progression or death was higher in the second cohort than the first of the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "251a20d8-2555-4929-9d01-c02311bdc93f"
        ]
    },
    "4fbd2d46-e17c-49a6-a763-9518c8a2e9d4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572727",
        "Secondary_id": "NCT00328783",
        "Statement": "patients participating in the primary clinical trial receive a greater dosage of bkm120 than those in the secondary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "51be7c95-8da4-419c-950c-91ebdd2c3fe5"
        ]
    },
    "40a1e141-19ba-44d6-94bd-5e2ec9cc5818": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00093795",
        "Statement": "pustular eruption is a diffuse or generalized outbreak of numerous pustules. the majority of participants in cohort 1 and 2 of the primary trial suffered some kind of disease Recurrence, Contralateral Breast Cancer, Second Primary Cancer, Death From Any Cause Prior to Recurrence or Second Primary Cancer.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "0ea29bd5-20be-40ea-8ad7-705d283d1d48"
        ]
    },
    "93eb226b-5c80-4fa3-972d-bf8ac42b3d2a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02131064",
        "Statement": "the primary clinical trial's cohort one showed 10 additional cases of left ventricular dysfunction compared to abdominal pain",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "1329dec6-fb2c-4219-9db6-3fef9d94b316"
        ]
    },
    "63dda50e-c0f6-40e2-86b3-a39707dc47d2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Statement": "the primary trial reports the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer side effects that are serious enough to prevent an increase in dose or level of that treatment. eventration is a localized protrusion of a structure into an adjacent structure or cavity.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "17bbea92-8f92-41f3-9b9d-cf6e62cf6798"
        ]
    },
    "5500ad7e-f1d1-40d5-8667-a9d2ff890ed0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "the primary clinical trial only accepts patients who have no radiologically confirmed brain metastases.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "a9bb6de9-c6f8-4c99-81cd-f101cbaab387"
        ]
    },
    "cfd99e6f-27c5-4d6d-8ef4-c13ddfdfbbe9": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00820170",
        "Secondary_id": "NCT00263588",
        "Statement": "inclusion and exclusion conditions are mirrored between the primary clinical trial and the secondary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "3a4003f6-ff1c-43d8-be48-f767266b2cf5"
        ]
    },
    "f6a87d5e-fd22-4920-97ce-9b59e93d81cc": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00331630",
        "Statement": "cardiac-related adverse events were observed in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "c7dc582a-4a58-4cb5-b980-b2d2b6a128c3"
        ]
    },
    "e4a767bf-0d90-47ea-9fd9-a8a802772249": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Statement": "according to the primary clinical trial, patients treated with neratinib in combination with paclitaxel do not experience any major side effects that could prevent an increase in treatment dosage level.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "17bbea92-8f92-41f3-9b9d-cf6e62cf6798"
        ]
    },
    "3f420880-9ab1-4669-acfa-767c0eb40237": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Statement": "anaemia emerged as the prevalent adverse incident in cohorts 1 and 2 of the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "fbb62216-2cf2-4813-ad41-12a86940610f"
        ]
    },
    "9e1d6e67-c362-4ff9-86e5-3f3303a18dc2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02915744",
        "Statement": "cohort 1 and 2 of the primary clinical trial are administered different interventions",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "8e9611fc-89f8-44cb-af09-8d71a13ca082"
        ]
    },
    "d74ddec4-56f7-406e-9024-2b8d98908bdf": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "separated is a person who is separated from their spouse, whether or not there is a legal arrangement. to be eligible for the primary trial candidates must be over the age of 18, have a severe disability and Adequate hepatic, renal and heart functions aswell as Adequate hematology levels.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "f45ff82d-e0f5-456a-9d78-ddc2dc6ab929"
        ]
    },
    "0fa585db-287f-4137-ad6b-21b6ee4fbacb": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00328783",
        "Statement": "adverse events in the primary trial have been extensively recorded and analyzed",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "fef5aedb-21c0-4130-b8a3-cb1df5017c7a"
        ]
    },
    "aaae88fe-5cca-4250-af51-17b54af18862": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00428922",
        "Statement": "the primary endpoint of the primary clinical trial is the time it takes from the start of treatment until the disease gets worse.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "3facad41-0221-42f8-834d-470e65c4aad5"
        ]
    },
    "da8736d3-581a-44e1-82a1-00178463fa47": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02915744",
        "Statement": "neither the secondary trial or the primary trial record the Overall Survival (OS) of Patients in their cohorts. swedish language is a north germanic language spoken as the official language of sweden.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "dc4c57b0-8c75-494e-81b0-3528df85ebff"
        ]
    },
    "303c033c-c326-4a28-9ccf-b23b4633639e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "for all patients belonging to the initial group of the primary clinical trial, their progression-free survival span was seen to exceed 8.8 months with the maximum recorded pfs nearing 10 months.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "b9e29ea8-6847-40d4-b5c3-81c496101695"
        ]
    },
    "3bbbd655-54fe-4681-8623-dbb685a95d02": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "all the primary trial patients achieved either disappearance of all target lesions, greater than or equal to 0.3 times decrease in the sum of the longest diameter of target lesions or a tumor that is neither growing nor shrinking.",
        "Label": "Entailment",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "7e5fd062-6ec3-480f-ab0e-e117eba2ffe7"
        ]
    },
    "f105cdef-1975-4a15-8720-aa71325776fc": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01307891",
        "Statement": "only one cohort of the primary clinical trial reported a case of neutropenia",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "a9907a2e-254a-45ca-af50-3e44fd2f7af3"
        ]
    },
    "1a094d28-1d64-4aa4-8879-b4e7e2d04890": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00570921",
        "Statement": "primary clinical trial participants are given intramuscular fulvestrant injections to the deltoid muscle and oral everolimus.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "32361e21-ee57-4c34-9390-833ba5048a10"
        ]
    },
    "cfdd5fbb-fb09-4683-8244-5e5d66b3c75a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Secondary_id": "NCT01644890",
        "Statement": "the percentage of individuals experiencing an objective response is calculated in the primary trial, however, the secondary clinical trial uses pfs as its measure.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "794269ca-e7ec-4a65-ace5-b0f24a8cdc15"
        ]
    },
    "eca4f3f5-c252-4c45-9ad2-5fa27ba1791e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01118624",
        "Statement": "adcs-adl - watch television is alzheimer's disease cooperative study-activities of daily living inventory (adcs-adl) in the past 4 weeks, did the subject watch television? the primary trial participants recieve doses of Pralatrexate that are calculated based on bodyweight.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "0ddb07ae-6e70-436d-8723-f609e59c57da"
        ]
    },
    "6dcf0366-4b87-4f24-b29a-22f6481414d1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02658734",
        "Statement": "Most patients in the primary trial experienced a grade 1 adverse events, the least common severity was grade 5, which only affected 8/70 patients. cdisc adas-cog - delayed word recall: word 5 is alzheimer's disease assessment scale-cognitive cdisc version (adas-cog cdisc version) delayed word recall task for word 5.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "40f699a1-fbc6-40de-8e80-85b28f71632f"
        ]
    },
    "358e2fe3-fcca-44cb-9ca1-1710fc286639": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "to be eligible for the primary trial candidates must be over the age of 216 months, have a severe disability and adequate hepatic, renal and heart functions aswell as adequate hematology levels.",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "f45ff82d-e0f5-456a-9d78-ddc2dc6ab929"
        ]
    },
    "5b57cde7-667d-4cad-a3c5-8d1adbcad5da": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02679755",
        "Statement": "every adverse event documented in the primary clinical trial has only impacted a single patient",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "f46a7d27-a94f-4389-a1a0-4a8f5177b354"
        ]
    },
    "3a4003f6-ff1c-43d8-be48-f767266b2cf5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00820170",
        "Secondary_id": "NCT00263588",
        "Statement": "the secondary trial and the primary trial do not have the same inclusion and exclusion conditions",
        "Label": "Entailment"
    },
    "925dc08b-903d-427a-8168-aed1c2b1674f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Secondary_id": "NCT00121992",
        "Statement": "the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial did not report any. hooked tail is a finding that the tail has an approximate 180 degree bend or curve.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "a5617ae4-05a3-42d0-9e14-141de5f8c010"
        ]
    },
    "c9a162ab-cda1-43c7-a4b3-b21174445b69": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Secondary_id": "NCT00325234",
        "Statement": "primary clinical trial records a higher incidence of urosepsis cases than the secondary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "7271e0db-bb82-423f-ad95-5ffa84fab97e"
        ]
    },
    "a8b750af-53e6-4008-a33f-a6c4dce11838": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00374322",
        "Statement": "in the primary clinical trial, a patient group had been given a placebo as a form of intervention",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "c40fdf91-9f81-454a-bba9-ec5c950cef6e"
        ]
    },
    "9ee46a2b-4859-4d64-a375-b192aa6d9bfc": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02131064",
        "Statement": "in cohort 1 of the primary clinical trial, abdominal pain was less reported compared to left ventricular dysfunction",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "3a0c517d-9b9a-4497-9675-50ff12cd02b7"
        ]
    },
    "c1a0a809-2af2-4843-b092-2bb2c991dd17": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00503906",
        "Statement": "participants of the primary trial will receive the intervention for a total of 241920 minutes",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "6499b181-7a23-4073-8459-ad46ff02b20f"
        ]
    },
    "398f25a7-0d33-4914-b3dd-ff6b41af2a65": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "extracranial metastases presence is a factor that disqualifies a patient from the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "b9491012-49ba-4eb1-8230-1966f54ea012"
        ]
    },
    "5feaf498-f6d4-475d-9e8d-2280cb86b4ec": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00754325",
        "Statement": "during the course of the primary clinical trial, the risk of disease progression or death was comparably low between patients receiving fulvestrant and herceptin.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "ba9daeb9-796d-49ab-a30c-4d8acbdf4d37"
        ]
    },
    "8c6314f7-34f5-42a7-ba66-b95d050a6315": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01644890",
        "Statement": "The shortest PFS in cohort 1 of the primary trial was 1.4 months below average",
        "Label": "Entailment"
    },
    "7e67541c-1299-435a-b364-9b0fcc50a739": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00333775",
        "Statement": "in the primary clinical trial, both cohorts are given equal doses of docetaxel, but 100 mg/m^2 of placebo is exclusively administered to cohort 1.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "a5e388b9-da3c-437e-a6af-7ba76ad8bf1d"
        ]
    },
    "bd941d3e-bf89-47a6-ab93-2279a3b609c3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02658734",
        "Statement": "in the primary clinical trial, severe or grade 4 adverse events were most commonly reported, while mild or grade 1 events were the least common.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "878c09e7-3fd9-404e-921e-5b549e9578fb"
        ]
    },
    "a1eaaace-2aba-48e5-8e1d-a6cff7553e3e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Secondary_id": "NCT01644890",
        "Statement": "the primary trial measures number of participants with disease progression (pd) or death, while the secondary trial determines the percentage of participants in its cohorts with objective response.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "f42e1874-343a-43ed-bb0c-884509c4793c"
        ]
    },
    "9c57b700-3a34-496d-b67c-1554c81d5c4a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00331630",
        "Statement": "cardiac-related adverse events were noted in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "553f00ea-5197-4233-b1e0-e5727856b599"
        ]
    },
    "29b2fa29-5a76-4877-95bb-1a8de7973d33": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Statement": "Only 6/67 patients in cohort 1 of the primary trial suffered adverse events",
        "Label": "Entailment"
    },
    "82ef081a-f776-4691-acea-63c880079978": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00570921",
        "Statement": "in the primary clinical trial, fulvestrant is provided through intramuscular injections into the deltoid, and everolimus is taken orally.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "32361e21-ee57-4c34-9390-833ba5048a10"
        ]
    },
    "2825d63b-8f22-4fb8-829f-9567845251c6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02186015",
        "Statement": "adults and children can take part in the primary trial",
        "Label": "Contradiction"
    },
    "a729482d-39e2-4a01-8179-7e6537967f71": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Secondary_id": "NCT00281697",
        "Statement": "both the primary clinical trial and the secondary clinical trial had a substantial number of participants suffering from enterocolitis.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f"
        ]
    },
    "1d1f57f8-85f7-448c-a4bb-15957da568fd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "the primary trial intervention protocol will continue until patients achieve complete response or suffer disease progression",
        "Label": "Entailment"
    },
    "eb1bfb08-eba0-4130-b328-00f56c0f84a6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Secondary_id": "NCT00876395",
        "Statement": "Diarrhoea is the most common adverse event in the primary trial and the secondary trial",
        "Label": "Contradiction"
    },
    "d4ffa15e-1299-4a75-94f0-c4054b9e988b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00503906",
        "Statement": "multiple known primary tumors absent at initial melanoma diagnosis is a response that multiple known primary tumors were absent at the initial melanoma diagnosis. Participants of the primary trial will receive the intervention for a total of 12 cycles (28 days).",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "6499b181-7a23-4073-8459-ad46ff02b20f"
        ]
    },
    "62466593-c6d1-4702-9892-60f7424bfec1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232505",
        "Statement": "patients with histologically confirmed breast cancer stage i-iii may participate in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "75cf4ec2-9f2b-4d5b-8772-af247eaca07b"
        ]
    },
    "fa0ccc7c-b8ba-485d-890f-eb696797f6aa": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01905592",
        "Statement": "diffuse residue following swallowing is a finding of diffuse residue following swallowing. there were 4 types of Adverse events which did not affect any of the patients in cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "2655c892-216e-4b96-a8f2-6f64403215c5"
        ]
    },
    "2e76c74a-b6dd-47d8-a674-c1e80b0a3a65": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274469",
        "Statement": "to be eligible for the primary trial patients must be diagnosed with hormone receptor positive advanced breast cancer, and have received prior chemotherapy for this cancer.",
        "Label": "Contradiction"
    },
    "eb550215-687e-4f2d-bfbc-0798f892f0be": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00593346",
        "Statement": "instead of presenting data on pfs or objective response rate, the primary clinical trial discloses the fraction of patients who had dermatitis",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "88668508-dfd4-4a39-91cd-cf1654a6dfc4"
        ]
    },
    "88b8527c-3a6d-4ccb-9b19-45b9bac0202c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00127933",
        "Statement": "neither eliane who is 56 nor alex who is 32 can participate in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "a792bbac-0e8a-4bf7-9cc5-56fad481e2fb"
        ]
    },
    "3158472a-00b1-4cc2-bb64-44f06ecb8b23": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00450723",
        "Statement": "the procedure for the primary clinical trial includes the oral intake of a medication, while the secondary clinical trial entails a medical procedure.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "f0e845f9-8991-45b5-a520-51e934756f7a"
        ]
    },
    "8f64416e-8ef6-4ff1-a02e-560db4f60efe": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01011946",
        "Secondary_id": "NCT00066573",
        "Statement": "participants in the primary trial receive medication through injection and suppository means, on the other hand, the secondary trial patients are treated with intravenous drugs.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "8ddf8b88-6e06-4c71-9e28-45f73a637af0"
        ]
    },
    "478f96bc-6f9c-4420-a893-d3f0cd6b2daa": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290758",
        "Secondary_id": "NCT02370238",
        "Statement": "while endocrine therapy disqualifies patients from participating in the primary clinical trial, it doesn't affect their eligibility for the secondary clinical trial, even if they aren't receiving adjuvant therapy.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "4a41ac73-538a-43e5-b7ce-8c8e2d56286e"
        ]
    },
    "7208bed0-6e16-4c6a-912f-c3e7eacb51c6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "gamma glutamyl transpeptidase measurement is a quantitative measurement of the amount of gamma glutamyl transpeptidase present in a sample. Presence of hot flashes for at least 4 month prior to study registration is required for all patients that want to participate in the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "a5baab2c-9c32-4301-a574-4ba5a0c2eb00"
        ]
    },
    "8ac9c8bb-5d15-4065-a224-8e0bf15166b7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02915744",
        "Statement": "recurrent genetic abnormalities present is a laboratory test result indicating the presence of recurrent genetic abnormalities in cells. Cohort 1 and 2 of the primary trial do not receive the same intervention.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "8e9611fc-89f8-44cb-af09-8d71a13ca082"
        ]
    },
    "7068776d-2bb8-4348-b4ab-07f7855c7167": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00127933",
        "Statement": "despite their interest, eliane and elizabeth's ages of 56 and 32 respectively are grounds for automatic disqualification from the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "f0273b8c-460d-46fe-9c52-8ff4b08e439b"
        ]
    },
    "c82595b5-0928-4b42-b506-f8d6aae908f2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02340221",
        "Statement": "how much bothered by feeling worried is a question about how much feeling worried bothered or troubled an individual. Prior treatment with fulvestrant or with a phosphatidylinositol 3-kinase (PI3K) inhibitor is not admissible for the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "6b35bc10-f591-4b84-abac-40a74be949fa"
        ]
    },
    "402eca5e-a646-4fb3-b888-6c4607926b0a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "patients with radiographically confirmed brain metastases are eligible for the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "a9bb6de9-c6f8-4c99-81cd-f101cbaab387"
        ]
    },
    "b2de40fa-59e5-400e-ab44-8781fc29f556": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02419807",
        "Statement": "the results section for the primary clinical trial provides two different sets of measurements, pertaining to all three cohorts.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "d0b50aeb-aad8-4a8d-aae6-5c58a7d382c7"
        ]
    },
    "89b82caf-35d0-4f67-9781-17610e663386": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290758",
        "Secondary_id": "NCT02370238",
        "Statement": "women engaging in endocrine treatment at this time aren't eligible for the primary clinical trial nor the secondary clinical trial, with the exception of those who are receiving adjuvant therapy.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "4a41ac73-538a-43e5-b7ce-8c8e2d56286e"
        ]
    },
    "fef0996e-1a5e-414d-8ee6-923e89953154": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Secondary_id": "NCT00325234",
        "Statement": "the primary clinical trial has more reported instances of holocraneal cephale and catheter-associated infections than the secondary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "9c033072-5f94-4d79-af47-126d531f0d6e"
        ]
    },
    "4ec56624-4de6-42dc-a362-82056ee22be8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01998906",
        "Statement": "dosages of medication in the primary clinical trial fluctuate throughout the 17 cycles",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "2a2c16a7-f427-4fdb-8153-94aac304e4b8"
        ]
    },
    "6834503a-e251-45a7-95c4-b3eca8e01b0d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00022516",
        "Statement": "T1 N0 M0 patients are eligible for the primary trial. bone marrow lymphoplasmacytic infiltrate is a morphologic finding indicating the presence of a lymphoplasmacytic infiltrate in a bone marrow specimen.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "978d19fc-e7f6-485e-b8bd-cfcde06441ab"
        ]
    },
    "5abfbd10-2e63-4fed-9082-6aaf6756a624": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02186015",
        "Statement": "the primary clinical trial allows for both adults and children to participate",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "2825d63b-8f22-4fb8-829f-9567845251c6"
        ]
    },
    "ad8925f0-1402-43f9-aec2-9dfbe6abd7d8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Statement": "Anaemia was the most common adverse event in cohort 1 and 2 of the primary trial. lymphatic invasion is a term referring to the presence of tumor emboli or tumor masses within lymphatic vessels.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "fbb62216-2cf2-4813-ad41-12a86940610f"
        ]
    },
    "dd41d93e-710d-4f08-8552-42d23d47047d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00331630",
        "Statement": "both cardiac and bowel-related adverse events were documented in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "553f00ea-5197-4233-b1e0-e5727856b599"
        ]
    },
    "70a37fa7-1eb8-44b4-8b38-28ecfe13a6e3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00009945",
        "Statement": "in the primary clinical trial, no single adverse event impacts more than 100 patients.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "1314146f-2869-4525-8034-7f732d238385"
        ]
    },
    "91bb7e66-5ddd-4092-86e2-9cbd15f61590": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Secondary_id": "NCT03098550",
        "Statement": "all participants of the primary trial have stage 2 or 3 histologically or cytologically confirmed invasive breast cancer, there is no specific stage of cancer required for entry to the secondary trial. likert score 3 is a subjective score of 3 on a likert scale.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "07042b0f-d422-49c3-8d53-81319927a4b3"
        ]
    },
    "0fc4be6e-1eed-44e5-9c1c-d263bcda0229": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00477464",
        "Statement": "the primary trial participants receive significantly higher doses of Capecitabine than of Lapatinib. neuroimmunology is a subdiscipline of immunology with a focus on the nervous system and its interactions with the immune system.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "a3390ae6-d41d-4dc7-899e-de9534adfd6b"
        ]
    },
    "c0ff7fd6-eada-4f39-a7d8-ce66c706abf1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT03176238",
        "Statement": "selected normal sample aliquot indicator is an indicator specifying which normal sample aliquot was used in a nucleotide sequencing run. There more cases of Acute myocardial infarction, Cardiopulmonary failure and Supraventricular tachycardia in cohort 1 of the secondary trial than in the entire patient cohort of the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "5c975af8-6b7f-4a5d-b4a6-257c76763ce9"
        ]
    },
    "03fcba10-de05-4cde-9aa8-ef6cb3349c0c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00915603",
        "Statement": "small intestinal hodgkin lymphoma is a hodgkin lymphoma that arises from the small intestine. at least 2 participants of the primary trial, at least one from each cohort, had a Progression-Free Survival of 10.8 months.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "47ba01d6-edc7-4acb-ab49-b0e86f4eeaf7"
        ]
    },
    "2472eb08-3800-4675-beec-be6c3af227bd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042938",
        "Statement": "there is no specification of the severity of dermatitis in radiation treatment site for the curcumin c3 complex group and the placebo group in the primary trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "4a15ec5e-4904-4f01-a0a2-c51e83c8c070"
        ]
    },
    "8e10da9c-1886-4465-8412-ffe6c8cdeee9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01830933",
        "Statement": "the types of adverse events reported in the primary clinical trial and the secondary clinical trial are identical.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "c7a953b0-ac96-4e0a-9c1d-98cf8af2861d"
        ]
    },
    "f7531404-6d58-4cad-86cc-b5330fc878f6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02301988",
        "Statement": "ipatasertib administration is not exclusive to cohort 1 patients in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "faa65e54-aa04-4595-8dae-05cf00b4c887"
        ]
    },
    "c1806e37-d013-468b-a441-08b18b2139fb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00376597",
        "Statement": "the primary clinical trial is open to stage 4 cancer patients.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "b1dd7632-ed92-40a9-9293-bce68619c658"
        ]
    },
    "2a372896-53bc-424a-b186-a6bd10c94e8c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02131064",
        "Statement": "in cohort 1 of the primary clinical trial, there were more cases of abdominal pain than left ventricular dysfunction",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "3a0c517d-9b9a-4497-9675-50ff12cd02b7"
        ]
    },
    "7a41fe40-e645-43ef-9566-2552fbfc108c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "a patient with a node positive t2 n2 m0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of over 20mm",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "016943fa-57ea-4293-8131-03292ea1836c"
        ]
    },
    "328533c0-08a4-400f-84cd-63cdc76a42ce": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Statement": "ongoing flucytosine treatments are necessary for all participants of the primary trial, treatments must have started at least 0.5 years before study entry",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "565d7982-aa9a-4c01-987c-1d67bc9c212d"
        ]
    },
    "2b933a69-6b38-4f29-b00f-91bda9e82840": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01905592",
        "Statement": "there were two types of Adverse events which did not affect any of the patients in cohort 1 of the primary trial. oral dysesthesia, ctcae is a disorder characterized by a burning or tingling sensation on the lips, tongue or entire mouth.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "30483d7e-7703-459c-bd10-e2bd259c2a4f"
        ]
    },
    "55a75585-f10e-4f6a-b25d-a6c0252c2ca3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274469",
        "Statement": "patients with hormone receptor positive breast cancer but with one course of radiation therapy behind them can engage in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "b1219e71-fbf5-4bba-8a93-a27ae444e3e1"
        ]
    },
    "f705d47d-acdb-4b6f-81c9-1d2ae9f566eb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02924883",
        "Statement": "Only patients with triple negative breast cancer are eligible for the primary trial. astrocytoma, idh-wildtype is astrocytoma lacking mutations in idh1 or idh2 genes. it includes diffuse astrocytoma, idh-wildtype and anaplastic astrocytoma, idh-wildtype.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "c10eea1a-5768-442d-ae07-20b4f8f4b583"
        ]
    },
    "8c705edd-4b0a-4967-9688-49bf6fa6126b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00328783",
        "Statement": "in the primary clinical trial, the incidence rate of 12 different adverse events is covered in the adverse events section.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "97fd111c-6969-43ab-93af-b3dff09960e5"
        ]
    },
    "c5bfb2bd-b12b-4f35-87d4-9a6e7afe3ffb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03098550",
        "Statement": "in the primary clinical trial, the identical interventions are experienced by both cohorts, but they differ in the patients' cancer varieties.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "b0b61978-57db-4a1c-812c-509e8b05f2dc"
        ]
    },
    "b85b8f0e-9913-42c7-9f08-9006719f28cf": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00612560",
        "Secondary_id": "NCT01216176",
        "Statement": "all of the primary trial participants are given a placebo, while all participants in the secondary trial receive flaxseed.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "b0046821-ba27-4a90-8869-cb708b843aa4"
        ]
    },
    "d6eb3503-a4da-4eb0-bba9-654e00208467": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00612560",
        "Secondary_id": "NCT01216176",
        "Statement": "none of the primary trial participants receive anastrazole in any form, however, all secondary trial participants are prescribed anastrazole",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "e9fd065c-342c-4dfb-9c1c-a4c0c44d0acd"
        ]
    },
    "dfda82f7-d50e-46ea-a482-9850501fed7b": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02915744",
        "Statement": "the secondary trial and the primary trial do not record the same metrics in their results section. allergic bronchopulmonary aspergillosis is an immune reaction to aspergillus in patients usually suffering from asthma or cystic fibrosis.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "dd2f3c3d-fa95-4fca-a3f0-795fd4f3abf1"
        ]
    },
    "4bbff807-491b-4d3e-93f8-08c0d3a2ff7f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02679755",
        "Statement": "multiple patients have been affected by individual aes reported in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "f46a7d27-a94f-4389-a1a0-4a8f5177b354"
        ]
    },
    "36de2591-aaed-4aa2-9243-93023d388848": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "several patients in the primary clinical trial had an increase in the sum of the longest diameter of target lesions.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "985bc5a0-bc21-447f-92f1-150e23ede3f5"
        ]
    },
    "c0557a85-284e-4d59-96c8-960e7de1d102": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00240071",
        "Statement": "the primary clinical trial only involves surgical intervention, excluding avastin, bevacizumab and radiotherapy as a part of the treatment",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "045ad91e-44fa-42cc-ac22-a7aab26a9009"
        ]
    },
    "97e81392-97cc-47db-9526-7c05f155135d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Statement": "hypertension and bradycardia were the most significant adverse events reported for cohorts 1 and 2 respectively in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "ec1e269e-470d-43d9-8f23-8a19a5c96fcc"
        ]
    },
    "40896ec4-239b-4d89-a2f6-e3e2c6b48d04": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02915744",
        "Statement": "nktr-102 is administered to cohort 2 of the primary clinical trial by an infusion method.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "4309860d-042d-45a4-8a0a-a9fdd075247a"
        ]
    },
    "11730915-097f-4ee6-bf69-dbda9d02f43f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00357110",
        "Statement": "all participants in cohort 1 of the primary clinical trial survived, while cohort 2 had a mortality rate of 5%.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "f114846e-79d8-4712-add0-bb34b65d418f"
        ]
    },
    "95eaee53-556a-4703-bedf-175cdbdaa7e2": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Secondary_id": "NCT00325234",
        "Statement": "sebaceous gland neoplasm is a benign or malignant neoplasm that arises from the sebaceous glands. representative examples include sebaceous adenoma and sebaceous carcinoma. There are more cases of Holocraneal cephale and Catheter - related infections in the primary trial than in the secondary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "9c033072-5f94-4d79-af47-126d531f0d6e"
        ]
    },
    "18a87cab-7c17-4aca-8671-d1ade940b468": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01011946",
        "Secondary_id": "NCT00066573",
        "Statement": "while the primary clinical trial does not involve the administration of oral medications for participants, the secondary clinical trial relies solely on oral treatments for managing patients.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "6402e13a-7cfb-4774-b7f9-80ecb79fda2a"
        ]
    },
    "71130023-1967-44a3-9d16-91cef3ee8f2e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "take is as pertains to a medication: ingest, inhale, instill, or inject. A patient with a node positive T2 N2 M0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of over 2cm.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "016943fa-57ea-4293-8131-03292ea1836c"
        ]
    },
    "1842904b-5371-49ee-b6f4-8831b879098b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting more than 5% of patients",
        "Label": "Entailment"
    },
    "de26cf6a-c769-46e1-bf8c-5a62827190f0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00376597",
        "Statement": "patients with stage 4 cancer are eligible for the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "75a65913-5655-4377-b441-ecdd4dd75175"
        ]
    },
    "52f026dd-b3a8-4198-aeeb-472990a07545": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02340221",
        "Statement": "Prior treatment with fulvestrant or with a phosphatidylinositol 3-kinase (PI3K) inhibitor is not admissible for the primary trial. comparison of health status is a question about how an individual considers their health status in comparison to others of the same age.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "6b35bc10-f591-4b84-abac-40a74be949fa"
        ]
    },
    "24a95259-d1e6-4a5e-bf06-0c46e4745a0e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00240071",
        "Statement": "the primary trial participants receive more than one type of medication during the study. likert score 10 is a subjective score of 10 on a likert scale.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "82a3e542-f784-44d7-90f6-34d7e969283c"
        ]
    },
    "917833bb-9248-43d5-8e4c-4998b3aa4ecf": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00281697",
        "Statement": "only patients confirmed with her2-positive status are allowed to participate in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "43ee7645-ce1e-42d5-9a74-3e379f6f367b"
        ]
    },
    "582d7f6f-fd0a-413d-9d2f-fc3236f3455c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290758",
        "Secondary_id": "NCT02370238",
        "Statement": "Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial. csf analysis table is a table of data specifically regarding cerebrospinal fluid analysis.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "5d0ccb93-71ec-4079-92c6-d7cbf951a7bb"
        ]
    },
    "de9d444e-f39d-4dc7-adc7-572c08384308": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01042535",
        "Statement": "the most common adverse event in the primary clinical trial was nausea and vomiting",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "4f705481-5dd0-414c-b375-c56e8c235b42"
        ]
    },
    "5635c847-72b5-4dd4-98a5-5ed535ce9e94": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "the interventions in the primary clinical trial indeed demonstrated objective benefits for the majority of its participants.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "75affd49-4905-4d43-9a5c-ef795281bac4"
        ]
    },
    "0202c2b4-a183-4334-a5cb-97d3bf4da2fb": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01307891",
        "Statement": "many patients in both cohorts of the primary clinical trial experienced neutropenia",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "734423d5-4b47-4448-ab98-811015d626f0"
        ]
    },
    "2ad0fc33-c001-4404-9cd5-7c4aabdb2319": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "infiltrating bladder urothelial carcinoma with trophoblastic differentiation is a variant of infiltrating bladder urothelial carcinoma. it is characterized by the presence of trophoblastic differentiation within the carcinoma. the primary trial intervention protocol will continue until patients achieve complete response or suffer disease progression.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "1d1f57f8-85f7-448c-a4bb-15957da568fd"
        ]
    },
    "35f580c7-8fc1-4eea-a68f-31cbda77bc08": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00240071",
        "Statement": "the primary clinical trial utilises solely chemotherapy for treatment without any implementation of avastin, bevacizumab or radiotherapy",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "045ad91e-44fa-42cc-ac22-a7aab26a9009"
        ]
    },
    "87a5c7ba-08c9-45b0-bf5b-c1064aa5f309": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00915603",
        "Statement": "cohort 1 of the primary clinical trial indicated the shortest pfs to be less than 7 months, while the briefest pfs in cohort 2 exceeded 7 months.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "0cef8c8e-7986-46c7-a597-c5733a9899c0"
        ]
    },
    "8846e30d-b441-4f1c-a15a-6dcca3b5fcbc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00063570",
        "Statement": "chief complaint caused by trauma is an indication that the chief complaint was caused by a traumatic event. patients with a Malignant brain tumour diagnosis are excluded from the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "62e449ad-16b3-479d-94a5-ffc435b5e99c"
        ]
    },
    "a0065d58-e03b-4dd0-9c81-cbbf651a6d45": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00820170",
        "Secondary_id": "NCT00263588",
        "Statement": "any patient eligible for the secondary trial will also be eligible for the primary trial ",
        "Label": "Contradiction"
    },
    "0c4146df-19e6-408a-9d93-0de82f54311c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00593346",
        "Statement": "the primary trial does not report the PFS or objective response rate of its patient cohort. cerebral convexity is area within the sulci of the brain, usually anterior to the rolandic fissure.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "cc1f712a-2116-4e40-9810-f315e3fa5ff8"
        ]
    },
    "d52b112d-7779-4f6d-9e0e-4bd60972bf46": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00333775",
        "Statement": "every cohort in the primary clinical trial is administered identical amounts of docetaxel",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "9bcc31df-c1f6-4785-9235-f673213acf3a"
        ]
    },
    "808f63c0-b6bf-450d-aac1-6dcd70ec7f27": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "the primary clinical trial opens its doors to patients displaying a node positive t2 n2 m0 adenocarcinoma of the breast or a node negative adenocarcinoma of the breast with a tumor measuring 1.5cm in diameter.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "e6a4e9a6-56b8-4a30-9743-eb02688c090f"
        ]
    },
    "101d49d4-10aa-47b0-a2d9-6d05c08bb947": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Secondary_id": "NCT01644890",
        "Statement": "in the primary clinical trial, the metric used is the proportion of participants exhibiting an objective response, in contrast to the secondary clinical trial where they assess pfs.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "794269ca-e7ec-4a65-ace5-b0f24a8cdc15"
        ]
    },
    "9e6d7d6f-dfdf-4387-b13f-22fef2dc532a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01830933",
        "Statement": "the primary trial and the secondary trial report the same types of adverse events. have good range of movement in my arm or leg is a question about whether an individual has or had good range of movement in their arm or leg.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "c7a953b0-ac96-4e0a-9c1d-98cf8af2861d"
        ]
    },
    "ee38e7be-2557-4b38-80b2-98b64fb70a3d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02301988",
        "Statement": "cohort 1 patients of the primary trial are administered higher doses of Ipatasertib and  Placebo than cohort 2 patients. aids-related plasmablastic lymphoma of mucosa site is a plasmablastic mucosal site lymphoma in a patient with acquired immunodeficiency syndrome.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "973f090a-8967-4d75-bb8e-6166c868337c"
        ]
    },
    "bb62f22b-fd05-4926-9ae1-87873837eef5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01224678",
        "Secondary_id": "NCT01042535",
        "Statement": "There were more cases of mental health disorders, PLEUROPERICARDITIS, ATRIAL THROMBOSIS  and Anemia in the secondary trial than in the primary trial. grade 1 pulmonary valve disease, ctcae is asymptomatic valvular thickening with or without mild valvular regurgitation or stenosis by imaging",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "57b2ae97-0d1d-4d5d-bc4b-109e8e5acb32"
        ]
    },
    "212c15a5-190f-4027-8685-3804804f3c24": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00944047",
        "Statement": "under 3/10 primary trial patients in the intervention arm experienced pathologic complete response",
        "Label": "Entailment",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "9f7d476e-9db3-4c00-abe6-4c2f0160470a"
        ]
    },
    "0a8bef56-5911-425d-8c41-23d6c93d32d7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01042535",
        "Statement": "constipation was not encountered as a side effect during the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "16c29502-4683-4087-9410-ff1b786556f5"
        ]
    },
    "f45d7fab-639f-49d6-bc26-46af896f1926": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00915603",
        "Statement": "in cohort 2 of the primary clinical trial, the minimal pfs did not reach the 7-month period.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "0cef8c8e-7986-46c7-a597-c5733a9899c0"
        ]
    },
    "09ce5c9c-06ad-41bd-9894-248413367d1d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00503750",
        "Secondary_id": "NCT00005879",
        "Statement": "by transitioning the units from days to months, one can compare the outcomes from both the primary and secondary clinical trials",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "7d52734c-0801-413d-9ae2-d190b972cde5"
        ]
    },
    "90cebd71-6c9a-4e49-8d5e-a1f87006807d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Secondary_id": "NCT00325234",
        "Statement": "There are more cases of Urosepsis in the primary trial than in the secondary trial. curled tail is a finding that the tail is curved or coiled into a circular shape.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "7271e0db-bb82-423f-ad95-5ffa84fab97e"
        ]
    },
    "a273885c-be6d-4c27-b07b-ab4812092700": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02679755",
        "Statement": "the primary clinical trial records do not indicate any individual adverse events affecting more than 10% of the population.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "c09fa61c-967a-40ae-96b0-c87b7cde237b"
        ]
    },
    "33de1760-a96a-4b6d-ad04-5e3368112485": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00733408",
        "Statement": "female non-neoplastic reproductive system disorder is a non-neoplastic disorder that affects the female reproductive system. representative examples include endometriosis, pelvic inflammatory disease, and endometritis. Infections were the most common adverse events recorded in the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "4dfff980-6a2b-4f01-9194-6ec831d6fed7"
        ]
    },
    "1329dec6-fb2c-4219-9db6-3fef9d94b316": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02131064",
        "Statement": "in cohort 1 of the primary trial there were 10 more cases of Left ventricular dysfunction than Abdominal pain",
        "Label": "Contradiction"
    },
    "08ec32e8-3f2c-4ebd-b67f-79c3165ff084": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Statement": "Anaemia was the most common adverse event in cohort 1 of the primary trial and tachycardia was the most common in cohort 2. formalin-fixed paraffin-embedded b-cell (cd20) slide is a biospecimen consisting of formalin-fixed, paraffin embedded cd20-positive b-cells affixed to a slide for light microscopy",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "ec1e269e-470d-43d9-8f23-8a19a5c96fcc"
        ]
    },
    "ef733cc6-ef45-4df4-8d9f-ce116f8ac63d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "the most regular adverse event in the primary clinical trial was non-cardiac chest pain, affecting fewer than 5% of the participants in the initial group.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "2da13cd4-7189-4f85-be4d-5c1e213ae293"
        ]
    },
    "e2e6de49-bb17-42b5-b18e-e32e2e8e8afa": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00374322",
        "Statement": "aditoprim is a long-acting, selective, reversible inhibitor of dihydrofolate reductase with application as a broad-spectrum antibacterial agent in animals. One patient cohort in the primary trial received a placebo intervention.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "c40fdf91-9f81-454a-bba9-ec5c950cef6e"
        ]
    },
    "5c318436-cc7a-4880-ba48-9368e8d379f0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00376597",
        "Statement": "only patients diagnosed with stage 2 and 3 cancer can participate in the primary clinical trial, those with stage 4 cannot",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "b1dd7632-ed92-40a9-9293-bce68619c658"
        ]
    },
    "74256e75-c886-4a7a-937e-d85506f684da": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00425854",
        "Secondary_id": "NCT01224678",
        "Statement": "patients experiencing extremely low ejection fraction are not acceptable for the primary clinical trial, but those who are of 55 years of age or less could be allowed in the secondary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "d1b7105d-0b7d-4b10-92a7-d63243ff0629"
        ]
    },
    "2f7f0ef8-60c2-46ae-be4a-17c6027569e3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "chemistry test is a laboratory test designed for the quantification of an organic or inorganic chemical within a biological specimen. to be eligible for the primary trial candidates must be over the age of 18, have a Karnofsky score over 80 and Adequate hepatic, renal and heart functions aswell as Adequate hematology levels.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "7c7418d2-32d7-4517-874b-eb3db24ea16a"
        ]
    },
    "62b73920-0b99-408f-b3a6-17d61beb3ccb": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00450723",
        "Secondary_id": "NCT00290758",
        "Statement": "cohort 2 of the secondary trial solely documented all the instances of musculoskeletal adverse events, in contrast to the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "f3cb9150-32c6-4877-9a87-4fac45a24948"
        ]
    },
    "251a20d8-2555-4929-9d01-c02311bdc93f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00754325",
        "Statement": "a higher proportion of patients suffered Disease Progression or Death in cohort 2 of the primary trial than in cohort 1",
        "Label": "Entailment"
    },
    "653c17af-4b09-4dca-b8b7-86cc86539250": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00606931",
        "Statement": "glandular (acinar)/tubular differentiation is a morphologic finding indicating the presence of acinar and tubular differentiation  in a tissue sample of an epithelial neoplasm. There adverse events section in the primary trial describes the number of patients that suffered Hypotension, Hemorrhage and Bradycardia when taking part in the study.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "175044aa-72b1-405d-8506-30002f5098e4"
        ]
    },
    "927ed567-1344-45b0-a3cd-576514f82896": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "presence of hot flashes for 400 days prior to study registration is required for all patients that want to participate in the primary trial, but not necessary for entry to the secondary trial.",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "31105b43-832b-48bc-a78d-ee90c155ca44"
        ]
    },
    "7206194b-5726-40f2-8ccd-52215538625f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Statement": "patients with a life expectancy of 30 years or lesser can participate in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "4b97a844-8d52-48bb-8eda-ca205268f016"
        ]
    },
    "176cc578-242c-42f9-9c18-721481db526a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00733408",
        "Statement": "infections were the predominant undesirable events documented in the primary clinical trial.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "4dfff980-6a2b-4f01-9194-6ec831d6fed7"
        ]
    },
    "fc0fde82-0e0b-4680-b73c-556f8d644100": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00915603",
        "Statement": "the shortest PFS in cohort 1 of the primary trial was under 7 months, in cohort 2 the shortest was just over 7 months. cellular ependymoma is an ependymoma which shows conspicuous cellularity without a significant increase in mitotic rate. (adapted from who)",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "0cef8c8e-7986-46c7-a597-c5733a9899c0"
        ]
    },
    "7e5fd062-6ec3-480f-ab0e-e117eba2ffe7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "All the primary trial patients achieved either Disappearance of all target lesions, >=30% decrease in the sum of the longest diameter of target lesions or a tumor that is neither growing nor shrinking.",
        "Label": "Entailment"
    },
    "2e2dbfc0-3697-4440-86fd-32015c7d3518": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00820170",
        "Secondary_id": "NCT00263588",
        "Statement": "a patient ineligible for the secondary trial can still be eligible for the primary trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "a0065d58-e03b-4dd0-9c81-cbbf651a6d45"
        ]
    },
    "a35b3b12-c70a-4293-aa9f-86020a28c276": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01011946",
        "Secondary_id": "NCT00066573",
        "Statement": "participants in the primary clinical trial do not receive medication orally, while the patients in the secondary clinical trial are treated only through oral medication.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "6402e13a-7cfb-4774-b7f9-80ecb79fda2a"
        ]
    },
    "c76fd3df-0e0f-40ff-87af-c413c7b392c5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01912612",
        "Statement": "the primary clinical trial recorded no incidences of congestive heart failure in cohort 1.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "9cbc00e9-3a2d-4471-a93e-72c95132fb6a"
        ]
    },
    "68b9a23d-ee07-4e4b-a8da-ef9cd8a9fb02": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02131064",
        "Statement": "in the first cohort of the primary clinical trial, instances of left ventricular dysfunction exceeded those of abdominal pain",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "3a0c517d-9b9a-4497-9675-50ff12cd02b7"
        ]
    },
    "0fab6be7-bddd-4f2c-bd73-d00122c5bf22": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00593346",
        "Statement": "the primary clinical trial discloses the objective response rate of its patient population.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "cc1f712a-2116-4e40-9810-f315e3fa5ff8"
        ]
    },
    "5b1c9304-67f3-43d9-9acf-88e426e4c648": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00281697",
        "Statement": "her2 status is not a criterion for the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "43ee7645-ce1e-42d5-9a74-3e379f6f367b"
        ]
    },
    "add0874e-b9f3-427f-bf1a-514113a18ee4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Secondary_id": "NCT00274469",
        "Statement": "both the primary clinical trial and the secondary clinical trial are exclusively open for patients of any gender with initial level skin cancer.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "06fad978-1dc3-46f5-b45f-5ac6577f28b9"
        ]
    },
    "ebb19c2b-bba0-4f8a-8dfb-5ae2acf018d2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00944047",
        "Statement": "a majority of 80% of the primary trial patients in the intervention arm reported pathologic complete response",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "9f7d476e-9db3-4c00-abe6-4c2f0160470a"
        ]
    },
    "e1c70d3a-921f-4d18-a62b-ce33ea9b6977": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Statement": "Anaemia was the most common adverse event in cohort 1 and 2 of the primary trial. macau is a special administrative region of china, bordering the south china sea, west of hong kong.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "fbb62216-2cf2-4813-ad41-12a86940610f"
        ]
    },
    "2db33813-d738-434e-af1e-e243f32160dc": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01581619",
        "Secondary_id": "NCT00106002",
        "Statement": "the primary clinical trial has significantly dissimilar outcome measures compared to the secondary trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "1180dd58-61b8-4c48-ab00-7d458e68c85b"
        ]
    },
    "a8ab15da-3c47-4cb7-ad6c-d2db75bc8a11": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00503750",
        "Secondary_id": "NCT00005879",
        "Statement": "the secondary clinical trial and the primary clinical trial exhibit a substantial overlap in research outcomes",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "dca4c9f7-bb2a-4f73-b390-93b7ced87c73"
        ]
    },
    "49ba06b2-576d-4db2-80b6-51673416f2ba": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT02340221",
        "Statement": "the primary trial and the secondary trial measure the Percent Change in Net Influx Constant (Ki) by FLT PET in their patient cohorts",
        "Label": "Contradiction"
    },
    "b818e25a-bd76-44b7-b39f-05bbe632804d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting most patients in the trial. kras exon 4 mutation is a molecular genetic abnormality indicating the presence of a mutation in exon 4 of the kras gene.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "614d7ade-0fa7-4d77-bc19-1d3a2f2f48c2"
        ]
    },
    "512a8109-4221-474a-a6c6-7ffb4c0042ba": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00281697",
        "Statement": "a patient with a HER2-positive status can not take part in the primary trial. hyperlactemia is abnormally high level of lactate in the blood.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "00822101-fa21-4a26-bf45-3b1f535da005"
        ]
    },
    "8dff2b9e-e901-4a4f-a54a-2386eaa3fbb5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "Patients with Extracranial metastases can be eligible for the primary trial. anti-tobacco advertisement is advertisement designed to persuade individuals to cease, or not start, the use of tobacco.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "b9491012-49ba-4eb1-8230-1966f54ea012"
        ]
    },
    "1e192144-39f4-4c33-b44d-e213bac64858": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Secondary_id": "NCT03098550",
        "Statement": "pain felt around rectum is a question about how much pain an individual had around their rectum. all participants of the primary trial have stage 3 cytologically confirmed invasive breast cancer, there is no specific stage of cancer required for entry to the secondary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "7f3fe97e-68ee-470f-b06e-21cdddb67aa8"
        ]
    },
    "36ae2f60-1969-4700-96aa-7924784a57ca": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Secondary_id": "NCT00281697",
        "Statement": "comprehensive analysis of patient profiles in the secondary clinical trial and the primary clinical trial reveals that in no case was enterocolitis diagnosed in the participants.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f"
        ]
    },
    "5e2d6ac3-8603-421f-aeb5-960516effa01": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "patients wanting to take part in the primary trial must have a known and documented tnbc status and an lvef of at least 0.5",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "9abb10d7-496e-44fd-915d-d86aedf6c9b6"
        ]
    },
    "a8504c1b-534c-4399-b0cc-3edbcfde225f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Secondary_id": "NCT03098550",
        "Statement": "all participants of the primary trial have stage 2 or 3 histologically or cytologically confirmed invasive breast cancer, there is no specific stage of cancer required for entry to the secondary trial. cd8 negative is an indication that expression of the cd8 complex has not been detected in a sample.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "07042b0f-d422-49c3-8d53-81319927a4b3"
        ]
    },
    "5ae5215b-920c-405d-ae97-29137f2d2f46": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00503906",
        "Statement": "for the primary clinical trial participants, the intervention won't be administered for a specified number of cycles, but will carry on until progression of the disease is noticed",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "59cd7909-00c3-4c23-9a08-a42dbc8eabdd"
        ]
    },
    "95f07495-e042-424f-a4ba-99c552db920b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00428922",
        "Statement": "the main metric of the primary clinical trial is the patient's subjective report of pain relief.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "3facad41-0221-42f8-834d-470e65c4aad5"
        ]
    },
    "5cfe60bd-79c5-4168-8433-5a6ce5673b07": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Statement": "in the primary clinical trial, surgery or oral medication are not mandatory for either of the cohorts involved in the intervention.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "63a0a9fc-80b9-450f-b2c6-7aee37ce26a9"
        ]
    },
    "a59b47b8-fafb-438a-a353-edc1ebc6e90a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02915744",
        "Statement": "if completed specify type of brain pet is a request to specify the type of brain positron emission tomography. Cohort 1 and 2 of the primary trial do not receive NKTR-102 by infusion.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "4309860d-042d-45a4-8a0a-a9fdd075247a"
        ]
    },
    "021a275a-b4a0-4423-9f01-d4a436919440": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00606931",
        "Statement": "adverse events are specifically reported and evaluated in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "21611c2a-e6eb-4012-a209-9b6781e1f260"
        ]
    },
    "eb7618d8-c0c1-41ce-ade4-f2ee464916e3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01905592",
        "Statement": "in the first cohort of the primary clinical trial, four types of adverse events were reported, but none affected any patient.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "2655c892-216e-4b96-a8f2-6f64403215c5"
        ]
    },
    "28db1da0-e3ec-4182-ba0c-b1dc7b3a77ad": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02679755",
        "Statement": "none of the individual aes recorded in the primary trial affect more than 10 out of every 100 people in the population.",
        "Label": "Entailment",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "c09fa61c-967a-40ae-96b0-c87b7cde237b"
        ]
    },
    "a929eb26-54d0-4df6-a65e-ad5d46764dcf": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02301988",
        "Statement": "only the first cohort of patients in the primary clinical trial receive ipatasertib",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "faa65e54-aa04-4595-8dae-05cf00b4c887"
        ]
    },
    "33f7910f-ffbd-4719-82f3-6e2a34c8257e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "patients wanting to take part in the primary trial must have a known and documented tnbc status and an lvef of at least 92.8 percent (%)",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "9abb10d7-496e-44fd-915d-d86aedf6c9b6"
        ]
    },
    "184ada9c-7dfe-4005-9fe1-f7e657adb459": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02915744",
        "Statement": "cohort 1 of the primary clinical trial receives nktr-102 via infusion.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "4309860d-042d-45a4-8a0a-a9fdd075247a"
        ]
    },
    "42d1fcd3-8faa-4065-bbba-42cc90ab67fb": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00856492",
        "Secondary_id": "NCT00009945",
        "Statement": "the secondary trial and the primary trial do not both measure the pCR of their patient cohorts.",
        "Label": "Entailment"
    },
    "efb9604a-c183-4d6b-bfb5-a6a654bc0a7c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02301988",
        "Statement": "Only cohort 1 patients of the primary trial are administered Ipatasertib. 2q12.2 is a chromosome band present on 2q",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "faa65e54-aa04-4595-8dae-05cf00b4c887"
        ]
    },
    "e4aeb013-7713-4b73-acbd-f8379cc6a494": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005879",
        "Statement": "there was a higher percentage of patients with slipped disks in cohort 2 of the primary trial than in cohort 1",
        "Label": "Entailment"
    },
    "03499e47-6db3-419d-805e-4279935d02bf": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00856492",
        "Secondary_id": "NCT00009945",
        "Statement": "both the primary clinical trial and the secondary clinical trial involve measuring the pcr and tumor diameter in their patient populations.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "70677d5f-7022-404c-8410-d1f89366d92f"
        ]
    },
    "39ef91f9-78cd-441e-affc-c5be87243c2a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01929395",
        "Statement": "patients with visible carcinomas only in their stomach are eligible for the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "79ca2ee8-6c9c-40e6-a87c-925b50d3d3d2"
        ]
    },
    "fe0d8de0-366f-48e0-a2e1-c2bf0b5f1d09": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005879",
        "Statement": "cohort 1 of the primary clinical trial had a higher percentage of patients with slipped disks than cohort 2",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "e4aeb013-7713-4b73-acbd-f8379cc6a494"
        ]
    },
    "59308b6f-0e1d-48ff-b475-2be11669f517": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Secondary_id": "NCT00425854",
        "Statement": "the secondary trial and the primary trial use Objective Response as the outcome measurement for their interventions. . fgfr2 rearrangement analysis is a procedure used to detect and identify rearrangements involving the fgfr2 gene.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "402f0dbf-cf67-4425-b300-a0a3df4d59d3"
        ]
    },
    "5d0ccb93-71ec-4079-92c6-d7cbf951a7bb": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290758",
        "Secondary_id": "NCT02370238",
        "Statement": "Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial",
        "Label": "Entailment"
    },
    "193f5998-b470-4a70-bfa6-eac3f520455a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Secondary_id": "NCT00425854",
        "Statement": "the secondary trial and the primary trial use Objective Response as the outcome measurement for their interventions. . skin response test is a character or string that represents the long name of the skin response assessment.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "402f0dbf-cf67-4425-b300-a0a3df4d59d3"
        ]
    },
    "2f95313b-7d30-4bf6-85c8-67620aaf9792": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00572728",
        "Statement": "unlabored is an action that occurs with a normal amount of effort or energy (as in unlabored breathing). Patients must be able to undergo a PET scan to participate in the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "32ed503c-1cfd-44f6-b8bb-23d9d175d73d"
        ]
    },
    "218b6a6a-e27c-4006-afa5-56d4f4985bbc": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "all the primary trial patients had a minimum of 75% decrease in the sum of the longest diameter of target lesions",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "985bc5a0-bc21-447f-92f1-150e23ede3f5"
        ]
    },
    "96215b20-ca59-43a5-adc6-4af2d6431109": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Statement": "all accepted pregnant patients in the primary clinical trial are free from any prior breast cancer treatment",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "b1d28450-fc7d-496a-9c7c-bf711b28f8e4"
        ]
    },
    "5c1e360c-fd93-4dd4-b855-71ba416d34cb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00263588",
        "Statement": "patients must be able to receive medication orally to participate in the primary trial",
        "Label": "Entailment"
    },
    "3479b456-ff0c-4ad0-8618-7e97774d8d5c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "patients wanting to take part in the primary trial must have a known and documented her2+ status and an lvef greater than or equal to 1/2",
        "Label": "Entailment",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "6b33b4ae-36f2-4a53-a954-6f246f6e023d"
        ]
    },
    "99955363-d674-429a-9f00-22d9d6f09d98": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02419807",
        "Statement": "the results section of the primary clinical trial reports two separate measurements for each of the three cohorts.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "d0b50aeb-aad8-4a8d-aae6-5c58a7d382c7"
        ]
    },
    "31309d8d-411a-4f5d-8ecf-370a51c7fe86": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "neither of the interventions in the primary trial resulted in an objective benefit for more than 80% of patients, in fact over 2% of patients receiving the docetaxel then liposomal doxorubicin intervention suffered fatal complications",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "74e376d7-5713-43f3-93f1-9608059c9547"
        ]
    },
    "db680214-67c5-4c70-babd-edf794cc92af": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290758",
        "Secondary_id": "NCT02370238",
        "Statement": "picogram per milliliter per microgram per meter squared per day is a unit of concentration equal to picograms per milliliter, divided by micrograms per meter squared per day. Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial, unless they are recieiving adjuvant therapy.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "4a41ac73-538a-43e5-b7ce-8c8e2d56286e"
        ]
    },
    "97b0814b-b283-45de-8164-21a71cd25dba": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "the primary clinical trial mandates that all participants should have been suffering from hot flashes for a minimum duration of 30 days prior to study enrollment while the secondary clinical trial has no such requirement.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "31105b43-832b-48bc-a78d-ee90c155ca44"
        ]
    },
    "702cbd77-c6fa-4535-89de-874087c25913": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00733408",
        "Statement": "the primary clinical trial noted infections as the predominant negative events.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "4dfff980-6a2b-4f01-9194-6ec831d6fed7"
        ]
    },
    "c2b64c47-0355-4321-9f4b-1a90ca896a09": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Secondary_id": "NCT00876395",
        "Statement": "average time other aerobic exercise is a question about the average time that an individual spent doing other aerobic exercise. Diarrhoea is the most common adverse event in the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "eb1bfb08-eba0-4130-b328-00f56c0f84a6"
        ]
    },
    "051b14b1-271e-4c6f-ad28-1a71cf3a031c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02915744",
        "Statement": "both cohort 1 and 2 of the primary clinical trial undergo the same treatment method",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "8e9611fc-89f8-44cb-af09-8d71a13ca082"
        ]
    },
    "25211337-9901-45c6-af9c-83dae7165fe1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00570921",
        "Statement": "periodontal route of administration is administration of a substance within the tissues surrounding a tooth or teeth. the primary trial participants are administered Fulvestrant intramuscularly and Everolimus orally.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "45ccd2c8-6e02-4f0f-a370-eed18d26e6dc"
        ]
    },
    "804b399a-ca1b-482d-9b4a-19f848c7b820": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01998906",
        "Statement": "participants in the primary clinical trial undergo a series of 20 cycles, each spanning a duration of 6 weeks.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "43ce26e5-03fa-4e9d-b0eb-6ea356295753"
        ]
    },
    "014e8e58-4fbf-4477-b29c-a4977b95b369": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005879",
        "Statement": "there were no patients with slipped disks present in cohort 2, in comparison to cohort 1 of the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "ce8464bd-951e-44aa-97d9-10b917b055ce"
        ]
    },
    "0a24e40e-4f65-4814-966b-e9f84dde30b0": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Secondary_id": "NCT00274469",
        "Statement": "Patients must be female and have confirmed advanced breast cancer to be eligible for the secondary trial and the primary trial. phf6 gene mutation is a change in the nucleotide sequence of the phf6 gene.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "68379456-775b-463b-bfdb-d8aa42c9124b"
        ]
    },
    "11a76209-a69a-4648-91b2-6a5d53f5fef7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01307891",
        "Statement": "There was one case of  Neutropenia in both cohorts of the primary trial. acute physiology and chronic health evaluation ii apch110 original result - 46-49.9 is acute physiology and chronic health evaluation ii apch110 original result - 46-49.9.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "a9907a2e-254a-45ca-af50-3e44fd2f7af3"
        ]
    },
    "9de0f028-fcd5-4ee7-8a2e-d55bcaf1429a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00331630",
        "Statement": "the primary clinical trial reported no adverse events pertaining to cardiac or neural health",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "c7dc582a-4a58-4cb5-b980-b2d2b6a128c3"
        ]
    },
    "64814bcb-d7ee-4b20-9122-f0d7bf950bb4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00263588",
        "Statement": "participation in the primary clinical trial necessitates that patients have her2- breast cancer.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "215a5c4a-d90c-4500-8284-0679ce311734"
        ]
    },
    "6fe0d308-0205-4f82-b4e5-c8b806775e03": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02131064",
        "Statement": "unspecified external cause status is a status indicating that the patient's illness or injury is due to an external cause that is not specified. in cohort 1 of the primary trial there were 10 more cases of Left ventricular dysfunction than Abdominal pain.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "1329dec6-fb2c-4219-9db6-3fef9d94b316"
        ]
    },
    "1011b43d-adb9-4e79-a9f1-5f679497f632": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00357110",
        "Statement": "in the primary clinical trial, cohort 1 had 6 fatalities while cohort 2 reported 7.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "f114846e-79d8-4712-add0-bb34b65d418f"
        ]
    },
    "0a096475-e2b2-4174-a15c-86ad274aa50f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00333775",
        "Statement": "both the primary trial cohorts receive identical doses of Docetaxel, with cohort 1 also receiving 100 mg/m^2 of Placebo. scientific method is a method of investigation involving observation and theory to test scientific hypotheses.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "a5e388b9-da3c-437e-a6af-7ba76ad8bf1d"
        ]
    },
    "35216ac1-59a5-49b8-90ff-4f99eb80407a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572727",
        "Secondary_id": "NCT00328783",
        "Statement": "the dosage of bkm120 is the same for patients in both the primary and secondary trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "51be7c95-8da4-419c-950c-91ebdd2c3fe5"
        ]
    },
    "00866e64-a0d0-4916-a473-0a9e07b4525e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT02340221",
        "Statement": "in their respective patient cohorts, the primary and secondary clinical trials gauge the percentage shift in net influx constant (ki) via flt pet.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "49ba06b2-576d-4db2-80b6-51673416f2ba"
        ]
    },
    "9c574107-8aee-4a18-bda5-c8589322171e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02658734",
        "Statement": "most patients in the primary trial experienced a grade 3 adverse events, the least common severity was grade 4, which only affected 80/7000 patients.",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "40f699a1-fbc6-40de-8e80-85b28f71632f"
        ]
    },
    "ddb313e4-ee69-45ea-a9db-9967e5ca960e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT03176238",
        "Statement": "the secondary clinical trial's first cohort has an increased incidence of acute myocardial infarction, cardiopulmonary failure and supraventricular tachycardia compared to the second cohort of the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "080da381-b5dd-46d3-99c4-18112da153c1"
        ]
    },
    "0131ebe3-746b-45a5-ba60-fdd326974fec": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01262027",
        "Secondary_id": "NCT02301988",
        "Statement": "the primary trial and the secondary trial use comparable outcome measurements",
        "Label": "Entailment"
    },
    "aa988207-b233-47ef-af7b-f5c9ff13ee10": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00915603",
        "Statement": "a minimum of two participants from the primary clinical trial, one from each cohort, exhibited a progression-free survival of 10.8 months",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "47ba01d6-edc7-4acb-ab49-b0e86f4eeaf7"
        ]
    },
    "db6380b8-f295-4640-95d2-969ebcfd7cb9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "there were fewer total adverse events (aes) in cohort 1 of the primary clinical trial than in cohort 2",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "1c4e3fe3-b5fe-4ea3-8d9e-0ce1502080e7"
        ]
    },
    "da4e3503-d910-4600-a2f3-f92b5c6e72e3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "in the primary clinical trial, febrile neutropenia was the adverse event recorded most frequently, impacting over 5% of the participating patients",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "1842904b-5371-49ee-b6f4-8831b879098b"
        ]
    },
    "93cae9f2-1a82-4bfd-922a-452d677d9470": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Statement": "patients must have a life expectancy of at least 2 months to enroll in the primary trial'",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "618a3ae1-b22c-4c35-86a6-190c1b5b5d21"
        ]
    },
    "1fed33ee-6c6a-4444-9e8c-1ea5cf33c376": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Statement": "the primary trial reports the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer side effects that are serious enough to prevent an increase in dose or level of that treatment. abnormal cardiac event monitoring finding is a history of having had an abnormal finding during cardiac event monitoring.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "17bbea92-8f92-41f3-9b9d-cf6e62cf6798"
        ]
    },
    "dca4c9f7-bb2a-4f73-b390-93b7ced87c73": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00503750",
        "Secondary_id": "NCT00005879",
        "Statement": "The results from the secondary trial and the primary trial are non-comparable",
        "Label": "Entailment"
    },
    "3629158c-e839-41f6-97fb-4000a8f08e72": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01830933",
        "Statement": "the primary clinical trial routinely reports adverse events, as does the secondary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "fb360514-14be-45ab-8b74-ea5a7eb181d7"
        ]
    },
    "cf2a08ba-6d52-4c93-8463-fa9994848b22": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00428922",
        "Statement": "the primary clinical trial's outcome measure is how long a patient continues to live with the disease without it worsening, both during and after treatment.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "d01fda83-5dc8-4ad5-92b8-7553dabd7046"
        ]
    },
    "a7acdc55-2a2b-4822-8bcf-67013755954e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Secondary_id": "NCT03098550",
        "Statement": "the primary clinical trial includes participants with cytologically confirmed stage 3 invasive breast cancer only. however, the stage of cancer for admission in the secondary clinical trial is not specifically defined.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "7f3fe97e-68ee-470f-b06e-21cdddb67aa8"
        ]
    },
    "e7bd29e0-231b-4b0c-b002-bc49ad18a0e5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02924883",
        "Statement": "only those afflicted with triple negative breast cancer can participate in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "c10eea1a-5768-442d-ae07-20b4f8f4b583"
        ]
    },
    "4521fa72-b92d-47de-bf6c-ca40dd4cb3ae": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Secondary_id": "NCT00425854",
        "Statement": "the interventions of both the secondary and primary clinical trials employ objective response as the gauge for outcomes.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "402f0dbf-cf67-4425-b300-a0a3df4d59d3"
        ]
    },
    "52e3a698-9bf7-4461-8d36-428ec18b6070": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02915744",
        "Statement": "cohort 1 and 2 of the primary clinical trial both receive identical intervention",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "8e9611fc-89f8-44cb-af09-8d71a13ca082"
        ]
    },
    "78f019d5-7a02-4648-81d8-208344b4cd7e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00022516",
        "Statement": "wallet pack dosage form is a multi-panel, re-closable end-user pack for tablet blisters. T4 N2 M4 patients are eligible for the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "4a75574c-fa86-4e62-a210-81c7b98a3807"
        ]
    },
    "24ff3bfe-f20d-411d-9cda-5ec02f138322": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232505",
        "Statement": "individuals diagnosed with stage ii of breast cancer, confirmed via histopathology, are fit for inclusion in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "75cf4ec2-9f2b-4d5b-8772-af247eaca07b"
        ]
    },
    "a3f55817-8703-4f16-bcc8-cd1e8cb738da": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Secondary_id": "NCT00425854",
        "Statement": "the secondary clinical trial uses disease-free survival as the outcome measurement for its intervention and utilizes a uniform definition for complete response, inconsistent with the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "8d9f94e3-871b-4fb4-a522-0a73d9d0ec3c"
        ]
    },
    "2955ab74-392e-4a75-965c-ec4a726bf7b4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00915603",
        "Statement": "at least 2 participants of the primary trial, at least one from each cohort, had a progression-free survival of 0.9 years",
        "Label": "Entailment",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "47ba01d6-edc7-4acb-ab49-b0e86f4eeaf7"
        ]
    },
    "dcead51e-bbd3-40eb-bbfd-af8e9dac3f62": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00022516",
        "Statement": "patients diagnosed with t4 n2 m4 can participate in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "4a75574c-fa86-4e62-a210-81c7b98a3807"
        ]
    },
    "9fdf4f2f-8683-44c1-b5aa-7e014a3bdd0e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572727",
        "Secondary_id": "NCT00328783",
        "Statement": "patients in the primary and secondary trials do not receive any doses of bkm120",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "51be7c95-8da4-419c-950c-91ebdd2c3fe5"
        ]
    },
    "cc497c8c-6a4f-4068-b1c3-ff2f6c4e8439": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005879",
        "Statement": "in the primary clinical trial, cohort 2 had a higher number of patients with slipped disks compared to cohort 1",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "e4aeb013-7713-4b73-acbd-f8379cc6a494"
        ]
    },
    "b964291e-af78-4251-8228-c44edcc80d1a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00856492",
        "Secondary_id": "NCT00009945",
        "Statement": "the secondary trial and the primary trial do not both measure the pCR of their patient cohorts. defined option relationship comment is additional description of the option relationship.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "42d1fcd3-8faa-4065-bbba-42cc90ab67fb"
        ]
    },
    "f4c20972-9568-42c7-918a-cab9eb3dff7c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00063570",
        "Statement": "patients with a Malignant brain tumour or colon cancer diagnosis are eligible for the primary trial. low hemoglobin level is a lower than average level of hemoglobin in a sample.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "015dd869-db90-45a9-a951-9dc7dc2b2e01"
        ]
    },
    "2acab941-0e01-4faa-8996-037dc27c2509": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Secondary_id": "NCT00274469",
        "Statement": "individuals with a gender-neutral diagnosis of colorectal cancer are qualified only if they are male for both the primary clinical trial and secondary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "68379456-775b-463b-bfdb-d8aa42c9124b"
        ]
    },
    "1180dd58-61b8-4c48-ab00-7d458e68c85b": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01581619",
        "Secondary_id": "NCT00106002",
        "Statement": "the results of the secondary trial and the primary trial report the same outcome measures",
        "Label": "Contradiction"
    },
    "62f4fa44-32c9-4f7b-97de-010cfe488ea6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00450723",
        "Statement": "the primary clinical trial intervention relies on a complex surgical procedure while the secondary trial employs an orally administered drug.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "f0e845f9-8991-45b5-a520-51e934756f7a"
        ]
    },
    "72e1f7de-d6d9-433e-adba-4aa062838ca1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01644890",
        "Statement": "setosphaeria is a genus of fungi in the phylum ascomycota. The shortest PFS in cohort 1 of the primary trial was less than 3 weeks.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "961a956e-fece-4baa-a2ad-d3a5320bd9d2"
        ]
    },
    "b197de6f-955b-4037-9449-1ad65a05fa5d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT03176238",
        "Statement": "the amount of acute myocardial infarction, cardiopulmonary failure, and supraventricular tachycardia cases in the primary trial surpasses those in cohort 1 of the secondary trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "5c975af8-6b7f-4a5d-b4a6-257c76763ce9"
        ]
    },
    "95d2a3f3-ada4-42de-b2be-b747034a762c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03012477",
        "Secondary_id": "NCT02419807",
        "Statement": "lymph node by anatomic site is a lymph node named according to its location in the body. the primary trial and the secondary trial report their results as perecentages but use different units of measure.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "0e609fad-9a28-4fb6-90b6-32a731e3b02c"
        ]
    },
    "fabc5163-cc3d-42cd-9978-dcdc7a84cc21": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00820170",
        "Secondary_id": "NCT00263588",
        "Statement": "certain patients eligible for the secondary trial may be excluded from the primary trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "a0065d58-e03b-4dd0-9c81-cbbf651a6d45"
        ]
    },
    "b9b9a89d-3bec-4e24-bc3e-407dde0cb951": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00374322",
        "Statement": "0.8 of patients in the primary trial received a placebo intervention",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "e147796d-2edd-42d1-ac53-300fb8bd5eb6"
        ]
    },
    "e92f796b-f7c3-48a3-bbc2-0645dd40ff25": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01042535",
        "Statement": "skin infection was the prevalent adverse event in the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "4f705481-5dd0-414c-b375-c56e8c235b42"
        ]
    },
    "5b565bbc-aa53-4776-8890-1eb599bef6d6": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00503750",
        "Secondary_id": "NCT00005879",
        "Statement": "The results from the secondary trial and the primary trial can be compared by changing the units from days to months. cobalt gray equivalent is a unit of relative biological effectiveness of protons equivalent to 60 cobalt gamma rays.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "7d52734c-0801-413d-9ae2-d190b972cde5"
        ]
    },
    "14b7dc8a-0ac4-422f-a8a2-80905630260b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01644890",
        "Statement": "the shortest pfs in cohort 1 of the primary clinical trial was not statistically significant",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "8c6314f7-34f5-42a7-ba66-b95d050a6315"
        ]
    },
    "98c30617-ad5d-4a0d-902d-1c1d2d8fbdb3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00374322",
        "Statement": "all patient groups in the primary clinical trial were given active treatment",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "c40fdf91-9f81-454a-bba9-ec5c950cef6e"
        ]
    },
    "5a5c9f6a-f808-4a07-8237-009e146e2800": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00331630",
        "Statement": "neurological adverse events were documented in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "c7dc582a-4a58-4cb5-b980-b2d2b6a128c3"
        ]
    },
    "56b90182-ad7a-43c4-a7ed-f94ee85a1c28": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00127933",
        "Statement": "eliane, a woman of 56 years, and alex, a man of 32 years, both can be suitable for the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "a792bbac-0e8a-4bf7-9cc5-56fad481e2fb"
        ]
    },
    "97977de7-92d5-4584-be68-229420f2ac7e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02924883",
        "Statement": "patients diagnosed with her2-ve breast cancer are included in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "446f3c69-0de5-475c-a8e2-ff40ece90672"
        ]
    },
    "f68d9113-99b2-4b9f-9eb6-283bda52372f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "a person diagnosed with a t2 n2 m0 adenocarcinoma of the breast with positive nodes is qualified for the primary clinical trial, along with those individuals whose breast adenocarcinoma is node negative and has a tumor size of 1.5cm.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "e6a4e9a6-56b8-4a30-9743-eb02688c090f"
        ]
    },
    "8ca73496-dae0-49f0-8ddb-26a643a465bd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01224678",
        "Secondary_id": "NCT01042535",
        "Statement": "there were fewer reported instances of mental health disorders, pleuropericarditis, atrial thrombosis, and anemia in the secondary clinical trial compared to the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "57b2ae97-0d1d-4d5d-bc4b-109e8e5acb32"
        ]
    },
    "679047a8-266d-4c5e-91ad-d789afa7eabf": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01125566",
        "Statement": "ECOG score < 2 is necessary to be eligible for the primary trial. defect in the gene for mis type ii receptor is a defect in the misr ii gene.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "7137dec6-5c98-4156-8035-7bbaaf0b649d"
        ]
    },
    "29fef6df-7848-4c4f-a15a-4c002a10db74": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01644890",
        "Statement": "in the primary clinical trial, the briefest progression free survival (pfs) in the first group spanned a minimum of six months.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "961a956e-fece-4baa-a2ad-d3a5320bd9d2"
        ]
    },
    "cf412c8d-9a30-470e-99f4-f29a2ef9b35b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01998906",
        "Statement": "in the primary clinical trial, all cohorts are subjected to a total of 17 cycles, each extending for a period of 3 weeks.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "43ce26e5-03fa-4e9d-b0eb-6ea356295753"
        ]
    },
    "9eddf602-5b51-4d74-b7cb-e5cbac4246fc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232505",
        "Statement": "those with confirmed histological evidence of stage i-iv breast cancer are not suitable for the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "3cb71095-8e01-40dc-bbf5-eeffed55f354"
        ]
    },
    "7d2de568-c1c9-4e5c-ab44-c0f43e429e84": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042938",
        "Statement": "regret having bone marrow transplant is a question about whether an individual regrets or regretted having a bone marrow transplant. the primary trial reports the Severity of Dermatitis in Radiation Treatment Site for the Curcumin C3 Complex cohort and the placebo cohort.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "4a15ec5e-4904-4f01-a0a2-c51e83c8c070"
        ]
    },
    "1314146f-2869-4525-8034-7f732d238385": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00009945",
        "Statement": "none of the individual adverse events in the primary trial affect more than 100 patients.",
        "Label": "Entailment"
    },
    "0d09a49a-dc7d-4436-b93d-a827e0bddec6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00754325",
        "Statement": "in the primary trial, patients that received Fulvestrant were much more likely  to suffer Disease Progression or Death than patients receiving herceptin. tape device is a long, thin, flat, flexible material often used for measuring, binding or fastening, or as a recording medium.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "ba9daeb9-796d-49ab-a30c-4d8acbdf4d37"
        ]
    },
    "915f3fc7-4757-4256-819c-bccdce407f4d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "to be considered for the primary clinical trial, it's not necessary to have adequate hematology levels.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "7c7418d2-32d7-4517-874b-eb3db24ea16a"
        ]
    },
    "dd315c04-0380-49ab-926d-b624b93c2845": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "patients bearing extracranial metastases may qualify for the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "b9491012-49ba-4eb1-8230-1966f54ea012"
        ]
    },
    "10b6701d-4ca1-4140-b40c-640e76c6b3ab": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Statement": "none of the patients in cohort 1 of the primary clinical trial experienced adverse events",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "29b2fa29-5a76-4877-95bb-1a8de7973d33"
        ]
    },
    "9c033072-5f94-4d79-af47-126d531f0d6e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Secondary_id": "NCT00325234",
        "Statement": "There are more cases of Holocraneal cephale and Catheter - related infections in the primary trial than in the secondary trial",
        "Label": "Contradiction"
    },
    "148a2a1f-1b4c-4279-90bc-6b1e62b28e1e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Secondary_id": "NCT00325234",
        "Statement": "There are more cases of Holocraneal cephale and Catheter - related infections in the primary trial than in the secondary trial. upper gi complete response gvhd is an nih upper gi score of 0 after previous gvhd involvement.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "9c033072-5f94-4d79-af47-126d531f0d6e"
        ]
    },
    "17856e85-db4d-4f69-8267-1e7113101b01": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00281697",
        "Statement": "btk-targeting agent is any agent that targets  bruton's agammaglobulinemia tyrosine kinase (btk). a patient with a HER2-positive status can not take part in the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "00822101-fa21-4a26-bf45-3b1f535da005"
        ]
    },
    "a0c56690-346f-426c-a805-517325fad068": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00009945",
        "Statement": "trial summary group identifier is a character or string that represents a trial summary group. none of the individual adverse events in the primary trial affect more than 100 patients, in total less than 30 patients suffer adverse events.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "8648c7df-582a-42a9-9330-414b2430ac56"
        ]
    },
    "a0014c42-99e8-4bf3-b415-bc007d762f3c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00425854",
        "Secondary_id": "NCT01224678",
        "Statement": "the primary clinical trial categorically excludes those with markedly increased ejection fractions, but these patients can be deemed fit for the secondary clinical trial if they are older than 55 years.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "6b9162d0-0816-46d4-81af-c60028dcc63b"
        ]
    },
    "6cb09e45-5c8e-4fcc-8a32-ebc212eca56d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00063570",
        "Statement": "patients having a diagnosed malignant brain tumour are not acceptable for the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "62e449ad-16b3-479d-94a5-ffc435b5e99c"
        ]
    },
    "2679fe92-def8-40a7-a283-e7ff3c96bf00": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00503750",
        "Secondary_id": "NCT00005879",
        "Statement": "medium heart murmur is a heart murmur that occurs for a medium length of time after a valve closure sound. The results from the secondary trial and the primary trial can be compared by changing the units from days to months.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "7d52734c-0801-413d-9ae2-d190b972cde5"
        ]
    },
    "9c648e82-e641-4787-a377-50a399c47327": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01125566",
        "Statement": "having an ecog score of more than 2 is compulsory for participation in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "b2cdbcb8-de26-4a44-8a94-dd68c13f7e41"
        ]
    },
    "7c767090-9532-45dc-8a15-30948bac24d4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02658734",
        "Statement": "Most patients in the primary trial experienced a grade 1 adverse events, the least common severity was grade 5, which only affected 8/70 patients. patient did not have a safety follow up as required is an indication that a subject's safely follow up did not occur as required by the study protocol.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "40f699a1-fbc6-40de-8e80-85b28f71632f"
        ]
    },
    "19326824-329b-42b1-bc64-ea0fe58886c1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "in order to be eligible for the primary clinical trial, prospective patients must have their her2+ status verified and have an lvef at least at 50 percent",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "6b33b4ae-36f2-4a53-a954-6f246f6e023d"
        ]
    },
    "ec1e269e-470d-43d9-8f23-8a19a5c96fcc": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Statement": "Anaemia was the most common adverse event in cohort 1 of the primary trial and tachycardia was the most common in cohort 2",
        "Label": "Contradiction"
    },
    "d10cc0f8-e22c-4d89-80f0-3fa7a796e027": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00374322",
        "Statement": "cervical and lumbosacral spinal cord ependymal tumor is a finding indicating the presence of an ependymal tumor in the cervical and lumbosacral regions of spinal cord. 80% of patients in the primary trial received a placebo intervention.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "e147796d-2edd-42d1-ac53-300fb8bd5eb6"
        ]
    },
    "9b7557f6-e985-4dd5-87b1-1b855704ffab": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01929395",
        "Statement": "patients without any visible stomach or neck carcinomas can participate in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "79ca2ee8-6c9c-40e6-a87c-925b50d3d3d2"
        ]
    },
    "29562b81-d0ee-4073-a3c8-e45d98467a00": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Secondary_id": "NCT00121992",
        "Statement": "only one incident of conjunctivitis was identified in the secondary clinical trial, but no such case was identified in the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "a5617ae4-05a3-42d0-9e14-141de5f8c010"
        ]
    },
    "8c8b4511-eb40-4443-81bc-c3ad4ff78658": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03098550",
        "Statement": "the primary clinical trial comprises two cohorts that undergo identical interventions, where the distinction lies in the cancer types of the patients. cohort 1 is categorized as her2 positive cancer patients, and cohort 2 is pr-.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "3adcc8fc-b76b-407a-a006-729a13f571fb"
        ]
    },
    "f6f27dbf-3e5e-4cf5-8e9c-2f183067cf99": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "more total adverse events were observed in cohort 1 of the primary clinical trial than in cohort 2",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "1c4e3fe3-b5fe-4ea3-8d9e-0ce1502080e7"
        ]
    },
    "6aa76b24-a4eb-4831-99d0-0b45bdd7e75f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Secondary_id": "NCT00281697",
        "Statement": "a majority of participants in the secondary trial and the primary trial were diagnosed with enterocolitis.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "2ef186d0-b4ab-44de-b785-a63e9e95851a"
        ]
    },
    "e4724d4c-dbaf-4010-b308-38688790d27e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Secondary_id": "NCT00121992",
        "Statement": "both the primary and secondary trials reported multiple cases of conjunctivitis",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "a5617ae4-05a3-42d0-9e14-141de5f8c010"
        ]
    },
    "abaf724e-c962-42c5-8233-3ae526a9a4da": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "no cases of febrile neutropenia were reported during the course of the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "614d7ade-0fa7-4d77-bc19-1d3a2f2f48c2"
        ]
    },
    "5de2e33b-402d-4496-ad63-e9b05ca323f7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Secondary_id": "NCT00425854",
        "Statement": "the secondary trial utilises progression-free survival as its primary outcome measurement for interventions.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "402f0dbf-cf67-4425-b300-a0a3df4d59d3"
        ]
    },
    "d5258b52-b563-4e1a-8e0d-c3bb8e448001": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00570921",
        "Statement": "in the primary clinical trial, fulvestrant is delivered via an iv drip, while everolimus is administered via an intramuscular injection.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "32361e21-ee57-4c34-9390-833ba5048a10"
        ]
    },
    "da56d13b-0347-4968-bfdf-a7b77bf0d33d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00374322",
        "Statement": "700% of patients in the primary trial received a placebo intervention",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "e147796d-2edd-42d1-ac53-300fb8bd5eb6"
        ]
    },
    "794269ca-e7ec-4a65-ace5-b0f24a8cdc15": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Secondary_id": "NCT01644890",
        "Statement": "the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures PFS",
        "Label": "Entailment"
    },
    "a95fe8cf-74b3-4d1d-bed7-b183cf3727f0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01929395",
        "Statement": "patients with non-palpable carcinomas can participate in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "24b85b44-b9e6-4c28-b3aa-1bd97102b7f1"
        ]
    },
    "dbe5f0c4-9c1e-4cff-a9aa-9b5b23090d5f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01929395",
        "Statement": "the primary clinical trial requires patients to have a perceptible carcinoma for inclusion",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "24b85b44-b9e6-4c28-b3aa-1bd97102b7f1"
        ]
    },
    "115ad363-91ef-488c-ac13-ef1c033ee491": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "one of the interventions in the primary clinical trial resulted in an objective benefit for more than 60% of patients.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "75affd49-4905-4d43-9a5c-ef795281bac4"
        ]
    },
    "2015e7a7-70a1-46b5-a192-060190c59f36": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01998906",
        "Statement": "all groups in the primary clinical trial experience 17 complete cycles, with each cycle being 3 weeks long.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "43ce26e5-03fa-4e9d-b0eb-6ea356295753"
        ]
    },
    "7e0ac5fd-ea58-47e2-b49f-967799540177": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02658734",
        "Statement": "the majority of patients in the primary clinical trial faced a grade 1 adverse event while the least common severity, being grade 5, affected just 8 out of 70 individuals.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "40f699a1-fbc6-40de-8e80-85b28f71632f"
        ]
    },
    "0e05e8c3-1f00-4a31-a987-509d6dceeec6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Statement": "dedifferentiated lesion is a lesion composed of cells that have undergone transformation to less mature forms. Patients must have a Life expectancy of 75+ years to enroll in the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "4b97a844-8d52-48bb-8eda-ca205268f016"
        ]
    },
    "acccf00e-874d-4c26-8d1d-f64e82d9f686": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "the primary trial intervention protocol lasts a total of 20160 minutes",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "236780db-9e59-4dc9-8da0-e786287011cf"
        ]
    },
    "3ff08487-5043-455f-86e7-712d737808de": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00450723",
        "Statement": "The the primary trial intervention involves one drug taken orally and the secondary trial intervention is based on a medical procedure. biological aunt is a female relative who is a sibling of either of the biological parents, and who share a common ancestor.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "d310ec4e-993e-4827-8dc5-9aca053972db"
        ]
    },
    "d470d678-2b23-41c8-949b-fb8095352a94": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00357110",
        "Statement": "peritumoral route of administration is administration of a medicinal product directly into the region surrounding a tumor. there were 6 recorded deaths in cohort 1 of the primary trial and 7 in cohort 2.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "f114846e-79d8-4712-add0-bb34b65d418f"
        ]
    },
    "4f644e85-6431-4867-929b-7cdb2bd9c56e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00127933",
        "Statement": "the primary clinical trial specifically excludes participants who are 32 and 56 years old from eligibility",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "f0273b8c-460d-46fe-9c52-8ff4b08e439b"
        ]
    },
    "fb8fec1a-2851-4e09-a9d7-23620751eb92": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02131064",
        "Statement": "during the first segment of the primary clinical trial, there was an excess of 10 more cases of left ventricular dysfunction than abdominal pain",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "1329dec6-fb2c-4219-9db6-3fef9d94b316"
        ]
    },
    "24cfd5f8-588f-4d1c-a9ad-e0f39884052e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02915744",
        "Statement": "the primary trial and the secondary trial both record identical metrics in their results section",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "dd2f3c3d-fa95-4fca-a3f0-795fd4f3abf1"
        ]
    },
    "4928eade-ee0b-40dd-9827-55d4ec660c45": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00503750",
        "Secondary_id": "NCT00005879",
        "Statement": "the results across the primary clinical trial and the secondary clinical trial cannot be aligned as their units are recorded in seconds and decades respectively",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "7d52734c-0801-413d-9ae2-d190b972cde5"
        ]
    },
    "f80b2ad2-fcee-4fd4-9315-d049c1f44a3d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01416389",
        "Statement": "the primary trial reports the changes in the number of lesions for patients in its cohorts. deleterious grem1 gene mutation is a change in the nucleotide sequence of the grem1 gene that is associated with increased risk of disease.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "812bd63c-4bfb-49cb-8fa9-baa3f8f6dabe"
        ]
    },
    "3fd62b00-5145-4cbd-afe1-6ced2a75a63d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820222",
        "Statement": "retinopathy of prematurity finding is an ophthalmoscopic finding that refers to retinopathy of prematurity. the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher precentage of patients with Grade 3 or 4 skin/subcutaneous or pulmonary toxicities, than the Lapatinib Plus Capecitabine group.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "566bdc2d-7c4a-4547-87da-ac81447ecca8"
        ]
    },
    "f3cb9150-32c6-4877-9a87-4fac45a24948": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00450723",
        "Secondary_id": "NCT00290758",
        "Statement": "Between the secondary trial and the primary trial, all the recorded casesof Musculoskeletal adverse events occurred in cohort 2 of the secondary trial",
        "Label": "Contradiction"
    },
    "91028830-817a-4b4c-a125-aa463ffa9354": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00450723",
        "Secondary_id": "NCT00290758",
        "Statement": "in comparison to the primary trial, all reported cases of dyspnea were found in the first cohort of the secondary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "f04d9695-81b8-4d70-877b-59caddf901bd"
        ]
    },
    "4a41ac73-538a-43e5-b7ce-8c8e2d56286e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290758",
        "Secondary_id": "NCT02370238",
        "Statement": "Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial, unless they are recieiving adjuvant therapy.",
        "Label": "Contradiction"
    },
    "1b2a0ae3-f026-4777-8c8a-d2c6031877a4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00754325",
        "Statement": "a higher proportion of patients suffered Disease Progression or Death in cohort 2 of the primary trial than in cohort 1. lateral ventricle ependymal tumor is a finding indicating the presence of an ependymal tumor in a lateral ventricle of the brain.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "251a20d8-2555-4929-9d01-c02311bdc93f"
        ]
    },
    "ada93797-0bf8-493f-a19d-f0ee66279f65": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02131064",
        "Statement": "in cohort 1 of the primary clinical trial, there were no cases of left ventricular dysfunction",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "1329dec6-fb2c-4219-9db6-3fef9d94b316"
        ]
    },
    "530562e7-141f-4e85-90c1-8e69b4a7d168": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "patients wishing to participate in the primary clinical trial need to have a documented tnbc status and lvef level of at least 50%",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "9abb10d7-496e-44fd-915d-d86aedf6c9b6"
        ]
    },
    "127a2998-a45b-442a-ad88-5f3b38b73d6e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005879",
        "Statement": "cohort 2 of the primary clinical trial contained a significantly lower percentage of patients with slipped disks compared to cohort 1",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "ce8464bd-951e-44aa-97d9-10b917b055ce"
        ]
    },
    "8560b9a7-581c-4696-b4fa-6deeae73c2d4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Secondary_id": "NCT00325234",
        "Statement": "unilateral optic nerve hypoplasia is a congenital abnormality characterized by the underdevelopment of one optic nerve. There are more cases of Urosepsis in the primary trial than in the secondary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "7271e0db-bb82-423f-ad95-5ffa84fab97e"
        ]
    },
    "4a4ccce1-6431-4df7-8426-83fb75e7940c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01596751",
        "Statement": "patients with documented progressive breast cancer are required for participation in the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "bc2024fc-5b39-4fa6-badf-f034d6fe8bb8"
        ]
    },
    "3433100b-5ec5-4908-b377-702bb35ce5ca": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Secondary_id": "NCT01439945",
        "Statement": "story is a location comprising a single level of a multilevel building. There is one case of Diarrhea in the secondary trial and none in the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "bebfc78e-b35f-4677-8342-9567a7e795a1"
        ]
    },
    "7ebbf891-ce94-4add-91c1-871ca7dcb411": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Secondary_id": "NCT01439945",
        "Statement": "the primary clinical trial reports zero cases of diarrhea while the secondary clinical trial reports one.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "bebfc78e-b35f-4677-8342-9567a7e795a1"
        ]
    },
    "95214e57-14c6-4816-84a1-5c454cb4f656": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Secondary_id": "NCT00281697",
        "Statement": "a significant number of the participants in the secondary trial and the primary trial suffered from Enterocolitis. kilogram per mole is a unit of mass commonly used to express the molar mass of a substance in kilogram(s) per mole.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f"
        ]
    },
    "647035c0-77c0-4adb-b23b-218ee66e0ca9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT03176238",
        "Statement": "There less cases of Acute myocardial infarction, Cardiopulmonary failure and Supraventricular tachycardia in cohort 1 of the secondary trial than in cohort 2 of the primary trial. urinary system paraganglioma is an extra-adrenal paraganglioma that arises from the urinary system.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "080da381-b5dd-46d3-99c4-18112da153c1"
        ]
    },
    "66d64235-f9d0-4ad7-a1ce-23d01dd29a67": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02679755",
        "Statement": "in the primary clinical trial, more than one patient has been impacted by the individual aes recorded",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "f46a7d27-a94f-4389-a1a0-4a8f5177b354"
        ]
    },
    "cf99580d-feeb-4ea1-82a0-ffb96aa4ada6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01118624",
        "Statement": "the primary trial participants recieve less than 300,000\u00b5g/m^2 doses of pralatrexate",
        "Label": "Entailment",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "e9a4bd91-f58b-4234-9037-75e0699d1bbd"
        ]
    },
    "aacb7e7e-2d20-48ad-8db2-e3a4ecbf851e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "a patient with a node positive t20 n20 m0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of over 20cm",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "016943fa-57ea-4293-8131-03292ea1836c"
        ]
    },
    "eca8ba38-5f89-465e-bfe9-7fc0c4cd418b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01644890",
        "Statement": "air displacement agent is a gaseous substance used to replace air in product packaging. The shortest PFS in cohort 1 of the primary trial was 1.4 months below average.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "8c6314f7-34f5-42a7-ba66-b95d050a6315"
        ]
    },
    "d6b75b21-3e36-40a2-88e5-2e23436c87e1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820222",
        "Statement": "the primary clinical trial results reveal that the lapatinib plus capecitabine group had a higher percentage of patients with grade 3 or 4 skin/subcutaneous or pulmonary toxicities, compared to the trastuzumab plus capecitabine group.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "566bdc2d-7c4a-4547-87da-ac81447ecca8"
        ]
    },
    "8bc11552-6c0a-41ac-a7e5-fac99cdffd18": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232505",
        "Statement": "patients who have a definite histological diagnosis of stage i to iii breast cancer are not suitable for the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "75cf4ec2-9f2b-4d5b-8772-af247eaca07b"
        ]
    },
    "0dcff74d-96bd-42c4-a6de-48a4c386d1c8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00093795",
        "Statement": "none of the participants in cohort 1 and 2 of the primary clinical trial experienced disease recurrence, contralateral breast cancer, second primary cancer, or death from any cause prior to recurrence or second primary cancer",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "0ea29bd5-20be-40ea-8ad7-705d283d1d48"
        ]
    },
    "b56096c8-0c0c-4c47-bb9e-e5a68ada2055": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00066573",
        "Statement": "the divergences in the inferences from the two primary clinical trial cohorts are minimal",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "fe876bb0-7ce3-4197-81ad-920f1f77938e"
        ]
    },
    "c40fdf91-9f81-454a-bba9-ec5c950cef6e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00374322",
        "Statement": "One patient cohort in the primary trial received a placebo intervention",
        "Label": "Entailment"
    },
    "e20efea4-7199-48cb-8238-4a5fdd575556": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01581619",
        "Secondary_id": "NCT00106002",
        "Statement": "it's not possible to compare the results of the secondary clinical trial with those of the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "0a6d1b4c-244e-44e2-a229-62e4cbdfa979"
        ]
    },
    "c24af3ec-3903-43bb-b843-2ed5a7e44b02": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00856492",
        "Secondary_id": "NCT00009945",
        "Statement": "measurement of the pcr in the patient cohorts is not a common characteristic of both the primary and secondary clinical trials.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "42d1fcd3-8faa-4065-bbba-42cc90ab67fb"
        ]
    },
    "b0413781-ca30-4ba4-a5ba-ccd8307a8fd3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042938",
        "Statement": "in the primary clinical trial, the curcumin c3 complex group shows a noticeably higher severity of dermatitis in radiation treatment site than the group given a placebo.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "e62f5a3f-0091-4980-9822-db8f4dc2502a"
        ]
    },
    "1816d517-3caf-4415-b34d-b22606da617b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02924883",
        "Statement": "the eligibility for the primary clinical trial is exclusive to patients with her2+ breast cancer",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "446f3c69-0de5-475c-a8e2-ff40ece90672"
        ]
    },
    "044fd81e-4ff7-42a3-bed4-ac372e060d66": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00376597",
        "Statement": "Patients with stage 4 cancer are excluded from the primary trial. difficulty concentrating reading newspaper or watching television is a question about whether an individual has or had difficulty concentrating while reading a newspaper or watching the television.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "75a65913-5655-4377-b441-ecdd4dd75175"
        ]
    },
    "00033033-2c02-4a51-bffa-1b240b9cb52c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02924883",
        "Statement": "discrete set person name data type is a data type comprised of a collection of a discrete set of person names. Only patients with HER2+ve breast cancer are eligible for the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "446f3c69-0de5-475c-a8e2-ff40ece90672"
        ]
    },
    "844c2dbe-dfa9-48af-8aae-5c0f56aab6a4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00009945",
        "Statement": "over 300 patients experienced individual adverse events in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "1314146f-2869-4525-8034-7f732d238385"
        ]
    },
    "56be5668-34a8-41f0-b361-9d07f6b10f6e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00477464",
        "Statement": "participants in the primary clinical trial receive significantly lower doses of capecitabine compared to lapatinib.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "a3390ae6-d41d-4dc7-899e-de9534adfd6b"
        ]
    },
    "0fd4b575-560f-4e6e-8972-62fefb864858": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00376597",
        "Statement": "the primary clinical trial excludes patients that are diagnosed with stage 4 cancer",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "75a65913-5655-4377-b441-ecdd4dd75175"
        ]
    },
    "ec2eabec-93a4-45b3-acef-0f7f1cb1c630": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00570921",
        "Statement": "the primary trial participants are administered Fulvestrant intramuscularly (to the deltoid) and Everolimus orally. trouble swallowing is a question about whether an individual has or had trouble swallowing.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "32361e21-ee57-4c34-9390-833ba5048a10"
        ]
    },
    "1666ff6c-543a-47a8-b213-b2f039dbfc30": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00428922",
        "Statement": "the outcome measurement of the primary trial is The length of time during and after the treatment, that a patient lives with the disease but it does not get worse. familial hypertrophic cardiomyopathy type 3 is an autosomal dominant subtype of familial hypertrophic cardiomyopathy caused by mutation(s) in the tpm1 gene, encoding tropomyosin alpha-1 chain.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "d01fda83-5dc8-4ad5-92b8-7553dabd7046"
        ]
    },
    "e96955ce-a97a-4afa-95c0-422ce6c62f7a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00428922",
        "Statement": "the outcome measurement of the primary trial is The length of time during and after the treatment, that a patient lives with the disease but it does not get worse. for-profit corporation is an organization which aims to earn profit through its operations and is concerned with its own interests.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "d01fda83-5dc8-4ad5-92b8-7553dabd7046"
        ]
    },
    "52db6d97-285b-4524-893a-92988b81d7f1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Secondary_id": "NCT01644890",
        "Statement": "the main criteria of the primary clinical trial is the percentage of participants experiencing objective response, as opposed to the secondary clinical trial which measures participants count with disease progression or death.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "f42e1874-343a-43ed-bb0c-884509c4793c"
        ]
    },
    "5d452d0b-6e8b-42b4-a0bb-c03fbe201b91": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01581619",
        "Secondary_id": "NCT00106002",
        "Statement": "the results from the secondary trial differ in outcome measures when compared to findings from the primary trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "1180dd58-61b8-4c48-ab00-7d458e68c85b"
        ]
    },
    "9df97e04-3599-47d2-95fc-eeeb00811fb1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00428922",
        "Statement": "poems syndrome is a syndrome characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes.  it is often associated with osteosclerotic myeloma. the outcome measurement of the primary trial is The length of time during and after the treatment that a patient survives with the disease .",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "3facad41-0221-42f8-834d-470e65c4aad5"
        ]
    },
    "2d21e0da-ac39-4100-b47f-2258dfa96e3e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01581619",
        "Secondary_id": "NCT00106002",
        "Statement": "both the secondary clinical trial and the primary clinical trial yield the same outcome measures in their findings",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "1180dd58-61b8-4c48-ab00-7d458e68c85b"
        ]
    },
    "ffcca742-9df2-4a09-a88a-34c8ea799d2e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02419807",
        "Statement": "the primary clinical trial results section reports three different measurements, one for each cohort separately in the trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "d0b50aeb-aad8-4a8d-aae6-5c58a7d382c7"
        ]
    },
    "91a6d76e-6ae2-4c52-ae91-c7633fc366cc": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01042535",
        "Statement": "The most common adverse event in the primary trial was skin infection. randoms correction indicator is an indication as to whether the device was set to correct for random noise generated by deflected positrons.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "4f705481-5dd0-414c-b375-c56e8c235b42"
        ]
    },
    "d7fcb909-6b5e-4135-b15d-3e1a29fa3434": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01644890",
        "Statement": "map2k2 gene mutation is a change in the nucleotide sequence of the map2k2 gene. The shortest PFS in cohort 1 of the primary trial was 1.4 months below average.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "8c6314f7-34f5-42a7-ba66-b95d050a6315"
        ]
    },
    "15045f9f-5ad5-427c-9ad7-2b4c891b9499": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Secondary_id": "NCT00876395",
        "Statement": "locally advanced carcinoid tumor is a carcinoid tumor that has spread to nearby tissues or lymph nodes. Diarrhoea is the most common adverse event in the primary trial, and Anaemia is the most common in the secondary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "324562e6-2b61-4a07-b937-86f99689f2d5"
        ]
    },
    "ee010ba5-b10c-44fb-a867-abcc98ce0eae": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01998906",
        "Statement": "both cohorts of the primary trial undergo a total of 4 cycles, each lasting 1 week , patients receive the same types and dosages of medication throughout all 6 cycles",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "2a2c16a7-f427-4fdb-8153-94aac304e4b8"
        ]
    },
    "97303297-d143-43ee-bbb9-2d80ba1b5004": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00093795",
        "Statement": "in cohort 1 and 2 of the primary clinical trial, the incidences of disease recurrence, contralateral breast cancer, second primary cancer, or death from any cause prior to recurrence or second primary cancer were not reported",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "0ea29bd5-20be-40ea-8ad7-705d283d1d48"
        ]
    },
    "b9534165-9464-4b9a-b9ed-e3033bcfb411": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Secondary_id": "NCT01439945",
        "Statement": "the primary trial recorded multiple diarrhea cases, while the secondary clinical trial reported none",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "bebfc78e-b35f-4677-8342-9567a7e795a1"
        ]
    },
    "c321af19-ae90-4a9b-b3be-4d4083133874": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "to be eligible for the primary trial candidates must be over the age of 81, have a severe disability and adequate hepatic, renal and heart functions aswell as adequate hematology levels.",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "f45ff82d-e0f5-456a-9d78-ddc2dc6ab929"
        ]
    },
    "646d5ec2-5907-4c72-99f6-bc39eb278dcb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232505",
        "Statement": "the primary clinical trial accepts enrollees diagnosed with stage iii histologically proven breast cancer.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "75cf4ec2-9f2b-4d5b-8772-af247eaca07b"
        ]
    },
    "c2217d42-e90c-4ffe-b084-e653b9ace4d5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT00852930",
        "Statement": "the primary trial and the secondary trial do not record any cardiac or infection related adverse events, but they both record several instances of epilepsy",
        "Label": "Contradiction"
    },
    "44ca21fa-c30c-4e55-8d4f-25859a4da463": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00066573",
        "Statement": "there is a 86.8% difference between the results from the two the primary trial cohorts",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "1adc970c-d433-44d0-aa09-d3834986f7a2"
        ]
    },
    "a9bb6de9-c6f8-4c99-81cd-f101cbaab387": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "Patients must have no radiographically confirmed metastases to the brain in order to be eligible for the primary trial",
        "Label": "Contradiction"
    },
    "bc2024fc-5b39-4fa6-badf-f034d6fe8bb8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01596751",
        "Statement": "Breast cancer patients must have documented progressive disease to participate in the primary trial",
        "Label": "Entailment"
    },
    "9cdd0bcc-f0d3-43cc-9aa2-87b38fe4fe2e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01011946",
        "Secondary_id": "NCT00066573",
        "Statement": "the primary trial participants are not administered any oral medication whereas the secondary trial patients only receive treatment orally. grade 1 rectal adenocarcinoma is a rectal adenocarcinoma characterized by the presence of a malignant cellular infiltrate with more than 95% glandular formation.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "6402e13a-7cfb-4774-b7f9-80ecb79fda2a"
        ]
    },
    "e773e964-bf8f-4828-9149-82f29f84a98e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "performed clinical interpretation toxicity term code is a coded value specifying the degree to which a substance is able to damage an exposed organism. The most common AE in the primary trial was Non-cardiac chest pain, which affected less than 5% of participants in cohort 1.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "2da13cd4-7189-4f85-be4d-5c1e213ae293"
        ]
    },
    "398ada29-6f2d-4b76-aa5b-3bea079236bd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03098550",
        "Statement": "both cohorts of the primary trial receive identical interventions, the difference between the two cohorts is the types of cancer that the patients have. sputum cytology is an examination of cells obtained from a sample of sputum.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "b0b61978-57db-4a1c-812c-509e8b05f2dc"
        ]
    },
    "585be6e7-a45d-433d-8023-b30a0e97ac69": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00612560",
        "Secondary_id": "NCT01216176",
        "Statement": "low cardiac output is a below normal volume of blood pumped from the right or left ventricle of the heart per unit time. All the primary trial participants are administered flaxseed, but none of the secondary trial receive any flaxseed.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "b0046821-ba27-4a90-8869-cb708b843aa4"
        ]
    },
    "82db6bdd-0256-4772-8001-cb88ce8f4e1e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02419807",
        "Statement": "the primary clinical trial results section does not report any measurements",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "8b91cab9-d858-45f3-bf8d-3d6fc55b4818"
        ]
    },
    "5c3e96f6-760e-420e-95ac-633e4d3762e5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Statement": "in the primary clinical trial, neither group members are obliged to have surgery or any oral drug intake as part of the treatment process.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "63a0a9fc-80b9-450f-b2c6-7aee37ce26a9"
        ]
    },
    "c3ff2263-3af3-4bb8-802c-274bf388bfc8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "neither of the interventions in the primary trial resulted in an objective benefit for more than 2/5 of patients.",
        "Label": "Entailment",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "75affd49-4905-4d43-9a5c-ef795281bac4"
        ]
    },
    "8a86a67a-022d-4140-964e-4e9c98991245": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT00232505",
        "Statement": "patients in the primary clinical trial receive medication subcutaneously, while those in the secondary clinical trial are given medication intravenously",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "7edba90d-076d-4f55-b9d6-a1765ceb48bd"
        ]
    },
    "e6a4e9a6-56b8-4a30-9743-eb02688c090f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "A patient with a node positive T2 N2 M0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of 1.5cm",
        "Label": "Entailment"
    },
    "b8322b23-a4f6-4cba-9761-be826b509de7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01224678",
        "Secondary_id": "NCT01042535",
        "Statement": "There were more cases of Eye disorders, Abdominal pain, Febrile neutropenia and Anemia in the secondary trial than in the primary trial",
        "Label": "Entailment"
    },
    "aa2281af-1367-46c6-a1db-9fcaba5a0332": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00240071",
        "Statement": "f2 gene mutation is a change in the nucleotide sequence of the f2 gene. the primary trial participants receive more than one type of medication during the study.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "82a3e542-f784-44d7-90f6-34d7e969283c"
        ]
    },
    "e36544f5-a487-4629-b59d-695e71b67cec": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01118624",
        "Statement": "pralatrexate doses in the primary clinical trial range from 500mg/m^2 to 1000mg/m^2.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "e9a4bd91-f58b-4234-9037-75e0699d1bbd"
        ]
    },
    "e4bfdefc-f469-4a3a-892b-782e44b0db7a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting more than 5% of patients. fallopian tube squamous cell carcinoma is a rare squamous cell carcinoma that arises from the fallopian tube.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "1842904b-5371-49ee-b6f4-8831b879098b"
        ]
    },
    "78ffb4d9-0fb3-4f82-8aa7-ffc598129f08": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00754325",
        "Statement": "in the primary clinical trial, individuals who were administered fulvestrant had a higher tendency to experience disease progression or death compared to those given herceptin.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "ba9daeb9-796d-49ab-a30c-4d8acbdf4d37"
        ]
    },
    "b552dab9-37cf-4cce-95aa-e79603e05189": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00328783",
        "Statement": "invasive candidiasis is a fungal infection by any of the candida species in a sterile body compartment. The adverse events section in the primary trial is reports the incidence rate of 12 different Aes.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "97fd111c-6969-43ab-93af-b3dff09960e5"
        ]
    },
    "3cb71095-8e01-40dc-bbf5-eeffed55f354": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232505",
        "Statement": "Patients with Histologically confirmed breast cancer stage I-IV are not eligible for the primary trial",
        "Label": "Contradiction"
    },
    "4ac5f1bf-9829-4e8b-b6a9-b9a38002e1d7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00915603",
        "Statement": "none of the participants in the primary clinical trial achieved a progression-free survival of 10.8 months",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "47ba01d6-edc7-4acb-ab49-b0e86f4eeaf7"
        ]
    },
    "bb445f2b-992b-4062-aa27-bad468a5c3f6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02340221",
        "Statement": "previous administration of fulvestrant or a phosphatidylinositol 3-kinase (pi3k) inhibitor disqualifies a patient from participation in the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "6b35bc10-f591-4b84-abac-40a74be949fa"
        ]
    },
    "8c23dfa0-6319-4e1f-8b38-3c3134d95db3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00425854",
        "Secondary_id": "NCT01224678",
        "Statement": "patients with a normal ejection fraction are the primary target for the primary clinical trial, but are strictly disqualified from the secondary clinical trial if they are under 55 years of age",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "6b9162d0-0816-46d4-81af-c60028dcc63b"
        ]
    },
    "a52332bb-f21c-4d6c-a759-1d373b080cf2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00374322",
        "Statement": "placebo intervention was provided to 80% of the patients participating in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "e147796d-2edd-42d1-ac53-300fb8bd5eb6"
        ]
    },
    "80096fb9-9b4f-48fe-b25a-9c352e31216a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00009945",
        "Statement": "in the primary clinical trial, one adverse event alone impacted 200 patients.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "1314146f-2869-4525-8034-7f732d238385"
        ]
    },
    "2439b4bb-561f-435c-9f7a-23d913609984": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00503906",
        "Statement": "the intervention in the primary clinical trial will be administered for a continuous period of 34 days without any cycles.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "6499b181-7a23-4073-8459-ad46ff02b20f"
        ]
    },
    "b9491012-49ba-4eb1-8230-1966f54ea012": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "Patients with Extracranial metastases can be eligible for the primary trial",
        "Label": "Entailment"
    },
    "c08e2721-d4bd-4868-a5be-af95bde347e2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "a patient with a node positive t1 n1 m0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of 2 m",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "e6a4e9a6-56b8-4a30-9743-eb02688c090f"
        ]
    },
    "33462dcc-a666-4b29-bb4b-4461ef697f81": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT03176238",
        "Statement": "cohort 1 in the secondary clinical trial reports higher cases of acute myocardial infarction, cardiopulmonary failure, and supraventricular tachycardia vis-a-vis the total patient cohort in the primary clinical trial.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "5c975af8-6b7f-4a5d-b4a6-257c76763ce9"
        ]
    },
    "fc24384f-4c93-481f-8901-5b87e779c782": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00063570",
        "Statement": "primary clinical trial is open for those diagnosed with leukemia or lymphoma",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "015dd869-db90-45a9-a951-9dc7dc2b2e01"
        ]
    },
    "1b71fae0-eee8-429e-b7e5-f84757a08803": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00240071",
        "Statement": "participants in the primary clinical trial are provided with more than one kind of medication during the study period",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "82a3e542-f784-44d7-90f6-34d7e969283c"
        ]
    },
    "21ecd791-8343-4fd0-b9df-584a9b70c2c6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00127933",
        "Statement": "eliane is a 56 year old woman, and alex is a 32 year old man, both eliane and alex can both be eligible for the primary trial. deleterious atr gene mutation is a change in the nucleotide sequence of the atr gene that is associated with increased risk of disease.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "a792bbac-0e8a-4bf7-9cc5-56fad481e2fb"
        ]
    },
    "035c124e-1124-4aa0-8bc5-8fe197fda381": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT00232505",
        "Statement": "neither the primary clinical trial nor the secondary clinical trial involves the administration of medication via intravenous injection",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "7edba90d-076d-4f55-b9d6-a1765ceb48bd"
        ]
    },
    "4670b4b0-e1cd-42dd-8892-8426e2d1f678": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00450723",
        "Statement": "the intervention in the primary clinical trial involves taking a single drug orally, whereas the intervention in the secondary clinical trial is a medical procedure.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "d310ec4e-993e-4827-8dc5-9aca053972db"
        ]
    },
    "eb3a0096-2cb0-4edf-baa0-cf5ceb872630": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00856492",
        "Secondary_id": "NCT00009945",
        "Statement": "the primary clinical trial only measures the overall survival rate of its patients, while the secondary clinical trial focuses only on patient reported outcomes.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "70677d5f-7022-404c-8410-d1f89366d92f"
        ]
    },
    "53b20646-1508-4cc8-9278-238b370d92a0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Secondary_id": "NCT00876395",
        "Statement": "constipation is the most commonly reported side effect in the primary clinical trial and the secondary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "eb1bfb08-eba0-4130-b328-00f56c0f84a6"
        ]
    },
    "c7103b09-ce4e-4576-ab39-eeccbbcf3b1b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00240071",
        "Statement": "the protocol of the primary clinical trial involves administering only one type of medicine to its participants.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "82a3e542-f784-44d7-90f6-34d7e969283c"
        ]
    },
    "533242e5-64f1-4d67-b04f-595de62b7d3a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00477464",
        "Statement": "in the primary clinical trial, the dosage of capecitabine is intentionally prescribed lower than lapatinib.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "a3390ae6-d41d-4dc7-899e-de9534adfd6b"
        ]
    },
    "e6eee476-a9f8-4976-a3d7-5ef925049523": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00503906",
        "Statement": "participants in the primary clinical trial will not be given any intervention.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "6499b181-7a23-4073-8459-ad46ff02b20f"
        ]
    },
    "8e491376-6029-43d2-aca5-2beed9aaab93": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02658734",
        "Statement": "jeb regimen is a regimen consisting of bleomycin, etoposide and carboplatin used to treat advanced-stage ovarian and testicular germ-cell tumors in children. Most patients in the primary trial experienced a grade 1 adverse events, the least common severity was grade 4.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "878c09e7-3fd9-404e-921e-5b549e9578fb"
        ]
    },
    "7478dd00-89a1-44ef-9d12-ca3b96eac2c1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Secondary_id": "NCT03098550",
        "Statement": "all participants in the primary clinical trial are required to have stage 2 cervical cancer with histological confirmation. however, for admission into the secondary clinical trial, a specific diagnosis of stage 3 pancreatic cancer is mandatory",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "7f3fe97e-68ee-470f-b06e-21cdddb67aa8"
        ]
    },
    "d30d20f9-4ef9-4d5b-8edc-142a25e9b275": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "some of the patients in the primary clinical trial showed no change in the sum of the longest diameter of target lesions.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "985bc5a0-bc21-447f-92f1-150e23ede3f5"
        ]
    },
    "c4eedf9f-0765-40cf-ae6b-ad8b4946c214": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02679755",
        "Statement": "in the primary clinical trial, none of the individual adverse events recorded impact more than 10% of the participants.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "c09fa61c-967a-40ae-96b0-c87b7cde237b"
        ]
    },
    "1d041ae1-d35c-4506-a5e1-e717776ce5e1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572727",
        "Secondary_id": "NCT00328783",
        "Statement": "the dosage of bkm120 administered to patients in the primary clinical trial exceeds that given to patients in the secondary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "51be7c95-8da4-419c-950c-91ebdd2c3fe5"
        ]
    },
    "5bff6024-f266-4eff-88b0-707fabb3ae92": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "simtrazene is a tetrazene derivative with carcinostatic activity, but lacks measurable bone marrow destruction in animal models. Patients wanting to take part in the primary trial must have a Known and documented HER2+ status and an LVEF of at least 50 percent (%).",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "6b33b4ae-36f2-4a53-a954-6f246f6e023d"
        ]
    },
    "8adee6df-ea11-49a9-b05a-6324c2321e40": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00093795",
        "Statement": "the majority of participants in cohort 1 and 2 of the primary trial achieved Disease-free Survival for 5 years. milligram per square meter per week is a dose calculation unit expressed in milligram(s) per square meter per period of time equal to seven days.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "2729a321-709b-4392-9604-dd7237bedb17"
        ]
    },
    "7ce3e54b-bcf1-474b-b966-b47343d2fee5": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Secondary_id": "NCT00425854",
        "Statement": "the secondary trial and the primary trial use Objective Response as the outcome measurement for their interventions. . acute promyelocytic leukemia in remission is acute promyelocytic leukemia not growing; responding to treatment.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "402f0dbf-cf67-4425-b300-a0a3df4d59d3"
        ]
    },
    "dd29a281-8b9c-4a36-b85e-f31693304b3d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Secondary_id": "NCT00281697",
        "Statement": "apache ii - arterial ph is acute physiology and chronic health evaluation ii (apache ii) arterial ph (preferred). a significant number of the participants in the secondary trial and the primary trial suffered from Enterocolitis.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f"
        ]
    },
    "f365aaf4-9986-4200-9101-004e0717d457": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00425854",
        "Secondary_id": "NCT01224678",
        "Statement": "patients with significantly elevated ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 6600 weeks of age or over",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "6b9162d0-0816-46d4-81af-c60028dcc63b"
        ]
    },
    "00759658-92e7-4d65-9411-eeb335bd0ea7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Statement": "prior endocrine therapy for breast cancer has been administered to all pregnant patients participating in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "b1d28450-fc7d-496a-9c7c-bf711b28f8e4"
        ]
    },
    "668a1c98-e025-4320-9c87-6fa24594b535": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01416389",
        "Statement": "delusions, ctcae is a disorder characterized by false personal beliefs held contrary to reality, despite contradictory evidence and common sense. the primary trial reports the changes in the number of lesions for patients in its cohorts.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "812bd63c-4bfb-49cb-8fa9-baa3f8f6dabe"
        ]
    },
    "0162a7b2-db19-4dd1-8854-bc6d0f0d60c4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00570921",
        "Statement": "the primary clinical trial participants are administered fulvestrant orally and everolimus by a subcutaneous injection",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "45ccd2c8-6e02-4f0f-a370-eed18d26e6dc"
        ]
    },
    "55a7df80-791c-4681-a375-0439019a7540": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "those desiring to participate in the primary clinical trial must have a confirmed her2+ status and their lvef measurement must be no less than 50 percent",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "6b33b4ae-36f2-4a53-a954-6f246f6e023d"
        ]
    },
    "764b7162-4000-4a8e-98d3-ecd21f03be97": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "patients wanting to take part in the primary trial must have a known and documented tnbc status and an lvef of at least 200 percent (%)",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "9abb10d7-496e-44fd-915d-d86aedf6c9b6"
        ]
    },
    "5b56c5d3-a22d-46d1-88bf-2c7623ab5404": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "Patients wanting to take part in the primary trial must have a Known and documented HER2+ status and an LVEF of at least 50 percent (%). fms-like tyrosine kinase 3 ligand measurement is a measurement of the fms-like tyrosine kinase 3 ligand in a sample.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "6b33b4ae-36f2-4a53-a954-6f246f6e023d"
        ]
    },
    "9165bbad-b621-4001-bbac-0d310e2372eb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00127933",
        "Statement": "urologist 1 is an urologist performing the assessment who is given the designation of one. eliane is a 56 year old woman, and alex is a 32 year old man, both eliane and alex can both be eligible for the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "a792bbac-0e8a-4bf7-9cc5-56fad481e2fb"
        ]
    },
    "6b362026-02b7-48b4-8188-adcd422d24f8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "neither of the interventions in the primary trial resulted in an objective benefit for more than 0.4 of patients, in fact over 86% of patients receiving the docetaxel then liposomal doxorubicin intervention suffered fatal complications",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "74e376d7-5713-43f3-93f1-9608059c9547"
        ]
    },
    "dc20aa24-8e67-43e3-8cc3-8a0fe515e3e7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Secondary_id": "NCT00274469",
        "Statement": "the eligibility for both the primary and secondary clinical trials is restricted to female patients with a confirmed diagnosis of late-stage breast cancer",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "68379456-775b-463b-bfdb-d8aa42c9124b"
        ]
    },
    "cfc5e853-300d-45d2-98cc-7fee1d034eb8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "the most common adverse event in the primary clinical trial was febrile neutropenia, which had affected beyond 5% of the patients",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "1842904b-5371-49ee-b6f4-8831b879098b"
        ]
    },
    "b5156ead-ec87-4279-ae8d-c9fc8abf25cc": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00328783",
        "Statement": "The adverse events section in the primary trial is reports the incidence rate of 12 different Aes. hole is an aperture or hollow space within a solid mass",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "97fd111c-6969-43ab-93af-b3dff09960e5"
        ]
    },
    "ad43da60-7331-4b1d-995a-5624f25814a0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Statement": "every participant in the primary clinical trial has previously received endocrine therapy as a part of their breast cancer treatment",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "6d621974-c719-46df-8a50-d94e49583e33"
        ]
    },
    "f4b0d0bf-0f61-46f2-9c68-290fc1f77b4c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "febrile neutropenia was the most common adverse event recorded in the primary trial, affecting less than 1% of patients",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "1842904b-5371-49ee-b6f4-8831b879098b"
        ]
    },
    "90be82d6-1799-4e3f-8fea-a064956b4816": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00331630",
        "Statement": "bowel-related adverse events became evident in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "553f00ea-5197-4233-b1e0-e5727856b599"
        ]
    },
    "649aaa26-951d-4682-8919-c0be232c5a45": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00503750",
        "Secondary_id": "NCT00005879",
        "Statement": "the primary clinical trial and the secondary clinical trial produce identical results",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "dca4c9f7-bb2a-4f73-b390-93b7ced87c73"
        ]
    },
    "fef9e623-5ea2-4fae-a2f8-278a27baa6e8": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02915744",
        "Statement": "both the primary clinical trial and the secondary clinical trial don't match in the type of metrics they record in their results",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "dd2f3c3d-fa95-4fca-a3f0-795fd4f3abf1"
        ]
    },
    "a67303fe-bccd-4b63-b9b6-a0f03a01b4dd": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01262027",
        "Secondary_id": "NCT02301988",
        "Statement": "the outcome measurements used in both the primary clinical trial and the secondary clinical trial are identical",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "f2275929-7cfe-4bb1-a9f6-6bd0c4d5bf85"
        ]
    },
    "3a3988a3-2b1c-4d88-9a40-03b1cca28724": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "infiltrating bladder urothelial carcinoma, plasmacytoid variant is a variant of infiltrating bladder urothelial carcinoma. it is characterized by plasmacytoid-like features. All patients in cohort 1 of the primary trial had a PFS of over 8.8 months, with the highest PFS being just under 10 months.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "b9e29ea8-6847-40d4-b5c3-81c496101695"
        ]
    },
    "77c8fb3d-0317-4a4d-94ab-6ceacfbc4a65": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00425854",
        "Secondary_id": "NCT01224678",
        "Statement": "patients with low ejection fraction and under the age of 55 are directly eligible for the primary clinical trial, but are blanket excluded from the secondary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "6b9162d0-0816-46d4-81af-c60028dcc63b"
        ]
    },
    "9b24c516-6bd0-4a26-a6ae-58c1da647626": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02915744",
        "Statement": "the secondary trial and the primary trial do not record the same metrics in their results section. extent have felt ill is a question about the extent to which an individual feels or felt ill.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "dd2f3c3d-fa95-4fca-a3f0-795fd4f3abf1"
        ]
    },
    "0cef8c8e-7986-46c7-a597-c5733a9899c0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00915603",
        "Statement": "the shortest PFS in cohort 1 of the primary trial was under 7 months, in cohort 2 the shortest was just over 7 months",
        "Label": "Contradiction"
    },
    "d8f7f179-4f56-4cf6-84bc-8bc67f834b6c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572727",
        "Secondary_id": "NCT00328783",
        "Statement": "all patients in the secondary trial receive higher doses of bkm120 than patients in the primary trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "51be7c95-8da4-419c-950c-91ebdd2c3fe5"
        ]
    },
    "7640d604-f615-4c0e-988b-d580187b8ae5": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Secondary_id": "NCT00425854",
        "Statement": "although the primary clinical trial and the secondary clinical trial both employ objective response to track therapeutic outcomes, they disagree on the definition of a total response",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "8d9f94e3-871b-4fb4-a522-0a73d9d0ec3c"
        ]
    },
    "15f4257f-ad84-4555-a653-02c9fed0b28f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Statement": "at least one cohort in the primary clinical trial will undergo surgical intervention as part of the trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "0a079cca-abde-42cf-9cec-a76e7a380e14"
        ]
    },
    "e3e9cbba-af65-48ed-b4be-2e8bdf53f5ae": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01998906",
        "Statement": "in the primary clinical trial, participants are subject to 14 cycles with each extending to 4 weeks.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "43ce26e5-03fa-4e9d-b0eb-6ea356295753"
        ]
    },
    "c16d10c2-8413-4fae-9698-740ffd1feb2a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00915603",
        "Statement": "exactly one participant in each cohort of the primary clinical trial had a progression-free survival time of 9 months",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "47ba01d6-edc7-4acb-ab49-b0e86f4eeaf7"
        ]
    },
    "581275d5-a79d-488a-a987-2eabc6a247b9": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "A patient with a node positive T2 N2 M0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of 1.5cm. eighteen is a natural number greater than seventeen and less than nineteen and the quantity that it denotes.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "e6a4e9a6-56b8-4a30-9743-eb02688c090f"
        ]
    },
    "9abb10d7-496e-44fd-915d-d86aedf6c9b6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "Patients wanting to take part in the primary trial must have a Known and documented TNBC status and an LVEF of at least 50 percent (%)",
        "Label": "Contradiction"
    },
    "ed0b067e-79d5-49e0-ace7-012f52a786f0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00428922",
        "Statement": "the outcome measurement of the primary clinical trial is the reduction in size of tumor after treatment",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "d01fda83-5dc8-4ad5-92b8-7553dabd7046"
        ]
    },
    "e92a67a5-a2df-4bbc-add2-6245cc830ce6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Statement": "participants of the primary clinical trial are not required to take any flucytosine treatments prior to study commencement",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "565d7982-aa9a-4c01-987c-1d67bc9c212d"
        ]
    },
    "a3390ae6-d41d-4dc7-899e-de9534adfd6b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00477464",
        "Statement": "the primary trial participants receive significantly higher doses of Capecitabine than of Lapatinib",
        "Label": "Entailment"
    },
    "b0139564-63e3-4d65-a6e5-0f242bb08929": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01118624",
        "Statement": "the primary clinical trial administers a fixed dosage of pralatrexate to all participants, irrespective of their bodyweight.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "0ddb07ae-6e70-436d-8723-f609e59c57da"
        ]
    },
    "94ddaa37-2102-487a-9013-66e47cac6eca": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "lead site av6 is an augmented unipolar lead placed at the sixth intercostal space on the midaxillary line. All patients in cohort 1 of the primary trial had a PFS of over 8.8 months, with the highest PFS being just under 10 months.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "b9e29ea8-6847-40d4-b5c3-81c496101695"
        ]
    },
    "07c477ca-5e72-4007-bf5c-860391043dbc": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572727",
        "Secondary_id": "NCT00328783",
        "Statement": "All patients in the primary trial receive higher doses of Paclitaxel than patients in the secondary trial. lumbosacral lipoma is a benign well-circumscribed tumor, composed of lobules of mature adipocytes, that arises within the lumbosacral tissue of the spine.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "3ba42f68-a643-4d10-afd0-cbb358d05a6f"
        ]
    },
    "0898bbef-0c0b-45b0-9ca1-d939e0bf0c57": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT03176238",
        "Statement": "There more cases of Acute myocardial infarction, Cardiopulmonary failure and Supraventricular tachycardia in cohort 1 of the secondary trial than in the entire patient cohort of the primary trial. posterior annular ligament is a ligament that surrounds the head of the radius.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "5c975af8-6b7f-4a5d-b4a6-257c76763ce9"
        ]
    },
    "ce22f005-351b-420e-a953-70b7f7cb913e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "both interventions in the primary clinical trial led to an objective benefit for 50% of participating patients.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "75affd49-4905-4d43-9a5c-ef795281bac4"
        ]
    },
    "929e25d4-5774-49be-a58d-648505ecf5ec": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00093795",
        "Statement": "the participants in cohort 1 and 2 of the primary clinical trial remained free from disease recurrence, contralateral breast cancer, second primary cancer, or death from any cause prior to recurrence or second primary cancer",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "0ea29bd5-20be-40ea-8ad7-705d283d1d48"
        ]
    },
    "18ea06c5-5b3b-4f15-a1b5-d60dcff07ca8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "a patient with a node positive t1 n1 m0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of over 1 meter",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "016943fa-57ea-4293-8131-03292ea1836c"
        ]
    },
    "5bbfc8c4-e247-4578-bb09-dc964009e669": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00333775",
        "Statement": "both the primary trial cohorts receive identical doses of Docetaxel, with cohort 1 also receiving 100 mg/m^2 of Placebo. grade 1 hemorrhoids, ctcae is asymptomatic; clinical or diagnostic observations only; intervention not indicated",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "a5e388b9-da3c-437e-a6af-7ba76ad8bf1d"
        ]
    },
    "db4e4601-5042-4894-b49d-83f2b2e4ab48": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01596751",
        "Statement": "Breast cancer patients must have documented stable disease to participate in the primary trial. benign diencephalic neoplasm is a benign neoplasm of the diencephalon.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "89f610a7-9e81-43a4-8c1e-5503233b2be1"
        ]
    },
    "3ba42f68-a643-4d10-afd0-cbb358d05a6f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572727",
        "Secondary_id": "NCT00328783",
        "Statement": "All patients in the primary trial receive higher doses of Paclitaxel than patients in the secondary trial",
        "Label": "Entailment"
    },
    "27005d46-555b-4437-a2b3-64f5c43976ef": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00333775",
        "Statement": "in the primary clinical trial, cohort 1 receives a lower dose of docetaxel compared to cohort 2, and no placebo is administered.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "a5e388b9-da3c-437e-a6af-7ba76ad8bf1d"
        ]
    },
    "7137dec6-5c98-4156-8035-7bbaaf0b649d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01125566",
        "Statement": "ECOG score < 2 is necessary to be eligible for the primary trial",
        "Label": "Entailment"
    },
    "5ade8efb-305b-46a3-990a-c1646872a738": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00374322",
        "Statement": "6p22 is a chromosome band present on 6p One patient cohort in the primary trial received a placebo intervention.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "c40fdf91-9f81-454a-bba9-ec5c950cef6e"
        ]
    },
    "b4ffc854-6424-4615-971d-9c1353f74ee0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00331630",
        "Statement": "in the primary clinical trial, no harmful incidents related to the heart or bowel were recorded.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "553f00ea-5197-4233-b1e0-e5727856b599"
        ]
    },
    "913d959a-c715-40bc-8d6e-843b1c8b9902": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Secondary_id": "NCT01644890",
        "Statement": "the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures Number of Participants With Disease Progression (PD) or Death. 3' flank mutation is any gene mutation that occurs in the sequences downstream from a coding region of interest.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "f42e1874-343a-43ed-bb0c-884509c4793c"
        ]
    },
    "a81ead45-34d1-415b-8bc3-8d81f24889eb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Statement": "dental retraction is a posterior movement of teeth. the primary trial reports the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer 0 side effects.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "cdadcb0a-20c5-47f7-a63a-39f5c6f26ae2"
        ]
    },
    "4a92e073-a70b-4914-928b-ae3425ab4f9a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "having confirmed radiographic evidence of brain metastases does not disqualify a patient from the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "a9bb6de9-c6f8-4c99-81cd-f101cbaab387"
        ]
    },
    "31105b43-832b-48bc-a78d-ee90c155ca44": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "Presence of hot flashes for  30 days prior to study registration is required for all patients that want to participate in the primary trial, but not necessary for entry to the secondary trial.",
        "Label": "Entailment"
    },
    "4aed7f2d-18ea-464b-9f3d-db969c827924": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Secondary_id": "NCT01439945",
        "Statement": "the secondary trial has numerous instances of diarrhea recorded, whereas the primary trial has just a single type of ae recorded in its cohorts.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "4519d1cf-7f78-4aa8-85d6-ac94f7eb75a3"
        ]
    },
    "e8ab21c2-6d1b-4467-9f92-c1d53dcad932": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01042535",
        "Statement": "the most frequent adverse event in the primary clinical trial was constipation",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "16c29502-4683-4087-9410-ff1b786556f5"
        ]
    },
    "2a7ea888-f68b-4049-a576-b06f9ee22f56": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00944047",
        "Statement": "less than 25% of the patients in the intervention arm of the primary clinical trial experienced pathologic complete response.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "48f516ff-abb4-4312-9b00-02f53fb16218"
        ]
    },
    "c63d2051-c0dc-444c-a80f-ed14177b7a44": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00606931",
        "Statement": "in the primary clinical trial, the section on adverse events details the count of participants who experienced hypotension, hemorrhage, and bradycardia during the research period",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "175044aa-72b1-405d-8506-30002f5098e4"
        ]
    },
    "7c7418d2-32d7-4517-874b-eb3db24ea16a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "to be eligible for the primary trial candidates must be over the age of 18, have a Karnofsky score over 80 and Adequate hepatic, renal and heart functions aswell as Adequate hematology levels.",
        "Label": "Entailment"
    },
    "dfa26b9d-b90a-40f5-b985-2c8156842e36": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00333775",
        "Statement": "rat neuroblastoma is a tumor of the rat that arises from nerve tissue outside of the central nervous system. both the primary trial cohorts receive identical doses of Docetaxel .",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "9bcc31df-c1f6-4785-9235-f673213acf3a"
        ]
    },
    "2513280e-067f-4047-9d9d-f1612528d440": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00900627",
        "Statement": "less than 1% of cohort 2 patients in the primary clinical trial reported experiencing keratitis.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "09fc4356-6154-427e-b710-ed5df6470aff"
        ]
    },
    "f262bb2e-0985-4900-ab51-297fcf32b9c4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01998906",
        "Statement": "both cohorts of the primary trial undergo a total of 2 cycles, each lasting 10 weeks.",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "43ce26e5-03fa-4e9d-b0eb-6ea356295753"
        ]
    },
    "20394124-c7e7-4cbf-add4-2487ab191c10": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274469",
        "Statement": "patients diagnosed with hormone receptor negative early stage breast cancer are eligible for the primary clinical trial, regardless of their previous treatment history.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "2e76c74a-b6dd-47d8-a674-c1e80b0a3a65"
        ]
    },
    "dcbb7c7e-d360-4753-a81b-dd0ca45b0000": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Secondary_id": "NCT00325234",
        "Statement": "a greater number of holocraneal cephale and catheter-related infections cases are being observed in the primary clinical trial as opposed to the secondary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "9c033072-5f94-4d79-af47-126d531f0d6e"
        ]
    },
    "614d7ade-0fa7-4d77-bc19-1d3a2f2f48c2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting most patients in the trial",
        "Label": "Contradiction"
    },
    "4e151b90-d6af-464c-81aa-6b1b7b0a6537": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Secondary_id": "NCT00281697",
        "Statement": "the majority of participants in both the secondary clinical trial and the primary clinical trial did not experience enterocolitis",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "2ef186d0-b4ab-44de-b785-a63e9e95851a"
        ]
    },
    "c7a765c7-11da-4db2-a430-aef43407fcb8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00612560",
        "Secondary_id": "NCT01216176",
        "Statement": "while all participants from the primary clinical trial are provided with flaxseed, none from the secondary clinical trial are given any",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "b0046821-ba27-4a90-8869-cb708b843aa4"
        ]
    },
    "426dc8c4-a5b6-4122-b7f8-4e611b3e6576": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "normal range comparison result is a value that specifies the relationship of a value to a normal range or reference range of values. neither of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "75affd49-4905-4d43-9a5c-ef795281bac4"
        ]
    },
    "20bba0f7-0fa1-4fcd-a25a-f90718de68fe": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01644890",
        "Statement": "The shortest PFS in cohort 1 of the primary trial was less than 3 weeks. refractory malignant solid neoplasm is a malignant solid neoplasm that does not respond to treatment.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "961a956e-fece-4baa-a2ad-d3a5320bd9d2"
        ]
    },
    "a80eaac1-7755-4d45-b006-7e72fd7189b8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00022516",
        "Statement": "the primary clinical trial allows t4 n2 m4 patients to be eligible",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "4a75574c-fa86-4e62-a210-81c7b98a3807"
        ]
    },
    "c9c694cb-b9d3-48f0-bd7c-d80aeea853d8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Secondary_id": "NCT01439945",
        "Statement": "both primary and secondary clinical trials have yielded an identical number of aes and both noted a significant number of diarrhea cases in their cohorts.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "4519d1cf-7f78-4aa8-85d6-ac94f7eb75a3"
        ]
    },
    "4d9435ab-d12b-408a-9b77-5dcf6b752b41": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "the primary trial intervention protocol lasts a total of 167 days",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "236780db-9e59-4dc9-8da0-e786287011cf"
        ]
    },
    "2cb59db5-0c3e-4839-944a-ed006c0824d7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Secondary_id": "NCT00274469",
        "Statement": "Patients must be female and have confirmed advanced breast cancer to be eligible for the secondary trial and the primary trial. malignant uveal neoplasm is a primary or metastatic malignant neoplasm that affects the choroid, ciliary body, or iris.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "68379456-775b-463b-bfdb-d8aa42c9124b"
        ]
    },
    "9e3d9284-e313-4b88-95b0-4a73df8ea72b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Statement": "grade 2 malabsorption, ctcae is altered diet; oral intervention indicated neither of the cohorts in the primary trial are required to undergo surgery or receive any oral medication as part of the intervention.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "63a0a9fc-80b9-450f-b2c6-7aee37ce26a9"
        ]
    },
    "e7b271a8-3ac2-48d5-a836-717f174c74c4": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00856492",
        "Secondary_id": "NCT00009945",
        "Statement": "the primary clinical trial and the secondary clinical trial both observe and record the pcr of their patient cohorts.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "42d1fcd3-8faa-4065-bbba-42cc90ab67fb"
        ]
    },
    "9258e53e-ea6a-40d1-b382-672666ee019a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00900627",
        "Statement": "in the primary clinical trial, keratitis was experienced by 50% of patients from cohort 2",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "09fc4356-6154-427e-b710-ed5df6470aff"
        ]
    },
    "450869b5-d0b3-4c8f-baf4-d7b22707d07b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT03176238",
        "Statement": "communication contact is a channel for communication between groups. There less cases of Acute myocardial infarction, Cardiopulmonary failure and Supraventricular tachycardia in cohort 1 of the secondary trial than in cohort 2 of the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "080da381-b5dd-46d3-99c4-18112da153c1"
        ]
    },
    "9b3f1e4b-de13-4200-b470-bac4d3024dcc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274469",
        "Statement": "7p14-p13 is a chromosome band present on 7p to be eligible for the primary trial patients must be diagnosed with hormone receptor positive advanced breast cancer, and have received prior chemotherapy for this cancer.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "2e76c74a-b6dd-47d8-a674-c1e80b0a3a65"
        ]
    },
    "510b1a91-444f-45b5-a540-0b3a05bebae7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00612560",
        "Secondary_id": "NCT01216176",
        "Statement": "All the primary trial participants are administered flaxseed, but none of the secondary trial receive any flaxseed. deleterious atr gene mutation is a change in the nucleotide sequence of the atr gene that is associated with increased risk of disease.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "b0046821-ba27-4a90-8869-cb708b843aa4"
        ]
    },
    "a97a5479-682a-4474-bebb-25addfd0a56a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00333775",
        "Statement": "both the primary trial cohorts receive identical doses of Docetaxel . 8q13-qter is a chromosome band present on 8q",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "9bcc31df-c1f6-4785-9235-f673213acf3a"
        ]
    },
    "c100a7cd-e3a2-4901-a3e0-12336f769c7b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Secondary_id": "NCT00121992",
        "Statement": "the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial reported 16",
        "Label": "Contradiction"
    },
    "ab0f604e-59ef-47b6-89b9-fcf942cf5c24": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02419807",
        "Statement": "tumor-infiltrating follicular helper t cell is a follicular helper t cell that has migrated into a tumor. The the primary trial results section reports two different measurements.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "8b91cab9-d858-45f3-bf8d-3d6fc55b4818"
        ]
    },
    "24b85b44-b9e6-4c28-b3aa-1bd97102b7f1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01929395",
        "Statement": "Patients must have a palpable carcinoma to be included in the primary trial",
        "Label": "Entailment"
    },
    "a5617ae4-05a3-42d0-9e14-141de5f8c010": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Secondary_id": "NCT00121992",
        "Statement": "the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial did not report any",
        "Label": "Entailment"
    },
    "b1140b07-2d74-49ed-afd4-8c62a76f15d3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290758",
        "Secondary_id": "NCT02370238",
        "Statement": "neither the primary nor secondary clinical trials accept women currently receiving endocrine therapy, unless the treatment being received is adjuvant.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "4a41ac73-538a-43e5-b7ce-8c8e2d56286e"
        ]
    },
    "3771169a-e0ba-47c7-8114-28e7a7b10690": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Secondary_id": "NCT00425854",
        "Statement": "both the primary clinical trial and the secondary clinical trial use overall survival instead of objective response as the outcome measurement for their interventions.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "402f0dbf-cf67-4425-b300-a0a3df4d59d3"
        ]
    },
    "390a40d3-bc67-43cd-a57c-20a4fe7b08fe": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Statement": "patients with a life expectancy of less than 75 years are eligible for the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "4b97a844-8d52-48bb-8eda-ca205268f016"
        ]
    },
    "ded8e70d-2d9b-438e-873e-5f69b3683e72": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Secondary_id": "NCT00121992",
        "Statement": "neither the primary nor the secondary trial reported any cases of conjunctivitis",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "a5617ae4-05a3-42d0-9e14-141de5f8c010"
        ]
    },
    "4afcfae4-3f6e-4519-8a2a-f364493cadea": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01929395",
        "Statement": "nras gene mutation negative is a genetic finding indicating that nras gene mutations have not been detected in a sample. Patients must have several visible carcinomas in the stomach and neck areas to be included in the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "79ca2ee8-6c9c-40e6-a87c-925b50d3d3d2"
        ]
    },
    "7f3fe97e-68ee-470f-b06e-21cdddb67aa8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Secondary_id": "NCT03098550",
        "Statement": "all participants of the primary trial have stage 3 cytologically confirmed invasive breast cancer, there is no specific stage of cancer required for entry to the secondary trial",
        "Label": "Contradiction"
    },
    "2b721a87-08f3-4c17-be24-00b44c18a650": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02679755",
        "Statement": "no individual adverse event recorded affects more than 10% of the population in the primary clinical trial.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "c09fa61c-967a-40ae-96b0-c87b7cde237b"
        ]
    },
    "e8783516-cb73-40da-8063-d8dfefb81168": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00503906",
        "Statement": "participants in the primary clinical trial are scheduled to undergo the intervention for twelve 28-day cycles",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "6499b181-7a23-4073-8459-ad46ff02b20f"
        ]
    },
    "58b6577d-7414-4ac8-a376-ff3a7d046d68": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00503906",
        "Statement": "participants of the primary trial will receive the intervention for a total of 4032 hours",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "6499b181-7a23-4073-8459-ad46ff02b20f"
        ]
    },
    "19f674b3-2c9e-4626-b798-730847f41275": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Statement": "in the primary clinical trial, the proportion of patients experiencing severe side effects that block the increase in treatment dose or intensity is reported for those undergoing a combined treatment of neratinib and paclitaxel.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "17bbea92-8f92-41f3-9b9d-cf6e62cf6798"
        ]
    },
    "7da4ea6d-420e-410c-9514-601b25c8785e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02419807",
        "Statement": "The the primary trial results section reports two different measurements. gram per capsule is a capsule dosing unit expressed in gram(s) per capsule.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "8b91cab9-d858-45f3-bf8d-3d6fc55b4818"
        ]
    },
    "50142eb4-e911-4ea6-9531-582164cee7b6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01224678",
        "Secondary_id": "NCT01042535",
        "Statement": "There were more cases of Eye disorders, Abdominal pain, Febrile neutropenia and Anemia in the secondary trial than in the primary trial. tachometer device is a device designed to measure a speed of rotation.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "b8322b23-a4f6-4cba-9761-be826b509de7"
        ]
    },
    "06700dc6-04c1-423c-8fc8-5fd63df2e8c8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01998906",
        "Statement": "patients in the first cohort of the primary clinical trial undergo 10 cycles, each lasting 2 weeks, while those in the second cohort undergo 20 cycles",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "2a2c16a7-f427-4fdb-8153-94aac304e4b8"
        ]
    },
    "2a8542b3-ba9f-4002-866b-15449eb4fb1f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01905592",
        "Statement": "feel upset is a question about whether an individual feels upset. there were two types of Adverse events which did not affect any of the patients in cohort 1 of the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "30483d7e-7703-459c-bd10-e2bd259c2a4f"
        ]
    },
    "a4c3bbe2-989b-405c-a313-def0775527de": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00428922",
        "Statement": "cyclin gene mutation is a change in the nucleotide sequence in a cyclin family gene. the outcome measurement of the primary trial is The length of time during and after the treatment, that a patient lives with the disease but it does not get worse.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "d01fda83-5dc8-4ad5-92b8-7553dabd7046"
        ]
    },
    "a78836a1-f7b8-4e6c-b938-27a6f18f612f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232505",
        "Statement": "Patients with Histologically confirmed breast cancer stage I-III are not eligible for the primary trial. hypergammaglobulinemia is a laboratory test result indicating abnormally high concentrations of gamma globulins in the blood.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "75cf4ec2-9f2b-4d5b-8772-af247eaca07b"
        ]
    },
    "324562e6-2b61-4a07-b937-86f99689f2d5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Secondary_id": "NCT00876395",
        "Statement": "Diarrhoea is the most common adverse event in the primary trial, and Anaemia is the most common in the secondary trial",
        "Label": "Entailment"
    },
    "3f5a4eea-4cce-4e4d-bb00-b2499e8e546e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00944047",
        "Statement": "over half of the primary trial patients in the intervention arm experienced pathologic complete response",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "48f516ff-abb4-4312-9b00-02f53fb16218"
        ]
    },
    "ce315b63-ce9b-419c-9f04-b770d024026c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00733408",
        "Statement": "cardiac issues were the most frequently observed adverse events in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "4dfff980-6a2b-4f01-9194-6ec831d6fed7"
        ]
    },
    "21a01547-8030-437d-b466-5948c7d30f4f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00820170",
        "Secondary_id": "NCT00263588",
        "Statement": "the inclusion and exclusion conditions are identical in the primary clinical trial and the secondary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "3a4003f6-ff1c-43d8-be48-f767266b2cf5"
        ]
    },
    "53165d19-39d2-49c3-a9cb-c32eeb114287": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005879",
        "Statement": "plutonium-238 alpha particle radiation is alpha rays produced by the decay of plutonium-238. there was a significantly higher percentage of patients with slipped disks in cohort 2 of the primary trial than in cohort 1.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "ce8464bd-951e-44aa-97d9-10b917b055ce"
        ]
    },
    "542522de-6276-4e2d-a531-9d7a674ca0ad": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01596751",
        "Statement": "the primary clinical trial necessitates breast cancer patients to have a certified stable disease for participation",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "89f610a7-9e81-43a4-8c1e-5503233b2be1"
        ]
    },
    "43ee7645-ce1e-42d5-9a74-3e379f6f367b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00281697",
        "Statement": "only patients with a HER2-positive status can take part in the primary trial",
        "Label": "Contradiction"
    },
    "3c43a57f-80a0-4bee-b5dc-8808ca853411": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Statement": "the primary clinical trial provides data on the proportion of patients receiving combined treatment of neratinib and paclitaxel who encounter serious enough side effects that obstruct an escalation in treatment dose or intensity.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "17bbea92-8f92-41f3-9b9d-cf6e62cf6798"
        ]
    },
    "61c53df6-d9a2-4fa0-9dbc-9e4631417e5c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "neither of the interventions in the primary trial resulted in an objective benefit for more than 2% of patients.",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "75affd49-4905-4d43-9a5c-ef795281bac4"
        ]
    },
    "70b48059-f6ed-4126-95bf-72be2457d094": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Statement": "in the primary clinical trial, none of the cohorts are mandated to have surgery as part of the intervention.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "0a079cca-abde-42cf-9cec-a76e7a380e14"
        ]
    },
    "d3f9215c-5349-4dde-a25f-7712e1a3397f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "none of the patients in cohort 1 of the primary clinical trial managed to reach a pfs of 7 months; the maximum pfs was well below that mark",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "b8eaa8fd-61cf-4ca9-aaec-267d61c1fae3"
        ]
    },
    "2c4673d8-555b-4e30-8608-d4c43a76210a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00733408",
        "Statement": "Infections were the most common adverse events recorded in the primary trial. skin response test code is a character or string that represents the short code name of the skin response assessment.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "4dfff980-6a2b-4f01-9194-6ec831d6fed7"
        ]
    },
    "ed34edfb-6326-47d6-afe2-2e042aa99871": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00022516",
        "Statement": "generalized atherosclerosis is atherosclerosis that is not localized. T1 N0 M0 patients are eligible for the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "978d19fc-e7f6-485e-b8bd-cfcde06441ab"
        ]
    },
    "5117b7fe-be93-494f-bc42-063b9602bbfc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274469",
        "Statement": "the candidacy for the primary clinical trial involves patients being diagnosed with hormone receptor positive advanced breast cancer but disqualifies those who have received any former treatment for this advanced cancer",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "b1219e71-fbf5-4bba-8a93-a27ae444e3e1"
        ]
    },
    "928a000d-4afc-4981-9997-0bba2273813d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "the primary clinical trial accepts eligible candidates that are over 18, have a major disability and sufficient hepatic, renal, heart functions as well as appropriate hematology levels.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "f45ff82d-e0f5-456a-9d78-ddc2dc6ab929"
        ]
    },
    "1236b13c-ea9f-4cdd-a6cd-a8cf1e8ca7c0": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03012477",
        "Secondary_id": "NCT02419807",
        "Statement": "both the primary clinical trial and the secondary clinical trial present their findings as percentages, despite utilizing different measurement units.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "0e609fad-9a28-4fb6-90b6-32a731e3b02c"
        ]
    },
    "405c3db8-9563-45ab-8324-1a2e63f4f436": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00450723",
        "Statement": "oral medication is the intervention method for the primary clinical trial, and for the secondary clinical trial, it is a medical procedure.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "d310ec4e-993e-4827-8dc5-9aca053972db"
        ]
    },
    "420c56cb-0aa6-4372-a90b-2c8486338061": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02679755",
        "Statement": "none of the individual aes recorded in the primary trial affect more than 1% of the population.",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "c09fa61c-967a-40ae-96b0-c87b7cde237b"
        ]
    },
    "2361d4e9-3445-434e-bd44-a3ba9fb7d236": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00425854",
        "Secondary_id": "NCT01224678",
        "Statement": "patients with significantly decreased ejection fraction are excluded from the primary trial, but can remain unqualified for the secondary trial if they are 35 years of age or under",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "6b9162d0-0816-46d4-81af-c60028dcc63b"
        ]
    },
    "7ea57d46-81b2-4508-8367-6478ecb51c45": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01224678",
        "Secondary_id": "NCT01042535",
        "Statement": "the primary trial had higher instances of eye disorders, abdominal pain, febrile neutropenia and anemia than the secondary trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "b8322b23-a4f6-4cba-9761-be826b509de7"
        ]
    },
    "8b33bd66-37e6-4977-adfa-cb238a9a0acb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00944047",
        "Statement": "less than 30% of patients in the intervention group of the primary clinical trial showed a pathologic complete response",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "9f7d476e-9db3-4c00-abe6-4c2f0160470a"
        ]
    },
    "a2c2dabe-ab04-4d54-8a76-42c2cbe369bc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00425854",
        "Secondary_id": "NCT01224678",
        "Statement": "older patients, above the age of 55, exhibiting high ejection fraction are welcomed to participate in the primary clinical trial but are barred from participating in the secondary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "d1b7105d-0b7d-4b10-92a7-d63243ff0629"
        ]
    },
    "00d12ce6-3a96-4317-a839-5765cea96fe3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01262027",
        "Secondary_id": "NCT02301988",
        "Statement": "different outcome measurements are employed in the primary trial and the secondary trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "f2275929-7cfe-4bb1-a9f6-6bd0c4d5bf85"
        ]
    },
    "6653f227-59d7-4335-9bc1-00a724ae6edd": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00328783",
        "Statement": "the adverse events section in the primary clinical trial does not contain any information on incidence rates of aes.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "97fd111c-6969-43ab-93af-b3dff09960e5"
        ]
    },
    "435f1ab3-93ef-4ad1-910a-7368077c4f98": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Secondary_id": "NCT01644890",
        "Statement": "the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures Number of Participants With Disease Progression (PD) or Death. tumor differentiation assessment is an evaluation of the tissue architecture of the tumor in comparison to the non-pathological tissue the tumor arose from.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "f42e1874-343a-43ed-bb0c-884509c4793c"
        ]
    },
    "dc4c57b0-8c75-494e-81b0-3528df85ebff": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02915744",
        "Statement": "neither the secondary trial or the primary trial record the Overall Survival (OS) of Patients in their cohorts",
        "Label": "Contradiction"
    },
    "d6254bd6-3139-4055-b2b9-5f5a6dcc7b39": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Statement": "Anaemia was the most common adverse event in cohort 1 of the primary trial and tachycardia was the most common in cohort 2. how big a problem is watery bowel movements is a question about an individual's assessment of how big a problem watery bowel movements have been.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "ec1e269e-470d-43d9-8f23-8a19a5c96fcc"
        ]
    },
    "0f7e8787-e2eb-4eae-ae63-e01d8e768f33": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01929395",
        "Statement": "Patients must have a palpable carcinoma to be included in the primary trial. leporine experimental organism diagnosis is a condition that is relevant to either disease states or models of disease in rabbits.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "24b85b44-b9e6-4c28-b3aa-1bd97102b7f1"
        ]
    },
    "877d5929-8dc6-454c-812f-09e08f0fa883": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "lacks energy is a question about whether an individual has or had a lack of energy. the primary trial intervention protocol lasts a total of 14 days.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "236780db-9e59-4dc9-8da0-e786287011cf"
        ]
    },
    "f740842c-74ba-4ff6-9f07-6bd4f2167157": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Statement": "picogram per milliliter per milligram per meter squared per day is a unit of concentration equal to picograms per milliliter, divided by milligrams per meter squared per day. Anaemia was the most common adverse event in cohort 1 and 2 of the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "fbb62216-2cf2-4813-ad41-12a86940610f"
        ]
    },
    "0a6d1b4c-244e-44e2-a229-62e4cbdfa979": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01581619",
        "Secondary_id": "NCT00106002",
        "Statement": "the results of the secondary trial and the primary trial are non-comparable",
        "Label": "Entailment"
    },
    "fe07792a-ab4d-4d9a-b9e3-9e8fd91b74e9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01118624",
        "Statement": "participants in the primary clinical trial are given over 600mg/m^2 doses of pralatrexate.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "e9a4bd91-f58b-4234-9037-75e0699d1bbd"
        ]
    },
    "79f122ab-c95c-4dd0-a4c3-8eb60a355ac5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00754325",
        "Statement": "in the primary clinical trial, more patients faced disease progression or death in cohort 2 than in cohort 1",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "251a20d8-2555-4929-9d01-c02311bdc93f"
        ]
    },
    "1a24a18f-9fee-4de8-9af0-5fe40b9fc737": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01830933",
        "Statement": "the primary trial reports certain adverse events that are not reported in the secondary trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "c7a953b0-ac96-4e0a-9c1d-98cf8af2861d"
        ]
    },
    "e46641ca-6e08-470d-bfe8-369de495921d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Secondary_id": "NCT00121992",
        "Statement": "one case of conjunctivitis was reported in the secondary clinical trial, while the primary clinical trial did not report such a case",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "a5617ae4-05a3-42d0-9e14-141de5f8c010"
        ]
    },
    "8a5223fa-407d-4f95-9f3c-9ac69693803a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT03176238",
        "Statement": "there are no cases of acute myocardial infarction, cardiopulmonary failure and supraventricular tachycardia reported in cohort 1 of the secondary trial while these conditions are prevalent in cohort 2 of the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "080da381-b5dd-46d3-99c4-18112da153c1"
        ]
    },
    "408465e8-70f1-4622-8173-7447adc3d71b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01011946",
        "Secondary_id": "NCT00066573",
        "Statement": "patients in the primary trial receive both oral and topical medication unlike those in the secondary trial who only receive oral treatment.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "8ddf8b88-6e06-4c71-9e28-45f73a637af0"
        ]
    },
    "9d3f1ee7-49a8-4400-acc9-a4e4e2787aa0": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00820170",
        "Secondary_id": "NCT00263588",
        "Statement": "ypel5 gene rearrangement is a molecular abnormality indicating rearrangement of the ypel5 gene. the secondary trial and the primary trial do not have the same inclusion and exclusion conditions.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "3a4003f6-ff1c-43d8-be48-f767266b2cf5"
        ]
    },
    "f114846e-79d8-4712-add0-bb34b65d418f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00357110",
        "Statement": "there were 6 recorded deaths in cohort 1 of the primary trial and 7 in cohort 2.",
        "Label": "Contradiction"
    },
    "d5187a1f-78ba-42dd-99dc-7dfa2802e4ee": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01118624",
        "Statement": "fgfr2 fusion positive is an indication that expression of a fusion containing sequences from fgfr2 has been detected in a sample. the primary trial participants recieve less than 300mg/m^2 doses of Pralatrexate.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "e9a4bd91-f58b-4234-9037-75e0699d1bbd"
        ]
    },
    "1f6a14ae-e22b-4b40-b389-217570dbf38e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00900627",
        "Statement": "50% of cohort 2 patients in the primary trial suffered  Dose Limiting Toxicities ",
        "Label": "Entailment"
    },
    "8eea4089-59e4-46d2-b1bc-4e3139cbad91": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00754325",
        "Statement": "a larger number of patients experienced disease progression or death in the second cohort compared to the first cohort of the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "251a20d8-2555-4929-9d01-c02311bdc93f"
        ]
    },
    "5eb422ca-d748-4730-8c0f-51f11a226a7b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02340221",
        "Statement": "previous usage of either fulvestrant or a phosphatidylinositol 3-kinase (pi3k) inhibitor excludes one from eligibility for the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "904061c0-14fa-4f13-9118-9a41e24fa8eb"
        ]
    },
    "055e4314-c7dc-4043-94ec-7763a277c23e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01307891",
        "Statement": "There were multiple patients which suffered Neutropenia in both cohorts of the primary trial. ccnd2 gene rearrangement is a molecular abnormality indicating rearrangement of the ccnd2 gene.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "734423d5-4b47-4448-ab98-811015d626f0"
        ]
    },
    "68e4635f-7629-45ae-99b1-b29697cbf021": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01262027",
        "Secondary_id": "NCT02301988",
        "Statement": "the primary trial and the secondary trial use identical outcome measurements. moderate activities such as moving a table, pushing a vacuum cleaner, bowling, or playing golf is a question about moderate activities such as moving a table, pushing a vacuum cleaner, bowling, or playing golf.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "f2275929-7cfe-4bb1-a9f6-6bd0c4d5bf85"
        ]
    },
    "961a956e-fece-4baa-a2ad-d3a5320bd9d2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01644890",
        "Statement": "The shortest PFS in cohort 1 of the primary trial was less than 3 weeks",
        "Label": "Contradiction"
    },
    "3604545b-f2b2-486a-84d4-701fdcc4bcd0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00477464",
        "Statement": "the dispensation frequency of lapatinib surpasses that of capecitabine in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "a52b2d4f-0b06-4960-a9c3-88cb92df0980"
        ]
    },
    "4bb7749b-6ee7-4ff2-a6a2-d1b38b0ba23e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Secondary_id": "NCT00876395",
        "Statement": "Diarrhoea is the most common adverse event in the primary trial, and Anaemia is the most common in the secondary trial. deca regimen is a regimen consisting of dexamethasone, etoposide, cytarabine, used for the treatment of recurrent childhood hodgkin lymphoma.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "324562e6-2b61-4a07-b937-86f99689f2d5"
        ]
    },
    "080553fc-c295-4b27-94ba-d4236969c561": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02915744",
        "Statement": "overall survival data of the specific cohorts isn't captured in either the primary clinical trial or the secondary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "dc4c57b0-8c75-494e-81b0-3528df85ebff"
        ]
    },
    "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Secondary_id": "NCT00281697",
        "Statement": "a significant number of the participants in the secondary trial and the primary trial suffered from Enterocolitis",
        "Label": "Contradiction"
    },
    "a94bb475-8095-43cf-9f1c-d353e1e378d5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02340221",
        "Statement": "primary purpose code is a coded value specifying the most important reason or intention for an activity, event or entity. Prior treatment with fulvestrant or with a phosphatidylinositol 3-kinase (PI3K) inhibitor will not prevent a patient from participating in the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "904061c0-14fa-4f13-9118-9a41e24fa8eb"
        ]
    },
    "77119511-2b10-476c-87e1-9c267f06052c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "the most frequently occurring ae in the primary clinical trial was nausea, impacting at least 20% of the participants from cohort 1.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "2da13cd4-7189-4f85-be4d-5c1e213ae293"
        ]
    },
    "e9824f07-a27b-4350-bb46-60f37820448a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01224678",
        "Secondary_id": "NCT01042535",
        "Statement": "eye disorders, abdominal pain, febrile neutropenia, and anemia were more prevalent in the secondary trial than in the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "b8322b23-a4f6-4cba-9761-be826b509de7"
        ]
    },
    "f9856e12-345a-43da-a179-beab5fec4ae9": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Statement": "the primary clinical trial requires all of its participants to have been on a consistent flucytosine treatment regimen for a minimum of six months before starting the study.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "565d7982-aa9a-4c01-987c-1d67bc9c212d"
        ]
    },
    "9a269ed4-da2a-474a-b259-9bd1f4c62902": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00093795",
        "Statement": "in the primary clinical trial, the majority of individuals in cohorts 1 and 2 did not reach 5 years without the recurrence of disease.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "2729a321-709b-4392-9604-dd7237bedb17"
        ]
    },
    "306eb0e7-8491-4344-afcb-9c2e292f7966": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Statement": "leukopenia was the most frequent adverse event in both cohorts of the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "fbb62216-2cf2-4813-ad41-12a86940610f"
        ]
    },
    "3b2318b3-fae4-4af0-98f1-23236227b731": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01596751",
        "Statement": "patients with no documented progression of breast cancer can participate in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "bc2024fc-5b39-4fa6-badf-f034d6fe8bb8"
        ]
    },
    "fc0aa412-4696-4942-97e2-9fdaf71558aa": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02658734",
        "Statement": "Most patients in the primary trial experienced a grade 1 adverse events, the least common severity was grade 4. cooking your own meals is a question about an individual's ability to cook their own meals.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "878c09e7-3fd9-404e-921e-5b549e9578fb"
        ]
    },
    "7e072139-a6f1-4b1c-86f2-7408a6fa1b64": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02915744",
        "Statement": "sewing ring device is a ring of supportive material designed to provide a stable surface for attachment to surrounding tissues. Cohort 1 and 2 of the primary trial do not receive NKTR-102 by infusion.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "4309860d-042d-45a4-8a0a-a9fdd075247a"
        ]
    },
    "f7f516a1-df08-43b1-a82a-a1b9ffc3d228": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02186015",
        "Statement": "epidermal cgvhd score 0 is a score of 0 describing clear skin where residual hyperpigmentation may be present. adults and children can take part in the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "2825d63b-8f22-4fb8-829f-9567845251c6"
        ]
    },
    "b0612168-99e7-480e-9be4-1865289e1c75": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "patients wanting to take part in the primary trial must have a known and documented her2+ status and an lvef of at most 30 percent (%)",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "6b33b4ae-36f2-4a53-a954-6f246f6e023d"
        ]
    },
    "3284ad2c-dc97-4e01-b0de-6dccd2919b2f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01125566",
        "Statement": "qualification for the primary clinical trial requires an ecog score that is \u2264 2.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "b2cdbcb8-de26-4a44-8a94-dd68c13f7e41"
        ]
    },
    "46ee3d33-aa5a-4276-b2fa-6cb0c749c219": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "ashamed of skin condition is a response indicating that an individual feels ashamed of their skin condition. Presence of hot flashes for  30 days prior to study registration is required for all patients that want to participate in the primary trial, but not necessary for entry to the secondary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "31105b43-832b-48bc-a78d-ee90c155ca44"
        ]
    },
    "1d8b1523-635e-4035-b532-92ed02fc412f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Statement": "no instances of serious side effects linked to dosage or treatment levels with neratinib and paclitaxel have been documented in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "17bbea92-8f92-41f3-9b9d-cf6e62cf6798"
        ]
    },
    "9fcc6dc8-dc87-49a3-b8d2-8bc3de7a4ff8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274469",
        "Statement": "to qualify for the primary clinical trial, patients must be identified as having hormone receptor positive advanced breast cancer, and must have had previous chemotherapy treatment for this",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "2e76c74a-b6dd-47d8-a674-c1e80b0a3a65"
        ]
    },
    "1ed29a92-b231-437b-837c-51c45a18a526": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00009945",
        "Statement": "not a single individual adverse event in the primary clinical trial impacts over 100 patients, and the combined total of patients suffering adverse events is less than 30",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "8648c7df-582a-42a9-9330-414b2430ac56"
        ]
    },
    "60fb73fa-b77d-4799-aac8-9607bc1ca4b8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00503906",
        "Statement": "the protocol of the primary clinical trial involves administering the intervention over twelve 28-day cycles to the participants",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "6499b181-7a23-4073-8459-ad46ff02b20f"
        ]
    },
    "33f2dcb9-3f64-4335-ac25-2a1d863e2641": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Secondary_id": "NCT01644890",
        "Statement": "cep43 gene rearrangement is a molecular abnormality indicating rearrangement of the cep43 gene. the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures PFS.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "794269ca-e7ec-4a65-ace5-b0f24a8cdc15"
        ]
    },
    "73a17ced-cd61-4743-9f91-8c2421fed348": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232505",
        "Statement": "the primary clinical trial does not accept patients with a histologically confirmed diagnosis of stage i-iv breast cancer",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "3cb71095-8e01-40dc-bbf5-eeffed55f354"
        ]
    },
    "74c1caf1-b35c-4d39-848f-44ed820c5dcb": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "rete testis is a network of tubules that convey sperm from the seminiferous tubules within the testicles to the efferent ducts. Presence of hot flashes for at least 4 month prior to study registration is required for all patients that want to participate in the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "a5baab2c-9c32-4301-a574-4ba5a0c2eb00"
        ]
    },
    "d259dd4d-bc7a-4bf6-a711-cef8a2b833ec": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Secondary_id": "NCT00274469",
        "Statement": "advanced breast cancer is a prerequisite for female patients who wish to participate in both the primary and secondary clinical trials",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "68379456-775b-463b-bfdb-d8aa42c9124b"
        ]
    },
    "b3916071-d104-4d4c-9b2a-c6c902b8ce3b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00477464",
        "Statement": "the primary trial participants receive Capecitabine less often than they receive Lapatinib. lymph node pain, ctcae 5.0 is a disorder characterized by a sensation of marked discomfort in a lymph node.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "a52b2d4f-0b06-4960-a9c3-88cb92df0980"
        ]
    },
    "1d8e0d43-f71a-4d83-a4a0-0f7af6d9529e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00374322",
        "Statement": "in the primary clinical trial, 80% of the patients were given a placebo treatment",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "e147796d-2edd-42d1-ac53-300fb8bd5eb6"
        ]
    },
    "a8e53bf2-e5ed-44c6-8579-45ae92d06b7a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02131064",
        "Statement": "in cohort 1 of the primary clinical trial, there were 20 more cases of abdominal pain than left ventricular dysfunction",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "1329dec6-fb2c-4219-9db6-3fef9d94b316"
        ]
    },
    "a4f2426e-a075-45e8-ac61-35e140836c04": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02419807",
        "Statement": "dart device is a pointed missile which on contact with an animal delivers its medicinal content. The the primary trial results section reports two different measurements, for all 3 cohorts.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "d0b50aeb-aad8-4a8d-aae6-5c58a7d382c7"
        ]
    },
    "df300037-3c8f-4575-9064-58a679a0f29f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Statement": "surgery is not an obligatory part of the intervention for any cohorts in the primary clinical trial.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "0a079cca-abde-42cf-9cec-a76e7a380e14"
        ]
    },
    "8ddf8b88-6e06-4c71-9e28-45f73a637af0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01011946",
        "Secondary_id": "NCT00066573",
        "Statement": "the primary trial participants are administered oral and topical medication, whereas the secondary trial patients only receive treatment orally.",
        "Label": "Contradiction"
    },
    "5f00dff5-d1c7-4026-8f6d-89f8bbe19a5b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00428922",
        "Statement": "high-performance liquid chromatography/ion-exchange chromatography is a type of high performance liquid chromatography that separates proteins based on net charge. the outcome measurement of the primary trial is The length of time during and after the treatment that a patient survives with the disease .",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "3facad41-0221-42f8-834d-470e65c4aad5"
        ]
    },
    "55f1014c-88dc-4f97-85b6-16e4b8f12403": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290758",
        "Secondary_id": "NCT02370238",
        "Statement": "Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial. did caregiving responsibilities make it difficult to do work without making mistakes is a question about if an individual's caregiving responsibilities made it difficult for them to do work without making mistake.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "5d0ccb93-71ec-4079-92c6-d7cbf951a7bb"
        ]
    },
    "876c3d71-0162-41e2-ac9b-853fc7448425": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT02340221",
        "Statement": "neither the primary clinical trial nor the secondary clinical trial require measures of the percent change in net influx constant (ki) by flt pet for their patient cohorts",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "49ba06b2-576d-4db2-80b6-51673416f2ba"
        ]
    },
    "d3888087-dc20-48d6-8bff-e674b20ab034": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00915603",
        "Statement": "in the primary clinical trial, at least two subjects, with each group being represented, showed a progression-free survival duration of 10.8 months",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "47ba01d6-edc7-4acb-ab49-b0e86f4eeaf7"
        ]
    },
    "3b8fd72a-30d4-404e-8c97-6d9bb25700eb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT00232505",
        "Statement": "the primary trial and the secondary trial participants do not receive any medication orally. audible device noise is an unintended or unpleasant sound that emanates from a device.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "e7604382-09cd-43b4-998f-a51b33f25c5a"
        ]
    },
    "bf8874a2-9d05-4952-bc5b-63bd6f944e2d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00450723",
        "Statement": "the primary clinical trial's intervention requires taking medication orally, while the intervention in the secondary clinical trial necessitates a medical procedure.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "d310ec4e-993e-4827-8dc5-9aca053972db"
        ]
    },
    "93bff638-f368-40f4-8fd2-3bd84d2b56c5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02186015",
        "Statement": "only individuals who have reached adulthood are allowed to participate in the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "a805f174-2707-4302-a195-05153ea8523e"
        ]
    },
    "56bae20d-be79-46ea-8b03-d69f208d54d8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "Presence of hot flashes for  30 days prior to study registration is required for all patients that want to participate in the primary trial, but not necessary for entry to the secondary trial. ultrasonic surgical aspiration is a procedure in which tissue is broken up into small fragments by ultrasound and then removed by aspiration.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "31105b43-832b-48bc-a78d-ee90c155ca44"
        ]
    },
    "74e376d7-5713-43f3-93f1-9608059c9547": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "neither of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients, in fact over 86% of patients receiving the Docetaxel Then Liposomal Doxorubicin intervention suffered fatal complications",
        "Label": "Contradiction"
    },
    "3bff7261-fab7-48aa-8873-f268435ecbad": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274469",
        "Statement": "broncho-esophageal fistula is an abnormal connection between a bronchus and the esophagus. to be eligible for the primary trial patients must be diagnosed with hormone receptor positive advanced breast cancer, but can not have received any previous treatment for this advanced cancer.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "b1219e71-fbf5-4bba-8a93-a27ae444e3e1"
        ]
    },
    "671e1aa1-5df6-4496-ada9-4ba1e1d6b758": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042938",
        "Statement": "the primary trial reports the Severity of Dermatitis in Radiation Treatment Site for the Curcumin C3 Complex cohort and the placebo cohort, there is no difference in the results from these two cohorts. suprasellar germ cell tumor is a germ cell tumor that arises from the suprasellar region.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "e62f5a3f-0091-4980-9822-db8f4dc2502a"
        ]
    },
    "bc1baff5-5960-4096-8761-b6ec7982caa0": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01262027",
        "Secondary_id": "NCT02301988",
        "Statement": "the outcome measurements used in the primary clinical trial and the secondary trial are not identical",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "f2275929-7cfe-4bb1-a9f6-6bd0c4d5bf85"
        ]
    },
    "62e449ad-16b3-479d-94a5-ffc435b5e99c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00063570",
        "Statement": "patients with a Malignant brain tumour diagnosis are excluded from the primary trial",
        "Label": "Entailment"
    },
    "4f5dc030-8dc8-4241-8fdb-b9589ea26006": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "a patient with a node positive t2 n2 m0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of over 0.2m",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "016943fa-57ea-4293-8131-03292ea1836c"
        ]
    },
    "5ee4df66-8382-43c6-b17f-e14da0f1ac26": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "a patient with a node positive t2 n2 m0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of over 0.00787feet",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "016943fa-57ea-4293-8131-03292ea1836c"
        ]
    },
    "f74cb54e-8d9a-472e-a4fd-e0e764a9ae04": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00093795",
        "Statement": "a majority of individuals from cohort 1 and 2 in the primary clinical trial lived for 5 years without any disease recurrence.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "2729a321-709b-4392-9604-dd7237bedb17"
        ]
    },
    "2b1dc956-f284-4c62-8bdb-a841acf20f95": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02186015",
        "Statement": "the primary clinical trial exclusively accepts adult participants",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "a805f174-2707-4302-a195-05153ea8523e"
        ]
    },
    "ca919239-737a-401c-abc8-7397dde0047d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01830933",
        "Statement": "both the primary clinical trial and secondary clinical trial have not documented any harmful situations",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "fb360514-14be-45ab-8b74-ea5a7eb181d7"
        ]
    },
    "5f4f71bc-546c-46ac-8909-8f07dcee3d57": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02679755",
        "Statement": "none of the individual aes recorded in the primary trial affect more than 3.45% of the population.",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "c09fa61c-967a-40ae-96b0-c87b7cde237b"
        ]
    },
    "2991196d-81a3-49ab-b2a6-eb2b996852f6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "the primary clinical trial intervention protocol will be prematurely halted regardless of patient response or disease progression",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "1d1f57f8-85f7-448c-a4bb-15957da568fd"
        ]
    },
    "5065259b-da0e-46c1-8532-c5358c66d153": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT00852930",
        "Statement": "adverse events linked to either cardiac conditions or infections are not recorded in the primary or secondary clinical trial, but both do record episodes of epilepsy",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "c2217d42-e90c-4ffe-b084-e653b9ace4d5"
        ]
    },
    "6244e7d1-ac6e-4b19-b816-98d01d3872bf": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Statement": "neither of the cohorts in the primary trial are required to undergo surgery as part of the intervention. mist is a suspension of fine drops of a liquid in a gas.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "0a079cca-abde-42cf-9cec-a76e7a380e14"
        ]
    },
    "203b5402-7514-4251-90d2-32ec7bea8857": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01644890",
        "Statement": "in cohort 1 of the primary clinical trial, the minimum pfs was less than 3 weeks",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "961a956e-fece-4baa-a2ad-d3a5320bd9d2"
        ]
    },
    "3a0c517d-9b9a-4497-9675-50ff12cd02b7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02131064",
        "Statement": "in cohort 1 of the primary trial there were more cases of Left ventricular dysfunction than Abdominal pain",
        "Label": "Entailment"
    },
    "f172425c-cfe9-4f05-a479-200b2fb02570": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01416389",
        "Statement": "changes in the quantity of lesions for its patient groups are noted in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "812bd63c-4bfb-49cb-8fa9-baa3f8f6dabe"
        ]
    },
    "6f13179a-b019-4099-beb2-c234e021af76": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Statement": "participants in the primary clinical trial are not allowed to receive continuous flucytosine treatments",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "f10f3b84-e039-4a02-a98b-86d149d9a16f"
        ]
    },
    "22580cdd-f56e-4a59-8289-d761d25b3902": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01118624",
        "Statement": "the primary trial participants recieve more than 2000mg/m^2 doses of pralatrexate",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "e9a4bd91-f58b-4234-9037-75e0699d1bbd"
        ]
    },
    "c8ac4a88-3a29-4f4a-b34c-e1effcb3676e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Secondary_id": "NCT00281697",
        "Statement": "medical examination reports confirm that enterocolitis was not identified among the population of participants involved in the secondary clinical trial and the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f"
        ]
    },
    "c215859a-6730-4f02-a385-4f492834e5e6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "neither of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients, in fact over 86% of patients receiving the Docetaxel Then Liposomal Doxorubicin intervention suffered fatal complications. endocervix tumor is an indication that the tumor is in the endocervix.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "74e376d7-5713-43f3-93f1-9608059c9547"
        ]
    },
    "b1102104-5708-4319-8dce-d9465d07d38e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Statement": "the primary clinical trial discloses the percentage of patients having no adverse reactions after being treated with neratinib and paclitaxel together",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "cdadcb0a-20c5-47f7-a63a-39f5c6f26ae2"
        ]
    },
    "be997ce0-6cd1-4272-90c2-e30277045754": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT02340221",
        "Statement": "smarcb1 gene mutation is a change in the nucleotide sequence of the smarcb1 gene. the primary trial and the secondary trial have non-comparable outcome measurements for their results.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "2a03c17f-3afe-40f1-a0db-4b876ee8c700"
        ]
    },
    "47371b5d-08ec-441b-98ce-206b6aaf5aa4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00263588",
        "Statement": "to partake in the primary clinical trial, patients are required to use a subcutaneous injection method for all medications",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "5c1e360c-fd93-4dd4-b855-71ba416d34cb"
        ]
    },
    "482b4439-89a6-436d-b48b-cdd49e8b7eb6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Statement": "all patients accepted into the primary trial have undergone Prior treatment for breast cancer with endocrine therapy. bothered by question is a question about whether an individual is bothered by something.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "6d621974-c719-46df-8a50-d94e49583e33"
        ]
    },
    "de8927d0-26e9-4bb9-8b89-df9a8803a64e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01011946",
        "Secondary_id": "NCT00066573",
        "Statement": "nipple deformity, ctcae is a disorder characterized by a malformation of the nipple. the primary trial participants are not administered any oral medication whereas the secondary trial patients only receive treatment orally.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "6402e13a-7cfb-4774-b7f9-80ecb79fda2a"
        ]
    },
    "49a51762-add1-4d95-a98d-c6363ac76d11": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02679755",
        "Statement": "None of the individual Aes recorded in the primary trial affect more than than one patient. unit of mole fraction is a ratio of number of moles of substance to total number of moles of all substances in the mixture.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "f46a7d27-a94f-4389-a1a0-4a8f5177b354"
        ]
    },
    "e49d5629-6769-40cb-a983-8919fd14c64b": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01262027",
        "Secondary_id": "NCT02301988",
        "Statement": "the potential results evaluated in the primary clinical trial and the secondary clinical trial are similar",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "0131ebe3-746b-45a5-ba60-fdd326974fec"
        ]
    },
    "6129ae39-c927-4811-9fd7-bc31633f33d6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "a minor with no disabilities and compromised renal function is eligible for the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "f45ff82d-e0f5-456a-9d78-ddc2dc6ab929"
        ]
    },
    "fd8909c6-d2ee-40fa-9ab4-987d1cfb1d4b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Statement": "the primary clinical trial lists the percentage of patients treated with neratinib in conjunction with paclitaxel that are affected by multiple side effects",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "cdadcb0a-20c5-47f7-a63a-39f5c6f26ae2"
        ]
    },
    "739e6111-bd84-4ede-b7df-61446babc6e5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01998906",
        "Statement": "Both cohorts of the primary trial undergo a total of 17 cycles, each lasting 21 days.",
        "Label": "Entailment",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "43ce26e5-03fa-4e9d-b0eb-6ea356295753"
        ]
    },
    "66bf6a56-9b67-4ebc-b3c9-b8b28b0e2043": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03098550",
        "Statement": "vulvar congenital melanocytic nevus is a benign nevus that arises from the vulva and is present at birth. both cohorts of the primary trial receive identical interventions, the difference between the two cohorts is the types of cancer that the patients have, with cohort 1 all being diagnosed with HER2 positive cancer and cohort 2 being PR-.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "3adcc8fc-b76b-407a-a006-729a13f571fb"
        ]
    },
    "c26f8788-8ba1-4c1c-84d3-9660b0c675ad": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Secondary_id": "NCT00121992",
        "Statement": "there were 8 reported cases of conjunctivitis in the secondary trial while none were reported in the primary trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "c100a7cd-e3a2-4901-a3e0-12336f769c7b"
        ]
    },
    "f2819f21-91ae-4cdd-a399-453902b2d1d5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00612560",
        "Secondary_id": "NCT01216176",
        "Statement": "none of the participants in the primary trial are given flaxseed, but all of the participants in the secondary trial are",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "b0046821-ba27-4a90-8869-cb708b843aa4"
        ]
    },
    "43ce26e5-03fa-4e9d-b0eb-6ea356295753": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01998906",
        "Statement": "Both cohorts of the primary trial undergo a total of 17 cycles, each lasting 3 weeks .",
        "Label": "Entailment"
    },
    "20b34c3d-14fe-4db9-a020-7d0cdc4361d1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Statement": "primary clinical trial has accepted patients without any history of prior treatment for breast cancer using endocrine therapy.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "6d621974-c719-46df-8a50-d94e49583e33"
        ]
    },
    "16aaefcd-d944-4c7c-8668-d0e27789f403": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02301988",
        "Statement": "the drug ipatasertib is administered solely to cohort 1 patients in the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "faa65e54-aa04-4595-8dae-05cf00b4c887"
        ]
    },
    "1a9d53a9-8c76-485b-afd2-5906662ca955": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "all the primary trial patients had a minimum of 1/2 decrease in the sum of the longest diameter of target lesions",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "985bc5a0-bc21-447f-92f1-150e23ede3f5"
        ]
    },
    "011a5c41-b218-4600-b9df-c1381f49f5aa": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00022516",
        "Statement": "another form of birth control was used is a response indicating that another form of birth control was used. T4 N2 M4 patients are eligible for the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "4a75574c-fa86-4e62-a210-81c7b98a3807"
        ]
    },
    "36b408b8-f2e8-41ae-a9f2-66ecf44354a9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01905592",
        "Statement": "in the primary clinical trial, none of the patients in the first cohort were impacted by the two types of adverse events",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "30483d7e-7703-459c-bd10-e2bd259c2a4f"
        ]
    },
    "97630bc1-42c3-4801-84fb-24b3c43ddad3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00328783",
        "Statement": "previous patients' adverse events are well documented in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "fef5aedb-21c0-4130-b8a3-cb1df5017c7a"
        ]
    },
    "a7ac1df0-b2fe-419e-867c-2acebe847ea4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00477464",
        "Statement": "the primary clinical trial adjusts dosage to ensure participants receive equivalent amounts of capecitabine and lapatinib.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "a3390ae6-d41d-4dc7-899e-de9534adfd6b"
        ]
    },
    "44ebb972-bbd9-4034-8f08-943cf134d03e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02301988",
        "Statement": "cohort 2 patients of the primary clinical trial are given a higher dosage of ipatasertib and placebo than the cohort 1 patients",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "973f090a-8967-4d75-bb8e-6166c868337c"
        ]
    },
    "30f5c6d2-0778-4089-9149-bd71323cc304": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01224678",
        "Secondary_id": "NCT01042535",
        "Statement": "during radiation therapy is a time point during radiation therapy. There were more cases of mental health disorders, PLEUROPERICARDITIS, ATRIAL THROMBOSIS  and Anemia in the secondary trial than in the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "57b2ae97-0d1d-4d5d-bc4b-109e8e5acb32"
        ]
    },
    "504819ee-b29e-4a35-a01c-571bdd1cbdf0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01596751",
        "Statement": "Breast cancer patients must have documented progressive disease to participate in the primary trial. acute physiology and chronic health evaluation ii apch110 standardized character result 2 is acute physiology and chronic health evaluation ii apch110 standardized character result 2 - 50-59.9; 20-29.9.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "bc2024fc-5b39-4fa6-badf-f034d6fe8bb8"
        ]
    },
    "fe13dab3-aaf3-4f22-bc93-231627d5a672": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02915744",
        "Statement": "nktr-102 infusion is not part of the treatment for cohorts 1 and 2 in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "4309860d-042d-45a4-8a0a-a9fdd075247a"
        ]
    },
    "5428a128-d5f0-45fe-9163-9c0f89409d30": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00572728",
        "Statement": "erysipelothrix is a genus of aerobic, gram positive, rod shaped bacterium assigned to the phylum firmicutes and the family erysipelotrichaceae. Patients must be able to undergo a PET scan to participate in the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "32ed503c-1cfd-44f6-b8bb-23d9d175d73d"
        ]
    },
    "de4c0474-03b4-457d-bb9c-0128d7cc5cb0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820222",
        "Statement": "the primary clinical trial's outcomes revealed a higher instance of patients in the trastuzumab plus capecitabine group experiencing grade 3 or 4 skin/subcutaneous or pulmonary harm, compared to the lapatinib plus capecitabine group.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "566bdc2d-7c4a-4547-87da-ac81447ecca8"
        ]
    },
    "92a68330-81b8-4409-a0b5-3e5844f94675": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Secondary_id": "NCT01439945",
        "Statement": "there are no cases of diarrhea reported in the secondary clinical trial, but one was reported in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "bebfc78e-b35f-4677-8342-9567a7e795a1"
        ]
    },
    "672bcb34-ecb0-4d9e-94b9-224b8bf34c3b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01998906",
        "Statement": "Both cohorts of the primary trial undergo a total of 17 cycles, each lasting 21 days , patients receive the same types and dosages of medication throughout all 17 cycles",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "2a2c16a7-f427-4fdb-8153-94aac304e4b8"
        ]
    },
    "1a293038-393e-402e-8c78-fbeadffb1593": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00263588",
        "Statement": "patients participating in the primary clinical trial must solely accept medication through a transdermal delivery system",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "5c1e360c-fd93-4dd4-b855-71ba416d34cb"
        ]
    },
    "c7e5594e-a2dc-49c2-8273-155c5773e051": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01596751",
        "Statement": "the primary clinical trial welcomes breast cancer patients showing a regression of the disease.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "bc2024fc-5b39-4fa6-badf-f034d6fe8bb8"
        ]
    },
    "ebb84e5f-3ae2-4476-937f-c439b23a03e6": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02915744",
        "Statement": "both the primary and secondary clinical trials actively track and document the overall survival (os) of patients participating in their respective studies.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "dc4c57b0-8c75-494e-81b0-3528df85ebff"
        ]
    },
    "c25cf962-ca35-4316-951c-c5c57b8e2a0d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005879",
        "Statement": "adoptive parent is a parent in the parent-child relationship established by a legal adoption proceeding. there was a higher percentage of patients with slipped disks in cohort 2 of the primary trial than in cohort 1.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "e4aeb013-7713-4b73-acbd-f8379cc6a494"
        ]
    },
    "4263a146-0a6a-4abc-a342-94f3896a65e0": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02915744",
        "Statement": "the primary clinical trial and the secondary clinical trial do not document the overall patient survival rates in their respective cohorts",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "dc4c57b0-8c75-494e-81b0-3528df85ebff"
        ]
    },
    "176e3f8c-45b3-46ed-8f34-b59edaf85961": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Secondary_id": "NCT00876395",
        "Statement": "nausea is the most reported side effect in the primary clinical trial, and thrombocytopenia is predominantly seen in the secondary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "324562e6-2b61-4a07-b937-86f99689f2d5"
        ]
    },
    "02c00290-81fb-4dc6-abd4-76d01f6d03a8": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Secondary_id": "NCT01644890",
        "Statement": "the primary trial evaluates the progression of the disease in its subjects, whereas the secondary trial measures the time until recurrence",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "794269ca-e7ec-4a65-ace5-b0f24a8cdc15"
        ]
    },
    "5d48d126-0dea-42c0-bdcb-ecf41244005d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "all the primary trial patients had a minimum of 0.5 decrease in the sum of the longest diameter of target lesions",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "985bc5a0-bc21-447f-92f1-150e23ede3f5"
        ]
    },
    "bef32974-10d7-4246-b1ab-af7a01ee74c1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Secondary_id": "NCT00425854",
        "Statement": "progression of the disease is utilized as the outcome measurement in both the primary and secondary clinical trials, both consistent in their criteria for complete response",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "8d9f94e3-871b-4fb4-a522-0a73d9d0ec3c"
        ]
    },
    "cec07655-9a23-46c8-9369-2b8e125e0085": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274469",
        "Statement": "the primary clinical trial requires patients to be identified with hormone receptor positive advanced breast cancer, and further, they should not have been subjected to any preceding therapy for this severe cancer",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "b1219e71-fbf5-4bba-8a93-a27ae444e3e1"
        ]
    },
    "44ac56b8-e3ff-4484-a63c-0043f8dd0bb4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00944047",
        "Statement": "over 65% of the primary trial patients in the intervention arm experienced pathologic complete response",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "9f7d476e-9db3-4c00-abe6-4c2f0160470a"
        ]
    },
    "3d14830c-7c21-4125-975b-f49835a8dabb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00127933",
        "Statement": "eliane who is 56 and alex who is 32 can both qualify for the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "a792bbac-0e8a-4bf7-9cc5-56fad481e2fb"
        ]
    },
    "c08a3552-f436-4e2d-b706-04d2511f2122": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Statement": "independent for stairs is a response indicating that an individual can go up and down stairs independently of help from others. ongoing flucytosine treatments are necessary for all participants of the primary trial, treatments must have started at least 6 months before study entry.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "565d7982-aa9a-4c01-987c-1d67bc9c212d"
        ]
    },
    "ddc4daca-855c-4499-93cc-7dbc71e1a81d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00503906",
        "Statement": "participants of the primary clinical trial will receive the intervention for a set number of cycles, regardless of the status of disease progression.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "59cd7909-00c3-4c23-9a08-a42dbc8eabdd"
        ]
    },
    "5873ebf2-d03e-4c05-bfa1-272a97b92feb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "individuals with substantial ambiguity regarding their her2 status or with an lvef less than 35% are allowed in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "6b33b4ae-36f2-4a53-a954-6f246f6e023d"
        ]
    },
    "1b663832-3612-4efb-810f-25e281b27449": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02340221",
        "Statement": "prior treatment with fulvestrant qualifies the patient for the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "6b35bc10-f591-4b84-abac-40a74be949fa"
        ]
    },
    "cadf86d3-6b90-477c-96d4-b82d61f42cf0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01125566",
        "Statement": "locally advanced lung neuroendocrine neoplasm is a lung neuroendocrine neoplasm that has spread from its original site of growth to nearby tissues or lymph nodes. ECOG score > 2 is necessary to be eligible for the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "b2cdbcb8-de26-4a44-8a94-dd68c13f7e41"
        ]
    },
    "fccc8e61-6443-49f4-af34-554a5afad54f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00503750",
        "Secondary_id": "NCT00005879",
        "Statement": "the findings from the secondary clinical trial and the primary clinical trial can be juxtaposed",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "dca4c9f7-bb2a-4f73-b390-93b7ced87c73"
        ]
    },
    "c927db2c-1bef-4f77-97d5-503bb4d168bc": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "25-hydroxyvitamin d less than 30 ng/ml is a semiquantitative finding indicating that the concentration of 25-hydroxyvitamin d2 plus 25-hydroxyvitamin d3 is less than 30 ng/ml. All patients in cohort 1 of the primary trial had a PFS of over 7 months, with the highest PFS being just under 10 months.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "b8eaa8fd-61cf-4ca9-aaec-267d61c1fae3"
        ]
    },
    "43dc73cf-4f75-4422-8356-00fc2d5f014a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01118624",
        "Statement": "participants of the primary clinical trial are administered doses of pralatrexate below 300mg/m^2",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "e9a4bd91-f58b-4234-9037-75e0699d1bbd"
        ]
    },
    "551f5b23-3bf1-4507-8dd2-d154f916dc57": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00477464",
        "Statement": "the primary trial participants receive significantly higher doses of Capecitabine than of Lapatinib. urinary system findings reference identifier is a character or string that represents a urinary system findings event reference.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "a3390ae6-d41d-4dc7-899e-de9534adfd6b"
        ]
    },
    "8a3b710b-782c-4c5c-9558-7b7b08715ab3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "the primary clinical trial accepts patients with a node positive grade 3 ductal carcinoma in situ (dcis) of the breast.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "016943fa-57ea-4293-8131-03292ea1836c"
        ]
    },
    "21c0837f-e47b-4601-9cc6-80156ac9d4b9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00915603",
        "Statement": "all participants in the primary clinical trial had less than 10.8 months of progression-free survival",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "47ba01d6-edc7-4acb-ab49-b0e86f4eeaf7"
        ]
    },
    "a5e388b9-da3c-437e-a6af-7ba76ad8bf1d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00333775",
        "Statement": "both the primary trial cohorts receive identical doses of Docetaxel, with cohort 1 also receiving 100 mg/m^2 of Placebo",
        "Label": "Contradiction"
    },
    "fc88a0c0-ab47-499e-ac49-2f0849fa4c3d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00376597",
        "Statement": "Patients with stage 4 cancer are excluded from the primary trial. high grade liver dysplastic nodule is a hepatic dysplastic nodule characterized by the presence of high grade atypical cellular changes.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "75a65913-5655-4377-b441-ecdd4dd75175"
        ]
    },
    "d14a31e0-2b50-4851-8b07-a4217a8657cd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00425854",
        "Secondary_id": "NCT01224678",
        "Statement": "evaluation conclusion code is a coded value specifying the findings from the assessment. Patients with significantly elevated ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or over.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "6b9162d0-0816-46d4-81af-c60028dcc63b"
        ]
    },
    "a842a276-9362-495d-bc75-5317ce39140a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "primary clinical trial allows participants with subpar hepatic, renal, and heart functions.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "7c7418d2-32d7-4517-874b-eb3db24ea16a"
        ]
    },
    "080da381-b5dd-46d3-99c4-18112da153c1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT03176238",
        "Statement": "There less cases of Acute myocardial infarction, Cardiopulmonary failure and Supraventricular tachycardia in cohort 1 of the secondary trial than in cohort 2 of the primary trial",
        "Label": "Contradiction"
    },
    "ea79062f-bd96-4fe0-b9dc-62b6134341e9": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01929395",
        "Statement": "only patients with a detectable tumor are admitted in the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "24b85b44-b9e6-4c28-b3aa-1bd97102b7f1"
        ]
    },
    "c88a520f-9a9f-41e8-81e6-9cc2745b8402": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00127933",
        "Statement": "eliane is a 56 year old woman, and elizabeth is a 32 year old woman, both eliane and elizabeth can both be eligible for the primary trial. hypercalciuria is abnormally high level of calcium in the urine.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "f0273b8c-460d-46fe-9c52-8ff4b08e439b"
        ]
    },
    "4e25e56d-07e9-409d-9b1d-3b29ab31ea75": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005879",
        "Statement": "the primary clinical trial indicated a significant increase in percentage of patients with slipped disks in the second cohort as compared to the first.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "ce8464bd-951e-44aa-97d9-10b917b055ce"
        ]
    },
    "eb036cc3-80d7-434a-b664-9098dc6bdb5e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "both interventions in the primary clinical trial could not yield an objective benefit for more than 40% of patients.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "75affd49-4905-4d43-9a5c-ef795281bac4"
        ]
    },
    "0b882a9c-bdb0-4bab-99a5-b7353edc2aeb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01998906",
        "Statement": "both cohorts in the primary clinical trial proceed through 17 identical cycles, each of three weeks duration, receiving the same medication types and dosages across all cycles.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "2a2c16a7-f427-4fdb-8153-94aac304e4b8"
        ]
    },
    "b05e2fb4-4952-4e83-9daa-c5a3dcfbf3d8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00376597",
        "Statement": "the primary clinical trial does not consider the cancer stage when determining eligibility.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "b1dd7632-ed92-40a9-9293-bce68619c658"
        ]
    },
    "625cb90b-0225-47f7-9cc5-3e778c689c37": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02131064",
        "Statement": "the number of left ventricular dysfunction cases was higher than that of abdominal pain in the first cohort of the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "3a0c517d-9b9a-4497-9675-50ff12cd02b7"
        ]
    },
    "dd3e9915-4b9a-4a05-a1fe-d963fc51dffa": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00425854",
        "Secondary_id": "NCT01224678",
        "Statement": "patients with a perfectly normal ejection fraction are the primary candidates for primary clinical trial and those above 55 years are excluded from secondary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "d1b7105d-0b7d-4b10-92a7-d63243ff0629"
        ]
    },
    "b28fba4e-020b-4560-8979-256ae9219f10": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "patients wanting to take part in the primary trial must have a known and documented her2+ status and an lvef of at least 0.50",
        "Label": "Entailment",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "6b33b4ae-36f2-4a53-a954-6f246f6e023d"
        ]
    },
    "7b0018a2-a9a7-4276-b50b-b9c750ef8798": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01596751",
        "Statement": "patients suffering from breast cancer are required to have a recorded stable condition in order to be included in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "89f610a7-9e81-43a4-8c1e-5503233b2be1"
        ]
    },
    "58fa5c1c-1bd4-42a8-b7aa-76ce284d6e50": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "patients in cohort 1 of the primary clinical trial had varying degrees of pfs, but none exceeded a 4-month duration",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "b8eaa8fd-61cf-4ca9-aaec-267d61c1fae3"
        ]
    },
    "260dd850-4eba-4360-95f8-56ee8742a550": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "A patient with a node positive T2 N2 M0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of 1.5cm. alternate protocol identifier is a unique code that identifies a specific protocol assigned by an affiliated governing body or other organization.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "e6a4e9a6-56b8-4a30-9743-eb02688c090f"
        ]
    },
    "f1d5f5b6-c9db-47dc-8423-0037731d6b48": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "patients wanting to take part in the primary trial must have a known and documented tnbc status and an lvef of at least 90 percent (%)",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "9abb10d7-496e-44fd-915d-d86aedf6c9b6"
        ]
    },
    "1839edce-6114-4614-94fd-fd22f7917ae0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232505",
        "Statement": "histologically confirmed stage iv breast cancer patients can enter the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "3cb71095-8e01-40dc-bbf5-eeffed55f354"
        ]
    },
    "074de540-1e1a-40a9-96a9-12206845e65b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01905592",
        "Statement": "in cohort 1 of the primary clinical trial, a single type of adverse event affected multiple patients intensely",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "2655c892-216e-4b96-a8f2-6f64403215c5"
        ]
    },
    "57b2ae97-0d1d-4d5d-bc4b-109e8e5acb32": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01224678",
        "Secondary_id": "NCT01042535",
        "Statement": "There were more cases of mental health disorders, PLEUROPERICARDITIS, ATRIAL THROMBOSIS  and Anemia in the secondary trial than in the primary trial",
        "Label": "Contradiction"
    },
    "46837100-9137-4576-913c-ac5c85205c5b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00944047",
        "Statement": "8p22-p11 is a chromosome band present on 8p under a quater of the primary trial patients in the intervention arm experienced Pathologic Complete Response.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "48f516ff-abb4-4312-9b00-02f53fb16218"
        ]
    },
    "feba7a9b-e82b-4c33-8159-42965e61c694": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT02340221",
        "Statement": "seropositive is a laboratory result which shows the presence of antibodies in the serum for the factor being tested. the primary trial and the secondary trial measure the Percent Change in Net Influx Constant (Ki) by FLT PET in their patient cohorts.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "49ba06b2-576d-4db2-80b6-51673416f2ba"
        ]
    },
    "a1da8ccb-7d2a-4681-b570-48626bf35b9c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01905592",
        "Statement": "there were 4 types of Adverse events which did not affect any of the patients in cohort 1 of the primary trial. circulating tumor-derived dna positive is an indication that circulating tumor-derived dna has been detected in a sample.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "2655c892-216e-4b96-a8f2-6f64403215c5"
        ]
    },
    "36212b23-29d1-41ba-b25e-0822829cc74f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01125566",
        "Statement": "patients with an ecog score of 2 or greater can participate in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "7137dec6-5c98-4156-8035-7bbaaf0b649d"
        ]
    },
    "aea2d41f-1ec9-4252-be36-7c1d920571b0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Secondary_id": "NCT01439945",
        "Statement": "one instance of diarrhea has been found in the secondary clinical trial with no such instance in the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "bebfc78e-b35f-4677-8342-9567a7e795a1"
        ]
    },
    "b1cc397b-8696-4352-8df3-625624fb2ef4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01929395",
        "Statement": "several observable carcinomas in the areas of the stomach and the neck are a prerequisite for patients to participate in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "79ca2ee8-6c9c-40e6-a87c-925b50d3d3d2"
        ]
    },
    "774ce742-6764-418d-bdb1-0c8f1a78b0f9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "febrile neutropenia was the most common adverse event recorded in the primary trial, affecting less than 1/20 patients",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "1842904b-5371-49ee-b6f4-8831b879098b"
        ]
    },
    "ecf9e11e-b2e3-4838-9936-cbe75a0e7ead": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Secondary_id": "NCT00876395",
        "Statement": "in the primary clinical trial and the secondary clinical trial, vomiting is the most frequent adverse event.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "eb1bfb08-eba0-4130-b328-00f56c0f84a6"
        ]
    },
    "afb8dcb2-a4e0-4d52-b1f9-de7447125f46": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03012477",
        "Secondary_id": "NCT02419807",
        "Statement": "the primary trial and the secondary trial report their results using different units of measure. gna11 gene expression analysis is a laboratory assay to determine the status of the gna11 gene which encodes guanine nucleotide-binding protein subunit alpha-11.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "8460a212-8054-4bd2-b4e6-af1d137a2f79"
        ]
    },
    "20766a52-36a7-4a4b-81e9-856df9fa62a0": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00425854",
        "Secondary_id": "NCT01224678",
        "Statement": "patients with significantly elevated ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 660 months of age or over",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "6b9162d0-0816-46d4-81af-c60028dcc63b"
        ]
    },
    "75d3e031-8581-4d22-82f4-f72916fed0f1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820222",
        "Statement": "the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher precentage of patients with CNS Metastases than the Lapatinib Plus Capecitabine group. fibrosarcoma is a malignant mesenchymal fibroblastic neoplasm affecting the soft tissue and bone.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "5de9caeb-9dd5-4535-8fe3-289450d9c626"
        ]
    },
    "1ccde2e8-870a-4cf9-8343-33c65bf36f01": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00915603",
        "Statement": "at least 2 participants of the primary trial, at least one from each cohort, had a Progression-Free Survival of 10.8 months. intra-abdominal hemangioma is a hemangioma arising from organs within the abdominal cavity.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "47ba01d6-edc7-4acb-ab49-b0e86f4eeaf7"
        ]
    },
    "a797a6f9-bd99-4731-8037-03b334426696": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "the primary trial intervention protocol lasts a total of 336 hours",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "236780db-9e59-4dc9-8da0-e786287011cf"
        ]
    },
    "85bae964-a547-4cae-9856-9104810985af": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Secondary_id": "NCT00876395",
        "Statement": "diarrhoea is identified as the most commonly experienced adverse event during the primary clinical trial, while anaemia is the primary concern in the secondary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "324562e6-2b61-4a07-b937-86f99689f2d5"
        ]
    },
    "1a371c25-604d-4c59-9ef4-45427abaca94": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Statement": "Only 6/67 patients in cohort 1 of the primary trial suffered adverse events. malignant breast spiradenoma is a rare tumor characterized by malignant transformation of an eccrine spiradenoma of the breast.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "29b2fa29-5a76-4877-95bb-1a8de7973d33"
        ]
    },
    "7558c243-b121-495d-8128-75156063e460": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01998906",
        "Statement": "both cohorts of the primary trial undergo a total of 30 cycles, each lasting 2 weeks.",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "43ce26e5-03fa-4e9d-b0eb-6ea356295753"
        ]
    },
    "c61396ad-eb66-4480-8794-af73fe3816db": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01307891",
        "Statement": "no recorded cases of neutropenia existed in any cohort of the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "734423d5-4b47-4448-ab98-811015d626f0"
        ]
    },
    "cef4f2aa-89fe-4570-97b5-fde30362a5fd": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Statement": "worry about others smelling stool on me is a question about how strongly an individual agrees that they worry about others smelling stool on them. Anaemia was the most common adverse event in cohort 1 of the primary trial and tachycardia was the most common in cohort 2.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "ec1e269e-470d-43d9-8f23-8a19a5c96fcc"
        ]
    },
    "5c2f08d0-4334-4122-9ccf-112f32696fc4": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01581619",
        "Secondary_id": "NCT00106002",
        "Statement": "the outcomes of the primary clinical trial and the secondary clinical trial cannot be compared",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "0a6d1b4c-244e-44e2-a229-62e4cbdfa979"
        ]
    },
    "23ed1f94-2193-4f35-b281-35af5093e94c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00606931",
        "Statement": "all of the time is a response indicating that something happens or happened all of the time. There is no adverse events section in the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "21611c2a-e6eb-4012-a209-9b6781e1f260"
        ]
    },
    "3e991b10-b871-4105-aaf7-e181ef385cd8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "patients wanting to take part in the primary trial must have a known and documented her2+ status and an lvef of no less than fifty percent",
        "Label": "Entailment",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "6b33b4ae-36f2-4a53-a954-6f246f6e023d"
        ]
    },
    "eb776a2f-2479-48e1-b2ab-e0f8d4a6e1fd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00263588",
        "Statement": "the ability to orally ingest medication is a requisite for patients participating in the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "5c1e360c-fd93-4dd4-b855-71ba416d34cb"
        ]
    },
    "f01f5948-1c30-418f-a727-a72adf622b95": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01998906",
        "Statement": "nectin4 positive is an indication that nectin4 expression has been detected in a sample. Both cohorts of the primary trial undergo a total of 17 cycles, each lasting 3 weeks .",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "43ce26e5-03fa-4e9d-b0eb-6ea356295753"
        ]
    },
    "03d4ddf2-ca72-4869-8f9e-bd9d65ed8561": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Secondary_id": "NCT03098550",
        "Statement": "participants of the primary clinical trial have stages 0 or 1 melanoma skin cancer solely, secondary clinical trial participants must present a specific stage of cancer for enrollment",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "07042b0f-d422-49c3-8d53-81319927a4b3"
        ]
    },
    "0522b99f-9c7e-4cbc-81c9-9228c8cdfb00": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01912612",
        "Statement": "in the primary clinical trial, none of the subjects in either cohorts experienced congestive heart failure.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "d1b217ae-76f3-4ba6-958e-5b2558703ba4"
        ]
    },
    "98bcf607-a6b8-4292-8144-4554eeef1521": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00357110",
        "Statement": "several fatalities were evident in the data from the primary clinical trial cohorts.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "751fd763-89fa-4d52-8bda-f09b490a5e78"
        ]
    },
    "0732d9de-1cb3-4d76-ada6-3f605750bc36": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00374322",
        "Statement": "80% of patients in the primary trial received a placebo intervention. problem is a difficulty, disorder, or condition needing resolution.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "e147796d-2edd-42d1-ac53-300fb8bd5eb6"
        ]
    },
    "50d74579-bbce-4913-ae45-a05fae56c21b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "a patient with node-negative adenocarcinoma of the lung with a tumor diameter of 3.0cm is eligible for the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "e6a4e9a6-56b8-4a30-9743-eb02688c090f"
        ]
    },
    "dc219d0a-e087-4d60-9757-d0985a3a6c02": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00944047",
        "Statement": "over 90% of the primary trial patients in the intervention arm experienced pathologic complete response",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "9f7d476e-9db3-4c00-abe6-4c2f0160470a"
        ]
    },
    "882b1061-de70-471f-918a-c1f2a8ac3634": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00357110",
        "Statement": "there were 6 recorded deaths in cohort 1 of the primary trial and 7 in cohort 2. findings about events or interventions sequence number is a number that identifies the ordering relations (in time, space, etc.) in a set of findings.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "f114846e-79d8-4712-add0-bb34b65d418f"
        ]
    },
    "1cfffa59-c8a8-41d9-9b1c-4aa576a32694": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00450723",
        "Secondary_id": "NCT00290758",
        "Statement": "all the documented episodes of musculoskeletal adverse effects took place in the cohort 2 of the secondary trial, as compared to the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "f3cb9150-32c6-4877-9a87-4fac45a24948"
        ]
    },
    "49a17441-348b-4fd9-9932-9f5715a5f4a4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Secondary_id": "NCT00121992",
        "Statement": "conjunctivitis was prevalent in the secondary trial with 15 cases while the primary trial reported just 2 cases",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "c100a7cd-e3a2-4901-a3e0-12336f769c7b"
        ]
    },
    "5b41ed73-7f61-409a-89af-0f614f469921": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02915744",
        "Statement": "neither the secondary trial or the primary trial record the Overall Survival (OS) of Patients in their cohorts. resultor is a genus of very small, flagellated green algae.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "dc4c57b0-8c75-494e-81b0-3528df85ebff"
        ]
    },
    "06a93159-a45c-4c6b-9d5e-cd4aea33e76d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00333775",
        "Statement": "the primary clinical trial groups each receive the same dosage of docetaxel",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "9bcc31df-c1f6-4785-9235-f673213acf3a"
        ]
    },
    "51be7c95-8da4-419c-950c-91ebdd2c3fe5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572727",
        "Secondary_id": "NCT00328783",
        "Statement": "All patients in the primary trial receive higher doses of BKM120 than patients in the secondary trial",
        "Label": "Contradiction"
    },
    "e4431653-796c-4ab8-b1eb-900ea7522ef6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00333775",
        "Statement": "both the primary trial cohorts receive identical doses of Docetaxel, with cohort 1 also receiving 100 mg/m^2 of Placebo. tape is a long thin piece of cloth or paper as used for binding or fastening.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "a5e388b9-da3c-437e-a6af-7ba76ad8bf1d"
        ]
    },
    "b1219e71-fbf5-4bba-8a93-a27ae444e3e1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274469",
        "Statement": "to be eligible for the primary trial patients must be diagnosed with hormone receptor positive advanced breast cancer, but can not have received any previous treatment for this advanced cancer",
        "Label": "Entailment"
    },
    "d387d20a-5d21-4fe7-af26-9aa981b1f5fd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "patients in cohort 1 of the primary clinical trial had a pfs of less than 3 months, and the maximum pfs recorded was 5 months",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "b8eaa8fd-61cf-4ca9-aaec-267d61c1fae3"
        ]
    },
    "ee57c0fd-ae73-46cd-9625-3eb4b1bd356e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01011946",
        "Secondary_id": "NCT00066573",
        "Statement": "anal cancer pnx tnm finding v8 is anal cancer in which the regional lymph nodes cannot be assessed.  (from ajcc 8th ed.) the primary trial participants are not administered any oral medication whereas the secondary trial patients only receive treatment orally.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "6402e13a-7cfb-4774-b7f9-80ecb79fda2a"
        ]
    },
    "579fc2af-883e-4758-bfc9-b513c907cbeb": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "in the primary clinical trial, febrile neutropenia was a rare adverse event, impacting less than 1% of the participants",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "1842904b-5371-49ee-b6f4-8831b879098b"
        ]
    },
    "f28608d0-6fdf-48d3-aafa-c6cd8215ede2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00374322",
        "Statement": "the majority of patients in the primary clinical trial were administered a therapeutic intervention",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "e147796d-2edd-42d1-ac53-300fb8bd5eb6"
        ]
    },
    "deaa8690-f5ac-4071-a8b7-d6cd2a37b1d3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00612560",
        "Secondary_id": "NCT01216176",
        "Statement": "have breast swelling is a question about whether an individual has or had breast swelling. All the primary trial participants are administered Anastrazole in a pill form, but none of the secondary trial receive any Anastrazole.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "e9fd065c-342c-4dfb-9c1c-a4c0c44d0acd"
        ]
    },
    "eb14e12b-39dc-46ac-972e-e3ea4bf6120a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00900627",
        "Statement": "in the primary clinical trial, half of the patients from cohort 2 experienced dose limiting toxicities",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "1f6a14ae-e22b-4b40-b389-217570dbf38e"
        ]
    },
    "f4be929a-a01c-4e7b-a90f-e0336d603719": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Secondary_id": "NCT01439945",
        "Statement": "no case of diarrhea has been reported in either the primary or the secondary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "bebfc78e-b35f-4677-8342-9567a7e795a1"
        ]
    },
    "a261a508-f595-4042-9dcb-afb01e8bd0e3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00063570",
        "Statement": "individuals diagnosed with a malignant brain tumour or colon cancer are suitable for the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "015dd869-db90-45a9-a951-9dc7dc2b2e01"
        ]
    },
    "0c370109-e0ae-4a91-aa6c-f21c7dec9c44": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02186015",
        "Statement": "participation in the primary clinical trial is open to both adults and children",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "2825d63b-8f22-4fb8-829f-9567845251c6"
        ]
    },
    "22533f8b-299d-4635-8a29-ccfb21204358": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00063570",
        "Statement": "jejunal fistula, ctcae is a disorder characterized by an abnormal communication between the jejunum and another organ or anatomic site. patients with a Malignant brain tumour diagnosis are excluded from the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "62e449ad-16b3-479d-94a5-ffc435b5e99c"
        ]
    },
    "78e42d55-5d87-4da0-98bf-44acfeef306b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Secondary_id": "NCT00325234",
        "Statement": "the number of urosepsis instances in the primary clinical trial is higher compared to the secondary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "7271e0db-bb82-423f-ad95-5ffa84fab97e"
        ]
    },
    "5bbfce59-7d9d-4b69-9b33-98f2ca0c8489": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Statement": "adverse events were experienced by more than one-sixth of patients in the first cohort of the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "8e91e404-086e-4063-8d54-83d1b8ebd969"
        ]
    },
    "ad02bc38-af82-4833-b533-9b4436ba1769": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00820170",
        "Secondary_id": "NCT00263588",
        "Statement": "any patient eligible for the secondary trial will also be eligible for the primary trial . south africa is a country in southern africa, at the southern tip of the continent of africa.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "a0065d58-e03b-4dd0-9c81-cbbf651a6d45"
        ]
    },
    "ab0565a9-309c-41a4-b72d-6cb5d0b0abde": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00450723",
        "Secondary_id": "NCT00290758",
        "Statement": "Between the secondary trial and the primary trial, all the recorded case of Dyspnea occurred in cohort 1 of the secondary trial. milliliter per microgram per meter squared per day is a unit of concentration equal to milliliter divided by microgram per meter squared per day.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "f04d9695-81b8-4d70-877b-59caddf901bd"
        ]
    },
    "49dc0ce3-768c-455c-a60f-7d9fd79bd097": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00263588",
        "Statement": "her2- breast cancer is a requirement for patients to engage in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "215a5c4a-d90c-4500-8284-0679ce311734"
        ]
    },
    "72187a4b-b593-4777-aaf4-7ab1e7210fae": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00754325",
        "Statement": "in the primary trial, patients that received Fulvestrant were much more likely  to suffer Disease Progression or Death than patients receiving herceptin. intra-abdominal hemangioma is a hemangioma arising from organs within the abdominal cavity.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "ba9daeb9-796d-49ab-a30c-4d8acbdf4d37"
        ]
    },
    "2fc86666-08df-4381-b1c3-6aeb2f761a7b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03098550",
        "Statement": "carcinoma of littre glands is an adenocarcinoma that arises from the littre glands. both cohorts of the primary trial receive identical interventions, the difference between the two cohorts is the types of cancer that the patients have, with cohort 1 all being diagnosed with HER2 positive cancer and cohort 2 being PR-.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "3adcc8fc-b76b-407a-a006-729a13f571fb"
        ]
    },
    "0d24aed8-d0b1-4e83-8b8b-9f3289c52674": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005879",
        "Statement": "the percentage of patients with slipped disks was equal in both cohorts of the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "e4aeb013-7713-4b73-acbd-f8379cc6a494"
        ]
    },
    "aaa4499c-ec30-4b7a-a7b0-6272d05b9abb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00374322",
        "Statement": "0.5% of patients in the primary trial received a placebo intervention",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "e147796d-2edd-42d1-ac53-300fb8bd5eb6"
        ]
    },
    "7dcbce2d-788f-4f09-b2c9-56aaeabdeab4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00503906",
        "Statement": "the treatment protocol of the primary clinical trial includes a pre-determined number of intervention cycles that will not be influenced by disease progression.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "59cd7909-00c3-4c23-9a08-a42dbc8eabdd"
        ]
    },
    "489abf71-505a-4897-8b60-0f33a293871a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Secondary_id": "NCT00876395",
        "Statement": "fatigue is noted as the most common adverse effect during the primary clinical trial, and neutropenia is the most commonly observed in the secondary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "324562e6-2b61-4a07-b937-86f99689f2d5"
        ]
    },
    "07210aae-3633-48ca-be20-ced39f79ad54": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00593346",
        "Statement": "iovance biotherapeutics is a biopharmaceutical company working to develop tumor-infiltrating lymphocyte therapies against cancer. the primary trial does not report the PFS or objective response rate of its patient cohort, instead reporting the proportion of patients which experience dermatitis.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "88668508-dfd4-4a39-91cd-cf1654a6dfc4"
        ]
    },
    "dd92c30d-cdb9-472d-bf0b-9d0867d9de6f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "grade ii heart sound is a heart sound that is as loud as the breath sounds. Patients with Extracranial metastases can be eligible for the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "b9491012-49ba-4eb1-8230-1966f54ea012"
        ]
    },
    "d87477cc-f052-4fe5-a2db-7f12057ddbb8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02658734",
        "Statement": "in the primary clinical trial, grade 1 adverse events were the most common among patients, with grade 4 being the least frequently occurred.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "878c09e7-3fd9-404e-921e-5b549e9578fb"
        ]
    },
    "743ebfba-fd55-4e3a-ad14-56d06eb4f47c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03098550",
        "Statement": "both cohorts of the the primary clinical trial consist of patients with different types of cancer, but they all have received a diagnosis of pik3ca mutation.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "3adcc8fc-b76b-407a-a006-729a13f571fb"
        ]
    },
    "0e1df21a-c99b-411c-b89a-7f05c77d543b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00428922",
        "Statement": "the primary clinical trial measures the increase in overall survival rate of the patients after the treatment",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "d01fda83-5dc8-4ad5-92b8-7553dabd7046"
        ]
    },
    "c9fb8161-feb4-44b2-8578-b00931b490fb": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Secondary_id": "NCT00325234",
        "Statement": "there are no recorded instances of holocraneal cephale and catheter - related infections in both the primary and secondary trials",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "9c033072-5f94-4d79-af47-126d531f0d6e"
        ]
    },
    "3793f53c-184f-46dc-92ce-5126f660c306": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00450723",
        "Secondary_id": "NCT00290758",
        "Statement": "among both primary and secondary clinical trials, it was cohort 2 of the secondary trial where all instances of musculoskeletal adverse events were reported.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "f3cb9150-32c6-4877-9a87-4fac45a24948"
        ]
    },
    "26e73b3d-a437-402f-a3c3-65f61e0b44ec": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00503750",
        "Secondary_id": "NCT00005879",
        "Statement": "shoulder presentation is a fetal presentation during delivery in which the shoulder descends into the birth canal first. The results from the secondary trial and the primary trial are non-comparable.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "dca4c9f7-bb2a-4f73-b390-93b7ced87c73"
        ]
    },
    "538bdb5c-f825-492e-9dd3-f0aa251971fa": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Secondary_id": "NCT00425854",
        "Statement": "in their interventions, both the primary and secondary clinical trials utilise objective response for outcome measurement.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "402f0dbf-cf67-4425-b300-a0a3df4d59d3"
        ]
    },
    "079784a9-8bc8-4b72-9947-50b4f095549a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "more than 5% of patients in the primary clinical trial experienced febrile neutropenia, marking it as the most common adverse event",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "1842904b-5371-49ee-b6f4-8831b879098b"
        ]
    },
    "d82013d5-0552-4377-9bf7-1c93a05f0cc3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "The most common AE in the primary trial was Non-cardiac chest pain, which affected less than 5% of participants in cohort 1. skin ewing sarcoma is a rare ewing sarcoma that arises from the skin.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "2da13cd4-7189-4f85-be4d-5c1e213ae293"
        ]
    },
    "e4f9f95d-c38c-4c28-89c4-6e30a9b5bfdf": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03012477",
        "Secondary_id": "NCT02419807",
        "Statement": "both the primary clinical trial and the secondary clinical trial present their findings in the form of a ratio but use different units of measure.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "0e609fad-9a28-4fb6-90b6-32a731e3b02c"
        ]
    },
    "e20afb12-a489-4d69-bbe3-1baba388e453": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00328783",
        "Statement": "the part of the primary clinical trial concerning adverse events is devoid of information",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "fef5aedb-21c0-4130-b8a3-cb1df5017c7a"
        ]
    },
    "19484738-75c7-453f-8aec-02624cab7734": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00503750",
        "Secondary_id": "NCT00005879",
        "Statement": "the primary and secondary clinical trial results can be juxtaposed by converting the measurement units from days to months",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "7d52734c-0801-413d-9ae2-d190b972cde5"
        ]
    },
    "0983850d-5e98-44eb-be39-b9b9d0bcd679": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274469",
        "Statement": "in order to qualify for the primary clinical trial, patients must have a diagnosis of hormone receptor-positive advanced breast cancer, without having undergone any prior treatment for this advanced condition",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "b1219e71-fbf5-4bba-8a93-a27ae444e3e1"
        ]
    },
    "7687c395-2d46-4a34-9484-a4480362ee08": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274469",
        "Statement": "patients who have been diagnosed with hormone receptor positive advanced breast cancer and have received chemotherapy for the same in the past are eligible to partake in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "2e76c74a-b6dd-47d8-a674-c1e80b0a3a65"
        ]
    },
    "e66897b9-753e-45d1-af1e-9cbe02a3b0cb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03098550",
        "Statement": "the two cohorts in the primary clinical trial are administered similar interventions, however, they are uniquely classified by the type of cancer. all patients in cohort 1 have been diagnosed with her2 positive cancer while those in cohort 2 are pr-.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "3adcc8fc-b76b-407a-a006-729a13f571fb"
        ]
    },
    "c7792119-1dd0-49dc-8865-9c18db247b2e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "6q26 is a chromosome band present on 6q The most common AE in the primary trial was Non-cardiac chest pain, which affected less than 5% of participants in cohort 1.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "2da13cd4-7189-4f85-be4d-5c1e213ae293"
        ]
    },
    "fb55e5f6-aa19-4d9b-8567-d01ee5f445c8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02131064",
        "Statement": "in cohort 1 of the primary trial there were 10 more cases of Left ventricular dysfunction than Abdominal pain. colorectal traditional serrated adenoma is an adenoma that arises from the colon or rectum.  it is characterized by prominent serration of the glands.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "1329dec6-fb2c-4219-9db6-3fef9d94b316"
        ]
    },
    "e7604382-09cd-43b4-998f-a51b33f25c5a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT00232505",
        "Statement": "the primary trial and the secondary trial participants do not receive any medication orally",
        "Label": "Entailment"
    },
    "6b33b4ae-36f2-4a53-a954-6f246f6e023d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "Patients wanting to take part in the primary trial must have a Known and documented HER2+ status and an LVEF of at least 50 percent (%)",
        "Label": "Entailment"
    },
    "e7f013a3-97f3-4634-b072-d0b41554c774": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820222",
        "Statement": "animal mix antigen igg antibody measurement is a measurement of the animal mix antigen igg antibody in a biological specimen. the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher precentage of patients with Grade 3 or 4 skin/subcutaneous or pulmonary toxicities, than the Lapatinib Plus Capecitabine group.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "566bdc2d-7c4a-4547-87da-ac81447ecca8"
        ]
    },
    "29008a90-878c-4b55-abc6-04f63f7f730c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "the primary clinical trial exclusively accepts patients with no history of extracranial metastases.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "b9491012-49ba-4eb1-8230-1966f54ea012"
        ]
    },
    "21445e52-9bf8-43bc-bf03-f39571701c34": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Statement": "over 1/6 patients in cohort 1 of the primary trial suffered adverse events. mcpyv positive is an indication that merkel cell polyomavirus has been detected in a sample.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "8e91e404-086e-4063-8d54-83d1b8ebd969"
        ]
    },
    "2a3ddce9-4b39-4081-8fc4-5dc2a1cac0f7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00944047",
        "Statement": "under 0.3 of the primary trial patients in the intervention arm experienced pathologic complete response",
        "Label": "Entailment",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "9f7d476e-9db3-4c00-abe6-4c2f0160470a"
        ]
    },
    "fb368ad1-36e2-48c6-b07a-361aac4bc850": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00944047",
        "Statement": "in the primary clinical trial, under 30% of the intervention arm participants experienced pathologic complete response",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "9f7d476e-9db3-4c00-abe6-4c2f0160470a"
        ]
    },
    "b353ff5b-540d-4073-9456-2ec1a465cb02": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00733408",
        "Statement": "the most recurrent adverse occurrence noted in the primary clinical trial was syncope",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "9d8b26d6-d574-4717-88b6-77458bc683f3"
        ]
    },
    "022d0a3c-a531-4b96-b73a-4ccff98d03d2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00333775",
        "Statement": "both cohorts in the primary clinical trial are treated with same amount of docetaxel, yet an additional dose of 100 mg/m^2 of placebo is given to cohort 1.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "a5e388b9-da3c-437e-a6af-7ba76ad8bf1d"
        ]
    },
    "ab491bed-d684-406a-9e36-c0ce182359c9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042938",
        "Statement": "the primary clinical trial reports a significant contrast between the severity of dermatitis in radiation treatment site in the curcumin c3 complex cohort versus the placebo cohort.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "e62f5a3f-0091-4980-9822-db8f4dc2502a"
        ]
    },
    "f600318b-19df-4963-bd75-a35d2229cf20": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Statement": "the proportion of patients with zero side effects after being treated with neratinib and paclitaxel has been reported in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "cdadcb0a-20c5-47f7-a63a-39f5c6f26ae2"
        ]
    },
    "1e1e4e1d-a776-4fbf-ae68-709d154bdda3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Statement": "all patients accepted into the primary trial have undergone Prior treatment for breast cancer with endocrine therapy. dry tap aspiration is an aspiration that does not yield any material.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "6d621974-c719-46df-8a50-d94e49583e33"
        ]
    },
    "d47f3e8d-4cda-419c-8deb-73b53a02cbf9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01224678",
        "Secondary_id": "NCT01042535",
        "Statement": "in the secondary clinical trial, instances of mental health issues, pleuropericarditis, atrial thrombosis, and anemia were more prevalent compared to the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "57b2ae97-0d1d-4d5d-bc4b-109e8e5acb32"
        ]
    },
    "38cde569-af36-4335-bd58-18aca8c4e1e3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00612560",
        "Secondary_id": "NCT01216176",
        "Statement": "all the primary trial participants are administered placebo in pill form, but all secondary trial participants receive anastrazole",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "e9fd065c-342c-4dfb-9c1c-a4c0c44d0acd"
        ]
    },
    "7114a258-718c-49a0-a60e-51dea0d93daa": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00328783",
        "Statement": "the adverse events section of the primary clinical trial has no record of any aes.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "97fd111c-6969-43ab-93af-b3dff09960e5"
        ]
    },
    "b6e33e5a-eff5-4006-96e0-0e74c0cb8959": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00009945",
        "Statement": "multiple adverse events in the primary clinical trial have affected more than 150 patients each.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "1314146f-2869-4525-8034-7f732d238385"
        ]
    },
    "0b6ae882-d74a-411a-83a5-f856198d28d3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00900627",
        "Statement": "symptoms of keratitis were not recorded for cohort 2 patients in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "09fc4356-6154-427e-b710-ed5df6470aff"
        ]
    },
    "de5e6615-d267-4923-a693-f973b4702d34": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Secondary_id": "NCT03098550",
        "Statement": "all participants of the primary trial have stage 3 cytologically confirmed invasive breast cancer, there is no specific stage of cancer required for entry to the secondary trial. refractometer is an optical instrument that can be used to determine the refractive index of a sample.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "7f3fe97e-68ee-470f-b06e-21cdddb67aa8"
        ]
    },
    "03043322-4f92-49d9-b85c-e321cd85c5b6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00428922",
        "Statement": "the measurement of outcome in the primary clinical trial is based on the length of time a patient lives with the disease without deterioration, encompassing the treatment period and thereafter.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "d01fda83-5dc8-4ad5-92b8-7553dabd7046"
        ]
    },
    "db454526-8e4a-4c8c-a656-7eaf33a3a59a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00944047",
        "Statement": "injection system device is a system designed to pump a gas or liquid into a space or environment. under 30% of the primary trial patients in the intervention arm experienced Pathologic Complete Response.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "9f7d476e-9db3-4c00-abe6-4c2f0160470a"
        ]
    },
    "d923c77d-f5dc-46d1-bfed-2615123adeca": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02915744",
        "Statement": "the metrics recorded in the results section of the primary clinical trial and the secondary clinical trial are not identical",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "dd2f3c3d-fa95-4fca-a3f0-795fd4f3abf1"
        ]
    },
    "0e79b14e-6f37-490c-bef0-e2a99c734ef4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01125566",
        "Statement": "an ecog score greater than 2 is a prerequisite for the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "7137dec6-5c98-4156-8035-7bbaaf0b649d"
        ]
    },
    "3a7683bf-e1e8-4483-b7ba-240265fd83c5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00240071",
        "Statement": "the primary trial participants are administered Avastin, Bevacizumab and radiotherapy as part of the intervention. razupenem is a broad-spectrum carbapenem with activity against gram-positive bacteria, including methicillin-resistant s. aureus.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "045ad91e-44fa-42cc-ac22-a7aab26a9009"
        ]
    },
    "e64889af-f735-4bae-8eef-dbb0f7ec002d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00477464",
        "Statement": "in the primary clinical trial, capecitabine is administered with greater frequency compared to lapatinib.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "a52b2d4f-0b06-4960-a9c3-88cb92df0980"
        ]
    },
    "9300ef96-4be2-4409-b752-86745a590498": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005879",
        "Statement": "there was a higher percentage of patients with slipped disks in cohort 2 of the primary trial than in cohort 1. progesterone receptor positive by immunohistochemistry 1-10 percent is an immunohistochemical staining finding indicating that 1-10 percent of the cells in a tissue sample are expressing progesterone receptor.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "e4aeb013-7713-4b73-acbd-f8379cc6a494"
        ]
    },
    "0e869af1-16f1-4136-9316-403f110e5d4e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Secondary_id": "NCT01644890",
        "Statement": "the primary clinical trial gauges the cohort's percentage of participants who have an objective response, while the secondary clinical trial monitors pfs.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "794269ca-e7ec-4a65-ace5-b0f24a8cdc15"
        ]
    },
    "e96e370c-8830-492c-ad2b-3e5cd5c09481": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820222",
        "Statement": "there was no difference in the percentage of patients with cns metastases between the trastuzumab plus capecitabine group and the lapatinib plus capecitabine group in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "5de9caeb-9dd5-4535-8fe3-289450d9c626"
        ]
    },
    "1c979775-45b3-41ca-833e-a9659ec96bd3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Statement": "the primary clinical trial stipulates that patients should have a life expectancy of at least 75 years.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "4b97a844-8d52-48bb-8eda-ca205268f016"
        ]
    },
    "4a2b8760-bca0-4675-8e28-3ee3c6e3bed2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00066573",
        "Statement": "the outcomes of the two primary clinical trial cohorts exhibit no difference.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "1adc970c-d433-44d0-aa09-d3834986f7a2"
        ]
    },
    "af62cfb4-50da-4294-ba18-e61e40e96592": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01905592",
        "Statement": "taenia is a genus of parasitic cestodes in the family teaniidae that infect mammals and are characterized by ribbon-like bodies. there were 4 types of Adverse events which did not affect any of the patients in cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "2655c892-216e-4b96-a8f2-6f64403215c5"
        ]
    },
    "2f0d3229-f77e-493b-aca2-905d9bb9370e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572727",
        "Secondary_id": "NCT00328783",
        "Statement": "patients in both the primary and secondary trial receive equivalent dosages of paclitaxel",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "3ba42f68-a643-4d10-afd0-cbb358d05a6f"
        ]
    },
    "c5f003f3-41a2-4471-80b7-3524d5c972dd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Statement": "all participants of the primary clinical trial must be under ongoing flucytosine treatments, which should have commenced no less than 6 months prior to entering the study.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "565d7982-aa9a-4c01-987c-1d67bc9c212d"
        ]
    },
    "a48dc2cd-b734-4880-913d-a4eb1e6805eb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02658734",
        "Statement": "most patients in the primary clinical trial experienced grade 4 adverse events, the least common severity was grade 1.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "878c09e7-3fd9-404e-921e-5b549e9578fb"
        ]
    },
    "1739cf44-7800-40bc-9a2e-20bb12078bc2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00376597",
        "Statement": "Patients with stage 4 cancer are excluded from the primary trial, only patients with stage 2 and 3 cancer can be eligible. upset by swallowing problem is a question about whether an individual is or was upset by their swallowing problem.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "b1dd7632-ed92-40a9-9293-bce68619c658"
        ]
    },
    "ae2ff99b-b6ce-4645-bea2-ea03336fdfae": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00063570",
        "Statement": "people with a diagnosis of malignant brain tumour or colon cancer can be part of the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "015dd869-db90-45a9-a951-9dc7dc2b2e01"
        ]
    },
    "f0d57882-27ff-4d4d-8033-1af2e1e9478f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Statement": "adverse events in the primary clinical trial's cohorts 1 and 2 were predominantly characterised by thrombocytopenia",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "fbb62216-2cf2-4813-ad41-12a86940610f"
        ]
    },
    "b498810f-c213-463b-a57d-9390a0ec221b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00093795",
        "Statement": "in cohorts 1 and 2 of the primary clinical trial, most participants experienced some form of disease relapse, contralateral breast cancer, second primary cancer or death from any cause before recurrence or secondary primary cancer",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "0ea29bd5-20be-40ea-8ad7-705d283d1d48"
        ]
    },
    "cde860c3-a89b-413a-9c08-732c02539bfe": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT00852930",
        "Statement": "no adverse events linked to cardiac issues or infections are recorded in the primary clinical trial and the secondary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "06f798d1-2956-4903-83e9-58a41fa425f7"
        ]
    },
    "f0e845f9-8991-45b5-a520-51e934756f7a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00450723",
        "Statement": "The the primary trial intervention involves one drug taken orally and the secondary trial intervention is based on a medical procedure.",
        "Label": "Entailment"
    },
    "4b5c809d-5a36-4093-9593-2df7d7ef7901": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00281697",
        "Statement": "her2-positive patients may participate in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "00822101-fa21-4a26-bf45-3b1f535da005"
        ]
    },
    "4226c092-9e04-44f7-8665-8e93f1b385f1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01416389",
        "Statement": "the primary trial reports the changes in the number of lesions for patients in its cohorts. pancreatic cystadenocarcinoma is a cystic adenocarcinoma that arises from the pancreas. it includes the acinar cell and serous cystadenocarcinoma subtypes.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "812bd63c-4bfb-49cb-8fa9-baa3f8f6dabe"
        ]
    },
    "94dd27c7-bc5c-47f4-b742-39961a4fc4eb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "the primary trial intervention protocol will continue until patients achieve complete response or suffer disease progression. peripheral pulmonary nodule is a pulmonary nodule located in the outer third of the lung.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "1d1f57f8-85f7-448c-a4bb-15957da568fd"
        ]
    },
    "206d0108-2c7b-4a20-be8f-cb76cb210623": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "febrile neutropenia was the most common adverse event recorded in the primary trial, affecting more than 0.05 of patients",
        "Label": "Entailment",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "1842904b-5371-49ee-b6f4-8831b879098b"
        ]
    },
    "9b6b4ed9-dcf5-4074-ba37-463f249edd79": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "all of the primary trial patients achieved either disappearance of all target lesions, >=90% decrease in the sum of the longest diameter of target lesions or a tumor that is neither growing nor shrinking.",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "7e5fd062-6ec3-480f-ab0e-e117eba2ffe7"
        ]
    },
    "865a0dc7-6fc6-40ce-a173-bfd116bd105f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00066573",
        "Statement": "the results of the two cohorts from the primary clinical trial drastically differ",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "fe876bb0-7ce3-4197-81ad-920f1f77938e"
        ]
    },
    "63b783f0-9527-4dc6-946d-ed90dd35728c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00593346",
        "Statement": "in the primary clinical trial, the pfs and objective response rate of the patient population is not indicated",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "cc1f712a-2116-4e40-9810-f315e3fa5ff8"
        ]
    },
    "b8a22e20-516b-405a-92d9-f098b19bb298": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "There were more total AEs in cohort 1 of  the primary trial than cohort 2. cubic inch is a traditional unit of volume equal to 16.3871 cubic centimeters, or 0.5541 us fluid ounce.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "1c4e3fe3-b5fe-4ea3-8d9e-0ce1502080e7"
        ]
    },
    "a52b2d4f-0b06-4960-a9c3-88cb92df0980": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00477464",
        "Statement": "the primary trial participants receive Capecitabine less often than they receive Lapatinib",
        "Label": "Contradiction"
    },
    "985bc5a0-bc21-447f-92f1-150e23ede3f5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "All the primary trial patients had a minimum of 50% decrease in the sum of the longest diameter of target lesions",
        "Label": "Contradiction"
    },
    "245dccf4-79d8-4231-91c0-b318a4c462d3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT03176238",
        "Statement": "There less cases of Acute myocardial infarction, Cardiopulmonary failure and Supraventricular tachycardia in cohort 1 of the secondary trial than in cohort 2 of the primary trial. plastic vial is a plastic container designed for use with parenteral drug products.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "080da381-b5dd-46d3-99c4-18112da153c1"
        ]
    },
    "0f0e95d3-fa6d-4f6a-bd82-7a94ab3d5871": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "patients with an unknown her2 status and a left ventricular ejection fraction (lvef) below 50% can participate in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "6b33b4ae-36f2-4a53-a954-6f246f6e023d"
        ]
    },
    "46364116-5130-4d21-bd72-8e0791f3d1ea": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02658734",
        "Statement": "most patients in the primary trial experienced a grade 6 adverse events, the least common severity was grade 10, which only affected 85/350 patients.",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "40f699a1-fbc6-40de-8e80-85b28f71632f"
        ]
    },
    "20109d6e-dfac-4362-8db9-0ad4e7f3dbf1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02915744",
        "Statement": "Cohort 1 and 2 of the primary trial do not receive the same intervention. walked for exercise is a question about whether an individual has walked for exercise.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "8e9611fc-89f8-44cb-af09-8d71a13ca082"
        ]
    },
    "51d69b9f-c040-42d9-b944-3ba40833494f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "an established her2+ diagnosis and a left ventricular ejection fraction (lvef) equal to or above 50 percent is necessary for patients interested in the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "6b33b4ae-36f2-4a53-a954-6f246f6e023d"
        ]
    },
    "55cbbd3c-3853-420b-85e3-b0606835a618": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02924883",
        "Statement": "those diagnosed with hormone receptor-positive breast cancer can participate in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "c10eea1a-5768-442d-ae07-20b4f8f4b583"
        ]
    },
    "ba9daeb9-796d-49ab-a30c-4d8acbdf4d37": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00754325",
        "Statement": "in the primary trial, patients that received Fulvestrant were much more likely  to suffer Disease Progression or Death than patients receiving herceptin",
        "Label": "Contradiction"
    },
    "f9addbf6-3cd6-4092-ba4f-f44aa32109e5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00900627",
        "Statement": "all patients in cohort 2 of the primary clinical trial experienced dose limiting toxicities.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "1f6a14ae-e22b-4b40-b389-217570dbf38e"
        ]
    },
    "de598b30-35d6-44d0-95c0-d86ff11d90d6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00900627",
        "Statement": "only 10% of cohort 2 patients in the primary clinical trial suffered from dose limiting toxicities.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "1f6a14ae-e22b-4b40-b389-217570dbf38e"
        ]
    },
    "13d48c91-e243-4409-9fea-a1935128462a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Secondary_id": "NCT00274469",
        "Statement": "the primary clinical trial and the secondary clinical trial are open to female patients diagnosed with progressive breast cancer",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "68379456-775b-463b-bfdb-d8aa42c9124b"
        ]
    },
    "f9d2c96a-8228-4e64-877b-16b0eef977cd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02186015",
        "Statement": "only adults are eligible for participation in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "2825d63b-8f22-4fb8-829f-9567845251c6"
        ]
    },
    "3d84aa71-13c1-4020-90f8-bf475ecb8f00": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Statement": "ongoing flucytosine treatments are not permitted for participants of the primary trial. difficult is a response indicating that something is or was difficult.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "f10f3b84-e039-4a02-a98b-86d149d9a16f"
        ]
    },
    "4e4a7e50-5542-4d0b-8173-83bf7f3b02c2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01416389",
        "Statement": "change in tumor size is not a parameter observed in the primary clinical trial for patient evaluation.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "7cde9a22-a91f-4feb-892d-7cbd35f96a27"
        ]
    },
    "5ac2492d-59c1-435b-9a8e-8ec61c12e7bf": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "the intervention protocol for the primary clinical trial will persist until patients reach full recovery or their ailments advance.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "1d1f57f8-85f7-448c-a4bb-15957da568fd"
        ]
    },
    "7a8bad77-3ec6-48f6-90d4-0c86ea857135": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Secondary_id": "NCT00425854",
        "Statement": "neurula is an stage in embryonic development during which neurulation takes place, and which follows the gastrula stage. the secondary trial and the primary trial use Objective Response as the outcome measurement for their interventions, however they use different definitions of complete response .",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "8d9f94e3-871b-4fb4-a522-0a73d9d0ec3c"
        ]
    },
    "0ddb07ae-6e70-436d-8723-f609e59c57da": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01118624",
        "Statement": "the primary trial participants recieve doses of Pralatrexate that are calculated based on bodyweight",
        "Label": "Contradiction"
    },
    "a957f614-db1e-4cc3-a980-395e66288472": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00331630",
        "Statement": "some is at least a small amount or number of, but not a large amount of, or often. no cardiac or neural adverse events were recorded in the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "c7dc582a-4a58-4cb5-b980-b2d2b6a128c3"
        ]
    },
    "04c3885b-7468-4093-9fbd-27c22f78ca18": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00425854",
        "Secondary_id": "NCT01224678",
        "Statement": "reader 3 is a reader performing the assessment that is given the designation of three. Patients with significantly low ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or younger .",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "d1b7105d-0b7d-4b10-92a7-d63243ff0629"
        ]
    },
    "9237751c-3f08-48ef-8e2e-3dec3f984059": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00820170",
        "Secondary_id": "NCT00263588",
        "Statement": "the conditions for participation vary between the primary clinical trial and the secondary clinical trial.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "3a4003f6-ff1c-43d8-be48-f767266b2cf5"
        ]
    },
    "4cb102da-fb0e-4ecf-90be-ade24c729c1e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01042535",
        "Statement": "skin infection was oftentimes the adverse event identified in the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "4f705481-5dd0-414c-b375-c56e8c235b42"
        ]
    },
    "035edcef-794e-46e4-9a3f-60075a79819d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00593346",
        "Statement": "the primary clinical trial does not disclose the progression-free survival or objective response rate of its patient group",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "cc1f712a-2116-4e40-9810-f315e3fa5ff8"
        ]
    },
    "b7df49ee-2935-4bbe-851e-7f32f6c74038": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Secondary_id": "NCT00274469",
        "Statement": "ability to do social activities after treatment is a question about an individual's ability to do social activities since treatment. Patients must be female and have confirmed advanced colon cancer to be eligible for the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "06fad978-1dc3-46f5-b45f-5ac6577f28b9"
        ]
    },
    "d13e3f09-cf3e-4965-90d3-a9dad3c4e6a2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00733408",
        "Statement": "the primary clinical trial recorded syncope as the most prevalent negative incident",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "9d8b26d6-d574-4717-88b6-77458bc683f3"
        ]
    },
    "6f219465-6f0d-485b-8579-52ba0f48a7c1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02658734",
        "Statement": "most patients in the primary clinical trial experienced a grade 5 adverse event, the least common severity was grade 1, affecting only a few participants.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "40f699a1-fbc6-40de-8e80-85b28f71632f"
        ]
    },
    "973f090a-8967-4d75-bb8e-6166c868337c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02301988",
        "Statement": "cohort 1 patients of the primary trial are administered higher doses of Ipatasertib and  Placebo than cohort 2 patients",
        "Label": "Contradiction"
    },
    "97301a86-9ebe-471a-99eb-a7c8a1b9c0f5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00503906",
        "Statement": "strong opioids answer is a response about using strong opioids. Participants of the primary trial will receive the intervention for a total of 12 cycles (28 days).",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "6499b181-7a23-4073-8459-ad46ff02b20f"
        ]
    },
    "a852894e-6a72-4e69-8d12-1e68334a4904": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Statement": "the primary clinical trial only considers patients with a life expectancy of over 75 years",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "4b97a844-8d52-48bb-8eda-ca205268f016"
        ]
    },
    "dda126ab-5db1-4302-b4d0-d3abd25c87c9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00093795",
        "Statement": "a significant proportion of participants in cohort 1 and 2 of the primary clinical trial encountered a form of disease recurrence, contralateral breast cancer, second primary cancer, or death that occurred independently of recurrence or second primary cancer",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "0ea29bd5-20be-40ea-8ad7-705d283d1d48"
        ]
    },
    "5200c273-2c7f-4420-bdab-28ffdcd6de77": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "the criteria for participation in the primary clinical trial accommodates patients having a t2 n2 m0 adenocarcinoma of the breast with node positivity, as well as those having a node negative adenocarcinoma of the breast with tumor size above 2cm.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "016943fa-57ea-4293-8131-03292ea1836c"
        ]
    },
    "fedfb45f-4ce9-4d42-8f72-2c36db94753d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "the primary clinical trial intervention protocol spans across an entire year",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "236780db-9e59-4dc9-8da0-e786287011cf"
        ]
    },
    "8778c14c-812a-4158-b053-3522011d9332": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00281697",
        "Statement": "primary clinical trial does not allow participation of patients with her2-positive status",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "00822101-fa21-4a26-bf45-3b1f535da005"
        ]
    },
    "3e255ff3-3a3f-406e-a77b-0b3bde901660": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00281697",
        "Statement": "inclusion in the primary clinical trial requires a her2-positive status",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "00822101-fa21-4a26-bf45-3b1f535da005"
        ]
    },
    "4885c5f1-4a14-4f4c-8291-00e8e6b783ae": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01912612",
        "Statement": "azacosterol hydrochloride is a hydrochloride salt form of azacosterol, a sterol derivative of cholesterol that acts as a hypocholesteremic. The only case of congestive heart failure in the primary trial occurred in cohort 1.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "9cbc00e9-3a2d-4471-a93e-72c95132fb6a"
        ]
    },
    "6e346b04-dad8-4256-b125-852fa0170766": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT03176238",
        "Statement": "acute myocardial infarction, cardiopulmonary failure and supraventricular tachycardia are more prevalent in cohort 1 of the secondary trial than in cohort 2 of the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "080da381-b5dd-46d3-99c4-18112da153c1"
        ]
    },
    "318520f4-4933-4d22-b7a1-ccfd0a7afebc": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT00232505",
        "Statement": "iv drug administration is not a method employed in either the primary or the secondary clinical trials",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "7edba90d-076d-4f55-b9d6-a1765ceb48bd"
        ]
    },
    "56fcbe6a-bf99-44c0-a2f1-86b2e82a566c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00570921",
        "Statement": "st segment depression by ecg finding is an electrocardiographic finding of st segment depression below the baseline, often described as up sloping, down sloping or horizontal. the primary trial participants are administered Fulvestrant intramuscularly (to the deltoid) and Everolimus orally.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "32361e21-ee57-4c34-9390-833ba5048a10"
        ]
    },
    "04a0a5f6-59b4-4cd0-87df-df0a573da799": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005879",
        "Statement": "there was a higher percentage of patients with slipped disks in cohort 2 of the primary trial than in cohort 1. intraoperative arterial injury, ctcae is a finding of damage to an artery during a surgical procedure.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "e4aeb013-7713-4b73-acbd-f8379cc6a494"
        ]
    },
    "e9049aa6-298d-46c8-8dd8-761f312da26c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00009945",
        "Statement": "the total number of patients affected by adverse events in the primary clinical trial exceeds 30",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "8648c7df-582a-42a9-9330-414b2430ac56"
        ]
    },
    "377337ed-837f-464e-b43d-dfa7c6215b50": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Statement": "patients diagnosed with advanced disease and having only few months to live are considered suitable for the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "618a3ae1-b22c-4c35-86a6-190c1b5b5d21"
        ]
    },
    "aa9bb9cc-db09-4046-b31d-171b9c22b0c1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00263588",
        "Statement": "patients with no sign of cancer are eligible for the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "215a5c4a-d90c-4500-8284-0679ce311734"
        ]
    },
    "33edfed2-2a37-4d4b-b4d9-cb36148752de": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01307891",
        "Statement": "udp-4 is an ureido-derivative of pyridine that induces differentiation in neoplastic cells, causing inhibition of cell proliferation. (nci) There was one case of  Neutropenia in both cohorts of the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "a9907a2e-254a-45ca-af50-3e44fd2f7af3"
        ]
    },
    "d9c1fe98-a801-4737-a231-91c91318df3a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02301988",
        "Statement": "fact-n questionnaire is a subscale complement to the fact-g developed specifically for evaluating the quality of life of cancer patients with neutropenia. cohort 1 patients of the primary trial are administered higher doses of Ipatasertib and  Placebo than cohort 2 patients.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "973f090a-8967-4d75-bb8e-6166c868337c"
        ]
    },
    "dd2f3c3d-fa95-4fca-a3f0-795fd4f3abf1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02915744",
        "Statement": "the secondary trial and the primary trial do not record the same metrics in their results section",
        "Label": "Entailment"
    },
    "7d40a85e-e1fe-443e-b30e-84083f17960a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "patients with no history of hot flashes can participate in both the primary clinical trial and the secondary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "a5baab2c-9c32-4301-a574-4ba5a0c2eb00"
        ]
    },
    "30aa2d58-eb39-4b3d-9e42-d008505f0e4e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01596751",
        "Statement": "participation in the primary clinical trial requires that patients with breast cancer have a documented stable disease",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "89f610a7-9e81-43a4-8c1e-5503233b2be1"
        ]
    },
    "71679535-9a98-445a-ad93-ac40bb855713": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "non-cardiac chest pain was the adverse event which was most commonly reported in the primary clinical trial, affecting under 5% of cohort 1's participants.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "2da13cd4-7189-4f85-be4d-5c1e213ae293"
        ]
    },
    "fd8bedf2-0677-44d6-a808-a89ae477e4f6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Secondary_id": "NCT00121992",
        "Statement": "sitting with legs dependent is a dependent position where the legs of a subject dangle or hang down while sitting. the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial reported 16.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "c100a7cd-e3a2-4901-a3e0-12336f769c7b"
        ]
    },
    "a4573df4-f375-49a5-9262-11e3a9a37114": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02658734",
        "Statement": "most patients in the primary trial experienced a grade 2 adverse events, the least common severity was grade 9, which only affected 1/2 patients.",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "40f699a1-fbc6-40de-8e80-85b28f71632f"
        ]
    },
    "417a275f-8dd2-40e5-8363-f2b737c9e845": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00063570",
        "Statement": "those diagnosed with prostate or lung cancer are suitable candidates for the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "015dd869-db90-45a9-a951-9dc7dc2b2e01"
        ]
    },
    "a792bbac-0e8a-4bf7-9cc5-56fad481e2fb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00127933",
        "Statement": "eliane is a 56 year old woman, and alex is a 32 year old man, both eliane and alex can both be eligible for the primary trial",
        "Label": "Contradiction"
    },
    "77a43610-e387-4337-a8d9-c466017b26d5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02131064",
        "Statement": "interested in sex is a question about whether an individual is or was interested in sex. in cohort 1 of the primary trial there were more cases of Left ventricular dysfunction than Abdominal pain.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "3a0c517d-9b9a-4497-9675-50ff12cd02b7"
        ]
    },
    "9151c8f8-ca9e-476e-88b9-b29abe21bf0b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02340221",
        "Statement": "Prior treatment with fulvestrant or with a phosphatidylinositol 3-kinase (PI3K) inhibitor is not admissible for the primary trial. fgfr4 gene fusion positive is an indication that a fgfr4 fusion gene has been detected in a sample.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "6b35bc10-f591-4b84-abac-40a74be949fa"
        ]
    },
    "942b6929-c878-4e35-8629-1c00d0663f5f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02301988",
        "Statement": "Only cohort 1 patients of the primary trial are administered Ipatasertib. us spanish is a form of the spanish language spoken in the united states.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "faa65e54-aa04-4595-8dae-05cf00b4c887"
        ]
    },
    "93813aa6-054b-4370-afb7-5fb14d977e66": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00733408",
        "Statement": "ulcerative colitis flare is an exacerbation of ulcerative colitis. Syncope was the most common adverse event recorded in the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "9d8b26d6-d574-4717-88b6-77458bc683f3"
        ]
    },
    "7c320edc-c8ee-4e28-adfc-875aabffd2d0": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00820170",
        "Secondary_id": "NCT00263588",
        "Statement": "a patient meeting the eligibility criteria for the secondary clinical trial will likewise meet the criteria for the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "a0065d58-e03b-4dd0-9c81-cbbf651a6d45"
        ]
    },
    "45e1f76a-1dfd-465f-9d23-6b60d9a2704e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00915603",
        "Statement": "at least 3 participants of the primary trial, at least three from each cohort, had a progression-free survival of 22.4 months",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "47ba01d6-edc7-4acb-ab49-b0e86f4eeaf7"
        ]
    },
    "06113f44-25aa-4072-bab9-1d7da5ab64fb": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Secondary_id": "NCT00281697",
        "Statement": "the majority of patients in the secondary clinical trial and the primary clinical trial were documented to have a clean bill of health, with no case of enterocolitis detected.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f"
        ]
    },
    "15ea9727-0087-4da2-aed9-be97ffd4b518": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00127933",
        "Statement": "both eliane, a 56 year old woman, and alex, a 32 year old man, might be candidates for the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "a792bbac-0e8a-4bf7-9cc5-56fad481e2fb"
        ]
    },
    "30c522e4-7041-4513-b3a7-3e73aab2f308": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00357110",
        "Statement": "no deaths were documented in the primary clinical trial cohorts.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "751fd763-89fa-4d52-8bda-f09b490a5e78"
        ]
    },
    "1526ee81-2d9f-4ac1-ac9a-314c46dbbbdc": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02419807",
        "Statement": "non-cancer related death is a death attributed to any cause other than the progression of a cancer-related pathologic condition. The the primary trial results section reports two different measurements, for all 3 cohorts.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "d0b50aeb-aad8-4a8d-aae6-5c58a7d382c7"
        ]
    },
    "13a6159e-e6f4-476f-be05-b13228bfcd7a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT00852930",
        "Statement": "the primary clinical trial and the secondary clinical trial routinely track any adverse events related to cardiac troubles or infections",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "06f798d1-2956-4903-83e9-58a41fa425f7"
        ]
    },
    "70ab3a82-1da2-43b7-9972-499d6d10e797": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Statement": "prior breast cancer treatment with endocrine therapy is a prerequisite for all participants in the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "6d621974-c719-46df-8a50-d94e49583e33"
        ]
    },
    "7e123359-a2b0-4229-8444-1885f3b0d5e8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00374322",
        "Statement": "4/5 of patients in the primary trial received a placebo intervention",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "e147796d-2edd-42d1-ac53-300fb8bd5eb6"
        ]
    },
    "819633e6-66ea-435b-afa3-3c83be888439": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00425854",
        "Secondary_id": "NCT01224678",
        "Statement": "patients with reduced ejection fraction, who are under 55 years of age, are accepted into the primary clinical trial, but are denied for the secondary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "6b9162d0-0816-46d4-81af-c60028dcc63b"
        ]
    },
    "16c29502-4683-4087-9410-ff1b786556f5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01042535",
        "Statement": "The least common adverse event in the primary trial was Constipation ",
        "Label": "Contradiction"
    },
    "1e65d572-9dc7-414f-bfcb-98ba61511352": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00570921",
        "Statement": "participants in the primary clinical trial receive fulvestrant through intramuscular injection and everolimus orally",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "45ccd2c8-6e02-4f0f-a370-eed18d26e6dc"
        ]
    },
    "19358f17-94a4-4478-a18a-c73abd459513": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00606931",
        "Statement": "the adverse events section in the primary clinical trial is devoid of any mention of patients experiencing hypotension, hemorrhage or bradycardia",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "175044aa-72b1-405d-8506-30002f5098e4"
        ]
    },
    "c6e84922-24d9-46c5-8a0f-362932051d73": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00357110",
        "Statement": "six deaths were noted in the first cohort and seven in the second within the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "f114846e-79d8-4712-add0-bb34b65d418f"
        ]
    },
    "02bafe8d-fe1e-4feb-af41-a07f9c079d37": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00328783",
        "Statement": "the section dealing with adverse events in the primary clinical trial does not contain any data",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "fef5aedb-21c0-4130-b8a3-cb1df5017c7a"
        ]
    },
    "4553d948-c401-443a-b4bf-70e41e7803db": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "to be eligible for the primary trial candidates must be over the age of 30, have a severe disability and adequate hepatic, renal and heart functions aswell as adequate hematology levels.",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "f45ff82d-e0f5-456a-9d78-ddc2dc6ab929"
        ]
    },
    "a6eb253e-0874-4ed7-ab08-83650adae0a4": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03012477",
        "Secondary_id": "NCT02419807",
        "Statement": "a variation in units of measure is observed in the reporting of results between the primary clinical trial and the secondary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "8460a212-8054-4bd2-b4e6-af1d137a2f79"
        ]
    },
    "65052336-0692-4db2-bf4b-3dc25c62b771": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02679755",
        "Statement": "none of the individual aes recorded in the primary trial affect more than 1/10 of the population.",
        "Label": "Entailment",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "c09fa61c-967a-40ae-96b0-c87b7cde237b"
        ]
    },
    "00eafacf-26de-4ec3-917b-3cdd06cbacb3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01912612",
        "Statement": "the lone instance of congestive heart failure in the primary clinical trial pertained to cohort 1",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "9cbc00e9-3a2d-4471-a93e-72c95132fb6a"
        ]
    },
    "f99948ff-b8d9-45c8-8a3c-fc28d7d5768e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02131064",
        "Statement": "the occurrences of left ventricular dysfunction and abdominal pain were equal in the first cohort of the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "3a0c517d-9b9a-4497-9675-50ff12cd02b7"
        ]
    },
    "fd423206-759a-4309-ae74-a6ffa8cbf56b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00612560",
        "Secondary_id": "NCT01216176",
        "Statement": "alpha-gal antibody is any immunoglobulin that recognizes the disaccharide epitope galactose-alpha-1,3-galactose (alpha-gal). All the primary trial participants are administered flaxseed, but none of the secondary trial receive any flaxseed.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "b0046821-ba27-4a90-8869-cb708b843aa4"
        ]
    },
    "9f6cc9ec-a95f-44fc-bf0e-e4056dd4dcaa": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Secondary_id": "NCT00425854",
        "Statement": "the primary clinical trial and the secondary clinical trial measure their intervention outcomes by progression free survival, and they use the same criteria for complete response",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "8d9f94e3-871b-4fb4-a522-0a73d9d0ec3c"
        ]
    },
    "734423d5-4b47-4448-ab98-811015d626f0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01307891",
        "Statement": "There were multiple patients which suffered Neutropenia in both cohorts of the primary trial",
        "Label": "Contradiction"
    },
    "9fdd430b-5390-4b71-a72f-753edb6009d7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02186015",
        "Statement": "infants are eligible for participation in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "a805f174-2707-4302-a195-05153ea8523e"
        ]
    },
    "75affd49-4905-4d43-9a5c-ef795281bac4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "neither of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients.",
        "Label": "Entailment"
    },
    "a9907a2e-254a-45ca-af50-3e44fd2f7af3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01307891",
        "Statement": "There was one case of  Neutropenia in both cohorts of the primary trial",
        "Label": "Entailment"
    },
    "e2880aeb-23b7-45ec-9171-497b8f2f10e4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00428922",
        "Statement": "the survival time of a patient with the disease during and following treatment is the measurement of outcome for the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "3facad41-0221-42f8-834d-470e65c4aad5"
        ]
    },
    "175044aa-72b1-405d-8506-30002f5098e4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00606931",
        "Statement": "There adverse events section in the primary trial describes the number of patients that suffered Hypotension, Hemorrhage and Bradycardia when taking part in the study",
        "Label": "Contradiction"
    },
    "d7c53eb3-8d9b-441e-8e70-5416bbc795f6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00503906",
        "Statement": "never or almost never is a response indicating that something happened never or almost never. Participants of the primary trial will receive the intervention for a total of 12 cycles (28 days).",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "6499b181-7a23-4073-8459-ad46ff02b20f"
        ]
    },
    "18fda903-1928-40f5-b4d4-c23fba88a8e2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572727",
        "Secondary_id": "NCT00328783",
        "Statement": "eq-5d-5l questionnaire question is a question associated with the eq-5d-5l questionnaire. All patients in the primary trial receive higher doses of Paclitaxel than patients in the secondary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "3ba42f68-a643-4d10-afd0-cbb358d05a6f"
        ]
    },
    "ec1f7658-9974-442c-af82-69c1d9ac97a3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02658734",
        "Statement": "most patients in the primary trial experienced a grade 1 adverse events, the least common severity was grade 5, which only affected 0.1142 of the patients.",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "40f699a1-fbc6-40de-8e80-85b28f71632f"
        ]
    },
    "2a03c17f-3afe-40f1-a0db-4b876ee8c700": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT02340221",
        "Statement": "the primary trial and the secondary trial have non-comparable outcome measurements for their results",
        "Label": "Entailment"
    },
    "43b724c0-c077-4a16-84d1-b554d4d7187b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT03176238",
        "Statement": "cohort 1 of the secondary trial and the entire patient cohort of the primary trial both have the same number of acute myocardial infarction, cardiopulmonary failure, and supraventricular tachycardia cases",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "5c975af8-6b7f-4a5d-b4a6-257c76763ce9"
        ]
    },
    "df5d0f4e-725e-49dc-907d-e1109b0f3d38": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00450723",
        "Secondary_id": "NCT00290758",
        "Statement": "all recorded cases of dyspnea occurred in cohort 2 of the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "f04d9695-81b8-4d70-877b-59caddf901bd"
        ]
    },
    "2ef186d0-b4ab-44de-b785-a63e9e95851a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Secondary_id": "NCT00281697",
        "Statement": "most participants in the secondary trial and the primary trial did not suffer from Enterocolitis",
        "Label": "Entailment"
    },
    "8ee9e103-e083-4b24-ada5-d5844e645838": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01912612",
        "Statement": "the primary clinical trial saw a multitude of congestive heart failure cases in cohort 1, however, all were absent in cohort 2",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "d1b217ae-76f3-4ba6-958e-5b2558703ba4"
        ]
    },
    "7d53b693-d5fe-46e8-b297-08cfe847e206": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Secondary_id": "NCT00425854",
        "Statement": "the primary clinical trial uses disease-free survival as the outcome measurement for its intervention.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "402f0dbf-cf67-4425-b300-a0a3df4d59d3"
        ]
    },
    "17340a5a-1f05-4495-b293-c797dfacc42e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00733408",
        "Statement": "headache was the most frequently recorded adverse event in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "9d8b26d6-d574-4717-88b6-77458bc683f3"
        ]
    },
    "0beecad2-be53-4a13-976d-992ce3c917fc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Statement": "ongoing flucytosine treatments are not permitted for participants of the primary trial. ovarian mass is an abnormal growth in the ovary.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "f10f3b84-e039-4a02-a98b-86d149d9a16f"
        ]
    },
    "b7857d8e-7481-4a56-9705-7d56361de529": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00450723",
        "Secondary_id": "NCT00290758",
        "Statement": "all the recorded cases of musculoskeletal adverse events occurred in cohort 1 of the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "f3cb9150-32c6-4877-9a87-4fac45a24948"
        ]
    },
    "3fcf5571-cba8-49fb-b578-24970540456c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Secondary_id": "NCT01439945",
        "Statement": "in the secondary clinical trial, only a single instance of diarrhea has been reported, whilst more than 14 different kinds of aes have been documented in the primary clinical trial cohorts.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "4519d1cf-7f78-4aa8-85d6-ac94f7eb75a3"
        ]
    },
    "dd729102-504d-4b46-ad56-185e0eba56c1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00572728",
        "Statement": "to participate in the primary clinical trial, patients must have the capacity to undergo a pet scan",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "32ed503c-1cfd-44f6-b8bb-23d9d175d73d"
        ]
    },
    "9bfb42f3-56c4-4f66-8d6e-99a85356d00d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01011946",
        "Secondary_id": "NCT00066573",
        "Statement": "the primary clinical trial relies on oral medication as a primary mode of treatment. in contrast, the secondary trial does not involve any form of oral medication.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "6402e13a-7cfb-4774-b7f9-80ecb79fda2a"
        ]
    },
    "97a9d6bb-feac-4d58-b3e6-609e7b2cf91e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290758",
        "Secondary_id": "NCT02370238",
        "Statement": "endocrine therapy is not a disqualifying factor for participation in the primary and secondary clinical trials",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "5d0ccb93-71ec-4079-92c6-d7cbf951a7bb"
        ]
    },
    "8d0334fe-e267-4a92-b25b-a41052e50422": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Statement": "from cohort 1 of the primary clinical trial, just 6 of the 67 patients had adverse events",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "29b2fa29-5a76-4877-95bb-1a8de7973d33"
        ]
    },
    "62728456-787a-41e6-863d-2a19d93dedc9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "febrile neutropenia turned out to be the most prevalent adverse event among the patients in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "614d7ade-0fa7-4d77-bc19-1d3a2f2f48c2"
        ]
    },
    "996ed4ba-b879-4adf-85c7-8d37b275cfd6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Secondary_id": "NCT00876395",
        "Statement": "in the primary clinical trial, the most frequently occurring adverse event is diarrhoea, whereas in the secondary clinical trial, the most common is anaemia",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "324562e6-2b61-4a07-b937-86f99689f2d5"
        ]
    },
    "c5c7e927-45ac-42a8-80ab-4e1012b5c8cb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02186015",
        "Statement": "adults and children can take part in the primary trial. metastatic carcinoma in the skin is a carcinoma that has spread to the skin from its original site of gowth.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "2825d63b-8f22-4fb8-829f-9567845251c6"
        ]
    },
    "618a3ae1-b22c-4c35-86a6-190c1b5b5d21": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Statement": "Patients must have a Life expectancy of at least 1 year to enroll in the primary trial",
        "Label": "Entailment"
    },
    "eaecd44d-e3e2-4047-acde-93cd02dcc875": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02924883",
        "Statement": "fever of unknown origin is a febrile process with an etiology that is not apparent or yet determined. Only patients with HER2+ve breast cancer are eligible for the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "446f3c69-0de5-475c-a8e2-ff40ece90672"
        ]
    },
    "2c13b56f-5cdd-4d6e-aa4c-106bfcb82a1f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Statement": "tachycardia was the most common adverse event in cohort 1 of the primary clinical trial and anaemia was the most common in cohort 2",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "ec1e269e-470d-43d9-8f23-8a19a5c96fcc"
        ]
    },
    "1eb99fa4-ecef-4535-8e97-3a01cd51bf14": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00328783",
        "Statement": "childhood lymphoblastic lymphoma is a lymphoblastic lymphoma occurring in children. The adverse events section in the primary trial is empty.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "fef5aedb-21c0-4130-b8a3-cb1df5017c7a"
        ]
    },
    "64f616e3-df65-4fc4-a158-45e03be2cda7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Secondary_id": "NCT01644890",
        "Statement": "mhis-nacc questionnaire question is a question associated with the mhis-nacc questionnaire. the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures PFS.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "794269ca-e7ec-4a65-ace5-b0f24a8cdc15"
        ]
    },
    "cae20d0e-a45d-4bf3-8aa3-d6d8e45e1ed1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00063570",
        "Statement": "the primary clinical trial does not include patients diagnosed with a malignant brain tumour",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "62e449ad-16b3-479d-94a5-ffc435b5e99c"
        ]
    },
    "76a105d8-13a2-4868-9ea5-93091bc7afce": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "All the primary trial patients had a minimum of 50% decrease in the sum of the longest diameter of target lesions. virtual reality device is a headset or other equipment that is designed to allow a user to experience a virtual reality environment.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "985bc5a0-bc21-447f-92f1-150e23ede3f5"
        ]
    },
    "e4cd88a3-51f1-4ef4-906e-cc7dacaa3352": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00331630",
        "Statement": "malignant lung neoplasm is a primary or metastatic malignant neoplasm involving the lung. no cardiac or bowel-related adverse events were recorded in the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "553f00ea-5197-4233-b1e0-e5727856b599"
        ]
    },
    "f0486ce7-d8f4-4645-9cda-79a40320ad24": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02679755",
        "Statement": "None of the individual Aes recorded in the primary trial affect more than than one patient. minutes seconds imputed is an imputed time that includes the minute and second of observation.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "f46a7d27-a94f-4389-a1a0-4a8f5177b354"
        ]
    },
    "3695e565-2b8b-4690-a7f7-38139a65d8cb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820222",
        "Statement": "in the primary clinical trial, it was observed that the section of patients undergoing treatment with trastuzumab plus capecitabine presented a higher prevalence of cns metastases than their lapatinib plus capecitabine counterparts.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "5de9caeb-9dd5-4535-8fe3-289450d9c626"
        ]
    },
    "637b7e8a-7d6d-48ef-81e1-3af84e112cd6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00450723",
        "Secondary_id": "NCT00290758",
        "Statement": "pdcd1lg2 gene rearrangement is a molecular abnormality indicating rearrangement of the pdcd1lg2 gene. Between the secondary trial and the primary trial, all the recorded casesof Musculoskeletal adverse events occurred in cohort 2 of the secondary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "f3cb9150-32c6-4877-9a87-4fac45a24948"
        ]
    },
    "a47ce28b-444b-451e-9e8e-5c4c3b543110": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "feel isolated from others because of my illness or treatment is a question about whether an individual feels or felt isolated from others because of their illness or treatment. All the primary trial patients had a minimum of 50% decrease in the sum of the longest diameter of target lesions.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "985bc5a0-bc21-447f-92f1-150e23ede3f5"
        ]
    },
    "25bb1b01-7c33-43c7-8b3f-44d802083f34": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01912612",
        "Statement": "The only case of congestive heart failure in the primary trial occurred in cohort 1. efficacy study with pre-exposure prophylaxis is a study that assesses the efficacy of prophylactic treatment (including radioprotectors) given before exposure to an agent(s).",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "9cbc00e9-3a2d-4471-a93e-72c95132fb6a"
        ]
    },
    "45ccd2c8-6e02-4f0f-a370-eed18d26e6dc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00570921",
        "Statement": "the primary trial participants are administered Fulvestrant intramuscularly and Everolimus orally",
        "Label": "Entailment"
    },
    "ef06ada4-7e7b-42c8-9955-09285e6f5673": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01581619",
        "Secondary_id": "NCT00106002",
        "Statement": "the primary clinical trial and the secondary clinical trial have yielded contrasting outcome measures",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "1180dd58-61b8-4c48-ab00-7d458e68c85b"
        ]
    },
    "7edba90d-076d-4f55-b9d6-a1765ceb48bd": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT00232505",
        "Statement": "the primary trial and the secondary trial participants do not receive any medication by IV",
        "Label": "Contradiction"
    },
    "f72de656-d878-4e32-a8de-89acff7d0be3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00022516",
        "Statement": "patients with t0 n0 m0 status can participate in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "4a75574c-fa86-4e62-a210-81c7b98a3807"
        ]
    },
    "23109ce2-7dd1-413e-8140-2a4362e8ecc1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00593346",
        "Statement": "the primary clinical trial doesn't share the patient cohort's pfs or objective response rate, and instead provides the proportion of patients experiencing dermatitis",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "88668508-dfd4-4a39-91cd-cf1654a6dfc4"
        ]
    },
    "b10f7adf-3a56-4d82-a644-390cc4866887": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00612560",
        "Secondary_id": "NCT01216176",
        "Statement": "only the primary clinical trial involves the administration of anastrazole in a pill form, unlike the secondary clinical trial where it is non-existent.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "e9fd065c-342c-4dfb-9c1c-a4c0c44d0acd"
        ]
    },
    "4fd7d1b5-f80a-463a-bbe0-d1911eaa2161": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00066573",
        "Statement": "the primary clinical trial shows a 77.8% disparity between the two cohorts.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "1adc970c-d433-44d0-aa09-d3834986f7a2"
        ]
    },
    "a94f14ba-a733-40f4-8a81-d6321ff0bdc9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005879",
        "Statement": "cohort 2 of the primary clinical trial displayed a noticeably larger percentage of patients suffering from slipped disks as opposed to cohort 1",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "ce8464bd-951e-44aa-97d9-10b917b055ce"
        ]
    },
    "5ecadec4-fb17-4734-8332-e2f8b749fc80": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00331630",
        "Statement": "there were no adverse events related to heart or brain noted in the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "c7dc582a-4a58-4cb5-b980-b2d2b6a128c3"
        ]
    },
    "b746243d-0bc0-4c2e-b4d1-e6389b0ce9d3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00612560",
        "Secondary_id": "NCT01216176",
        "Statement": "anastrazole is administered as an injectable to primary trial participants, and the same is given to secondary trial participants as well",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "e9fd065c-342c-4dfb-9c1c-a4c0c44d0acd"
        ]
    },
    "68379456-775b-463b-bfdb-d8aa42c9124b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Secondary_id": "NCT00274469",
        "Statement": "Patients must be female and have confirmed advanced breast cancer to be eligible for the secondary trial and the primary trial",
        "Label": "Entailment"
    },
    "832c3f3a-b805-4097-8280-e59a397bb552": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "presence of hot flashes for 730 hours prior to study registration is required for all patients that want to participate in the primary trial, but not necessary for entry to the secondary trial.",
        "Label": "Entailment",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "31105b43-832b-48bc-a78d-ee90c155ca44"
        ]
    },
    "3fef3b46-2e7c-422a-b52f-beb79f80cb55": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Secondary_id": "NCT00281697",
        "Statement": "in both the primary clinical trial and the secondary clinical trial, there was a significant incidence of enterocolitis amongst the participants.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f"
        ]
    },
    "aece7354-e087-4b32-a4c8-f5b682c3b3e2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00127933",
        "Statement": "eliane, who is 56 years old and elizabeth, who is 32 years old are ineligible for the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "f0273b8c-460d-46fe-9c52-8ff4b08e439b"
        ]
    },
    "932ff166-90f6-41f0-b319-b20d30b9e861": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Statement": "entity name person data type is a data type comprised of the name of a person. all pregnant patients accepted into the primary trial have undergone Prior treatment for breast cancer with endocrine therapy.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "b1d28450-fc7d-496a-9c7c-bf711b28f8e4"
        ]
    },
    "d9cc562a-951c-427d-9691-0cafb8eb04f0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01118624",
        "Statement": "the primary trial participants recieve doses of Pralatrexate that are calculated based on bodyweight. panoramic is a wide angle view.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "0ddb07ae-6e70-436d-8723-f609e59c57da"
        ]
    },
    "3b08791a-e0a8-49c7-9bb2-ab43ae2a3baf": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00263588",
        "Statement": "patients must be able to receive medication orally to participate in the primary trial. toe joint is any of the joints in the toes.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "5c1e360c-fd93-4dd4-b855-71ba416d34cb"
        ]
    },
    "e1f38da8-97a5-4c39-8d19-aa69c1287a1f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00281697",
        "Statement": "participation in the primary clinical trial is reserved for patients with a positive her2 status",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "43ee7645-ce1e-42d5-9a74-3e379f6f367b"
        ]
    },
    "ee1105f9-5171-48eb-90ab-0b3f514cdbd1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03098550",
        "Statement": "both cohorts of the primary trial receive identical interventions, the difference between the two cohorts is the types of cancer that the patients have. melanoma of unknown primary is a melanoma which has metastasized from an unknown primary anatomic site.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "b0b61978-57db-4a1c-812c-509e8b05f2dc"
        ]
    },
    "e9f721f6-f178-4f75-8924-4376c3024a02": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01307891",
        "Statement": "There were multiple patients which suffered Neutropenia in both cohorts of the primary trial. maintain positive outlook, even when things are going badly is a question about how often a person thought about maintaining a positive outlook, even when things are going badly.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "734423d5-4b47-4448-ab98-811015d626f0"
        ]
    },
    "bb9ff4e5-d008-4341-8340-0f32a1d91298": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT00852930",
        "Statement": "neither the primary clinical trial nor the secondary clinical trial document any adverse events related to cardiac or infection",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "06f798d1-2956-4903-83e9-58a41fa425f7"
        ]
    },
    "383a396b-7677-46c8-9823-b7b04978dadc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00503906",
        "Statement": "Participants of the primary trial will not receive the intervention for a set number of cycles, the cycles will continue until disease progression. ability to participate in my usual leisure activities is a question about an individual's ability to participate in their usual leisure activities.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "59cd7909-00c3-4c23-9a08-a42dbc8eabdd"
        ]
    },
    "c9c1d326-dd95-4d88-9d80-ca2a08a9353a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005879",
        "Statement": "there were no patients with slipped disks in either cohort of the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "e4aeb013-7713-4b73-acbd-f8379cc6a494"
        ]
    },
    "c7ab4b86-9bf9-450a-9f1d-b6a3540b2958": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT00232505",
        "Statement": "participants in the primary clinical trial are given medication orally",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "e7604382-09cd-43b4-998f-a51b33f25c5a"
        ]
    },
    "b2cdbcb8-de26-4a44-8a94-dd68c13f7e41": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01125566",
        "Statement": "ECOG score > 2 is necessary to be eligible for the primary trial",
        "Label": "Contradiction"
    },
    "3efbb1b7-4f51-4050-86ae-1a28073e961e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT00852930",
        "Statement": "the primary trial records a significant amount of heart-related adverse events and the secondary one records various infection related issues, but they both show no records of epilepsy",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "c2217d42-e90c-4ffe-b084-e653b9ace4d5"
        ]
    },
    "db41f20f-7ba9-4e37-81a1-4499a6f80230": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00281697",
        "Statement": "both her2-positive and her2-negative patients are welcomed in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "43ee7645-ce1e-42d5-9a74-3e379f6f367b"
        ]
    },
    "eae4fdd2-93d0-4a0d-8146-9351b30bfff4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00503906",
        "Statement": "in the primary clinical trial, the cycles of intervention aren't limited to a certain number, but will be continued until the disease advances",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "59cd7909-00c3-4c23-9a08-a42dbc8eabdd"
        ]
    },
    "a9e88448-5f92-4353-b632-a50f980ec30b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01830933",
        "Statement": "no adverse incidents have been reported in either the primary clinical trial or the secondary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "fb360514-14be-45ab-8b74-ea5a7eb181d7"
        ]
    },
    "9ab1b54d-a2df-49f0-be10-a411a45a5ad3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01262027",
        "Secondary_id": "NCT02301988",
        "Statement": "the metrics used in the primary clinical trial and the secondary clinical trial are alike",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "0131ebe3-746b-45a5-ba60-fdd326974fec"
        ]
    },
    "9722fd5e-532a-498b-940e-487503128c2b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT00852930",
        "Statement": "neither the primary clinical trial nor the secondary clinical trial keep a record of adverse events related to cardiac or infection issues, however they both have noted several occurrences of epilepsy",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "c2217d42-e90c-4ffe-b084-e653b9ace4d5"
        ]
    },
    "15348f3b-0567-437d-9a14-e4239e6a8555": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Statement": "only patients with a life expectancy exceeding 75 years are eligible for the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "4b97a844-8d52-48bb-8eda-ca205268f016"
        ]
    },
    "20e8b517-4cbd-4095-83c9-43ab4222329e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00281697",
        "Statement": "enrollment in the primary clinical trial is not open to patients who are her2-positive",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "00822101-fa21-4a26-bf45-3b1f535da005"
        ]
    },
    "1d11a969-5299-42f3-9444-22c8e36abb77": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042938",
        "Statement": "the primary clinical trial shows marked differences in the severity of dermatitis in radiation treatment site of the curcumin c3 complex cohort in comparison to the placebo cohort.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "e62f5a3f-0091-4980-9822-db8f4dc2502a"
        ]
    },
    "cb7c160e-4bc4-4f4c-8c58-ccc51aa913d4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01905592",
        "Statement": "as many as 7 types of adverse events have severely impacted the patients in cohort 1 of the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "2655c892-216e-4b96-a8f2-6f64403215c5"
        ]
    },
    "9cbc00e9-3a2d-4471-a93e-72c95132fb6a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01912612",
        "Statement": "The only case of congestive heart failure in the primary trial occurred in cohort 1",
        "Label": "Entailment"
    },
    "8691b823-6461-4573-b487-1fcef2a46b50": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Secondary_id": "NCT01644890",
        "Statement": "the aim of the primary clinical trial is to determine the percentage of participants who exhibit an objective response. however, the secondary clinical trial measures the count of participants who either exhibit disease progression or die.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "f42e1874-343a-43ed-bb0c-884509c4793c"
        ]
    },
    "06466759-32d6-4375-9d61-7a8ee7bf4c1d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Secondary_id": "NCT00325234",
        "Statement": "the secondary clinical trial has reported more instances of holocraneal cephale and catheter - related infections than the primary trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "9c033072-5f94-4d79-af47-126d531f0d6e"
        ]
    },
    "4f5b9c59-0a67-4dba-b540-e41db101ff50": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "bap1 gene mutation negative is a genetic finding indicating that bap1 gene mutations have not been detected in a sample. to be eligible for the primary trial candidates must be over the age of 18, have a severe disability and Adequate hepatic, renal and heart functions aswell as Adequate hematology levels.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "f45ff82d-e0f5-456a-9d78-ddc2dc6ab929"
        ]
    },
    "69b88bf3-a461-4f3b-b7d5-a7a9e18b32f5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "in the primary clinical trial, all patients showed a minimum 50% decrease in the total longest diameter of target lesions",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "985bc5a0-bc21-447f-92f1-150e23ede3f5"
        ]
    },
    "b0ac77f0-ab33-40bb-95a7-bd6f903a508a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01011946",
        "Secondary_id": "NCT00066573",
        "Statement": "egfr gene amplification is a molecular genetic abnormality indicating the presence of multiple copies of the egfr gene. the primary trial participants are administered oral and topical medication, whereas the secondary trial patients only receive treatment orally.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "8ddf8b88-6e06-4c71-9e28-45f73a637af0"
        ]
    },
    "ce5e811d-4ab2-464f-823d-8d8a787adf9a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01416389",
        "Statement": "the alterations in tumor size for patients in its groups are recorded in the primary clinical trial.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "7cde9a22-a91f-4feb-892d-7cbd35f96a27"
        ]
    },
    "604ebe0b-cced-45af-a7d4-3de492eb16f5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00450723",
        "Secondary_id": "NCT00290758",
        "Statement": "the primary clinical trial encountered no recorded cases of dyspnea in any of its cohorts",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "f04d9695-81b8-4d70-877b-59caddf901bd"
        ]
    },
    "f2a87cf8-c112-4927-8030-196440ba673f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "a patient with a node positive t2 n2 m0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of 0.591 inches",
        "Label": "Entailment",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "e6a4e9a6-56b8-4a30-9743-eb02688c090f"
        ]
    },
    "67b4024d-d1b2-4531-bf29-7fffc89e63dd": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00606931",
        "Statement": "there are no accounts of hypotension, hemorrhage and bradycardia in the adverse events recorded during the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "175044aa-72b1-405d-8506-30002f5098e4"
        ]
    },
    "f8fcc8a2-75dd-416f-ac32-a19dd0a71b5c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02658734",
        "Statement": "most patients in the primary trial experienced a grade 1 adverse events, the least common severity was grade 5, which only affected 11.42% of patients.",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "40f699a1-fbc6-40de-8e80-85b28f71632f"
        ]
    },
    "c0e1dbd1-c31e-4746-bcf1-f38de967db29": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00503906",
        "Statement": "primary clinical trial participants will be subjected to the intervention for only 6 cycles (14 days).",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "6499b181-7a23-4073-8459-ad46ff02b20f"
        ]
    },
    "6b847caf-9f4f-4da0-a4eb-74166dcfd975": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01905592",
        "Statement": "three types of adverse events caused serious complications among cohort 1 patients in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "30483d7e-7703-459c-bd10-e2bd259c2a4f"
        ]
    },
    "c23383da-e3c8-40a1-b93d-c7b3e22a51ff": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00093795",
        "Statement": "skin basal cell carcinoma with sarcomatoid differentiation is a basal cell carcinoma of the skin characterized by the presence of sarcomatoid features. the majority of participants in cohort 1 and 2 of the primary trial suffered some kind of disease Recurrence, Contralateral Breast Cancer, Second Primary Cancer, Death From Any Cause Prior to Recurrence or Second Primary Cancer.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "0ea29bd5-20be-40ea-8ad7-705d283d1d48"
        ]
    },
    "9220fcb8-5aa1-43de-b04a-8f598f242ffa": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00428922",
        "Statement": "the evaluation of results in the primary clinical trial is gauged by the duration a patient lives with the illness, during and post treatment.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "3facad41-0221-42f8-834d-470e65c4aad5"
        ]
    },
    "f531eb7c-08f8-41e1-a2ea-321849e438da": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "to be eligible for the primary trial candidates must be over the age of 18, have a severe disability and Adequate hepatic, renal and heart functions aswell as Adequate hematology levels. how often eat red meat is a question about how often an individual eats or ate red meat.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "f45ff82d-e0f5-456a-9d78-ddc2dc6ab929"
        ]
    },
    "c877181b-6f6e-47e9-a6c4-0eda7201fe4e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT00852930",
        "Statement": "the primary clinical trial and the secondary clinical trial do record several cardiac and infection-related adverse events, but they do not show any instances of epilepsy",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "c2217d42-e90c-4ffe-b084-e653b9ace4d5"
        ]
    },
    "0aee283b-0e9a-459b-8508-88d3bab6e4ab": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00570921",
        "Statement": "in the primary clinical trial, participants receive fulvestrant and everolimus both via a subcutaneous injection",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "45ccd2c8-6e02-4f0f-a370-eed18d26e6dc"
        ]
    },
    "4a716fcc-e39c-4bb2-86ed-cdb2545ab1e0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Statement": "in the primary trial, anaemia was the predominant adverse event encountered in the first cohort, whereas tachycardia was regularly observed in the second cohort",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "ec1e269e-470d-43d9-8f23-8a19a5c96fcc"
        ]
    },
    "375752af-f5a5-47de-ad97-3fce791422f9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Statement": "in cohort 1 of the primary clinical trial, more than a sixth of patients encountered negative incidents",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "8e91e404-086e-4063-8d54-83d1b8ebd969"
        ]
    },
    "9da2495b-b783-4707-913f-a77d988d9a6f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Secondary_id": "NCT00425854",
        "Statement": "the secondary trial and the primary trial use Objective Response as the outcome measurement for their interventions, however they use different definitions of complete response . was regional anesthesia administered is a question about whether regional anesthesia was administered.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "8d9f94e3-871b-4fb4-a522-0a73d9d0ec3c"
        ]
    },
    "37ab3765-a51a-4336-8a73-48b9c55d5af9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572727",
        "Secondary_id": "NCT00328783",
        "Statement": "how much distress other symptom 2 is a question about an individual's distress from the second of their other symptoms. All patients in the primary trial receive higher doses of BKM120 than patients in the secondary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "51be7c95-8da4-419c-950c-91ebdd2c3fe5"
        ]
    },
    "9f0140db-d335-45a2-add8-f6616dc5eb04": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02186015",
        "Statement": "participation in the primary clinical trial is restricted to adults only",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "a805f174-2707-4302-a195-05153ea8523e"
        ]
    },
    "10c618a3-430a-4c6e-8604-f8a8f2a0c3b8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Secondary_id": "NCT00325234",
        "Statement": "the number of urosepsis cases are identical in both the primary and secondary trials",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "7271e0db-bb82-423f-ad95-5ffa84fab97e"
        ]
    },
    "c596949f-7534-4d41-a09f-3829a02e3ab4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "the primary trial intervention protocol lasts a total of 3 hours",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "236780db-9e59-4dc9-8da0-e786287011cf"
        ]
    },
    "317b6f8a-89d2-4827-9086-65dde2a48c62": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00572728",
        "Statement": "only those patients who can carry out light or moderate physical activities are eligible for the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "62be4676-099f-4c42-8029-773af8fde6f7"
        ]
    },
    "db9f445e-54da-49a7-b01d-9515171fdc75": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00009945",
        "Statement": "cervical mucinous adenocarcinoma, intestinal-type is a cervical mucinous adenocarcinoma that resembles the large intestinal adenocarcinoma. none of the individual adverse events in the primary trial affect more than 100 patients.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "1314146f-2869-4525-8034-7f732d238385"
        ]
    },
    "26531f09-a2ff-4949-b6c3-63301a4c7062": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572727",
        "Secondary_id": "NCT00328783",
        "Statement": "the primary clinical trial involves administrating higher bkm120 doses to patients when compared to the secondary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "51be7c95-8da4-419c-950c-91ebdd2c3fe5"
        ]
    },
    "da612d85-8b4c-408e-842d-27f4dffdb30a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01581619",
        "Secondary_id": "NCT00106002",
        "Statement": "persistent neuroblastic cells is a morphologic finding indicating the continuing presence of neuroblastic cells in a set of tissue samples collected over time. the results of the secondary trial and the primary trial report the same outcome measures.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "1180dd58-61b8-4c48-ab00-7d458e68c85b"
        ]
    },
    "c8e2801c-c34d-4430-bf45-c89e9e7a2f0f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00944047",
        "Statement": "over 1/2 of the primary trial patients in the intervention arm experienced pathologic complete response",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "9f7d476e-9db3-4c00-abe6-4c2f0160470a"
        ]
    },
    "ea38c991-1e79-4c05-b0da-1bb982a745cf": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00263588",
        "Statement": "to be part of the primary clinical trial, patients are required to have her2- breast cancer.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "215a5c4a-d90c-4500-8284-0679ce311734"
        ]
    },
    "776437f3-1294-4907-9572-50e0b8ffc69b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00570921",
        "Statement": "participants in the primary clinical trial receive fulvestrant injections in the deltoid muscle and ingest everolimus orally.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "32361e21-ee57-4c34-9390-833ba5048a10"
        ]
    },
    "2c6a7454-c63d-43f9-9cd1-acec05d73765": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT00232505",
        "Statement": "the primary trial and the secondary trial participants do not receive any medication by IV. fanca gene amplification is a molecular genetic abnormality indicating the presence of multiple copies of the fanca gene.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "7edba90d-076d-4f55-b9d6-a1765ceb48bd"
        ]
    },
    "cb2383cc-6c27-475b-ac44-e8cfe01deb35": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820222",
        "Statement": "the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher precentage of patients with CNS Metastases than the Lapatinib Plus Capecitabine group. dysplasia negative is an indication that signs of dysplasia were not found in a sample.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "5de9caeb-9dd5-4535-8fe3-289450d9c626"
        ]
    },
    "779006a2-14dc-423d-9eac-2b09bcd53355": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01042535",
        "Statement": "constipation was the adverse event with the lowest occurrence during the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "16c29502-4683-4087-9410-ff1b786556f5"
        ]
    },
    "20ea8b27-5db5-44a2-b2c7-69fe6d1251e4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02186015",
        "Statement": "indeterminate peri-neural invasion is an indication that the perineural invasion is indeterminate. Only adults can take part in the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "a805f174-2707-4302-a195-05153ea8523e"
        ]
    },
    "b9e2c056-d917-427e-a3fd-888979d362ad": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00572728",
        "Statement": "pet scans are not a part of the primary clinical trial protocol",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "32ed503c-1cfd-44f6-b8bb-23d9d175d73d"
        ]
    },
    "abc66ed5-a867-468e-98a4-e6680bc3e1b4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Secondary_id": "NCT01439945",
        "Statement": "play golf, riding cart is a question about whether an individual plays golf, while riding a golf cart. There is only one case of Diarrhea in the secondary trial and over 14 different types of Aes recorded in the primary trial cohorts.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "4519d1cf-7f78-4aa8-85d6-ac94f7eb75a3"
        ]
    },
    "f0749dd1-89d8-4053-ae57-a577a4fca473": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "persons with adequate hepatic, renal and heart functions but with below normal hematology levels are qualified to participate in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "f45ff82d-e0f5-456a-9d78-ddc2dc6ab929"
        ]
    },
    "f0273b8c-460d-46fe-9c52-8ff4b08e439b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00127933",
        "Statement": "eliane is a 56 year old woman, and elizabeth is a 32 year old woman, both eliane and elizabeth can both be eligible for the primary trial",
        "Label": "Entailment"
    },
    "c8e170a7-ad0c-4f29-9fe0-1784264c9c5a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02915744",
        "Statement": "the outcomes of both primary and secondary trials are assessed using the same measurement standards",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "dd2f3c3d-fa95-4fca-a3f0-795fd4f3abf1"
        ]
    },
    "3e07f161-13be-438f-a442-5da9cd0052ea": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01596751",
        "Statement": "breast cancer patients with active disease progression are eligible for the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "89f610a7-9e81-43a4-8c1e-5503233b2be1"
        ]
    },
    "0688215f-f439-466c-9413-f1f9a4224350": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02915744",
        "Statement": "in the primary clinical trial, both cohorts 1 and 2 are administered nktr-102 through infusion.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "4309860d-042d-45a4-8a0a-a9fdd075247a"
        ]
    },
    "c7d0ce9e-77d4-4305-8b62-f20fb15f78b8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "Patients with Extracranial metastases can be eligible for the primary trial. alcoholic cardiomyopathy is a dilated cardiomyopathy which is associated with consumption of large amounts of alcohol over a period of years.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "b9491012-49ba-4eb1-8230-1966f54ea012"
        ]
    },
    "1fec669e-ed27-4543-a0c5-b6f073100317": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "neither of the interventions in the primary trial resulted in an objective benefit for less than 100% of patients.",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "75affd49-4905-4d43-9a5c-ef795281bac4"
        ]
    },
    "ae95cab2-eae8-4a33-bad5-8720ecacc423": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01905592",
        "Statement": "all patients in cohort 1 of the primary clinical trial experienced severe adverse events",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "30483d7e-7703-459c-bd10-e2bd259c2a4f"
        ]
    },
    "0118ebf9-d26b-49b5-bc1c-69c81cb96963": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Statement": "there were no reported instances of anaemia or tachycardia in either cohorts of the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "ec1e269e-470d-43d9-8f23-8a19a5c96fcc"
        ]
    },
    "43f3f748-e2d4-48d6-b8a0-aa6a5f7161af": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT03176238",
        "Statement": "There more cases of Acute myocardial infarction, Cardiopulmonary failure and Supraventricular tachycardia in cohort 1 of the secondary trial than in the entire patient cohort of the primary trial. head and neck muscle is any skeletal muscled located in the head or neck.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "5c975af8-6b7f-4a5d-b4a6-257c76763ce9"
        ]
    },
    "9b512421-d19a-4394-89b6-49ac5087fed1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00915603",
        "Statement": "the minimum pfs recorded in cohort 1 of the primary clinical trial was fewer than 7 months, while in cohort 2 it was slightly above 7 months.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "0cef8c8e-7986-46c7-a597-c5733a9899c0"
        ]
    },
    "5dfc6949-9881-4c91-9b48-c897822e75b1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00570921",
        "Statement": "monoclonal gammopathy is an abnormal laboratory test result indicating the presence of monoclonal immunoglobulins in the blood or urine. the primary trial participants are administered Fulvestrant intramuscularly (to the deltoid) and Everolimus orally.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "32361e21-ee57-4c34-9390-833ba5048a10"
        ]
    },
    "267860d5-0015-44d8-aea8-7d23c3007cff": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274469",
        "Statement": "moctamide is a linoleic acid derivative with antihyperlipidemic activity. to be eligible for the primary trial patients must be diagnosed with hormone receptor positive advanced breast cancer, and have received prior chemotherapy for this cancer.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "2e76c74a-b6dd-47d8-a674-c1e80b0a3a65"
        ]
    },
    "48114590-2c18-459a-9987-0a1bbe12c070": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01416389",
        "Statement": "nasal cavity lymphoma is a primary lymphoma that affects the nasal cavity and the bulk of the tumor is in this anatomic area. the primary trial reports the changes in tumor size for patients in its cohorts.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "7cde9a22-a91f-4feb-892d-7cbd35f96a27"
        ]
    },
    "ea35c80c-c980-46a4-a94d-91d0b8bf194d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "for the primary clinical trial, patients must have experienced hot flashes for no less than 30 days before registering for the study. however, the secondary clinical trial has no such prerequisite.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "31105b43-832b-48bc-a78d-ee90c155ca44"
        ]
    },
    "0ebc2a2f-2e3a-4893-90d1-35722c3fcbba": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01125566",
        "Statement": "acceptance into the primary clinical trial requires an ecog score exceeding 2.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "7137dec6-5c98-4156-8035-7bbaaf0b649d"
        ]
    },
    "c3532c48-a3f1-4593-b1d9-8ecb44bdf0fc": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00754325",
        "Statement": "during the primary clinical trial, patients treated with fulvestrant had a significantly higher probability of enduring disease progression or death rather than those indirectly treated with herceptin.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "ba9daeb9-796d-49ab-a30c-4d8acbdf4d37"
        ]
    },
    "efdd94eb-d177-468f-a18a-007bb535699b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Statement": "adverse events were experienced by less than 5% of patients in the initial cohort of the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "8e91e404-086e-4063-8d54-83d1b8ebd969"
        ]
    },
    "0e90d47e-0350-48a6-9ba2-b75166e18d46": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00425854",
        "Secondary_id": "NCT01224678",
        "Statement": "patients with insignificantly elevated ejection fraction are excluded from the primary trial, but can be disqualified for the secondary trial if they are 65 years of age or over",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "6b9162d0-0816-46d4-81af-c60028dcc63b"
        ]
    },
    "ddea46fe-f94f-4e8f-b522-45ca413ff613": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "cryptococcus neoformans is a species of the fungus cryptococcus, the causative agent of cryptococcosis. Patients wanting to take part in the primary trial must have a Known and documented HER2+ status and an LVEF of at least 50 percent (%).",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "6b33b4ae-36f2-4a53-a954-6f246f6e023d"
        ]
    },
    "cd73ef50-cf7f-4ce7-b805-f23bbbaf756c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00281697",
        "Statement": "a patient with a her2-positive status is eligible for the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "00822101-fa21-4a26-bf45-3b1f535da005"
        ]
    },
    "07c4184b-b53b-40c3-833f-0d94bf2bbca3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00572728",
        "Statement": "kir2dl1 polymorphism positive is an indication that polymorphism of the kir2dl1 gene has been detected in a sample. Patients must be bedbound or severaly disabled to participate in the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "62be4676-099f-4c42-8029-773af8fde6f7"
        ]
    },
    "1f96a4ce-84a6-4dbe-9a63-b35c4532d175": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00009945",
        "Statement": "no individual adverse event in the primary clinical trial affects more than 100 patients and the cumulative number of patients experiencing adverse events is under 30",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "8648c7df-582a-42a9-9330-414b2430ac56"
        ]
    },
    "bcfb2088-f57b-4dde-81ee-2c62b309ef3f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01581619",
        "Secondary_id": "NCT00106002",
        "Statement": "11q21-q22 is a chromosome band present on 11q the results of the secondary trial and the primary trial report the same outcome measures.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "1180dd58-61b8-4c48-ab00-7d458e68c85b"
        ]
    },
    "6f80d510-16a5-4e1d-9d2c-14ef8d0da854": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "There were more total AEs in cohort 1 of  the primary trial than cohort 2. tuple is a data object containing two or more components.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "1c4e3fe3-b5fe-4ea3-8d9e-0ce1502080e7"
        ]
    },
    "65933396-a686-4c7f-9c68-a79844998513": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "every patient in the first cohort of the primary clinical trial had a pfs duration greater than seven months, the highest one just short of ten months.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "b8eaa8fd-61cf-4ca9-aaec-267d61c1fae3"
        ]
    },
    "1988958d-eb5d-4bc0-ad52-4ac13a764401": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Statement": "pregnant patients in the primary clinical trial have never received endocrine therapy as treatment for breast cancer",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "b1d28450-fc7d-496a-9c7c-bf711b28f8e4"
        ]
    },
    "446f3c69-0de5-475c-a8e2-ff40ece90672": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02924883",
        "Statement": "Only patients with HER2+ve breast cancer are eligible for the primary trial",
        "Label": "Entailment"
    },
    "dd31185e-8e9c-4500-91b8-df6acd9b2bca": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00572728",
        "Statement": "participation in the primary clinical trial is limited to those who are bedbound or extremely disabled",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "62be4676-099f-4c42-8029-773af8fde6f7"
        ]
    },
    "b0b61978-57db-4a1c-812c-509e8b05f2dc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03098550",
        "Statement": "both cohorts of the primary trial receive identical interventions, the difference between the two cohorts is the types of cancer that the patients have",
        "Label": "Entailment"
    },
    "652aaddf-0174-4618-94a6-36defca53eff": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01224678",
        "Secondary_id": "NCT01042535",
        "Statement": "the number of reported cases of pleuropericarditis, atrial thrombosis, mental health disorders and anemia was evenly spread between the primary and secondary clinical trials",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "57b2ae97-0d1d-4d5d-bc4b-109e8e5acb32"
        ]
    },
    "76a39a28-95bf-4475-8554-30599431e67e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274469",
        "Statement": "patients with hormone receptor positive advanced lung cancer, who have undergone chemotherapy for this specific cancer, can participate in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "2e76c74a-b6dd-47d8-a674-c1e80b0a3a65"
        ]
    },
    "6f0aee86-6ae4-4f7c-979f-0bb037494293": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01998906",
        "Statement": "Both cohorts of the primary trial undergo a total of 17 cycles, each lasting 3 weeks . endocrine hypertension is a condition of high blood pressure occurring in association with diseases of the endocrine glands.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "43ce26e5-03fa-4e9d-b0eb-6ea356295753"
        ]
    },
    "dbf8a29f-70cb-4460-9d6d-3d2cf5813c55": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00820170",
        "Secondary_id": "NCT00263588",
        "Statement": "the primary clinical trial and the secondary clinical trial don't share identical criteria for inclusion and exclusion.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "3a4003f6-ff1c-43d8-be48-f767266b2cf5"
        ]
    },
    "b591cfb9-6ff9-4e7a-87e2-5e74f9cf898e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "a patient diagnosed with a t0 n0 m0 adenocarcinoma of the breast is eligible for the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "e6a4e9a6-56b8-4a30-9743-eb02688c090f"
        ]
    },
    "00822101-fa21-4a26-bf45-3b1f535da005": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00281697",
        "Statement": "a patient with a HER2-positive status can not take part in the primary trial",
        "Label": "Entailment"
    },
    "f6702696-a2d5-4322-847e-adefcb6a6ddb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00333775",
        "Statement": "the primary clinical trial cohorts receive differing doses of docetaxel.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "9bcc31df-c1f6-4785-9235-f673213acf3a"
        ]
    },
    "930497c2-8623-414b-834e-50810982aed9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01262027",
        "Secondary_id": "NCT02301988",
        "Statement": "the same outcome measurement techniques are employed in the secondary clinical trial as well as the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "f2275929-7cfe-4bb1-a9f6-6bd0c4d5bf85"
        ]
    },
    "886652dd-8d4c-41f9-9600-69c0e0177f15": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Secondary_id": "NCT00425854",
        "Statement": "the secondary trial and the primary trial use Objective Response as the outcome measurement for their interventions, however they use different definitions of complete response . doctor helped me understand all information is a question about whether an individual's doctor helped them understand all the information.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "8d9f94e3-871b-4fb4-a522-0a73d9d0ec3c"
        ]
    },
    "c2ad7d46-1199-454c-ad05-8501d9b46747": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01118624",
        "Statement": "the primary trial participants recieve over 6.8g/m^2 doses of pralatrexate",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "e9a4bd91-f58b-4234-9037-75e0699d1bbd"
        ]
    },
    "7eb56711-1858-4a39-b8af-ef8c0edb495d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01830933",
        "Statement": "the primary clinical trial and the secondary clinical trial both provide a comprehensive report of all adverse events",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "fb360514-14be-45ab-8b74-ea5a7eb181d7"
        ]
    },
    "a53e0d49-9b72-4a4c-a8a7-ab582e97d6e7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Statement": "all pregnant participants in the primary clinical trial have previously been treated for breast cancer with endocrine therapy",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "b1d28450-fc7d-496a-9c7c-bf711b28f8e4"
        ]
    },
    "e45200f3-3c43-4639-a2a2-e70df85fde85": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Secondary_id": "NCT00876395",
        "Statement": "had neuropsychological problems is a question about whether an individual has or had a neuropsychological problems. Diarrhoea is the most common adverse event in the primary trial, and Anaemia is the most common in the secondary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "324562e6-2b61-4a07-b937-86f99689f2d5"
        ]
    },
    "fe94187d-60b0-48d6-ad81-784bddba95e5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "patients wanting to take part in the primary trial must have a known and documented her2+ status and an lvef of at least 95 percent (%)",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "6b33b4ae-36f2-4a53-a954-6f246f6e023d"
        ]
    },
    "688a8ddd-a2cd-47ae-a5fa-2044fb6af045": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Secondary_id": "NCT01439945",
        "Statement": "one solitary case of diarrhea has arisen in the secondary clinical trial, on the other hand, an excess of 14 different aes have been observed in the cohorts of the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "4519d1cf-7f78-4aa8-85d6-ac94f7eb75a3"
        ]
    },
    "fbea666a-24a0-4846-bc24-4f3fd8f77dd2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01912612",
        "Statement": "the singular occurrence of congestive heart failure in the primary clinical trial was seen in cohort 1",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "9cbc00e9-3a2d-4471-a93e-72c95132fb6a"
        ]
    },
    "f93de76c-aa18-469f-8fbf-0e655a704ce8": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00856492",
        "Secondary_id": "NCT00009945",
        "Statement": "it is a common and shared practice between the secondary and primary clinical trials to evaluate the patient cohort's pcr.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "42d1fcd3-8faa-4065-bbba-42cc90ab67fb"
        ]
    },
    "7ce9b019-ac30-4613-9914-866d39683a4e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00944047",
        "Statement": "in the primary clinical trial, less than one-fourth of the patients under intervention had a pathologic complete response.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "48f516ff-abb4-4312-9b00-02f53fb16218"
        ]
    },
    "3f4ffdff-ca66-4e26-b8c5-e6d5d994a8c1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02924883",
        "Statement": "the primary clinical trial is open to patients with all types of cancer, not just those with her2+ve breast cancer",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "446f3c69-0de5-475c-a8e2-ff40ece90672"
        ]
    },
    "50cbc0d6-99d7-4776-b7a0-7285b0f6c9f6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00127933",
        "Statement": "panss clinical classification question is a question associated with the panss clinical classification. eliane is a 56 year old woman, and elizabeth is a 32 year old woman, both eliane and elizabeth can both be eligible for the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "f0273b8c-460d-46fe-9c52-8ff4b08e439b"
        ]
    },
    "2a2a7bbc-c71d-4562-a279-b1e8d867a988": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Secondary_id": "NCT03098550",
        "Statement": "the primary clinical trial accepts participants diagnosed with histologically or cytologically confirmed invasive breast cancer at stage 2 or 3. the secondary clinical trial does not mandate any particular stage of cancer for eligibility.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "07042b0f-d422-49c3-8d53-81319927a4b3"
        ]
    },
    "4234b296-9312-4e35-80b5-f4b55c660cd2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00450723",
        "Statement": "the treatment for the primary clinical trial involves the oral administration of a drug, whereas the secondary clinical trial involves a medical procedure.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "f0e845f9-8991-45b5-a520-51e934756f7a"
        ]
    },
    "ec2d6fba-d403-4447-8171-4b54a8a7bb88": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01998906",
        "Statement": "both cohorts of the primary trial undergo a total of 70 cycles, each lasting 6 weeks , patients receive the same types and dosages of medication throughout all 10 cycles.",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "2a2c16a7-f427-4fdb-8153-94aac304e4b8"
        ]
    },
    "a3d24785-bc4a-472a-b238-ddfb417651f1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01042535",
        "Statement": "the most frequent adverse event during the primary clinical trial was hair loss",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "4f705481-5dd0-414c-b375-c56e8c235b42"
        ]
    },
    "d35db622-84ba-40a3-a81d-09b733b86e4a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01929395",
        "Statement": "patients are admitted to primary clinical trial without palpable carcinoma",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "24b85b44-b9e6-4c28-b3aa-1bd97102b7f1"
        ]
    },
    "c8d1fab0-695c-4a42-be7a-a3afa27b34ee": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01118624",
        "Statement": "the primary trial participants recieve less than 300mg/m^2 doses of Pralatrexate. cd4 negative is an indication that cd4 expression has not been detected in a sample.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "e9a4bd91-f58b-4234-9037-75e0699d1bbd"
        ]
    },
    "8460a212-8054-4bd2-b4e6-af1d137a2f79": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03012477",
        "Secondary_id": "NCT02419807",
        "Statement": "the primary trial and the secondary trial report their results using different units of measure",
        "Label": "Entailment"
    },
    "5dd3ee8b-861d-4970-968d-08074bfa6504": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "cd-1 nude mouse is an inbred strain of athymic, nude mouse developed by transferring the foxn1nu gene to a cd1 mouse. Patients must have no radiographically confirmed metastases to the brain in order to be eligible for the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "a9bb6de9-c6f8-4c99-81cd-f101cbaab387"
        ]
    },
    "27f040bb-e800-48f3-bf51-88f8272698c0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00900627",
        "Statement": "50% of cohort 2 patients in the primary trial suffered Keratitis. how concerned about possibility of cancer recurrence is a question about how concerned an individual is or was about the possibility of cancer recurrence.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "09fc4356-6154-427e-b710-ed5df6470aff"
        ]
    },
    "8f97509f-bef1-4029-9d6d-9984eb39756d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01596751",
        "Statement": "having a progressive breast cancer disease does not disqualify a patient from the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "89f610a7-9e81-43a4-8c1e-5503233b2be1"
        ]
    },
    "63602d8c-918c-42a0-99f9-3c58016ca157": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00477464",
        "Statement": "in the primary clinical trial, the administration of capecitabine is less frequent than that of lapatinib",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "a52b2d4f-0b06-4960-a9c3-88cb92df0980"
        ]
    },
    "3d89f1d3-7399-4f97-abc3-6c0d088de4a0": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Secondary_id": "NCT01644890",
        "Statement": "primary clinical trial is focused on determining progression free survival while the secondary trial uses kaplan-meier estimates to measure survival chances.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "f42e1874-343a-43ed-bb0c-884509c4793c"
        ]
    },
    "ed80779e-e688-484d-9b3c-6d81ed07b2e6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "a patient with a node positive t2 n2 m0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of 0.0015km",
        "Label": "Entailment",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "e6a4e9a6-56b8-4a30-9743-eb02688c090f"
        ]
    },
    "a2cf8a38-5d34-46fc-a970-93ff4f275ef3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01912612",
        "Statement": "in the primary clinical trial, cohort 1 witnessed numerous instances of congestive heart failure, whereas cohort 2 reported no such cases",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "d1b217ae-76f3-4ba6-958e-5b2558703ba4"
        ]
    },
    "644962ba-276f-4376-9f65-c78eb134cffc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00374322",
        "Statement": "none of the patients in the primary clinical trial were given a placebo",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "e147796d-2edd-42d1-ac53-300fb8bd5eb6"
        ]
    },
    "16bbf480-aab1-4367-8800-c55bab1c3203": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Statement": "the primary clinical trial presents data on the proportion of patients administered neratinib together with paclitaxel that exhibit various types of adverse effects",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "cdadcb0a-20c5-47f7-a63a-39f5c6f26ae2"
        ]
    },
    "d3de845d-3802-4bae-9698-482789ab3545": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "a patient with a node positive t2 n2 m0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of 15mm",
        "Label": "Entailment",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "e6a4e9a6-56b8-4a30-9743-eb02688c090f"
        ]
    },
    "6858277a-9a3b-4feb-8239-a0f41730ba8f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042938",
        "Statement": "in the primary clinical trial, the severity of dermatitis in the radiation treatment site is reported for the curcumin c3 complex group as well as the placebo group, with no variation in the results of these two groups",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "e62f5a3f-0091-4980-9822-db8f4dc2502a"
        ]
    },
    "3cd5fd68-a454-4fc4-a536-7967a0fe182c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820222",
        "Statement": "the primary clinical trial findings demonstrate that the trastuzumab plus capecitabine group manifested a lower percentage of patients with grade 3 or 4 skin/subcutaneous or pulmonary toxicities, than the lapatinib plus capecitabine group.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "566bdc2d-7c4a-4547-87da-ac81447ecca8"
        ]
    },
    "01682f8c-bce8-4068-afe6-00e73f674ef9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00856492",
        "Secondary_id": "NCT00009945",
        "Statement": "the secondary trial and the primary trial both measure the pCR and tumor diameter of their patient cohorts. perfusion culture is a type of culture in which cells are grown and are continuously fed new culture media.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "70677d5f-7022-404c-8410-d1f89366d92f"
        ]
    },
    "e186b5eb-da4b-4e2a-b30f-a07dfbc4c854": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "neither of the interventions in the primary trial resulted in an objective benefit for more than 5% of patients, in fact over 100% of patients receiving the docetaxel then liposomal doxorubicin intervention suffered fatal complications",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "74e376d7-5713-43f3-93f1-9608059c9547"
        ]
    },
    "2b35522f-ca61-4a6a-b7ea-9d6a07a1703a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT02340221",
        "Statement": "the primary trial and the secondary trial have non-comparable outcome measurements for their results. urothelial neoplasm is a benign or malignant neoplasm affecting the urothelium.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "2a03c17f-3afe-40f1-a0db-4b876ee8c700"
        ]
    },
    "918cac59-128c-4f0f-9227-97e1f4f79355": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "experiencing hot flashes within the last 4 months is not a factor for eligibility in either the primary clinical trial or the secondary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "a5baab2c-9c32-4301-a574-4ba5a0c2eb00"
        ]
    },
    "efcff264-9288-4b38-bde0-b1fcd4559201": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT00852930",
        "Statement": "the primary trial and the secondary trial do not record any cardiac or infection related adverse events. dhekelia is a british overseas territory on the southeast coast of cyprus.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "06f798d1-2956-4903-83e9-58a41fa425f7"
        ]
    },
    "83ade271-5710-491a-aadb-38b867aede17": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00572728",
        "Statement": "chief complaint was not witnessed is an indication that the chief complaint was not witnessed. Patients must be bedbound or severaly disabled to participate in the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "62be4676-099f-4c42-8029-773af8fde6f7"
        ]
    },
    "a4adf303-66d6-447b-a265-ae8294ccc2ae": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "a documented lvef of less than 50 percent (%) is not a disqualifier for patients wanting to join the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "9abb10d7-496e-44fd-915d-d86aedf6c9b6"
        ]
    },
    "d9f7654c-e2d6-47be-b140-cd7f1b7683be": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01830933",
        "Statement": "detailed reports of adverse events are a mandatory part of both the primary and secondary clinical trials",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "fb360514-14be-45ab-8b74-ea5a7eb181d7"
        ]
    },
    "606e7dc4-93a9-4078-b016-0ebf7afa0a9a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00606931",
        "Statement": "the primary clinical trial includes a dedicated section for the documentation of adverse events.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "21611c2a-e6eb-4012-a209-9b6781e1f260"
        ]
    },
    "b2e641e1-f894-4a92-86d0-d91ab2c0a96e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Statement": "afraid of being rejected is a question about whether an individual is or was afraid of being rejected. all pregnant patients accepted into the primary trial have undergone Prior treatment for breast cancer with endocrine therapy.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "b1d28450-fc7d-496a-9c7c-bf711b28f8e4"
        ]
    },
    "3cede781-6588-4e0e-9cb8-a2e3f0602787": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00612560",
        "Secondary_id": "NCT01216176",
        "Statement": "every primary clinical trial participant is treated with flaxseed, while those in the secondary clinical trial are not administered any flaxseed",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "b0046821-ba27-4a90-8869-cb708b843aa4"
        ]
    },
    "e73219b4-1767-4dc7-ba0d-391f4a418847": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00606931",
        "Statement": "the adverse events portion of the primary clinical trial outlines the number of study participants who had hypotension, hemorrhage, and bradycardia.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "175044aa-72b1-405d-8506-30002f5098e4"
        ]
    },
    "04544786-f77f-48fd-b0ea-08bc7a43950f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820222",
        "Statement": "the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher precentage of patients with Grade 3 or 4 skin/subcutaneous or pulmonary toxicities, than the Lapatinib Plus Capecitabine group. difficulty paying attention to things is a question about whether an individual has difficulty paying attention to things.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "566bdc2d-7c4a-4547-87da-ac81447ecca8"
        ]
    },
    "64ae0223-58bd-46d0-91f0-0d5470b9ff89": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02186015",
        "Statement": "the primary clinical trial is open to participants of all ages",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "a805f174-2707-4302-a195-05153ea8523e"
        ]
    },
    "53d308d5-1b4d-446d-95a6-b0064041929e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02301988",
        "Statement": "all cohorts of the primary clinical trial receive ipatasertib.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "faa65e54-aa04-4595-8dae-05cf00b4c887"
        ]
    },
    "39f4f60e-8129-452d-a219-9d5f73464a6b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "4q31 is a chromosome band present on 4q to be eligible for the primary trial candidates must be over the age of 18, have a Karnofsky score over 80 and Adequate hepatic, renal and heart functions aswell as Adequate hematology levels.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "7c7418d2-32d7-4517-874b-eb3db24ea16a"
        ]
    },
    "520b2b21-b677-4c8c-8ebc-dc2db0768311": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01998906",
        "Statement": "patients in the primary clinical trial receive different types of medication depending on their cohort",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "2a2c16a7-f427-4fdb-8153-94aac304e4b8"
        ]
    },
    "3319e577-bba5-4306-8a23-8bb40a750d0c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01118624",
        "Statement": "the primary trial participants recieve less than 0.0003kg/m^2 doses of pralatrexate",
        "Label": "Entailment",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "e9a4bd91-f58b-4234-9037-75e0699d1bbd"
        ]
    },
    "66667835-132b-4276-96be-45e03be6ebdb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00754325",
        "Statement": "in the primary trial, patients that received Fulvestrant were much more likely  to suffer Disease Progression or Death than patients receiving herceptin. ret gene mutation is a change in the structure of the ret gene.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "ba9daeb9-796d-49ab-a30c-4d8acbdf4d37"
        ]
    },
    "14ca3259-85fc-43e2-8ea0-99c14f35a4ac": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Secondary_id": "NCT00121992",
        "Statement": "the secondary trial did not report any cases of conjunctivitis, whereas the primary trial reported multiple cases",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "a5617ae4-05a3-42d0-9e14-141de5f8c010"
        ]
    },
    "402f0dbf-cf67-4425-b300-a0a3df4d59d3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Secondary_id": "NCT00425854",
        "Statement": "the secondary trial and the primary trial use Objective Response as the outcome measurement for their interventions. ",
        "Label": "Entailment"
    },
    "b4ff2e1c-47f6-4bc7-98b9-10061b96dc28": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Secondary_id": "NCT01644890",
        "Statement": "the primary trial measures the overall survival rate of its participants, whereas the secondary trial measures disease-free survival",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "794269ca-e7ec-4a65-ace5-b0f24a8cdc15"
        ]
    },
    "912dbe2c-7f11-497b-be8f-b9891fc6f5b9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Secondary_id": "NCT01439945",
        "Statement": "There is only one case of Diarrhea in the secondary trial and over 14 different types of Aes recorded in the primary trial cohorts. have ostomy appliance is a question about whether an individual has an ostomy appliance.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "4519d1cf-7f78-4aa8-85d6-ac94f7eb75a3"
        ]
    },
    "c7a953b0-ac96-4e0a-9c1d-98cf8af2861d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01830933",
        "Statement": "the primary trial and the secondary trial report the same types of adverse events",
        "Label": "Contradiction"
    },
    "77548c5c-0502-4e39-bcbb-d313418f131c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01118624",
        "Statement": "the primary trial participants recieve less than 324\u00b5g/m^2 doses of pralatrexate",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "e9a4bd91-f58b-4234-9037-75e0699d1bbd"
        ]
    },
    "2915d502-5c3b-48ef-97ad-47013e892d20": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00754325",
        "Statement": "the progression or death rate of patients due to the disease was less in cohort 2 than in cohort 1 in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "251a20d8-2555-4929-9d01-c02311bdc93f"
        ]
    },
    "2bff41cd-5662-415e-aadc-c4c52597b2cc": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00009945",
        "Statement": "in the primary clinical trial, none of the separate adverse events impact more than 100 patients and fewer than 30 patients experience these adverse events in total",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "8648c7df-582a-42a9-9330-414b2430ac56"
        ]
    },
    "fd076463-3ee7-47c7-97f7-7041f869e07b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042938",
        "Statement": "the primary clinical trial discloses the intensity of dermatitis at the radiation therapy location for both the curcumin c3 complex group and the placebo group.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "4a15ec5e-4904-4f01-a0a2-c51e83c8c070"
        ]
    },
    "0a137be1-9683-4dee-a31b-7d085615c634": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01125566",
        "Statement": "ECOG score > 2 is necessary to be eligible for the primary trial. rad21 gene mutation is a change in the nucleotide sequence of the rad21 gene.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "b2cdbcb8-de26-4a44-8a94-dd68c13f7e41"
        ]
    },
    "06f798d1-2956-4903-83e9-58a41fa425f7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT00852930",
        "Statement": "the primary trial and the secondary trial do not record any cardiac or infection related adverse events",
        "Label": "Entailment"
    },
    "9bc4febb-d5a8-4c8e-8b82-d461344cbbd3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00331630",
        "Statement": "the primary clinical trial reported no adverse events concerning the heart or bowel.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "553f00ea-5197-4233-b1e0-e5727856b599"
        ]
    },
    "2e450b00-a6f3-48de-86bc-2c670454ba52": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01416389",
        "Statement": "the primary clinical trial does not record any alterations in the quantity of lesions present in its patient groups.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "812bd63c-4bfb-49cb-8fa9-baa3f8f6dabe"
        ]
    },
    "6222fcd1-3b3c-4aa6-b7cd-9b181dfe904a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02924883",
        "Statement": "patients with triple negative breast cancer are eligible for the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "446f3c69-0de5-475c-a8e2-ff40ece90672"
        ]
    },
    "35763e96-f7a8-464d-a5eb-faea7bfcf212": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00263588",
        "Statement": "iris disorder is a non-neoplastic or neoplastic disorder that affects the iris. patients must have HER2- breast cancer to participate in the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "215a5c4a-d90c-4500-8284-0679ce311734"
        ]
    },
    "ad273371-762e-4bf3-87d7-9543a7d728b8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820222",
        "Statement": "based on the results of the primary clinical trial, the occurrence of cns metastases was higher in patients receiving trastuzumab plus capecitabine, compared to the group being administered lapatinib plus capecitabine.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "5de9caeb-9dd5-4535-8fe3-289450d9c626"
        ]
    },
    "b6bff888-9f4d-4e25-874f-fc9845268119": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Statement": "both cohorts in the primary clinical trial will be subjected to surgical intervention",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "63a0a9fc-80b9-450f-b2c6-7aee37ce26a9"
        ]
    },
    "8841e637-a14f-4989-9422-ae686502cc29": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820222",
        "Statement": "the primary clinical trial results indicate that the trastuzumab plus capecitabine group had a lower precentage of patients with cns metastases than the lapatinib plus capecitabine group.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "5de9caeb-9dd5-4535-8fe3-289450d9c626"
        ]
    },
    "da205d3b-05a5-4903-bc29-2b0532e1a3ed": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274469",
        "Statement": "to be eligible for the primary trial patients must be diagnosed with hormone receptor positive advanced breast cancer, and have received prior chemotherapy for this cancer. meet goals set for myself is a question about whether an individual meets the goals they set for themself.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "2e76c74a-b6dd-47d8-a674-c1e80b0a3a65"
        ]
    },
    "cc77be90-cc1d-4c54-8f1b-fe8eeb379542": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02658734",
        "Statement": "most participants in the primary clinical trial encountered adverse events of grade 1 severity, with grade 5 being the lowest in occurrence as it affected a mere 8 out of the 70 patients.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "40f699a1-fbc6-40de-8e80-85b28f71632f"
        ]
    },
    "2d818b53-cd0a-48df-a366-420e55dae94d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "in the primary clinical trial, each patient in the first group experienced a pfs extending beyond 8.8 months, with the pinnacle pfs falling just shy of 10 months.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "b9e29ea8-6847-40d4-b5c3-81c496101695"
        ]
    },
    "1b705306-ed8d-4a53-8030-7917cbf9f201": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Secondary_id": "NCT00121992",
        "Statement": "unresectable periampullary adenocarcinoma is adenocarcinoma that arises from the periampullary region and is not amenable to surgical resection. the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial did not report any.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "a5617ae4-05a3-42d0-9e14-141de5f8c010"
        ]
    },
    "b3f09297-96de-4b67-8275-010dd404f827": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02340221",
        "Statement": "Prior treatment with fulvestrant or with a phosphatidylinositol 3-kinase (PI3K) inhibitor will not prevent a patient from participating in the primary trial. timeline is a chronological schedule of when activities or events occurred or will occur.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "904061c0-14fa-4f13-9118-9a41e24fa8eb"
        ]
    },
    "b0046821-ba27-4a90-8869-cb708b843aa4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00612560",
        "Secondary_id": "NCT01216176",
        "Statement": "All the primary trial participants are administered flaxseed, but none of the secondary trial receive any flaxseed",
        "Label": "Entailment"
    },
    "453cd494-3d2d-469d-934a-ccaf4d091fe7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00022516",
        "Statement": "patients with a t1 n0 m0 diagnosis can participate in the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "978d19fc-e7f6-485e-b8bd-cfcde06441ab"
        ]
    },
    "ebf8f704-756f-49f7-90b5-0987f9cc441e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00331630",
        "Statement": "no cardiac or bowel-related adverse events were recorded in the primary trial. ovarian adenomatoid tumor is a rare benign mesothelial tumor that arises from the ovary. it is characterized by the presence of gland-like structures.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "553f00ea-5197-4233-b1e0-e5727856b599"
        ]
    },
    "452aea51-bdfc-4ec0-a8fd-12bb4e5f0317": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03012477",
        "Secondary_id": "NCT02419807",
        "Statement": "the primary trial and the secondary trial report their results as perecentages but use different units of measure. was testing performed is a question to determine if specific tests were performed during the study.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "0e609fad-9a28-4fb6-90b6-32a731e3b02c"
        ]
    },
    "c21b9cd2-d174-4b04-852f-198f49d7c2a6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00733408",
        "Statement": "Syncope was the most common adverse event recorded in the primary trial. abnormal involuntary movement scale aims0101 through aims0107 standardized character result 1 is abnormal involuntary movement scale aims0101 through aims0107 standardized character result 1 - minimal, may be extreme normal .",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "9d8b26d6-d574-4717-88b6-77458bc683f3"
        ]
    },
    "17bbea92-8f92-41f3-9b9d-cf6e62cf6798": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Statement": "the primary trial reports the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer side effects that are serious enough to prevent an increase in dose or level of that treatment.",
        "Label": "Entailment"
    },
    "6df6fa87-157a-4203-b45b-73e3399da221": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042938",
        "Statement": "the primary clinical trial provides information on the seriousness of dermatitis in the treatment area for the cohort administered with curcumin c3 complex and the control group who received placebo.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "4a15ec5e-4904-4f01-a0a2-c51e83c8c070"
        ]
    },
    "7c9e3d5f-2830-4c2b-8642-47ffa2e96f56": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01125566",
        "Statement": "it is required to have an ecog score above 2 to qualify for the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "b2cdbcb8-de26-4a44-8a94-dd68c13f7e41"
        ]
    },
    "48eb88f9-6a54-4c11-89b7-f1acd4d293eb": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01262027",
        "Secondary_id": "NCT02301988",
        "Statement": "primary clinical trial utilizes a different set of parameters to measure outcomes compared to that of the secondary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "0131ebe3-746b-45a5-ba60-fdd326974fec"
        ]
    },
    "4eec9c49-8bbf-4152-8a91-c585006de941": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00376597",
        "Statement": "the primary clinical trial admits patients diagnosed with stage 4 cancer",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "75a65913-5655-4377-b441-ecdd4dd75175"
        ]
    },
    "676ee85c-c792-47a3-85a3-4e704e7f47a3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01125566",
        "Statement": "the primary clinical trial requires a participant to have an ecog score below 2",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "7137dec6-5c98-4156-8035-7bbaaf0b649d"
        ]
    },
    "49a16f4e-5ca5-43a0-898e-e1a8c31b9b2f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Secondary_id": "NCT03098550",
        "Statement": "all participants of the primary trial have stage 2 or 3 histologically or cytologically confirmed invasive breast cancer, there is no specific stage of cancer required for entry to the secondary trial. streptococcus pneumoniae is a gram-positive, alpha-hemolytic diplococcus aerotolerant anaerobe streptococcus species.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "07042b0f-d422-49c3-8d53-81319927a4b3"
        ]
    },
    "527f1487-c691-47bf-94fa-d6ea7326c314": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03012477",
        "Secondary_id": "NCT02419807",
        "Statement": "the primary clinical trial and the secondary clinical trial express their results logarithmically using the same units of measure.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "0e609fad-9a28-4fb6-90b6-32a731e3b02c"
        ]
    },
    "d2d66b5f-809c-41ea-a40c-0f29cc26e1bf": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "in the primary clinical trial, the most frequently observed adverse effect was febrile neutropenia, which impacted the majority of the participants",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "614d7ade-0fa7-4d77-bc19-1d3a2f2f48c2"
        ]
    },
    "5198628e-4586-471d-bfcb-eb41a77840f8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02131064",
        "Statement": "in cohort 1 of the primary clinical trial, the number of cases of left ventricular dysfunction and abdominal pain were the same",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "1329dec6-fb2c-4219-9db6-3fef9d94b316"
        ]
    },
    "5f540bfa-cc6a-4bd5-ba45-8f76b89ea958": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00754325",
        "Statement": "in the primary clinical trial, patients treated with fulvestrant had lower chances of disease progression or death than those treated with herceptin.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "ba9daeb9-796d-49ab-a30c-4d8acbdf4d37"
        ]
    },
    "9a024264-6433-4f1b-a85f-6bb7c40e3238": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01905592",
        "Statement": "four types of adverse events significantly impacted all patients in cohort 1 of the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "2655c892-216e-4b96-a8f2-6f64403215c5"
        ]
    },
    "936a8d84-d325-483c-9c5a-b57f8cfb6ac4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02679755",
        "Statement": "battlefield acupuncture is a form of acupuncture that uses needles placed in the ear as a protocol for pain management. None of the individual Aes recorded in the primary trial affect more than 10% of the population.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "c09fa61c-967a-40ae-96b0-c87b7cde237b"
        ]
    },
    "b8a402c2-6b20-4165-b064-633d4a365969": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00281697",
        "Statement": "a patient possessing a her2-positive status is ineligible for the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "00822101-fa21-4a26-bf45-3b1f535da005"
        ]
    },
    "ee54f36d-0ed3-41c0-8d3a-2394bedbc273": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00127933",
        "Statement": "eliane, at 56 years old, is not eligible for the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "a792bbac-0e8a-4bf7-9cc5-56fad481e2fb"
        ]
    },
    "3adcc8fc-b76b-407a-a006-729a13f571fb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03098550",
        "Statement": "both cohorts of the primary trial receive identical interventions, the difference between the two cohorts is the types of cancer that the patients have, with cohort 1 all being diagnosed with HER2 positive cancer and cohort 2 being PR-",
        "Label": "Contradiction"
    },
    "cda0aac0-348c-4624-bebc-7675ed180b10": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00572728",
        "Statement": "patients who are capable of having a pet scan are eligible to take part in the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "32ed503c-1cfd-44f6-b8bb-23d9d175d73d"
        ]
    },
    "7733e3d5-5317-4dcd-85ce-cd924c1d583b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00281697",
        "Statement": "the primary clinical trial is only open to patients who have been confirmed as her2-positive",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "43ee7645-ce1e-42d5-9a74-3e379f6f367b"
        ]
    },
    "45d33bc7-c3f1-4ca6-9934-54756494084e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02924883",
        "Statement": "participants of the primary clinical trial must have triple negative breast cancer.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "c10eea1a-5768-442d-ae07-20b4f8f4b583"
        ]
    },
    "20b01421-6265-459f-8916-f955e11fbcc6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT00852930",
        "Statement": "adverse events linked to heart conditions and infections are recorded consistently in primary and secondary clinical trials",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "06f798d1-2956-4903-83e9-58a41fa425f7"
        ]
    },
    "7b6ee6ac-a9c0-4162-810e-49dff1503156": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01581619",
        "Secondary_id": "NCT00106002",
        "Statement": "the conclusions drawn in the primary clinical trial and the secondary clinical trial are of a comparable nature",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "0a6d1b4c-244e-44e2-a229-62e4cbdfa979"
        ]
    },
    "9392b512-548f-4081-95f4-24262e928387": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01929395",
        "Statement": "locally advanced angiosarcoma is an angiosarcoma that has spread from its original site of growth to nearby tissues or lymph nodes. Patients must have several visible carcinomas in the stomach and neck areas to be included in the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "79ca2ee8-6c9c-40e6-a87c-925b50d3d3d2"
        ]
    },
    "9bcc31df-c1f6-4785-9235-f673213acf3a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00333775",
        "Statement": "both the primary trial cohorts receive identical doses of Docetaxel ",
        "Label": "Entailment"
    },
    "76d72618-9635-408d-982e-76eaff7aec19": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01905592",
        "Statement": "education type is an indication of the type of schooling an individual receives or received. there were two types of Adverse events which did not affect any of the patients in cohort 1 of the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "30483d7e-7703-459c-bd10-e2bd259c2a4f"
        ]
    },
    "141da146-9143-467e-9337-dd9e62c5541a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00606931",
        "Statement": "There adverse events section in the primary trial describes the number of patients that suffered Hypotension, Hemorrhage and Bradycardia when taking part in the study. nasal inhaler dosage form is a medication delivered as a mist to be inhaled through the nose as a measured dose",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "175044aa-72b1-405d-8506-30002f5098e4"
        ]
    },
    "8869f10b-ffb2-4de3-bb17-ed8cd91b854f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00328783",
        "Statement": "the primary clinical trial's adverse events section documents the occurrence rate of 12 distinct adverse events.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "97fd111c-6969-43ab-93af-b3dff09960e5"
        ]
    },
    "64febc6d-c695-42e7-ae15-2e1ad64e0a0e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT02340221",
        "Statement": "the primary clinical trial and the secondary clinical trial directly compare the same set of outcome measures in their respective results.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "2a03c17f-3afe-40f1-a0db-4b876ee8c700"
        ]
    },
    "6e50a13f-963d-430d-8f05-eae452a713e9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00856492",
        "Secondary_id": "NCT00009945",
        "Statement": "the secondary clinical trial and the primary clinical trial jointly measure the pathologic complete response (pcr) in their presented patient groups.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "42d1fcd3-8faa-4065-bbba-42cc90ab67fb"
        ]
    },
    "cdf6e0a8-42a0-4490-bbcf-20c122fbda9a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01262027",
        "Secondary_id": "NCT02301988",
        "Statement": "sf10 v1.0 children standard questionnaire question is a question associated with the sf10 v1.0 children standard questionnaire. the primary trial and the secondary trial use identical outcome measurements.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "f2275929-7cfe-4bb1-a9f6-6bd0c4d5bf85"
        ]
    },
    "a724df8c-213f-4008-bf41-d9a61211b96e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00328783",
        "Statement": "twelve different aes' occurrence rates are reported in the adverse events section of the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "97fd111c-6969-43ab-93af-b3dff09960e5"
        ]
    },
    "695e3890-d096-4c71-b7da-4d05d104746f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01596751",
        "Statement": "breast cancer patients with stable disease are eligible for the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "bc2024fc-5b39-4fa6-badf-f034d6fe8bb8"
        ]
    },
    "f2275929-7cfe-4bb1-a9f6-6bd0c4d5bf85": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01262027",
        "Secondary_id": "NCT02301988",
        "Statement": "the primary trial and the secondary trial use identical outcome measurements",
        "Label": "Contradiction"
    },
    "403d1204-efa0-4aa6-bb3a-0c4d8dacf4dc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01118624",
        "Statement": "participants in the primary clinical trial get pralatrexate doses of less than 300mg/m^2",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "e9a4bd91-f58b-4234-9037-75e0699d1bbd"
        ]
    },
    "194ee2ec-9a11-4b3e-acfe-60fdb16aea1b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00066573",
        "Statement": "there is an extensive divergence between the outcomes of two cohorts in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "fe876bb0-7ce3-4197-81ad-920f1f77938e"
        ]
    },
    "1cc9ac18-c8d8-4786-9424-2a7a8084a929": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00570921",
        "Statement": "the primary trial participants are administered Fulvestrant intramuscularly and Everolimus orally. methotrexate-associated hodgkin lymphoma is a hodgkin lymphoma that develops in patients who are immunosuppressed with methotrexate.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "45ccd2c8-6e02-4f0f-a370-eed18d26e6dc"
        ]
    },
    "2cdfe64e-68d4-48c8-8b48-150fb2ecee40": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01929395",
        "Statement": "inclusion in the primary clinical trial requires patients to have numerous detectable tumors in the gastric and neck regions.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "79ca2ee8-6c9c-40e6-a87c-925b50d3d3d2"
        ]
    },
    "caf2d427-0b16-4a24-984c-dccd41bcc0d6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02186015",
        "Statement": "the primary clinical trial does not accept either adults or children as participants.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "2825d63b-8f22-4fb8-829f-9567845251c6"
        ]
    },
    "5138f549-0331-489c-8c3b-faae07dcc90c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Statement": "patients must have a life expectancy of at least 12 months to enroll in the primary trial",
        "Label": "Entailment",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "618a3ae1-b22c-4c35-86a6-190c1b5b5d21"
        ]
    },
    "1efb5188-f958-4bba-881a-26278a6e1796": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Secondary_id": "NCT00281697",
        "Statement": "enterocolitis was not a common condition among the participants of both the primary and secondary clinical trials",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "2ef186d0-b4ab-44de-b785-a63e9e95851a"
        ]
    },
    "3b5d3461-0c6f-4ad0-b4ce-7bad82bf48d7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02419807",
        "Statement": "the primary clinical trial results section does not provide any measurements for the three cohorts in the study.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "d0b50aeb-aad8-4a8d-aae6-5c58a7d382c7"
        ]
    },
    "23eb9a8f-0f4d-4277-a830-2de833e7f31e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "brca gene mutation negative is a genetic finding indicating that brca family gene mutations have not been detected in a sample. Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting more than 5% of patients.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "1842904b-5371-49ee-b6f4-8831b879098b"
        ]
    },
    "91953e84-c914-47be-9ecc-c97362a1e076": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02301988",
        "Statement": "milliliter per gram per day is a dose calculation unit expressed in milliliter(s) per gram per period of time equal to twenty-four hours. cohort 1 patients of the primary trial are administered higher doses of Ipatasertib and  Placebo than cohort 2 patients.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "973f090a-8967-4d75-bb8e-6166c868337c"
        ]
    },
    "7cde9a22-a91f-4feb-892d-7cbd35f96a27": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01416389",
        "Statement": "the primary trial reports the changes in tumor size for patients in its cohorts.",
        "Label": "Entailment"
    },
    "11c13093-c1f9-49c1-a383-2aee6dff96fa": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00503906",
        "Statement": "participants of the primary trial will receive the intervention for a total of 30 cycles (210 days)",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "6499b181-7a23-4073-8459-ad46ff02b20f"
        ]
    },
    "b791361d-98b9-45fd-a744-39a82345286a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00450723",
        "Statement": "the primary trial intervention involves a medical device and the secondary trial intervention is based on various injections.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "f0e845f9-8991-45b5-a520-51e934756f7a"
        ]
    },
    "1263ba93-d4fd-46a4-9f69-93854bc47f38": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01118624",
        "Statement": "doses of pralatrexate, given to participants of the primary clinical trial, are estimated based on the weight of the person",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "0ddb07ae-6e70-436d-8723-f609e59c57da"
        ]
    },
    "d96132f6-5240-43f8-8ec3-01728122c710": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274469",
        "Statement": "individuals diagnosed with advanced lung cancer and have undergone chemotherapy are permitted to take part in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "b1219e71-fbf5-4bba-8a93-a27ae444e3e1"
        ]
    },
    "2ce5a2b3-0971-4f54-a032-e4cb9b2ced76": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00477464",
        "Statement": "the primary trial participants receive Capecitabine less often than they receive Lapatinib. accelerometry is a technique for quantifying movement using instruments that measure acceleration.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "a52b2d4f-0b06-4960-a9c3-88cb92df0980"
        ]
    },
    "7c74e082-35e6-4b38-b7e0-ae0c530fd2ed": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Statement": "patients who have never undergone endocrine therapy for breast cancer have been accepted into the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "6d621974-c719-46df-8a50-d94e49583e33"
        ]
    },
    "a2070492-ecbd-4163-98d4-45db6060957e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00944047",
        "Statement": "pathologic complete response was seen in under 25% of patients in the intervention arm of the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "48f516ff-abb4-4312-9b00-02f53fb16218"
        ]
    },
    "53fb9d67-4189-452e-973b-8629a1f43d62": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01596751",
        "Statement": "Breast cancer patients must have documented stable disease to participate in the primary trial. grade 1 prolapse of urostomy, ctcae is asymptomatic; clinical or diagnostic observations only; intervention not indicated",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "89f610a7-9e81-43a4-8c1e-5503233b2be1"
        ]
    },
    "5308041b-e1d9-4345-b7ae-a91b6a8d6b8d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT00232505",
        "Statement": "plutonium-239 alpha particle radiation is alpha rays produced by the decay of plutonium-239. the primary trial and the secondary trial participants do not receive any medication by IV.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "7edba90d-076d-4f55-b9d6-a1765ceb48bd"
        ]
    },
    "ecadbd66-5307-44e1-9144-81db3abe41fd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00428922",
        "Statement": "the outcome measurement of the primary clinical trial is the quantifiable reduction in tumor size.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "3facad41-0221-42f8-834d-470e65c4aad5"
        ]
    },
    "d9e63700-21cc-47c6-b71b-e1e1cd9ca5ad": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01581619",
        "Secondary_id": "NCT00106002",
        "Statement": "the outcome measures of the primary clinical trial and the secondary clinical trial are found to be identical",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "1180dd58-61b8-4c48-ab00-7d458e68c85b"
        ]
    },
    "f1716510-9a14-4300-957b-4f3c0be6aa79": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02340221",
        "Statement": "patients previously treated with a phosphatidylinositol 3-kinase (pi3k) inhibitor are admissible for the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "6b35bc10-f591-4b84-abac-40a74be949fa"
        ]
    },
    "b2032df0-5d74-4f6d-b2b9-86c48cd86d82": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00820170",
        "Secondary_id": "NCT00263588",
        "Statement": "the primary clinical trial and the secondary clinical trial both use the exact same criteria for inclusion and exclusion",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "3a4003f6-ff1c-43d8-be48-f767266b2cf5"
        ]
    },
    "672477a8-14c2-497b-bbf8-d789d2d61cc7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01830933",
        "Statement": "the types of adverse events reported in the secondary trial are completely different from those in the primary trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "c7a953b0-ac96-4e0a-9c1d-98cf8af2861d"
        ]
    },
    "f8f4e1ce-a2d0-41c0-9f25-511e43232dab": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "the primary trial intervention protocol will continue until patients achieve complete response or suffer disease progression. verapamil-sensitive ventricular tachycardia by ecg finding is an electrocardiographic finding of a ventricular tachycardia that is terminated successfully with verapamil administration.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "1d1f57f8-85f7-448c-a4bb-15957da568fd"
        ]
    },
    "64b88e40-6f32-4d8d-a502-60226eac86bc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00570921",
        "Statement": "in the primary clinical trial, fulvestrant is given intramuscularly and everolimus is administered orally to the participants",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "45ccd2c8-6e02-4f0f-a370-eed18d26e6dc"
        ]
    },
    "5c975af8-6b7f-4a5d-b4a6-257c76763ce9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT03176238",
        "Statement": "There more cases of Acute myocardial infarction, Cardiopulmonary failure and Supraventricular tachycardia in cohort 1 of the secondary trial than in the entire patient cohort of the primary trial",
        "Label": "Entailment"
    },
    "df6f7c4e-efa3-410b-8a2f-4b2996a1c89b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01912612",
        "Statement": "in the primary clinical trial, multiple instances of congestive heart failure were observed in cohort 1.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "9cbc00e9-3a2d-4471-a93e-72c95132fb6a"
        ]
    },
    "8ba02c2f-61c0-4b07-a447-e415362e3c02": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00022516",
        "Statement": "patients with the t3, n2 or m1 stage classification may enrol in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "978d19fc-e7f6-485e-b8bd-cfcde06441ab"
        ]
    },
    "7a5aa42d-4b0f-4b0a-bc65-f99410a26b66": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Secondary_id": "NCT00281697",
        "Statement": "a considerable proportion of the participants in both the secondary clinical trial and the primary clinical trial experienced enterocolitis.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f"
        ]
    },
    "9954ea94-893c-4cc4-a54f-ec1b682f362a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01998906",
        "Statement": "every cohort in the primary clinical trial goes through 17 full cycles, each persisting for three weeks.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "43ce26e5-03fa-4e9d-b0eb-6ea356295753"
        ]
    },
    "731b0d83-f179-4a06-b960-961eae8f4c91": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00503750",
        "Secondary_id": "NCT00005879",
        "Statement": "The results from the secondary trial and the primary trial can be compared by changing the units from days to months. performed exclusion criterion is a characteristic or requirement that disqualifies a subject from participation in a study.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "7d52734c-0801-413d-9ae2-d190b972cde5"
        ]
    },
    "3e976706-9f33-4793-b835-dc9f9fd56b03": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00425854",
        "Secondary_id": "NCT01224678",
        "Statement": "the primary clinical trial disqualifies patients with a markedly low ejection fraction, yet those below 56 years may be suitable for the secondary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "d1b7105d-0b7d-4b10-92a7-d63243ff0629"
        ]
    },
    "fef5aedb-21c0-4130-b8a3-cb1df5017c7a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00328783",
        "Statement": "The adverse events section in the primary trial is empty",
        "Label": "Entailment"
    },
    "c93b8762-4e44-4683-af9e-cfa9832ffe24": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03098550",
        "Statement": "the intervention is different for both cohorts in the primary clinical trial, with one cohort receiving targeted therapy, and the other receiving immunotherapy.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "3adcc8fc-b76b-407a-a006-729a13f571fb"
        ]
    },
    "d52e443e-2892-4233-8cd7-fa329a76c726": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00009945",
        "Statement": "liver fissure is any of the clefts or grooves on the surface of the liver. none of the individual adverse events in the primary trial affect more than 100 patients, in total less than 30 patients suffer adverse events.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "8648c7df-582a-42a9-9330-414b2430ac56"
        ]
    },
    "1b826620-742d-4635-88b5-ac87a9b8d6af": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "no adverse events were reported in either cohort 1 or cohort 2 of the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "1c4e3fe3-b5fe-4ea3-8d9e-0ce1502080e7"
        ]
    },
    "762691ea-723e-470c-b423-d7b4eef3d01b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00450723",
        "Statement": "the primary trial intervention is based on a medical procedure and the secondary trial intervention involves one drug administered intravenously.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "d310ec4e-993e-4827-8dc5-9aca053972db"
        ]
    },
    "b83aa93e-3006-426b-b344-3861aab02050": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00572728",
        "Statement": "participants of the primary clinical trial are not required to undergo a pet scan",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "32ed503c-1cfd-44f6-b8bb-23d9d175d73d"
        ]
    },
    "85281fc9-e8c2-47e7-8580-400b2147cbb6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Statement": "the primary clinical trial accepts patients with a life expectancy of 45 to 50 years",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "4b97a844-8d52-48bb-8eda-ca205268f016"
        ]
    },
    "3fdf012b-b88f-48b0-ae80-4d8cdd54d978": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Statement": "continued flucytosine treatment is allowed for the participants of the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "f10f3b84-e039-4a02-a98b-86d149d9a16f"
        ]
    },
    "5ca33735-8004-465a-88cf-478e488393c5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "to be eligible for the primary trial candidates must be over the age of 60, have a severe disability and adequate hepatic, renal and heart functions aswell as adequate hematology levels.",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "f45ff82d-e0f5-456a-9d78-ddc2dc6ab929"
        ]
    },
    "6d4db831-6164-48aa-9ff3-297cad3947bd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Secondary_id": "NCT03098550",
        "Statement": "for the primary clinical trial, all patients suffering from cytologically confirmed stage 3 invasive breast cancer are eligible. on the other hand, the secondary clinical trial has no explicit stipulation for the cancer stage.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "7f3fe97e-68ee-470f-b06e-21cdddb67aa8"
        ]
    },
    "09628316-6c91-459f-b503-73e80ffdf2aa": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02301988",
        "Statement": "advanced bladder carcinoma is a bladder carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment. Only cohort 1 patients of the primary trial are administered Ipatasertib.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "faa65e54-aa04-4595-8dae-05cf00b4c887"
        ]
    },
    "b04cf848-2566-4bf6-8b95-b42e7fd70fb2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00477464",
        "Statement": "participants in the primary clinical trial are given higher amounts of capecitabine in comparison to lapatinib",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "a3390ae6-d41d-4dc7-899e-de9534adfd6b"
        ]
    },
    "35ec5a43-d390-494f-ac7c-66853bc72a69": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "presence of hot flashes for at least 120 days prior to study registration is required for all patients that want to participate in the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "a5baab2c-9c32-4301-a574-4ba5a0c2eb00"
        ]
    },
    "b06ba929-ec99-47e9-b1b7-35e703776385": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01262027",
        "Secondary_id": "NCT02301988",
        "Statement": "the primary clinical trial and the secondary clinical trial both utilize the same outcome measurements",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "f2275929-7cfe-4bb1-a9f6-6bd0c4d5bf85"
        ]
    },
    "4a75574c-fa86-4e62-a210-81c7b98a3807": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00022516",
        "Statement": "T4 N2 M4 patients are eligible for the primary trial",
        "Label": "Contradiction"
    },
    "4c30987d-e896-4a71-8101-762ad11c6968": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00733408",
        "Statement": "in the primary clinical trial, the most frequently observed adverse events were infections.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "4dfff980-6a2b-4f01-9194-6ec831d6fed7"
        ]
    },
    "5623763d-07f2-45c5-bc1e-2d19280adca9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "over half the patients in the primary clinical trial reported objective benefits post-intervention, with docetaxel then liposomal doxorubicin demonstrating minimal serious side effects.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "74e376d7-5713-43f3-93f1-9608059c9547"
        ]
    },
    "6d3ac2c6-13cd-4039-b704-2411c6ae9425": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Secondary_id": "NCT00281697",
        "Statement": "most participants in the secondary trial and the primary trial did not suffer from Enterocolitis. seroma is a collection of serum in the body.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "2ef186d0-b4ab-44de-b785-a63e9e95851a"
        ]
    },
    "016943fa-57ea-4293-8131-03292ea1836c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "A patient with a node positive T2 N2 M0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of over 2cm",
        "Label": "Contradiction"
    },
    "147cda91-16db-4610-8695-7e1cf4349c6f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01262027",
        "Secondary_id": "NCT02301988",
        "Statement": "at time of diagnosis is a specification that indicates the time to assess is the time of diagnosis. the primary trial and the secondary trial use comparable outcome measurements.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "0131ebe3-746b-45a5-ba60-fdd326974fec"
        ]
    },
    "90e55317-64a6-4481-a9ef-1305d954c233": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Statement": "every pregnant patient enrolled in the primary clinical trial has received prior endocrine therapy for breast cancer",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "b1d28450-fc7d-496a-9c7c-bf711b28f8e4"
        ]
    },
    "2af3027c-5382-483b-8476-0bafb251afcf": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT00232505",
        "Statement": "received indicator is an indication as to whether the entity was received. the primary trial and the secondary trial participants do not receive any medication orally.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "e7604382-09cd-43b4-998f-a51b33f25c5a"
        ]
    },
    "a9fda4aa-12b9-4576-94fa-86b5067adeb0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "neither of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients. refractory histiocytic and dendritic cell neoplasm is a histiocytic and dendritic cell neoplasm that does not respond to treatment.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "75affd49-4905-4d43-9a5c-ef795281bac4"
        ]
    },
    "f04d9695-81b8-4d70-877b-59caddf901bd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00450723",
        "Secondary_id": "NCT00290758",
        "Statement": "Between the secondary trial and the primary trial, all the recorded case of Dyspnea occurred in cohort 1 of the secondary trial",
        "Label": "Entailment"
    },
    "ec02a752-e6ee-499c-8def-c61a0b0d2087": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01042535",
        "Statement": "in the primary clinical trial, constipation was identified as the least frequently encountered adverse event",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "16c29502-4683-4087-9410-ff1b786556f5"
        ]
    },
    "acc18ba0-b66a-4e6f-a99b-13bab7e7d5bc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Statement": "Patients must have a Life expectancy of 75+ years to enroll in the primary trial. differentiated granulocytic sarcoma is a granulocytic sarcoma composed of promyelocytes and more mature neutrophils (who 2001).",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "4b97a844-8d52-48bb-8eda-ca205268f016"
        ]
    },
    "cce4dada-4121-4e9a-9fd4-984476e05a9a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "in the primary clinical trial, the intervention protocol takes a total of two weeks to complete",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "236780db-9e59-4dc9-8da0-e786287011cf"
        ]
    },
    "970d34ca-8466-4f83-a1e7-e8a1d8037fd8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00066573",
        "Statement": "there is a 0.132 difference between the results from the two the primary trial cohorts",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "1adc970c-d433-44d0-aa09-d3834986f7a2"
        ]
    },
    "5ac4e596-300b-444e-9acf-809ccb552bc7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00066573",
        "Statement": "there is 0% discrepancy in the results from the two cohorts of the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "1adc970c-d433-44d0-aa09-d3834986f7a2"
        ]
    },
    "ff7d1db8-41a6-491f-b596-11807b654182": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572727",
        "Secondary_id": "NCT00328783",
        "Statement": "All patients in the primary trial receive higher doses of BKM120 than patients in the secondary trial. childhood gastric carcinoma is a rare carcinoma of the stomach that occurs during childhood.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "51be7c95-8da4-419c-950c-91ebdd2c3fe5"
        ]
    },
    "387a4a66-3805-4c74-a4a6-bbe5e1c1fc96": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00425854",
        "Secondary_id": "NCT01224678",
        "Statement": "Patients with significantly elevated ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or over. usual severity difficulty sleeping is a question about the usual severity of an individual's difficulty sleeping.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "6b9162d0-0816-46d4-81af-c60028dcc63b"
        ]
    },
    "6d1289c0-2247-4cfa-8e11-c9994ade3d54": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00820170",
        "Secondary_id": "NCT00263588",
        "Statement": "being eligible for the secondary clinical trial inherently makes the patient eligible for the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "a0065d58-e03b-4dd0-9c81-cbbf651a6d45"
        ]
    },
    "1886b57d-7778-47fb-a967-22b60181e084": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT00232505",
        "Statement": "there is no oral medication involved for participants in either the primary clinical trial or the secondary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "e7604382-09cd-43b4-998f-a51b33f25c5a"
        ]
    },
    "ba244d33-7f25-448d-b147-6ff66135ca24": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00477464",
        "Statement": "the primary trial participants receive Capecitabine less often than they receive Lapatinib. lowest grade is a morphologic grade that refers to the minimum grade that a malignant tumor can exhibit (usually grade i-well differentiated).",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "a52b2d4f-0b06-4960-a9c3-88cb92df0980"
        ]
    },
    "0e96d994-c04b-4d6d-bfb4-ae1d03d47969": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00900627",
        "Statement": "half of the patients in cohort 2 from the primary clinical trial encountered keratitis",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "09fc4356-6154-427e-b710-ed5df6470aff"
        ]
    },
    "a2b93886-d1d0-49a9-929a-89de961c0f52": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00425854",
        "Secondary_id": "NCT01224678",
        "Statement": "in the instance a patient has a considerably high ejection fraction, they would not qualify for the primary clinical trial, yet retaining the eligibility for the secondary clinical trial if they are at least 55 years old.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "6b9162d0-0816-46d4-81af-c60028dcc63b"
        ]
    },
    "2e1b66a7-2545-4f49-9618-a7c379076d24": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02679755",
        "Statement": "several individual aes reported in the primary clinical trial have impacted multiple patients",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "f46a7d27-a94f-4389-a1a0-4a8f5177b354"
        ]
    },
    "3b5a6773-f5b8-4bc3-867b-3491be19520b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01416389",
        "Statement": "lesion count modification in patients is not documented in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "812bd63c-4bfb-49cb-8fa9-baa3f8f6dabe"
        ]
    },
    "d40a4711-e32d-429a-aba0-97d698b27ac9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03012477",
        "Secondary_id": "NCT02419807",
        "Statement": "the primary trial and the secondary trial report their results using different units of measure. loss of chromosome 3 is a cytogenic abnormality that refers to loss of all or part of chromosome 3.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "8460a212-8054-4bd2-b4e6-af1d137a2f79"
        ]
    },
    "99c83cf6-162f-40b9-a378-879da18cb59f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Statement": "Only 6/67 patients in cohort 1 of the primary trial suffered adverse events. global relapse in skin is any disease recurrence in those with complete response.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "29b2fa29-5a76-4877-95bb-1a8de7973d33"
        ]
    },
    "60f3bdb0-9661-4c7d-82e9-74d516b6ffb0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01830933",
        "Statement": "soft s1 heart sound is an auscultated finding in which the sounds comprising the first heart sound are quieter than normal. (acc/aha) the primary trial and the secondary trial do not report adverse events.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "fb360514-14be-45ab-8b74-ea5a7eb181d7"
        ]
    },
    "ab316ff0-f3c0-4188-84b7-8b852bc51adb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01118624",
        "Statement": "in the primary clinical trial, participants are given doses of pralatrexate not more than 300mg/m^2",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "e9a4bd91-f58b-4234-9037-75e0699d1bbd"
        ]
    },
    "9c7c409d-21bc-4189-b9c8-d8621536f495": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00820170",
        "Secondary_id": "NCT00263588",
        "Statement": "any patient eligible for the secondary trial will also be eligible for the primary trial . part dosing unit is a fraction of a dosing unit.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "a0065d58-e03b-4dd0-9c81-cbbf651a6d45"
        ]
    },
    "11273441-8b51-42e4-ae37-2a2397d3a0e5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Secondary_id": "NCT00274469",
        "Statement": "only male patients diagnosed with early-stage pancreatic cancer are eligible for the primary clinical trial and secondary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "68379456-775b-463b-bfdb-d8aa42c9124b"
        ]
    },
    "fc241216-1d07-4b15-a63d-3396611583f2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "in the primary clinical trial, none of the patients met the outcome of disappearance of all target lesions, >=30% decrease in the sum of the longest diameter of target lesions, or a tumor that is neither growing nor shrinking.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "7e5fd062-6ec3-480f-ab0e-e117eba2ffe7"
        ]
    },
    "ab6edb23-90ef-4415-bab0-33c4599606c9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00915603",
        "Statement": "at least 2 participants of the primary trial, at least one from each cohort, had a progression-free survival of 324 days",
        "Label": "Entailment",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "47ba01d6-edc7-4acb-ab49-b0e86f4eeaf7"
        ]
    },
    "4e28a751-9472-4fd1-9979-3092d4782d1b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02340221",
        "Statement": "the primary clinical trial excludes individuals who have formerly experienced treatment using fulvestrant or a phosphatidylinositol 3-kinase (pi3k) inhibitor",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "6b35bc10-f591-4b84-abac-40a74be949fa"
        ]
    },
    "e0d3233d-a5d3-495d-a5a1-9322d8e28063": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00263588",
        "Statement": "primary clinical trial requires patients to have the ability to take medication orally",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "5c1e360c-fd93-4dd4-b855-71ba416d34cb"
        ]
    },
    "2eca5a45-c781-4be8-a165-c6f25c4d7811": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Statement": "the primary clinical trial includes individuals who have never had breast cancer and received endocrine therapy.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "6d621974-c719-46df-8a50-d94e49583e33"
        ]
    },
    "b1a9f9c4-c0a2-4342-bf4b-884108a93d00": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00733408",
        "Statement": "in the primary clinical trial, infections were rarely reported as adverse events",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "4dfff980-6a2b-4f01-9194-6ec831d6fed7"
        ]
    },
    "878c09e7-3fd9-404e-921e-5b549e9578fb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02658734",
        "Statement": "Most patients in the primary trial experienced a grade 1 adverse events, the least common severity was grade 4.",
        "Label": "Entailment"
    },
    "851d5484-a8ed-4ee3-8a58-35149ca831b2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00606931",
        "Statement": "the adverse effects, specifically hypotension, hemorrhage, and bradycardia, endured by patients during their participation in the primary clinical trial, are described in the dedicated section",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "175044aa-72b1-405d-8506-30002f5098e4"
        ]
    },
    "9de9f21c-f563-4431-be85-f5e2ef299ac6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT00852930",
        "Statement": "prostate inflammatory myofibroblastic tumor is a rare inflammatory myofibroblastic tumor that arises from the prostate gland. the primary trial and the secondary trial do not record any cardiac or infection related adverse events, but they both record several instances of epilepsy.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "c2217d42-e90c-4ffe-b084-e653b9ace4d5"
        ]
    },
    "8bd3950b-87eb-48eb-b1b7-cd04f7a8185a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "all the primary trial patients achieved either disappearance of all target lesions, >=60% decrease in the sum of the longest diameter of target lesions or a tumor that is neither growing nor shrinking.",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "7e5fd062-6ec3-480f-ab0e-e117eba2ffe7"
        ]
    },
    "087f86fc-c9e9-4cfb-a4c2-b9d3ab00ead6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "segmental mastectomy patients with a tumor diameter of less than 1cm are eligible for the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "016943fa-57ea-4293-8131-03292ea1836c"
        ]
    },
    "a4adf7b4-9ec2-442b-b924-6b3f53259c8f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00374322",
        "Statement": "80% of patients in the primary trial received a placebo intervention. col3a1 gene product is a protein encoded by the col3a1 gene.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "e147796d-2edd-42d1-ac53-300fb8bd5eb6"
        ]
    },
    "4309860d-042d-45a4-8a0a-a9fdd075247a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02915744",
        "Statement": "Cohort 1 and 2 of the primary trial do not receive NKTR-102 by infusion",
        "Label": "Contradiction"
    },
    "361cd42d-3e4f-48c3-8946-d6f9b5d2da98": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00612560",
        "Secondary_id": "NCT01216176",
        "Statement": "flaxseed is given to all participants in the primary clinical trial, but no participant in the secondary clinical trial receives flaxseed",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "b0046821-ba27-4a90-8869-cb708b843aa4"
        ]
    },
    "6e8248a5-bb6f-4168-b1b4-5c1d1c984862": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT02340221",
        "Statement": "the primary clinical trial and the secondary clinical trial involve patient populations for which there is no need to measure the percent change in net influx constant (ki) by flt pet",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "49ba06b2-576d-4db2-80b6-51673416f2ba"
        ]
    },
    "62b2f1a2-b987-4487-8439-4cc96bafc2fb": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "presence of hot flashes for at least 4 days prior to study registration is required for all patients that want to participate in the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "a5baab2c-9c32-4301-a574-4ba5a0c2eb00"
        ]
    },
    "4cc1341f-6bbc-4a53-9bdb-3dd3eb50005e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Secondary_id": "NCT00121992",
        "Statement": "the primary trial reported no incidents of conjunctivitis while the secondary trail reported 10",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "c100a7cd-e3a2-4901-a3e0-12336f769c7b"
        ]
    },
    "cc1f712a-2116-4e40-9810-f315e3fa5ff8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00593346",
        "Statement": "the primary trial does not report the PFS or objective response rate of its patient cohort",
        "Label": "Entailment"
    },
    "cea71962-0ae2-4cba-b11d-462c33f68439": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02658734",
        "Statement": "in the primary clinical trial, the most frequently occurring adverse event was of grade 5 severity, with a considerably higher number of patients affected as compared to grade 1.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "40f699a1-fbc6-40de-8e80-85b28f71632f"
        ]
    },
    "73f73264-ab93-4794-808d-a990571e9d57": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT00232505",
        "Statement": "neither the primary clinical trial nor the secondary clinical trial participants are administered any drugs by mouth",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "e7604382-09cd-43b4-998f-a51b33f25c5a"
        ]
    },
    "68f63c17-580d-47eb-9d62-dc90bd844cf1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01011946",
        "Secondary_id": "NCT00066573",
        "Statement": "in the primary clinical trial, participants are prescribed oral medication as part of their treatment plan, while the secondary trial administers treatment through a different route.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "6402e13a-7cfb-4774-b7f9-80ecb79fda2a"
        ]
    },
    "4b249d73-6b85-4ddf-9462-c69388603314": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00127933",
        "Statement": "eliane is a 56 year old woman, and elizabeth is a 32 year old woman, both eliane and elizabeth can both be eligible for the primary trial. degradable controlled release capsule dosage form is a capsule designed to dissolve after releasing the active and/or inert ingredient(s) at a controlled rate.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "f0273b8c-460d-46fe-9c52-8ff4b08e439b"
        ]
    },
    "74781e13-a829-4e5a-bc9e-c79adaaf6777": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01011946",
        "Secondary_id": "NCT00066573",
        "Statement": "oral medication is not given to the participants of the primary clinical trial, in contrast to the secondary clinical trial where patients are exclusively treated with oral medication.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "6402e13a-7cfb-4774-b7f9-80ecb79fda2a"
        ]
    },
    "4b9f51c7-1d12-48f2-a036-7e4138bb6d24": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02340221",
        "Statement": "patients previously treated with fulvestrant are barred from the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "904061c0-14fa-4f13-9118-9a41e24fa8eb"
        ]
    },
    "6792937d-655b-4d47-847d-f527f7efa33f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00093795",
        "Statement": "most participants in the first and second cohorts of the primary clinical trial had a disease-free survival of five years.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "2729a321-709b-4392-9604-dd7237bedb17"
        ]
    },
    "b38428da-a4bd-4ce6-9ec3-eb21ebcb81ad": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "the most common adverse event recorded in the primary clinical trial was nausea and vomiting, affecting a significant number of patients",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "1842904b-5371-49ee-b6f4-8831b879098b"
        ]
    },
    "68747ff9-74c3-4945-afd5-b2e259aa6924": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "presence of hot flashes for 6 days prior to study registration is required for all patients that want to participate in the primary trial, but not necessary for entry to the secondary trial.",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "31105b43-832b-48bc-a78d-ee90c155ca44"
        ]
    },
    "236780db-9e59-4dc9-8da0-e786287011cf": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "the primary trial intervention protocol lasts a total of 14 days",
        "Label": "Contradiction"
    },
    "82a3e542-f784-44d7-90f6-34d7e969283c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00240071",
        "Statement": "the primary trial participants receive more than one type of medication during the study",
        "Label": "Entailment"
    },
    "28c17602-cf94-4092-bd68-b4e9a77099cc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "the primary clinical trial could be suitable for patients with extracranial metastases",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "b9491012-49ba-4eb1-8230-1966f54ea012"
        ]
    },
    "f61a241d-7b43-46a2-83a5-82c646409791": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01830933",
        "Statement": "there are no reports of negative incidents in both the primary clinical trial and the secondary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "fb360514-14be-45ab-8b74-ea5a7eb181d7"
        ]
    },
    "7dd5d239-c3dc-4392-9dd9-fe9daead58c8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572727",
        "Secondary_id": "NCT00328783",
        "Statement": "All patients in the primary trial receive higher doses of Paclitaxel than patients in the secondary trial. would do better in school if could hear better is a question about whether an individual feels that they would do better in school if they could hear better.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "3ba42f68-a643-4d10-afd0-cbb358d05a6f"
        ]
    },
    "c3be7b91-ee4d-4d28-a228-af35b6c4073a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00063570",
        "Statement": "patients diagnosed with a malignant brain tumour or colon cancer can participate in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "015dd869-db90-45a9-a951-9dc7dc2b2e01"
        ]
    },
    "2ab15df7-8d32-4ba9-90e6-c4868b9dcbff": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "in the primary clinical trial, cohort 1 recorded more adverse events in comparison to cohort 2",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "1c4e3fe3-b5fe-4ea3-8d9e-0ce1502080e7"
        ]
    },
    "08e6373d-c1d8-4b22-9dae-b9017ca5406c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00240071",
        "Statement": "as part of their engagement with the primary clinical trial, participants receive treatment using avastin, bevacizumab, and radiotherapy",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "045ad91e-44fa-42cc-ac22-a7aab26a9009"
        ]
    },
    "5ee6f08b-b840-4df9-97ff-56516208d29d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00856492",
        "Secondary_id": "NCT00009945",
        "Statement": "perinatal depression is a condition characterized by cardiorespiratory and neurological depression following birth. the secondary trial and the primary trial both measure the pCR and tumor diameter of their patient cohorts.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "70677d5f-7022-404c-8410-d1f89366d92f"
        ]
    },
    "6ead53ab-a099-45cb-9a80-8b92055e3a58": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01262027",
        "Secondary_id": "NCT02301988",
        "Statement": "outcomes in the secondary clinical trial are assessed through distinct parameters than those employed in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "0131ebe3-746b-45a5-ba60-fdd326974fec"
        ]
    },
    "24138a93-d4a6-4183-8418-858e861b0987": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00754325",
        "Statement": "patients in the primary clinical trial who had been receiving herceptin were more prone to disease progression or death than those who were on fulvestrant treatment.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "ba9daeb9-796d-49ab-a30c-4d8acbdf4d37"
        ]
    },
    "9aa2c8f3-405a-4e4e-a25c-66f681a33367": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00374322",
        "Statement": "every participant in the primary clinical trial underwent an active medical treatment",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "e147796d-2edd-42d1-ac53-300fb8bd5eb6"
        ]
    },
    "8b3a36ee-1335-4bc2-a400-e484ad8d1711": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01125566",
        "Statement": "laryngeal tube is a supraglottic airway device. ECOG score < 2 is necessary to be eligible for the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "7137dec6-5c98-4156-8035-7bbaaf0b649d"
        ]
    },
    "45297d5c-e634-4c2b-acf3-019428952001": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00328783",
        "Statement": "The adverse events section in the primary trial is empty. cell viability process is a cellular process that directly affects the ability of a cell to repair damaged cell components. (nci)",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "fef5aedb-21c0-4130-b8a3-cb1df5017c7a"
        ]
    },
    "ba8f2ec2-2227-4e9b-83d9-7e2628dafe0d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT00232505",
        "Statement": "participants in the secondary clinical trial are given medication orally",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "e7604382-09cd-43b4-998f-a51b33f25c5a"
        ]
    },
    "5e93af82-90ff-4742-bb3a-72afe4fab9ba": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "every patient in the primary clinical trial recorded a decline of 50% minimum in the aggregate maximum diameter of their target lesions",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "985bc5a0-bc21-447f-92f1-150e23ede3f5"
        ]
    },
    "cf7f511a-d3ac-446c-b0d4-8fa621a63439": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00331630",
        "Statement": "the primary clinical trial did not register any adverse cardiac or neural events",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "c7dc582a-4a58-4cb5-b980-b2d2b6a128c3"
        ]
    },
    "d7c7f017-7d64-4289-91f0-a711c2e89163": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Secondary_id": "NCT00274469",
        "Statement": "to qualify for participation in the primary clinical trial and the secondary clinical trial, the patient must be a female with a confirmed case of advanced colon cancer",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "06fad978-1dc3-46f5-b45f-5ac6577f28b9"
        ]
    },
    "1fe3365c-2aff-470c-b084-7c1ffedb05cc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Statement": "patients must have a life expectancy of at least 10 years to enroll in the primary trial",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "618a3ae1-b22c-4c35-86a6-190c1b5b5d21"
        ]
    },
    "ef789791-2a2d-4579-9999-77ba1ed9b98d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Statement": "in the primary clinical trial, the most common negative effect observed in the first and second groups was anaemia",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "fbb62216-2cf2-4813-ad41-12a86940610f"
        ]
    },
    "da9c6e70-c157-48c2-9b4d-9e8a9e3ad0cc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01998906",
        "Statement": "in the primary clinical trial, the participants of both cohorts experience 17 cycles, each spanning over three weeks, with consistent medication types and dosages throughout the cycles.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "2a2c16a7-f427-4fdb-8153-94aac304e4b8"
        ]
    },
    "406f1970-92bb-438c-9584-c6c43fb3d7b0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02679755",
        "Statement": "the incidences of individual aes reported in the primary clinical trial exceed a 20% rate among its population.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "c09fa61c-967a-40ae-96b0-c87b7cde237b"
        ]
    },
    "0c66c3b7-3ec4-4e8e-a23d-b495b1a28464": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00820170",
        "Secondary_id": "NCT00263588",
        "Statement": "the secondary trial and the primary trial do not have the same inclusion and exclusion conditions. mossi language is a niger-congo gur language that is an official regional language of burkina faso.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "3a4003f6-ff1c-43d8-be48-f767266b2cf5"
        ]
    },
    "2f45aee5-064c-488a-a099-1972d6925f1a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00066573",
        "Statement": "the findings from the primary clinical trial's cohorts show a significant difference",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "fe876bb0-7ce3-4197-81ad-920f1f77938e"
        ]
    },
    "10a10b50-f799-42aa-b141-4e313e194bf0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "all the primary trial patients had a minimum of 93% decrease in the sum of the longest diameter of target lesions",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "985bc5a0-bc21-447f-92f1-150e23ede3f5"
        ]
    },
    "3c8bff4f-8e7a-4f88-9a60-526155d24373": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "none of the patients in the primary clinical trial experienced any decrease in the sum of the longest diameter of target lesions.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "985bc5a0-bc21-447f-92f1-150e23ede3f5"
        ]
    },
    "7fe53561-3910-41bd-bea2-551bba599f85": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT02340221",
        "Statement": "pretracheal lymph node is a lymph node located anterior to the trachea, between the isthmus of the thyroid gland and the innominate vein. the primary trial and the secondary trial have non-comparable outcome measurements for their results.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "2a03c17f-3afe-40f1-a0db-4b876ee8c700"
        ]
    },
    "a484e886-f9b3-470b-b7d1-d26acbe8f9b0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT03176238",
        "Statement": "fewer cases of acute myocardial infarction, cardiopulmonary failure, and supraventricular tachycardia have been noted in cohort 1 of the secondary clinical trial in comparison with cohort 2 of the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "080da381-b5dd-46d3-99c4-18112da153c1"
        ]
    },
    "b55bf284-921d-47ef-af80-11bc8b30767a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00915603",
        "Statement": "bothered by headaches is a question about whether an individual is or was bothered by headaches. the shortest PFS in cohort 1 of the primary trial was under 7 months, in cohort 2 the shortest was just over 7 months.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "0cef8c8e-7986-46c7-a597-c5733a9899c0"
        ]
    },
    "e86d769c-5ad6-4e25-a774-283d11b09ee9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01581619",
        "Secondary_id": "NCT00106002",
        "Statement": "the results of the secondary trial and the primary trial are non-comparable. hepatoblastoma with combined fetal and embryonal epithelial differentiation is a hepatoblastoma composed of cells resembling fetal epithelial cells and small round cells resembling blastema cells.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "0a6d1b4c-244e-44e2-a229-62e4cbdfa979"
        ]
    },
    "2da993bc-e099-43a1-b2a5-0acd8900e068": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Statement": "there was absolutely no occurrence of anaemia as an adverse event in any cohort of the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "fbb62216-2cf2-4813-ad41-12a86940610f"
        ]
    },
    "d0a6c3e6-515b-46aa-995d-d29f279acab0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00376597",
        "Statement": "Patients with stage 4 cancer are excluded from the primary trial, only patients with stage 2 and 3 cancer can be eligible. histogram is a bar chart representing a frequency distribution where the heights of the bars represent observed frequencies.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "b1dd7632-ed92-40a9-9293-bce68619c658"
        ]
    },
    "3a871cc4-7b14-4d93-9940-194e3f3333a5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00066573",
        "Statement": "liter per minute per milligram per day is a unit of concentration equal to liter per minute divided by milligram per day. there is a minimal difference between the results from the two the primary trial cohorts.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "fe876bb0-7ce3-4197-81ad-920f1f77938e"
        ]
    },
    "446977e2-1085-4056-b7da-7e79a391be9c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00066573",
        "Statement": "the results from the two cohorts of the primary clinical trial have an insignificant deviation",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "fe876bb0-7ce3-4197-81ad-920f1f77938e"
        ]
    },
    "a64d43de-474d-4e16-ab0d-116dfcb05a69": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Statement": "all cohorts in the primary clinical trial are scheduled for a surgical procedure as part of the treatment process.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "0a079cca-abde-42cf-9cec-a76e7a380e14"
        ]
    },
    "71bed8e4-5ffa-4be3-8916-79676e97a9e2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02419807",
        "Statement": "the primary clinical trial's results section details two separate measurements",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "8b91cab9-d858-45f3-bf8d-3d6fc55b4818"
        ]
    },
    "13d82ec0-e015-42f3-904b-e6405739ad8d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00856492",
        "Secondary_id": "NCT00009945",
        "Statement": "the primary clinical trial does not evaluate patient's tumor diameter or pcr levels, whereas the secondary clinical trial only measures disease-free survival rates.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "70677d5f-7022-404c-8410-d1f89366d92f"
        ]
    },
    "a3756a79-e909-49b9-9cca-b28c83b1bb92": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "until a complete response is achieved, or the disease progresses, the intervention protocol of the primary clinical trial will persist.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "1d1f57f8-85f7-448c-a4bb-15957da568fd"
        ]
    },
    "b4dd0f6a-ed97-4f04-9f86-4dd5c2d5c76c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005879",
        "Statement": "in the primary clinical trial, a greater proportion of patients with slipped disks was found in cohort 2 compared to cohort 1",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "ce8464bd-951e-44aa-97d9-10b917b055ce"
        ]
    },
    "9df29a81-f9f2-4b9a-bff4-8fecfe23e51c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "healthy individuals under the age of 18 with perfect functioning kidneys, liver and heart are eligible for the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "f45ff82d-e0f5-456a-9d78-ddc2dc6ab929"
        ]
    },
    "a895dd2f-95c8-4c09-b0a4-5289542f8a09": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02915744",
        "Statement": "the primary clinical trial maintains a record of the overall survival (os) rates amongst patients in their study groups.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "dc4c57b0-8c75-494e-81b0-3528df85ebff"
        ]
    },
    "7607dc7b-f210-4fff-bc1c-862b53b6257c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "patients wanting to participate in the primary clinical trial are not required to have been experiencing hot flashes for the 30 days prior to study registration, but for the secondary clinical trial, it's a mandatory condition.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "31105b43-832b-48bc-a78d-ee90c155ca44"
        ]
    },
    "3a43a68d-03dc-4525-b44c-f7bad1556fdc": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "febrile neutropenia was the most common adverse event recorded in the primary trial, affecting more than 1/20 of patients",
        "Label": "Entailment",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "1842904b-5371-49ee-b6f4-8831b879098b"
        ]
    },
    "76972935-b318-4933-bed7-263eb036aa13": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "neither of the interventions in the primary trial resulted in an objective benefit for more than 4/10 patients, in fact over 0.86 fraction of patients receiving the docetaxel then liposomal doxorubicin intervention suffered fatal complications",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "74e376d7-5713-43f3-93f1-9608059c9547"
        ]
    },
    "18a4b5c1-7e3d-421a-9503-9bed6dbdb556": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01262027",
        "Secondary_id": "NCT02301988",
        "Statement": "lipid measurement is a quantitative measurement of the amount of lipids (cholesterol, lipoproteins, and triglycerides) present in a sample. the primary trial and the secondary trial use comparable outcome measurements.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "0131ebe3-746b-45a5-ba60-fdd326974fec"
        ]
    },
    "904061c0-14fa-4f13-9118-9a41e24fa8eb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02340221",
        "Statement": "Prior treatment with fulvestrant or with a phosphatidylinositol 3-kinase (PI3K) inhibitor will not prevent a patient from participating in the primary trial",
        "Label": "Contradiction"
    },
    "6ae9b36b-76a6-42f0-9746-6c0bbae8d8a1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT03176238",
        "Statement": "cohort 1 of the secondary clinical trial differs from cohort 2 of the primary clinical trial by having fewer incidences of acute myocardial infarction, cardiopulmonary failure, and supraventricular tachycardia",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "080da381-b5dd-46d3-99c4-18112da153c1"
        ]
    },
    "cdadcb0a-20c5-47f7-a63a-39f5c6f26ae2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Statement": "the primary trial reports the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer 0 side effects",
        "Label": "Contradiction"
    },
    "79bd9059-5565-4b9f-be58-fbaa4d26eada": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00450723",
        "Statement": "The the primary trial intervention involves one drug taken orally and the secondary trial intervention is based on a medical procedure. husband is a male partner in marriage.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "f0e845f9-8991-45b5-a520-51e934756f7a"
        ]
    },
    "66869889-55ef-4396-a1ec-856ff0305254": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00572728",
        "Statement": "patients must be fully mobile and capable of self-care to participate in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "62be4676-099f-4c42-8029-773af8fde6f7"
        ]
    },
    "b2239248-d15c-46c3-b127-0608192308f9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "all the primary trial patients achieved either disappearance of all target lesions, <=10% increase in the sum of the longest diameter of target lesions or a tumor that is neither growing nor shrinking.",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "7e5fd062-6ec3-480f-ab0e-e117eba2ffe7"
        ]
    },
    "ce1f4529-c97d-418f-920f-a8e3dcd06f1e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00572728",
        "Statement": "the ability to undergo a pet scan isn't a criterion for inclusion in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "32ed503c-1cfd-44f6-b8bb-23d9d175d73d"
        ]
    },
    "0f426ae2-e451-4dd7-9c7f-ebc73de49e85": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "no patient in cohort 1 of the primary clinical trial had a pfs exceeding 8.8 months, with the highest pfs reaching 7.8 months.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "b9e29ea8-6847-40d4-b5c3-81c496101695"
        ]
    },
    "a5baab2c-9c32-4301-a574-4ba5a0c2eb00": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "Presence of hot flashes for at least 4 month prior to study registration is required for all patients that want to participate in the primary trial or the secondary trial.",
        "Label": "Contradiction"
    },
    "6d621974-c719-46df-8a50-d94e49583e33": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Statement": "all patients accepted into the primary trial have undergone Prior treatment for breast cancer with endocrine therapy",
        "Label": "Entailment"
    },
    "eef1f33b-41c9-4cdf-a81d-31b4551031f9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00357110",
        "Statement": "the cohorts of the primary clinical trial experienced no deaths.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "751fd763-89fa-4d52-8bda-f09b490a5e78"
        ]
    },
    "ffe15eca-6baa-48fe-8a02-f351f9039934": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01416389",
        "Statement": "the primary clinical trial does not account for changes in tumor size among the patients it studies.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "7cde9a22-a91f-4feb-892d-7cbd35f96a27"
        ]
    },
    "2842bb4d-15f8-4757-9e96-2f4ee66cf12f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00900627",
        "Statement": "dll3 gene positive is an indication that the dll3 gene has been detected in a sample. 50% of cohort 2 patients in the primary trial suffered Keratitis.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "09fc4356-6154-427e-b710-ed5df6470aff"
        ]
    },
    "f0d6bbfa-74da-44e2-a8f5-4507c7d16d86": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Statement": "the primary clinical trial does not require ongoing flucytosine treatments from its participants",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "565d7982-aa9a-4c01-987c-1d67bc9c212d"
        ]
    },
    "bc2d5bc0-ba5c-4070-b59f-e77741d93983": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01830933",
        "Statement": "the secondary trial reports only a subset of the adverse events that the primary trial reports",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "c7a953b0-ac96-4e0a-9c1d-98cf8af2861d"
        ]
    },
    "3c54caff-67b1-450c-ae68-0602974a40fe": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Statement": "milliliter per hour per milligram per kilogram per day is a unit of concentration equal to milliliter per hour divided by milligram per kilogram per day. neither of the cohorts in the primary trial are required to undergo surgery as part of the intervention.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "0a079cca-abde-42cf-9cec-a76e7a380e14"
        ]
    },
    "460c4a76-ec60-4d92-8f89-9cbb59a9d43a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232505",
        "Statement": "Patients with Histologically confirmed breast cancer stage I-IV are not eligible for the primary trial. pain interference score 8 is a subjective score of 8 on a scale that ranges from 0: does not interfere to 10: completely interferes.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "3cb71095-8e01-40dc-bbf5-eeffed55f354"
        ]
    },
    "b24f8094-fa4d-4d1c-ae8f-5b803382004f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00328783",
        "Statement": "the primary clinical trial's section on adverse events is blank",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "fef5aedb-21c0-4130-b8a3-cb1df5017c7a"
        ]
    },
    "779edb93-cf50-4dca-9a2d-73fc42ffa584": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00425854",
        "Secondary_id": "NCT01224678",
        "Statement": "persons with substantial ejection fraction rise are not suitable for participation in the primary clinical trial, but can still meet the criteria for the secondary clinical trial if above 55 years of age.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "6b9162d0-0816-46d4-81af-c60028dcc63b"
        ]
    },
    "f7c8d8e0-be13-4be4-9f2f-5dd799891c97": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02131064",
        "Statement": "in the first cohort of the primary clinical trial, the prevalence of left ventricular dysfunction was 10 cases higher than abdominal pain",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "1329dec6-fb2c-4219-9db6-3fef9d94b316"
        ]
    },
    "917d9ebe-5a92-4187-b1b4-bb551a7a3145": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Secondary_id": "NCT00876395",
        "Statement": "in both the primary and secondary trials, diarrhoea is recorded as the prevalent adverse event",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "eb1bfb08-eba0-4130-b328-00f56c0f84a6"
        ]
    },
    "1a1c437b-1975-4235-a82a-d6b61f94a7ba": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01416389",
        "Statement": "the primary clinical trial does not keep a record or monitor the fluctuations in the size of tumors in its patient cohorts.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "7cde9a22-a91f-4feb-892d-7cbd35f96a27"
        ]
    },
    "c664e401-0d80-4614-800e-c5103ba411fc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00022516",
        "Statement": "eligibility for the primary clinical trial extends to patients classified as t1 n0 m0",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "978d19fc-e7f6-485e-b8bd-cfcde06441ab"
        ]
    },
    "a3f44786-ec36-4b4d-8f3e-ee30988529d1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT02340221",
        "Statement": "the primary and secondary clinical trials both assess the percentage change in the net influx constant (ki) by using flt pet in their respective patient cohorts.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "49ba06b2-576d-4db2-80b6-51673416f2ba"
        ]
    },
    "76b0e520-f278-4933-a6c4-dd7acfbfc44c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00240071",
        "Statement": "the primary trial participants are administered Avastin, Bevacizumab and radiotherapy as part of the intervention. historical data type is a data type comprised of information concerning the historical aspects of a particular value.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "045ad91e-44fa-42cc-ac22-a7aab26a9009"
        ]
    },
    "6cdea115-b002-48c3-aef7-df48fdea6940": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820222",
        "Statement": "in the primary clinical trial, it was observed that the frequency of grade 3 or 4 skin/subcutaneous or pulmonary toxicities was higher in patients using trastuzumab plus capecitabine when compared to lapatinib plus capecitabine.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "566bdc2d-7c4a-4547-87da-ac81447ecca8"
        ]
    },
    "2bcad80f-319f-48b7-b5e3-a3fa9b9180e0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01125566",
        "Statement": "individuals with an ecog score of 2 or lower are welcome to participate in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "b2cdbcb8-de26-4a44-8a94-dd68c13f7e41"
        ]
    },
    "be413633-44f9-4707-8cea-3946f1d74979": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02301988",
        "Statement": "compared to cohort 2 patients, cohort 1 patients within the primary clinical trial are administered stronger doses of ipatasertib and placebo",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "973f090a-8967-4d75-bb8e-6166c868337c"
        ]
    },
    "4519d1cf-7f78-4aa8-85d6-ac94f7eb75a3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Secondary_id": "NCT01439945",
        "Statement": "There is only one case of Diarrhea in the secondary trial and over 14 different types of Aes recorded in the primary trial cohorts",
        "Label": "Contradiction"
    },
    "32f0fbd9-94eb-4799-b74e-905d6763e58f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00944047",
        "Statement": "igk positive is an indication that igk expression has been detected in a sample. under a quater of the primary trial patients in the intervention arm experienced Pathologic Complete Response.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "48f516ff-abb4-4312-9b00-02f53fb16218"
        ]
    },
    "baa300e7-9bb3-4c48-8275-066818129ee6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00915603",
        "Statement": "at least 7 participants of the primary trial, at least two from each cohort, had a progression-free survival of 12.2 months",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "47ba01d6-edc7-4acb-ab49-b0e86f4eeaf7"
        ]
    },
    "c07fd97b-9dd9-494d-8978-3b35460e7370": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Secondary_id": "NCT00325234",
        "Statement": "there are fewer cases of urosepsis in the primary trial than in the secondary trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "7271e0db-bb82-423f-ad95-5ffa84fab97e"
        ]
    },
    "47a0a446-7faf-479f-8084-2c80049f5fc7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00915603",
        "Statement": "at least 2 participants of the primary trial, at least one from each cohort, had a Progression-Free Survival of 10.8 months. deleterious rad51 gene mutation is a change in the nucleotide sequence of the rad51 gene that is associated with increased risk of disease.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "47ba01d6-edc7-4acb-ab49-b0e86f4eeaf7"
        ]
    },
    "94d83f6b-b1b4-424a-b29a-4a64ef062623": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03012477",
        "Secondary_id": "NCT02419807",
        "Statement": "identical units of measure are used by the primary clinical trial and the secondary clinical trial when disclosing their results",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "8460a212-8054-4bd2-b4e6-af1d137a2f79"
        ]
    },
    "c2ab01a5-4aef-4ebf-91a8-406cfa0ea80e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00606931",
        "Statement": "There adverse events section in the primary trial describes the number of patients that suffered Hypotension, Hemorrhage and Bradycardia when taking part in the study. behavioral assessment is assessment of individual responses to age appropriate stimuli.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "175044aa-72b1-405d-8506-30002f5098e4"
        ]
    },
    "2551a2f0-f669-4b12-8f5b-5efda610a077": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00263588",
        "Statement": "in order to partake in the primary clinical trial, patients need to be capable of receiving medication orally",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "5c1e360c-fd93-4dd4-b855-71ba416d34cb"
        ]
    },
    "f9c72fd3-310f-4c14-a3d4-a4a7040d0df3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01596751",
        "Statement": "Breast cancer patients must have documented progressive disease to participate in the primary trial. lactate dehydrogenase measurement is a quantitative measurement of the amount of lactate dehydrogenase present in a sample.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "bc2024fc-5b39-4fa6-badf-f034d6fe8bb8"
        ]
    },
    "3f00e53e-2678-4a24-8beb-87e8828394c0": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Secondary_id": "NCT01644890",
        "Statement": "the main measurement in the primary trial is the number of participants experiencing adverse events, and the secondary trial evaluates participants' overall survival.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "f42e1874-343a-43ed-bb0c-884509c4793c"
        ]
    },
    "386f6958-4d36-4b1b-ba48-4a35c15d8988": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00450723",
        "Secondary_id": "NCT00290758",
        "Statement": "Between the secondary trial and the primary trial, all the recorded casesof Musculoskeletal adverse events occurred in cohort 2 of the secondary trial. agree with prior crf is a question as to whether the user agrees with the previous case report form.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "f3cb9150-32c6-4877-9a87-4fac45a24948"
        ]
    },
    "ace73946-56e4-4616-9b4b-74fec4eac7b6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02658734",
        "Statement": "Most patients in the primary trial experienced a grade 1 adverse events, the least common severity was grade 5, which only affected 8/70 patients. flap regimen is a regimen consisting of leucovorin-enhanced fluorouracil, doxorubicin and cisplatin used for the treatment of advanced-stage gastric cancer.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "40f699a1-fbc6-40de-8e80-85b28f71632f"
        ]
    },
    "036ea65b-f0e6-4b1e-9b5c-fa3b07b4d04f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "the intervention protocol for the primary clinical trial spans a period of 14 days",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "236780db-9e59-4dc9-8da0-e786287011cf"
        ]
    },
    "2329be87-d868-422f-a639-313dfe64c86d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01905592",
        "Statement": "none of the patients in the first cohort of the primary clinical trial were affected by the four types of adverse events that were recorded.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "2655c892-216e-4b96-a8f2-6f64403215c5"
        ]
    },
    "9b463a8b-b407-427c-b8ae-a3dca3fe3ca0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00593346",
        "Statement": "the primary clinical trial discloses the patients' progression-free survival (pfs) rates",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "88668508-dfd4-4a39-91cd-cf1654a6dfc4"
        ]
    },
    "553f00ea-5197-4233-b1e0-e5727856b599": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00331630",
        "Statement": "no cardiac or bowel-related adverse events were recorded in the primary trial",
        "Label": "Contradiction"
    },
    "2965c20b-a31f-42be-90f7-b75d83e9870b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Secondary_id": "NCT00876395",
        "Statement": "the primary and secondary trials report nausea as the most common adverse event.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "eb1bfb08-eba0-4130-b328-00f56c0f84a6"
        ]
    },
    "95ac8e80-6816-4209-9688-8bc4a3fc9b02": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01830933",
        "Statement": "adverse events of the same type are reported in both the primary and the secondary clinical trials.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "c7a953b0-ac96-4e0a-9c1d-98cf8af2861d"
        ]
    },
    "a0f1e66b-ccc6-4a2a-a8aa-2992d0652dea": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02924883",
        "Statement": "primary clinical trial is restricted to patients with her2 positive breast cancer",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "446f3c69-0de5-475c-a8e2-ff40ece90672"
        ]
    },
    "1a613f72-f823-406b-a1b9-13de993d315d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01581619",
        "Secondary_id": "NCT00106002",
        "Statement": "the results of the primary clinical trial and the secondary clinical trial both report comparable outcome measures",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "1180dd58-61b8-4c48-ab00-7d458e68c85b"
        ]
    },
    "46745cc8-6de1-4cf4-a627-9a649d3d1961": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "presence of hot flashes for at least 400 weeks prior to study registration is required for all patients that want to participate in the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "a5baab2c-9c32-4301-a574-4ba5a0c2eb00"
        ]
    },
    "c4ef80c9-0185-4af6-bc01-40216480c6dd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01118624",
        "Statement": "the primary clinical trial's participants are administered pralatrexate dosages that are determined by their body weight",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "0ddb07ae-6e70-436d-8723-f609e59c57da"
        ]
    },
    "215a5c4a-d90c-4500-8284-0679ce311734": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00263588",
        "Statement": "patients must have HER2- breast cancer to participate in the primary trial",
        "Label": "Contradiction"
    },
    "fbd0d392-be4a-444d-8e6d-b7939c05c4d0": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02915744",
        "Statement": "neither the secondary trial or the primary trial record the Overall Survival (OS) of Patients in their cohorts. 3q13.31 is a chromosome band present on 3q",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "dc4c57b0-8c75-494e-81b0-3528df85ebff"
        ]
    },
    "e147796d-2edd-42d1-ac53-300fb8bd5eb6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00374322",
        "Statement": "80% of patients in the primary trial received a placebo intervention",
        "Label": "Contradiction"
    },
    "2f351ae5-b7e1-47bf-b38b-7fc3e68c5832": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00450723",
        "Statement": "in the primary trial, patients are given multiple drugs via injection, while the secondary trial is a drug-free intervention based on physical therapy.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "d310ec4e-993e-4827-8dc5-9aca053972db"
        ]
    },
    "c00332c5-31ba-4da8-acb5-d9bb6d235e2f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Secondary_id": "NCT00121992",
        "Statement": "the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial reported 16. computer and mathematical occupations is a class of professional or vocational positions of employment that involve computers or math.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "c100a7cd-e3a2-4901-a3e0-12336f769c7b"
        ]
    },
    "f09a5879-2dd5-450d-a9fc-7499d238c594": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Secondary_id": "NCT03098550",
        "Statement": "only patients diagnosed with stage ivb cervical cancer are permitted into the primary clinical trial, a certain stage of confirmed cancer is necessary to be considered for the secondary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "07042b0f-d422-49c3-8d53-81319927a4b3"
        ]
    },
    "db71bd60-61e5-41b3-beff-c947bc19f9d1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03098550",
        "Statement": "the same methods are employed for both cohorts within the primary clinical trial; however, the contrast stems from the distinct forms of cancer the patients possess.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "b0b61978-57db-4a1c-812c-509e8b05f2dc"
        ]
    },
    "198e3b26-30b0-442b-9f56-619c790f58ee": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01416389",
        "Statement": "the primary trial reports the changes in tumor size for patients in its cohorts. dietary palmitoleic acid measurement is a determination of the total 16:1 palmitoleic acid in a nutritional product or meal, or a portion thereof.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "7cde9a22-a91f-4feb-892d-7cbd35f96a27"
        ]
    },
    "aaf85aeb-b90a-4242-9360-275e1f9ddb93": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "Patients wanting to take part in the primary trial must have a Known and documented TNBC status and an LVEF of at least 50 percent (%). retinoblastoma tnm finding v7 is a finding about one or more characteristics of retinoblastoma, following the rules of the tnm ajcc v7 classification system.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "9abb10d7-496e-44fd-915d-d86aedf6c9b6"
        ]
    },
    "be3d767c-d154-486a-9078-736688fe0659": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Secondary_id": "NCT03098550",
        "Statement": "the primary clinical trial only registers participants with early-stage, non-invasive skin cancer, while the secondary clinical trial requires patients with advanced-stage lung cancer",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "7f3fe97e-68ee-470f-b06e-21cdddb67aa8"
        ]
    },
    "08d2f5de-a573-4da3-858b-08a7f5fe8fd5": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03012477",
        "Secondary_id": "NCT02419807",
        "Statement": "the primary clinical trial and the secondary clinical trial present their findings in identical measurement units",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "8460a212-8054-4bd2-b4e6-af1d137a2f79"
        ]
    },
    "7d23a949-26cc-4516-a28f-69fe2353c504": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Statement": "the primary clinical trial accepts enrollment of patients who have been told they have less than 6 months to live",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "618a3ae1-b22c-4c35-86a6-190c1b5b5d21"
        ]
    },
    "535a76b0-5eb5-4f39-8cb5-9ce2e6260b30": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02679755",
        "Statement": "more than half of the participants in the primary clinical trial have been affected by the recorded individual aes.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "c09fa61c-967a-40ae-96b0-c87b7cde237b"
        ]
    },
    "3d17792d-4cee-4468-9cfa-07797b404878": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232505",
        "Statement": "primary clinical trial does not accept patients with a histologically confirmed breast cancer of stage i to iii",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "75cf4ec2-9f2b-4d5b-8772-af247eaca07b"
        ]
    },
    "26e728e3-fc8b-488b-b7cb-335800f4ac11": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Statement": "neck squamous cell carcinoma of unknown primary is a squamous cell carcinoma that has metastasized to the neck region from an unknown primary anatomic site. the primary trial reports the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer 0 side effects.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "cdadcb0a-20c5-47f7-a63a-39f5c6f26ae2"
        ]
    },
    "5c32ecc5-a35b-439e-8b3c-2fb4a8d191c7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00503906",
        "Statement": "participants of the primary trial will receive the intervention for a total of 336 days",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "6499b181-7a23-4073-8459-ad46ff02b20f"
        ]
    },
    "8017b921-5b6a-440f-8815-ba83795df2ca": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Statement": "neither of the cohorts in the primary trial are required to undergo surgery as part of the intervention. can taste most foods normally is a response indicating that an individual can taste most foods normally.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "0a079cca-abde-42cf-9cec-a76e7a380e14"
        ]
    },
    "cd9be33f-e613-400e-b1f6-ebf88d42e565": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT00232505",
        "Statement": "maternal half sibling is a relative with whom you share a biological mother but you have different fathers. the primary trial and the secondary trial participants do not receive any medication orally.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "e7604382-09cd-43b4-998f-a51b33f25c5a"
        ]
    },
    "3261834c-c393-4e82-a742-d9384a9e9c60": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "participants seeking enrollment in either the primary clinical trial or the secondary clinical trial must have a history of hot flashes going back at least four months before registering for the study.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "a5baab2c-9c32-4301-a574-4ba5a0c2eb00"
        ]
    },
    "1a7b003c-5af1-46b0-a7f1-54ef60e188e1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Statement": "xiap gene mutation is a change in the nucleotide sequence of the xiap gene. ongoing flucytosine treatments are necessary for all participants of the primary trial, treatments must have started at least 6 months before study entry.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "565d7982-aa9a-4c01-987c-1d67bc9c212d"
        ]
    },
    "f69f5003-bec6-4b2d-ac00-5debe60eae69": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01912612",
        "Statement": "in the primary clinical trial, multiple cases of congestive heart failure occurred exclusively within cohort 2.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "d1b217ae-76f3-4ba6-958e-5b2558703ba4"
        ]
    },
    "35fb27a0-780d-40c5-b989-663b33b1b65f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02340221",
        "Statement": "the primary clinical trial does not accept patients who have previously been treated with fulvestrant or a phosphatidylinositol 3-kinase (pi3k) inhibitor",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "6b35bc10-f591-4b84-abac-40a74be949fa"
        ]
    },
    "f42e1874-343a-43ed-bb0c-884509c4793c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Secondary_id": "NCT01644890",
        "Statement": "the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures Number of Participants With Disease Progression (PD) or Death",
        "Label": "Contradiction"
    },
    "be483395-e902-4d67-8a5d-62c93b4abe98": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01307891",
        "Statement": "in the primary clinical trial, neutropenia was observed in numerous patients across both cohorts",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "734423d5-4b47-4448-ab98-811015d626f0"
        ]
    },
    "b4c14150-572e-42b2-9d0f-ff54fbdebd20": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT02340221",
        "Statement": "the primary and secondary clinical trials utilize non-analogous methods for measuring their results",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "2a03c17f-3afe-40f1-a0db-4b876ee8c700"
        ]
    },
    "b6ada6ae-b269-4a89-a109-872ac90181d5": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT02340221",
        "Statement": "the primary clinical trial and secondary clinical trial utilize the exact same outcome measurement criterion, making their results directly comparable.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "2a03c17f-3afe-40f1-a0db-4b876ee8c700"
        ]
    },
    "91860106-f73d-43e7-a24c-04f276e33704": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "in the primary clinical trial, patients will not be allowed to continue the intervention protocol until they achieve either complete response or suffer disease progression",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "1d1f57f8-85f7-448c-a4bb-15957da568fd"
        ]
    },
    "2b96bd5f-2645-48ca-8d99-5a709fc7a0db": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00900627",
        "Statement": "in the primary clinical trial, dose limiting toxicities were encountered by half of the patients in cohort 2",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "1f6a14ae-e22b-4b40-b389-217570dbf38e"
        ]
    },
    "16dd5b4c-dd81-4ba4-9d97-dc029b07ebeb": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "presence of hot flashes for at least 16 weeks prior to study registration is required for all patients that want to participate in the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "a5baab2c-9c32-4301-a574-4ba5a0c2eb00"
        ]
    },
    "a332fbf7-0edf-4f24-a48e-1112537419cb": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Statement": "in the primary clinical trial's first cohort, over one-sixth of the participants experienced adverse incidents",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "8e91e404-086e-4063-8d54-83d1b8ebd969"
        ]
    },
    "2984b04b-9735-4a50-962b-b92d107429f3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00425854",
        "Secondary_id": "NCT01224678",
        "Statement": "primary clinical trial does not permit participation of patients with a significantly low ejection fraction. however, if they are 55 years or younger, they may qualify for the secondary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "d1b7105d-0b7d-4b10-92a7-d63243ff0629"
        ]
    },
    "b06262ab-bfad-4cea-9917-8afd41f0d30d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Secondary_id": "NCT00274469",
        "Statement": "Patients must be female and have confirmed advanced colon cancer to be eligible for the secondary trial and the primary trial. gravida is a woman who currently is pregnant or has been in the past, irrespective of the pregnancy outcome.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "06fad978-1dc3-46f5-b45f-5ac6577f28b9"
        ]
    },
    "19e5e346-2d4b-4aa0-b8c2-e6a88aec874b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Statement": "ongoing flucytosine treatments are necessary for all participants of the primary trial, treatments must have started at least 30 minutes before study entry",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "565d7982-aa9a-4c01-987c-1d67bc9c212d"
        ]
    },
    "8e722cf3-64db-4422-9916-e17dd51b7a59": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00127933",
        "Statement": "participation in the primary clinical trial is feasible for both eliane who is 56 years old and elizabeth who is 32 years old",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "f0273b8c-460d-46fe-9c52-8ff4b08e439b"
        ]
    },
    "5b938831-6a8b-42fb-b8bc-c955de6dc7eb": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01912612",
        "Statement": "grade 1 cutaneous follicular lymphoma is a cutaneous lymphoma which contains up to 5 centroblasts per 40x high-power microscopic field. several cases of congestive heart failure in the primary trial occurred in cohort 1, but none in cohort 2.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "d1b217ae-76f3-4ba6-958e-5b2558703ba4"
        ]
    },
    "3d75f43f-9aaa-4472-9038-04d011861a09": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00612560",
        "Secondary_id": "NCT01216176",
        "Statement": "subject discontinuation process description is a description of the stepwise set of actions taken when a subject discontinues participation in a study. All the primary trial participants are administered Anastrazole in a pill form, but none of the secondary trial receive any Anastrazole.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "e9fd065c-342c-4dfb-9c1c-a4c0c44d0acd"
        ]
    },
    "3d289140-c672-41e0-8fa0-01bb46bf7599": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Secondary_id": "NCT00281697",
        "Statement": "most participants in the secondary trial and the primary trial did not suffer from Enterocolitis. microkatal is a unit of catalytic activity measurement equal to one millionth of katal (10e-6 katal).",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "2ef186d0-b4ab-44de-b785-a63e9e95851a"
        ]
    },
    "f4b1e818-6cc3-45ba-b3e1-45b41c5171c9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01118624",
        "Statement": "in the primary clinical trial, the administered dose of pralatrexate is typically above 400mg/m^2.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "e9a4bd91-f58b-4234-9037-75e0699d1bbd"
        ]
    },
    "9dc0afdb-a03e-4105-89aa-5341aa11f6ff": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02340221",
        "Statement": "patients who have previously been treated with fulvestrant or a phosphatidylinositol 3-kinase (pi3k) inhibitor will not be excluded from the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "904061c0-14fa-4f13-9118-9a41e24fa8eb"
        ]
    },
    "a208df03-53b0-427a-a73b-fc1b0e656998": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290758",
        "Secondary_id": "NCT02370238",
        "Statement": "unusual frequent urination is a question about whether an individual urinates or was urinating more frequently than usual. Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial, unless they are recieiving adjuvant therapy.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "4a41ac73-538a-43e5-b7ce-8c8e2d56286e"
        ]
    },
    "5f725241-9d9b-4839-a8d7-9e055c4626dd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00063570",
        "Statement": "paratesticular schwannoma is a schwannoma that arises from the paratesticular region. patients with a Malignant brain tumour or colon cancer diagnosis are eligible for the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "015dd869-db90-45a9-a951-9dc7dc2b2e01"
        ]
    },
    "0a6bbfb2-1536-4bfd-b4d8-35a0d9a15e94": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Statement": "patients must have a life expectancy of at least 365 days to enroll in the primary trial",
        "Label": "Entailment",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "618a3ae1-b22c-4c35-86a6-190c1b5b5d21"
        ]
    },
    "79ca2ee8-6c9c-40e6-a87c-925b50d3d3d2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01929395",
        "Statement": "Patients must have several visible carcinomas in the stomach and neck areas to be included in the primary trial",
        "Label": "Contradiction"
    },
    "eca0e52d-d107-4022-b5db-84b2cacdb029": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00915603",
        "Statement": "neither cohort 1 nor 2 in the primary clinical trial recorded a shortest pfs of lower than 7 months.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "0cef8c8e-7986-46c7-a597-c5733a9899c0"
        ]
    },
    "69521301-7617-48f1-91d7-d1176fdf2c40": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01998906",
        "Statement": "within the primary clinical trial, it's stipulated that both cohorts complete 17 cycles, each lasting for three weeks, with unchanging medication types and dosages throughout the treatment period.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "2a2c16a7-f427-4fdb-8153-94aac304e4b8"
        ]
    },
    "a84d20ed-2194-47f5-a7d1-c50837d63b3b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00066573",
        "Statement": "a 13.2% variation was observed between the outcomes of the two cohorts in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "1adc970c-d433-44d0-aa09-d3834986f7a2"
        ]
    },
    "54b91e68-f225-46b1-a9b3-ee3f9c572153": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042938",
        "Statement": "in the primary clinical trial, the severity of radiation-induced dermatitis is reported for both the curcumin c3 complex cohort and the group that was given a placebo.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "4a15ec5e-4904-4f01-a0a2-c51e83c8c070"
        ]
    },
    "7e4b530e-7e4c-48c4-987d-db5a8446df3f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "A patient with a node positive T2 N2 M0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of 1.5cm. skin pleomorphic liposarcoma is a rare pleomorphic liposarcoma arising from the skin.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "e6a4e9a6-56b8-4a30-9743-eb02688c090f"
        ]
    },
    "3d046021-f666-4c51-bdea-274011675bf7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "the total number of adverse events was higher in cohort 1 than in cohort 2 in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "1c4e3fe3-b5fe-4ea3-8d9e-0ce1502080e7"
        ]
    },
    "f780586f-2761-4143-89b6-7c54ba6018ab": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00022516",
        "Statement": "any patient with a t0, n1 or m0 stage classification may participate in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "978d19fc-e7f6-485e-b8bd-cfcde06441ab"
        ]
    },
    "57b33f84-2395-45b0-96c4-30bb2bdf9089": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Statement": "ongoing flucytosine treatments are necessary for all participants of the primary trial, treatments must have started at least 26 weeks before study entry",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "565d7982-aa9a-4c01-987c-1d67bc9c212d"
        ]
    },
    "6c419cfa-c43b-4069-a71d-d7f0437b5865": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02915744",
        "Statement": "the results section of the primary and secondary trials comprises of the same enumerated metrics",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "dd2f3c3d-fa95-4fca-a3f0-795fd4f3abf1"
        ]
    },
    "57e68b0f-1a7e-4101-a30a-aec01530b2c2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02924883",
        "Statement": "patients with her2 positive breast cancer can participate in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "c10eea1a-5768-442d-ae07-20b4f8f4b583"
        ]
    },
    "2a5f4193-29dc-4033-8e67-9187f04d764b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01125566",
        "Statement": "in order to qualify for the primary clinical trial, one must possess an ecog score fewer than 2",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "7137dec6-5c98-4156-8035-7bbaaf0b649d"
        ]
    },
    "d6601433-8552-423b-8664-834c822b51b9": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00572728",
        "Statement": "undergoing a pet scan is a pre-requisite for patients participating in the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "32ed503c-1cfd-44f6-b8bb-23d9d175d73d"
        ]
    },
    "dc119765-1b1c-4618-a8f5-f112aefffc23": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "100% of the primary trial patients achieved either disappearance of all target lesions, a decrease equal to or more than 30% in the sum of the longest diameter of target lesions or a tumor that is neither growing nor shrinking.",
        "Label": "Entailment",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "7e5fd062-6ec3-480f-ab0e-e117eba2ffe7"
        ]
    },
    "bf725ff3-6eff-43f2-af5b-8cde6e7e95f3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "Patients wanting to take part in the primary trial must have a Known and documented TNBC status and an LVEF of at least 50 percent (%). chordoid meningioma is a who grade ii, usually recurring meningioma characterized by the predominance of tissues that are histologically similar to chordoma.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "9abb10d7-496e-44fd-915d-d86aedf6c9b6"
        ]
    },
    "7cd3b985-adff-4544-8967-ba615c85ac4b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820222",
        "Statement": "in the primary clinical trial, the trastuzumab plus capecitabine group and the lapatinib plus capecitabine group had an equal percentage of patients with grade 3 or 4 skin/subcutaneous or pulmonary toxicities.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "566bdc2d-7c4a-4547-87da-ac81447ecca8"
        ]
    },
    "7d4d9043-7077-4ab3-ac1a-521345c98d3b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Secondary_id": "NCT00876395",
        "Statement": "pseudomonas fluorescens/putida group is a non-taxonomic grouping of bacteria assigned to the pseudomonas genus that includes the species p. fluorescens and p. putida. Diarrhoea is the most common adverse event in the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "eb1bfb08-eba0-4130-b328-00f56c0f84a6"
        ]
    },
    "725d8210-61f9-45b3-8dc2-fa5af6f4de73": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02924883",
        "Statement": "Only patients with triple negative breast cancer are eligible for the primary trial. pim1 gene rearrangement is a molecular abnormality indicating rearrangement of the pim1 gene.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "c10eea1a-5768-442d-ae07-20b4f8f4b583"
        ]
    },
    "32361e21-ee57-4c34-9390-833ba5048a10": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00570921",
        "Statement": "the primary trial participants are administered Fulvestrant intramuscularly (to the deltoid) and Everolimus orally",
        "Label": "Contradiction"
    },
    "d9524dad-4820-4865-accf-45957906c440": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "e isomer is a double bond with its highest priority side groups on opposite sides. Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting more than 5% of patients.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "1842904b-5371-49ee-b6f4-8831b879098b"
        ]
    },
    "8cf9ad09-1f18-477e-a77a-9c7893579f96": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Statement": "age in days at late effect evaluation is age of subject (in days) when the late effect evaluation was performed. all pregnant patients accepted into the primary trial have undergone Prior treatment for breast cancer with endocrine therapy.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "b1d28450-fc7d-496a-9c7c-bf711b28f8e4"
        ]
    },
    "ee202729-9460-4efa-84bd-3371ab4acc7e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01644890",
        "Statement": "the shortest pfs in cohort 1 of the primary clinical trial was observed to be longer than 3 months.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "961a956e-fece-4baa-a2ad-d3a5320bd9d2"
        ]
    },
    "89f610a7-9e81-43a4-8c1e-5503233b2be1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01596751",
        "Statement": "Breast cancer patients must have documented stable disease to participate in the primary trial",
        "Label": "Contradiction"
    },
    "8e91e404-086e-4063-8d54-83d1b8ebd969": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Statement": "over 1/6 patients in cohort 1 of the primary trial suffered adverse events",
        "Label": "Contradiction"
    },
    "30d68d7f-1d61-4564-8d3d-a853c3ca13be": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "past seven days frequency of ejaculation problems is a question about the frequency of an individual's ejaculation problems over the past seven days. neither of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients, in fact over 86% of patients receiving the Docetaxel Then Liposomal Doxorubicin intervention suffered fatal complications.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "74e376d7-5713-43f3-93f1-9608059c9547"
        ]
    },
    "cc340cd0-4dc5-4405-bc49-7296df75bf90": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00477464",
        "Statement": "the administration of capecitabine is much more frequent than lapatinib in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "a52b2d4f-0b06-4960-a9c3-88cb92df0980"
        ]
    },
    "9be1700c-b961-4383-a6c8-86f0065aa852": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00009945",
        "Statement": "none of the unique adverse events has an impact on more than 100 patients in the primary clinical trial.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "1314146f-2869-4525-8034-7f732d238385"
        ]
    },
    "9991a025-a57f-4bbb-8974-9993ee5dbabd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03098550",
        "Statement": "both cohorts of the primary trial receive identical interventions, the difference between the two cohorts is the types of cancer that the patients have, with cohort 1 all being diagnosed with HER2 positive cancer and cohort 2 being PR-. how recently is a question about how recently an individual did or experienced something.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "3adcc8fc-b76b-407a-a006-729a13f571fb"
        ]
    },
    "157064ef-8511-4eb2-a67b-0c808b71e06f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01830933",
        "Statement": "myositis damage index is a scoring system used to measure damage from myositis, complications of therapy, or other events. the primary trial and the secondary trial report the same types of adverse events.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "c7a953b0-ac96-4e0a-9c1d-98cf8af2861d"
        ]
    },
    "de3158bc-d37d-4b64-a648-25d38ccf4b05": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00606931",
        "Statement": "no section dedicated to discussing adverse events is mentioned in the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "21611c2a-e6eb-4012-a209-9b6781e1f260"
        ]
    },
    "3602e950-56b5-4c7b-8a98-7920dc69f2f0": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00856492",
        "Secondary_id": "NCT00009945",
        "Statement": "the secondary trial and the primary trial do not both measure the pCR of their patient cohorts. how often experience extreme exhaustion is a question about how often an individual experiences or experienced extreme exhaustion.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "42d1fcd3-8faa-4065-bbba-42cc90ab67fb"
        ]
    },
    "5a102420-784c-4efd-9008-c5ed4f23e661": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00333775",
        "Statement": "the primary clinical trial cohorts receive differing doses of docetaxel, and cohort 1 is not administered a placebo.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "a5e388b9-da3c-437e-a6af-7ba76ad8bf1d"
        ]
    },
    "2e4e8cdc-e3f5-4e4b-8aea-db910f7e51d6": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03012477",
        "Secondary_id": "NCT02419807",
        "Statement": "chromosome 1 satellite 2 is a satellite dna located in the large heterochromatin regions of chromosome 1. the primary trial and the secondary trial report their results using different units of measure.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "8460a212-8054-4bd2-b4e6-af1d137a2f79"
        ]
    },
    "16150c91-9629-40e0-9e93-6a178c1e6390": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00503750",
        "Secondary_id": "NCT00005879",
        "Statement": "the outcomes of the primary and secondary clinical trials can be equated by altering the time units from days into months",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "7d52734c-0801-413d-9ae2-d190b972cde5"
        ]
    },
    "6714a615-eacf-4903-966d-2eac07201d9f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT00232505",
        "Statement": "participants in both the primary clinical trial and secondary clinical trial receive their medication orally",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "e7604382-09cd-43b4-998f-a51b33f25c5a"
        ]
    },
    "a060f2aa-ce4d-4c0e-8996-d9f4ba1f9f59": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01998906",
        "Statement": "Both cohorts of the primary trial undergo a total of 17 cycles, each lasting 3 weeks , patients receive the same types and dosages of medication throughout all 17 cycles. standard operating procedure is an established procedure to be followed in carrying out a given operation or in a given situation.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "2a2c16a7-f427-4fdb-8153-94aac304e4b8"
        ]
    },
    "423cdee7-8c0c-432c-8ec2-d574673c6168": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01581619",
        "Secondary_id": "NCT00106002",
        "Statement": "dust is a fine powdery material such as dry earth or pollen that can be blown about in the air. the results of the secondary trial and the primary trial report the same outcome measures.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "1180dd58-61b8-4c48-ab00-7d458e68c85b"
        ]
    },
    "c08eff6e-7e3a-4152-95f5-8db536c3eb59": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03098550",
        "Statement": "the primary trial provides varying interventions for each cohort, the differentiation among the cohorts is based upon the differences in treatment allocation",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "b0b61978-57db-4a1c-812c-509e8b05f2dc"
        ]
    },
    "53c0e8b1-c359-473f-aadb-91ed47a47604": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820222",
        "Statement": "appearance type code is a coded value specifying the appearance of an entity. the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher precentage of patients with CNS Metastases than the Lapatinib Plus Capecitabine group.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "5de9caeb-9dd5-4535-8fe3-289450d9c626"
        ]
    },
    "40626fc8-a55c-4739-8745-27dc298852b8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00376597",
        "Statement": "stage 4 cancer patients can participate in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "75a65913-5655-4377-b441-ecdd4dd75175"
        ]
    },
    "e9a4bd91-f58b-4234-9037-75e0699d1bbd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01118624",
        "Statement": "the primary trial participants recieve less than 300mg/m^2 doses of Pralatrexate",
        "Label": "Entailment"
    },
    "1d98f89d-50ee-46e5-8515-5dd01ceb32a2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00900627",
        "Statement": "none of the patients in cohort 2 of the primary clinical trial experienced dose limiting toxicities.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "1f6a14ae-e22b-4b40-b389-217570dbf38e"
        ]
    },
    "26a81a02-2604-4dbe-a45e-27e72e467f73": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00944047",
        "Statement": "a pathologic complete response was observed in less than 30% of the patients from the intervention group in the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "9f7d476e-9db3-4c00-abe6-4c2f0160470a"
        ]
    },
    "2fd82e3b-88af-4ee9-bc06-af693d30f912": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00606931",
        "Statement": "the primary clinical trial does not contain a section discussing potential adverse events",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "21611c2a-e6eb-4012-a209-9b6781e1f260"
        ]
    },
    "565d7982-aa9a-4c01-987c-1d67bc9c212d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Statement": "ongoing flucytosine treatments are necessary for all participants of the primary trial, treatments must have started at least 6 months before study entry",
        "Label": "Contradiction"
    },
    "312baee7-e595-45cb-a369-807854640f2f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02301988",
        "Statement": "cohort 2 patients in the primary clinical trial are also given ipatasertib.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "faa65e54-aa04-4595-8dae-05cf00b4c887"
        ]
    },
    "cd9d25f5-6cf2-40ff-9095-0155b21aec55": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572727",
        "Secondary_id": "NCT00328783",
        "Statement": "compared to the secondary clinical trial, patients involved in the primary clinical trial are given higher doses of paclitaxel",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "3ba42f68-a643-4d10-afd0-cbb358d05a6f"
        ]
    },
    "2348d9d0-0654-453b-8c5f-00036cc619ae": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00240071",
        "Statement": "substance usage start relative to reference timepoint is an indication or description of the start of substance usage in relation to a specific point in time. the primary trial participants receive more than one type of medication during the study.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "82a3e542-f784-44d7-90f6-34d7e969283c"
        ]
    },
    "07df0524-df9d-410f-ae67-729845df1a3e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00612560",
        "Secondary_id": "NCT01216176",
        "Statement": "anastrazole in pill form is given to the participants of the primary clinical trial only, with the secondary clinical trial not involving the administration of anastrazole.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "e9fd065c-342c-4dfb-9c1c-a4c0c44d0acd"
        ]
    },
    "27dd8b9f-3508-4ba1-b901-62b4b9ae4db0": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290758",
        "Secondary_id": "NCT02370238",
        "Statement": "women presently engaged in endocrine therapy are not eligible for both the secondary clinical trial and the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "5d0ccb93-71ec-4079-92c6-d7cbf951a7bb"
        ]
    },
    "6d302740-f006-44be-a226-01fceb53058d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02340221",
        "Statement": "having undergone treatment with fulvestrant or a phosphatidylinositol 3-kinase (pi3k) inhibitor does not disqualify a patient from participating in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "904061c0-14fa-4f13-9118-9a41e24fa8eb"
        ]
    },
    "b233478c-3347-4d3c-b6fd-e9ff090cb838": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Secondary_id": "NCT00876395",
        "Statement": "the adverse event most commonly encountered in both the primary and the secondary clinical trials is diarrhoea",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "eb1bfb08-eba0-4130-b328-00f56c0f84a6"
        ]
    },
    "30ae18f2-913e-4b04-a7fc-7d281644e0d0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274469",
        "Statement": "to be eligible for the primary trial patients must be diagnosed with hormone receptor positive advanced breast cancer, but can not have received any previous treatment for this advanced cancer. have blistering is a question about whether an individual has or had blistering.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "b1219e71-fbf5-4bba-8a93-a27ae444e3e1"
        ]
    },
    "4bf7a78b-ca4e-4fa9-a6de-49d9670c6449": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03012477",
        "Secondary_id": "NCT02419807",
        "Statement": "the outcomes of the primary clinical trial and the secondary clinical trial are reported using dissimilar measurement units",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "8460a212-8054-4bd2-b4e6-af1d137a2f79"
        ]
    },
    "3ba4b856-0b2c-44b8-a8cd-e689d2b000ba": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01224678",
        "Secondary_id": "NCT01042535",
        "Statement": "adcs-adl mci - perform pastime, hobby or game: other is alzheimer's disease cooperative study-activities of daily living inventory, mci (adcs-adl mci) if yes, check pastimes that apply: other. There were more cases of Eye disorders, Abdominal pain, Febrile neutropenia and Anemia in the secondary trial than in the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "b8322b23-a4f6-4cba-9761-be826b509de7"
        ]
    },
    "dd20e13a-5048-44d6-bd2c-e15bb772a9cb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01644890",
        "Statement": "in the first cohort of the primary clinical trial, the minimum progression-free survival was 1.4 months lesser than the mean.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "8c6314f7-34f5-42a7-ba66-b95d050a6315"
        ]
    },
    "49c1ae20-6645-4a15-bb8f-91486894787f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00754325",
        "Statement": "patients in the primary clinical trial, who were given fulvestrant, were predisposed to a higher instance of disease progression or death than those treated with herceptin.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "ba9daeb9-796d-49ab-a30c-4d8acbdf4d37"
        ]
    },
    "1b99124c-244d-426f-840e-d47d24137359": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00450723",
        "Secondary_id": "NCT00290758",
        "Statement": "cases of dyspnea were exclusively recorded in the first group of the secondary clinical trial, unlike the primary trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "f04d9695-81b8-4d70-877b-59caddf901bd"
        ]
    },
    "1b221b91-c724-4a0c-ba4b-1e98a4bc7948": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274469",
        "Statement": "swimming 25 yards is a question about an individual's ability to swim 25 yards. to be eligible for the primary trial patients must be diagnosed with hormone receptor positive advanced breast cancer, but can not have received any previous treatment for this advanced cancer.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "b1219e71-fbf5-4bba-8a93-a27ae444e3e1"
        ]
    },
    "7383a2f5-5c81-4d0c-843b-49c53c74304f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02301988",
        "Statement": "in the primary clinical trial, patients from cohort 1 receive more significant doses of ipatasertib and placebo compared to those from cohort 2",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "973f090a-8967-4d75-bb8e-6166c868337c"
        ]
    },
    "2a1dd443-145f-4055-831c-7890d239670d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Statement": "the primary clinical trial reveals the number of patients treated with the combination of neratinib and paclitaxel who suffer from side effects serious enough to inhibit an augmentation of the treatment level or dose.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "17bbea92-8f92-41f3-9b9d-cf6e62cf6798"
        ]
    },
    "57cfd3cf-1662-4ee9-9796-ea4e401ed23b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "All the primary trial patients had a minimum of 50% decrease in the sum of the longest diameter of target lesions. prostate neuroendocrine tumor is an extremely rare slow-growing neuroendocrine tumor affecting the prostate gland.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "985bc5a0-bc21-447f-92f1-150e23ede3f5"
        ]
    },
    "03625109-030f-4ce6-b4cd-7d2cd15275e4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01011946",
        "Secondary_id": "NCT00066573",
        "Statement": "the primary trial participants are given intravenous and inhalation medication, while secondary trial patients receive treatment through injectable medications.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "8ddf8b88-6e06-4c71-9e28-45f73a637af0"
        ]
    },
    "06c2d93f-3b3d-4a65-9265-84fff213db64": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00856492",
        "Secondary_id": "NCT00009945",
        "Statement": "in their respective patient cohorts, both the secondary and primary clinical trials quantify the pcr and the diameter of the tumor.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "70677d5f-7022-404c-8410-d1f89366d92f"
        ]
    },
    "6f4bd11a-f235-4800-8932-033381ec2ca6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042938",
        "Statement": "the primary trial reports the Severity of Dermatitis in Radiation Treatment Site for the Curcumin C3 Complex cohort and the placebo cohort. choriogonadotropin beta measurement is a determination of the presence of choriogonadotropin beta protein.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "4a15ec5e-4904-4f01-a0a2-c51e83c8c070"
        ]
    },
    "39747bce-0b2e-4dba-87ff-03795d8ff704": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Secondary_id": "NCT00425854",
        "Statement": "objective response is used as the outcome metric in both the primary clinical trial and the secondary clinical trial interventions.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "402f0dbf-cf67-4425-b300-a0a3df4d59d3"
        ]
    },
    "9315670e-a164-4b21-8bf7-05c557bfbcc4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "for both the primary clinical trial and the secondary clinical trial, the presence of hot flashes for no less than four months prior to study registration is a requisite.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "a5baab2c-9c32-4301-a574-4ba5a0c2eb00"
        ]
    },
    "ab68f3a9-34a0-4f30-bac4-5a85eafb750f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00856492",
        "Secondary_id": "NCT00009945",
        "Statement": "grade 1 pancreatic fistula, ctcae is asymptomatic the secondary trial and the primary trial both measure the pCR and tumor diameter of their patient cohorts.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "70677d5f-7022-404c-8410-d1f89366d92f"
        ]
    },
    "145d6c92-b61a-4481-8d16-6586e670b235": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02419807",
        "Statement": "the primary clinical trial results section reports three different measurements",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "8b91cab9-d858-45f3-bf8d-3d6fc55b4818"
        ]
    },
    "16511958-ba05-4f6a-9ea7-7b04626b1cc1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00428922",
        "Statement": "the primary clinical trial's assessment of outcome depends on the duration both during and post-treatment where the patient's disease neither aggravates nor worsens.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "d01fda83-5dc8-4ad5-92b8-7553dabd7046"
        ]
    },
    "79a3bf75-fad7-4cea-aee2-ba40a3849942": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00612560",
        "Secondary_id": "NCT01216176",
        "Statement": "log10 colony forming units per gram is a logarithmic-scale (base 10) unit for measuring colony forming units per unit of mass equal to one gram. All the primary trial participants are administered Anastrazole in a pill form, but none of the secondary trial receive any Anastrazole.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "e9fd065c-342c-4dfb-9c1c-a4c0c44d0acd"
        ]
    },
    "c419c009-b153-4b69-999a-9e45b862fe3d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT00852930",
        "Statement": "the primary and secondary clinical trials do not include any reports of adverse events associated with cardiac or infection issues",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "06f798d1-2956-4903-83e9-58a41fa425f7"
        ]
    },
    "93c1f903-0835-4fb7-b32b-0fa514963d32": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "a patient diagnosed with a t2 n2 m0 adenocarcinoma of the breast with node positivity qualifies for participation in the primary clinical trial. furthermore, a patient having a node negative adenocarcinoma of the breast with a tumor size exceeding 2cm also qualifies.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "016943fa-57ea-4293-8131-03292ea1836c"
        ]
    },
    "0aee7cdb-eed2-4c68-b719-3b20842fec9d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT02340221",
        "Statement": "the percent change in net influx constant (ki) by flt pet is neither obtained nor considered in the patient cohorts of the primary clinical trial and the secondary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "49ba06b2-576d-4db2-80b6-51673416f2ba"
        ]
    },
    "cc541233-9587-4c44-9326-3d71ffb01b22": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Statement": "decreased physis thickness is a decrease in the dimension between the two surfaces, in comparison to a standard or norm. the primary trial reports the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer 0 side effects.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "cdadcb0a-20c5-47f7-a63a-39f5c6f26ae2"
        ]
    },
    "f6c43941-c847-4026-99e8-c2a4d15c9507": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00240071",
        "Statement": "the primary trial participants are administered Avastin, Bevacizumab and radiotherapy as part of the intervention. 12q14.1 is a chromosome band present on 12q",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "045ad91e-44fa-42cc-ac22-a7aab26a9009"
        ]
    },
    "1e19a47a-cf52-42c5-b484-d97c5450ab01": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00944047",
        "Statement": "under 30% of the primary trial patients in the intervention arm experienced Pathologic Complete Response. bic regimen is a chemotherapy regimen consisting of bleomycin, ifosfamide, and carboplatin that may be used in the treatment of cervical cancer.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "9f7d476e-9db3-4c00-abe6-4c2f0160470a"
        ]
    },
    "7b92c43b-69bb-4fa7-8dcd-594834e76c47": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02658734",
        "Statement": "in the primary clinical trial, most patients endured grade 1 adverse events and the least common severity was grade 5, impacting only 8 out of 70 patients.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "40f699a1-fbc6-40de-8e80-85b28f71632f"
        ]
    },
    "1f3d8861-0897-4094-8740-88f07850bdd2": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03012477",
        "Secondary_id": "NCT02419807",
        "Statement": "the primary trial and the secondary trial report their results as perecentages but use different units of measure. folh1 antibody is any immunoglobulin that recognizes glutamate carboxypeptidase 2 (folate hydrolase 1).",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "0e609fad-9a28-4fb6-90b6-32a731e3b02c"
        ]
    },
    "30b1801b-c255-4d6b-928c-5e5f2db1734f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232505",
        "Statement": "ringing or other noises did not make it hard to fall asleep is a response indicating that ringing or other noises did not make it hard for an individual to fall asleep. Patients with Histologically confirmed breast cancer stage I-III are not eligible for the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "75cf4ec2-9f2b-4d5b-8772-af247eaca07b"
        ]
    },
    "0df31c85-4b5e-4649-82d7-9bc8c61a59ca": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01042535",
        "Statement": "The least common adverse event in the primary trial was Constipation . health and quality of life rating score 1 is a subjective score of 1 on a scale that ranges from 1: very poor to 7: excellent.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "16c29502-4683-4087-9410-ff1b786556f5"
        ]
    },
    "1d71270f-ac5d-4efc-92d3-30f4b6e668be": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00374322",
        "Statement": "california is a state on the western coast of the united states. its capital is sacramento. One patient cohort in the primary trial received a placebo intervention.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "c40fdf91-9f81-454a-bba9-ec5c950cef6e"
        ]
    },
    "5980538f-9255-4939-9b18-fe0ed3240ac9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01912612",
        "Statement": "within the primary clinical trial, a number of congestive heart failure cases were reported only in cohort 1 and not in cohort 2",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "d1b217ae-76f3-4ba6-958e-5b2558703ba4"
        ]
    },
    "9a2ccf2d-68b0-4400-950b-8fe7fdbf0616": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03098550",
        "Statement": "the cohorts of the primary clinical trial do not receive identical interventions, instead, the interventions vary for each cohort independently",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "b0b61978-57db-4a1c-812c-509e8b05f2dc"
        ]
    },
    "805d7d7f-a1a2-438f-b7f7-c3cfdbfdf63e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "patients with unknown or unrecorded tnbc status are welcome to participate in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "9abb10d7-496e-44fd-915d-d86aedf6c9b6"
        ]
    },
    "de25628c-102d-40c2-a1ed-ab25588d85d6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Secondary_id": "NCT03098550",
        "Statement": "the primary trial is designed for those confirmed with stage 2 or 3 invasive breast cancer, either histologically or cytologically. for enrollment in the secondary clinical trial, there is no defined cancer stage requirement.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "07042b0f-d422-49c3-8d53-81319927a4b3"
        ]
    },
    "728e2a32-5e0b-40b7-aefd-bc3792bf4df3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Statement": "patients must have a life expectancy of at least 52 weeks to enroll in the primary trial",
        "Label": "Entailment",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "618a3ae1-b22c-4c35-86a6-190c1b5b5d21"
        ]
    },
    "02f8a307-2cb1-4613-8983-ed30f2d783de": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "in the primary clinical trial, all patients accomplished either the complete resolution of all target lesions, a decrease of 30% or more in the aggregate of the largest diameter of target lesions, or a tumor that remains static.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "7e5fd062-6ec3-480f-ab0e-e117eba2ffe7"
        ]
    },
    "e18d8dd1-90c7-4593-8c59-17517854bc5e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00063570",
        "Statement": "individuals with a confirmed diagnosis of malignant brain tumour can participate in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "62e449ad-16b3-479d-94a5-ffc435b5e99c"
        ]
    },
    "bfa75e20-c00c-4972-af3d-26143eac9f30": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01596751",
        "Statement": "only breast cancer patients with certified progressive disease can participate in the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "bc2024fc-5b39-4fa6-badf-f034d6fe8bb8"
        ]
    },
    "29f1e7e3-a6c2-48b2-a934-f8fb39713c76": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00503906",
        "Statement": "the intervention will be provided to the participants of the primary clinical trial for a total of twelve 28-day cycles",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "6499b181-7a23-4073-8459-ad46ff02b20f"
        ]
    },
    "eff7a08d-5da6-4655-983e-9f47a39b055d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01644890",
        "Statement": "in the first cohort of the primary clinical trial, the pfs dropped to less than three weeks at its lowest.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "961a956e-fece-4baa-a2ad-d3a5320bd9d2"
        ]
    },
    "3d33a556-7656-4981-ae4b-efd82d81222a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "a patient with a node positive t5 n5 m0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of over 19.5cm",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "016943fa-57ea-4293-8131-03292ea1836c"
        ]
    },
    "2f229f47-f349-4575-ac46-4c1a446e25da": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00066573",
        "Statement": "there is a 33/250 difference between the results from the two the primary trial cohorts",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "1adc970c-d433-44d0-aa09-d3834986f7a2"
        ]
    },
    "3fccfd7a-aee6-4486-a0ee-d36f347b38fe": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "in the primary clinical trial, no intervention offered objective benefits to more than 40% of the patients. moreover, the docetaxel then liposomal doxorubicin procedure caused lethal complications for over 86% of the subjects",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "74e376d7-5713-43f3-93f1-9608059c9547"
        ]
    },
    "5c86ed6e-df94-4a70-ba48-0c0459b7685f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00572728",
        "Statement": "only patients who are bedridden or significantly incapacitated can partake in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "62be4676-099f-4c42-8029-773af8fde6f7"
        ]
    },
    "166253b2-c4b6-4cc0-a740-96cc377f2cd2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01998906",
        "Statement": "Both cohorts of the primary trial undergo a total of 17 cycles, each lasting 3 weeks , patients receive the same types and dosages of medication throughout all 17 cycles. extraocular muscle paresis, ctcae is a disorder characterized by incomplete paralysis of an extraocular muscle.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "2a2c16a7-f427-4fdb-8153-94aac304e4b8"
        ]
    },
    "e2b3366d-0fae-4a57-9f52-0b7281ee9928": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Secondary_id": "NCT00121992",
        "Statement": "in the secondary clinical trial, there was only a single case of conjunctivitis compared to 16 cases in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "c100a7cd-e3a2-4901-a3e0-12336f769c7b"
        ]
    },
    "31454bca-826d-4dc3-a38b-da36807de45e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00503750",
        "Secondary_id": "NCT00005879",
        "Statement": "continuous set union data type is a data type comprised of the union of sets of unordered, quantitative values. The results from the secondary trial and the primary trial are non-comparable.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "dca4c9f7-bb2a-4f73-b390-93b7ced87c73"
        ]
    },
    "afe83e7a-d5f1-42d5-8897-21cf5056b1eb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00281697",
        "Statement": "patients with a her2-negative are eligible for the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "43ee7645-ce1e-42d5-9a74-3e379f6f367b"
        ]
    },
    "1e49b17a-3eb8-47bc-abfb-845a1ac57312": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00570921",
        "Statement": "fulvestrant is administered intramuscularly and everolimus is given orally to the participants of the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "45ccd2c8-6e02-4f0f-a370-eed18d26e6dc"
        ]
    },
    "9a6ef64a-5438-4e74-ac63-273adeafe34b": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03012477",
        "Secondary_id": "NCT02419807",
        "Statement": "the primary clinical trial and the secondary clinical trial report their results in absolute numbers using the same units of measure.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "0e609fad-9a28-4fb6-90b6-32a731e3b02c"
        ]
    },
    "3ba2e242-f8b4-426f-8538-e7b647faf77e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00009945",
        "Statement": "untreated childhood pleomorphic xanthoastrocytoma is a finding of pleomorphic xanthoastrocytoma in childhood that has not been treated. none of the individual adverse events in the primary trial affect more than 100 patients.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "1314146f-2869-4525-8034-7f732d238385"
        ]
    },
    "0835673b-9eb5-4769-be12-d36df31bf20a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "in the primary clinical trial, none of the treatments led to an objective benefit for over 40% of the participants. surprisingly, the docetaxel then liposomal doxorubicin procedure resulted in severe complications for more than 86% of the patients",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "74e376d7-5713-43f3-93f1-9608059c9547"
        ]
    },
    "3ca37ea6-7cf5-432b-9fe1-955783937dfe": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00450723",
        "Secondary_id": "NCT00290758",
        "Statement": "Between the secondary trial and the primary trial, all the recorded case of Dyspnea occurred in cohort 1 of the secondary trial. severity three out of four is a severity result of three, on a four level scale.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "f04d9695-81b8-4d70-877b-59caddf901bd"
        ]
    },
    "d038b7a7-1a0f-4d43-9281-60650ccb234b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01912612",
        "Statement": "numerous incidences were reported of congestive heart failure in both cohorts of the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "d1b217ae-76f3-4ba6-958e-5b2558703ba4"
        ]
    },
    "75baebe1-36ea-4333-984b-23325ec80968": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00331630",
        "Statement": "prefer not to hear a lot of details is a question about whether a person would prefer not to hear a lot of details. no cardiac or neural adverse events were recorded in the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "c7dc582a-4a58-4cb5-b980-b2d2b6a128c3"
        ]
    },
    "fe182e72-2b11-479d-85c2-1d3330d0afe6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00374322",
        "Statement": "the primary clinical trial involved administering a placebo intervention to 80% of its patients",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "e147796d-2edd-42d1-ac53-300fb8bd5eb6"
        ]
    },
    "962bcc0e-15ac-452d-b451-ba6f38917541": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Statement": "in the first cohort of the primary clinical trial, no patients reported experiencing adverse events.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "8e91e404-086e-4063-8d54-83d1b8ebd969"
        ]
    },
    "6c1ea896-8cf1-44ff-a3c5-a6681fd2f8a1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Statement": "ongoing flucytosine treatments are necessary for all participants of the primary trial, treatments must have started at least 180 days before study entry",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "565d7982-aa9a-4c01-987c-1d67bc9c212d"
        ]
    },
    "5d0ed4f0-8e5a-4c72-8583-5ad17e5898b4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00328783",
        "Statement": "genetic transcription interpretation is an interpretive summary of the pattern of genetic transcription. The adverse events section in the primary trial is reports the incidence rate of 12 different Aes.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "97fd111c-6969-43ab-93af-b3dff09960e5"
        ]
    },
    "a802ca85-2c93-478f-a935-1e03f10a44a1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00593346",
        "Statement": "the primary trial does not report the PFS or objective response rate of its patient cohort. cardiac teratoma is a teratoma that arises within the myocardium or cardiac chambers.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "cc1f712a-2116-4e40-9810-f315e3fa5ff8"
        ]
    },
    "a35c7261-ebdd-4f9e-b6a6-a1cd0aaebadf": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "with some help is a response indicating that an individual is able to do something only with assistance. the primary trial intervention protocol lasts a total of 14 days.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "236780db-9e59-4dc9-8da0-e786287011cf"
        ]
    },
    "f46a7d27-a94f-4389-a1a0-4a8f5177b354": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02679755",
        "Statement": "None of the individual Aes recorded in the primary trial affect more than than one patient",
        "Label": "Contradiction"
    },
    "1a851d7d-126e-43a5-90d3-19c68e10a718": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT00852930",
        "Statement": "murine monoclonal antibody d612 is a murine monoclonal antibody directed against human colorectal carcinoma-associated cell-surface antigen d612. (nci04) the primary trial and the secondary trial do not record any cardiac or infection related adverse events, but they both record several instances of epilepsy.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "c2217d42-e90c-4ffe-b084-e653b9ace4d5"
        ]
    },
    "e7ba5f6f-5d31-42ed-8386-1c6f53057852": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "all patients in the first cohort of the primary clinical trial exhibited a progression-free survival (pfs) of more than 8.8 months, and the longest pfs was slightly less than 10 months.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "b9e29ea8-6847-40d4-b5c3-81c496101695"
        ]
    },
    "fc1b00a1-dbb5-4a7b-9a26-7206c35f24ed": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290758",
        "Secondary_id": "NCT02370238",
        "Statement": "women receiving endocrine therapy are eligible to participate in the secondary clinical trial, but are excluded from the primary clinical trial even with adjuvant therapy.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "4a41ac73-538a-43e5-b7ce-8c8e2d56286e"
        ]
    },
    "fe33ebc4-34b1-4994-8e97-cba053c90f9f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02419807",
        "Statement": "grade 1 rectal fistula, ctcae is asymptomatic The the primary trial results section reports two different measurements.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "8b91cab9-d858-45f3-bf8d-3d6fc55b4818"
        ]
    },
    "1238f0e9-cbd9-4438-b9dd-f2cbd0839f69": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Secondary_id": "NCT00121992",
        "Statement": "the secondary clinical trial reported a singular case of conjunctivitis, in contrast, the primary clinical trial reported none",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "a5617ae4-05a3-42d0-9e14-141de5f8c010"
        ]
    },
    "01772731-8140-430c-b8c6-3173a599632f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00450723",
        "Secondary_id": "NCT00290758",
        "Statement": "each cohort of the primary and secondary clinical trial recorded an evenly distributed case of dyspnea",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "f04d9695-81b8-4d70-877b-59caddf901bd"
        ]
    },
    "ff3783af-2833-4baf-86d3-19d6456a3ad8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00944047",
        "Statement": "nearly 50% of the primary trial patients in the intervention arm showed pathologic complete response",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "9f7d476e-9db3-4c00-abe6-4c2f0160470a"
        ]
    },
    "3c4fd1d6-0bf4-41f7-a27e-a26bd0cee842": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Secondary_id": "NCT00121992",
        "Statement": "while the secondary clinical trial reported only one instance of conjunctivitis, the primary clinical trial reported as many as 16 cases",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "c100a7cd-e3a2-4901-a3e0-12336f769c7b"
        ]
    },
    "094e2583-02e1-42b4-b8ff-1d292073e05b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01830933",
        "Statement": "benign tracheal neoplasm is a non-metastasizing neoplasm that arises from the trachea. the primary trial and the secondary trial do not report adverse events.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "fb360514-14be-45ab-8b74-ea5a7eb181d7"
        ]
    },
    "5f2287d0-47c9-44b2-b088-ad071bd71f60": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01307891",
        "Statement": "in both sets of the primary clinical trial, a single case of neutropenia was reported",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "a9907a2e-254a-45ca-af50-3e44fd2f7af3"
        ]
    },
    "bf03b4ef-0f26-4f8f-a7ef-711934b68d86": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02131064",
        "Statement": "the primary clinical trial's first cohort recorded more left ventricular dysfunction cases than abdominal pain cases",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "3a0c517d-9b9a-4497-9675-50ff12cd02b7"
        ]
    },
    "dab7b1be-3beb-444c-b918-259149f035f1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Statement": "participants of the primary clinical trial may have started flucytosine treatments less than 6 months before study entry",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "565d7982-aa9a-4c01-987c-1d67bc9c212d"
        ]
    },
    "01416f88-4313-4755-8045-a36de3d8cff4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "patients with no knowledge of their tnbc status and an lvef below 50 percent (%) may partake in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "9abb10d7-496e-44fd-915d-d86aedf6c9b6"
        ]
    },
    "927b9fb5-e993-4e86-b5fe-4adc9b16a18c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "the primary clinical trial carries out an intervention protocol for a duration of 60 days",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "236780db-9e59-4dc9-8da0-e786287011cf"
        ]
    },
    "a8ec6ab5-900c-4445-b8fb-fc041e978b14": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Secondary_id": "NCT00876395",
        "Statement": "the primary clinical trial often results in diarrhoea as the leading adverse event, while the prevalent adverse event witnessed in the secondary clinical trial is anaemia",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "324562e6-2b61-4a07-b937-86f99689f2d5"
        ]
    },
    "30483d7e-7703-459c-bd10-e2bd259c2a4f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01905592",
        "Statement": "there were two types of Adverse events which did not affect any of the patients in cohort 1 of the primary trial",
        "Label": "Entailment"
    },
    "489c6447-a01a-4082-b2c1-7490a600b81c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03012477",
        "Secondary_id": "NCT02419807",
        "Statement": "the primary clinical trial and the secondary clinical trial employ distinct units for the reporting of their results",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "8460a212-8054-4bd2-b4e6-af1d137a2f79"
        ]
    },
    "a5cf30fc-3ca4-4c8b-a58f-dd277d0ead90": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02419807",
        "Statement": "two distinct measurements are reported in the results section of the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "8b91cab9-d858-45f3-bf8d-3d6fc55b4818"
        ]
    },
    "11df86d3-836a-40c7-bce7-9533f7a4b2c0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00450723",
        "Secondary_id": "NCT00290758",
        "Statement": "Between the secondary trial and the primary trial, all the recorded case of Dyspnea occurred in cohort 1 of the secondary trial. metastatic malignant genitourinary system neoplasm is a malignant neoplasm that arises from the genitourinary system and has metastasized to other anatomic sites.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "f04d9695-81b8-4d70-877b-59caddf901bd"
        ]
    },
    "8fb76389-8a33-48b6-bad8-e29dfae760a0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01416389",
        "Statement": "carboplatin/cisplatin/cyclophosphamide regimen is a chemotherapy regimen consisting of carboplatin, cisplatin and cyclophosphamide that may be used in the treatment of ovarian cancer. the primary trial reports the changes in tumor size for patients in its cohorts.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "7cde9a22-a91f-4feb-892d-7cbd35f96a27"
        ]
    },
    "9b3a918d-a513-46b5-b0a8-78ab13f42a79": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT00232505",
        "Statement": "primary clinical trial participants are administered medication via intravenous therapy whereas secondary clinical trial participants receive medication orally",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "7edba90d-076d-4f55-b9d6-a1765ceb48bd"
        ]
    },
    "2a165202-e3b6-4644-9d18-2e13cb0f301b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "the presence of radiographically detected brain metastases does not hinder the eligibility of a patient for the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "a9bb6de9-c6f8-4c99-81cd-f101cbaab387"
        ]
    },
    "65261116-dc86-4e41-b710-6681039d32ae": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "Patients wanting to take part in the primary trial must have a Known and documented TNBC status and an LVEF of at least 50 percent (%). distress over physical problem with getting around is a question about an individual's distress related to their physical problems with getting around.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "9abb10d7-496e-44fd-915d-d86aedf6c9b6"
        ]
    },
    "5a447501-4ff7-4b38-9aae-65e3e4e3cf38": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00425854",
        "Secondary_id": "NCT01224678",
        "Statement": "Patients with significantly low ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or younger . melanocytoma is a benign neoplastic melanocytic proliferation affecting the meninges or the eye.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "d1b7105d-0b7d-4b10-92a7-d63243ff0629"
        ]
    },
    "6d6fe729-f402-421e-a65e-92403d214a4e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "primary clinical trial patients reported a 100% increase in the sum of the longest diameter of target lesions with all tumors actively growing.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "7e5fd062-6ec3-480f-ab0e-e117eba2ffe7"
        ]
    },
    "46b0bf97-c369-43b5-a13e-33fa7621332d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00009945",
        "Statement": "individual adverse events in the primary clinical trial affects a significant percentage of patients, well over 100 cases reported",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "8648c7df-582a-42a9-9330-414b2430ac56"
        ]
    },
    "edaf58b3-5b58-409c-a746-fca252c7ccf0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01042535",
        "Statement": "The most common adverse event in the primary trial was skin infection. primary peritoneal clear cell adenocarcinoma is an extremely rare adenocarcinoma arising from the peritoneum. it is composed of malignant glandular epithelium containing clear cells.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "4f705481-5dd0-414c-b375-c56e8c235b42"
        ]
    },
    "4ac27c9d-c499-45ed-9eab-3fcf7339389b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00593346",
        "Statement": "the primary clinical trial presents comprehensive data on the progression-free survival (pfs) of its participants.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "cc1f712a-2116-4e40-9810-f315e3fa5ff8"
        ]
    },
    "40f699a1-fbc6-40de-8e80-85b28f71632f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02658734",
        "Statement": "Most patients in the primary trial experienced a grade 1 adverse events, the least common severity was grade 5, which only affected 8/70 patients.",
        "Label": "Contradiction"
    },
    "bab2b864-33f2-413e-81b9-4d3daf49d6f1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "in the primary clinical trial, the most frequently occurring adverse event was non-cardiac chest pain, impacting less than five percent of individuals in the first cohort.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "2da13cd4-7189-4f85-be4d-5c1e213ae293"
        ]
    },
    "32ed503c-1cfd-44f6-b8bb-23d9d175d73d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00572728",
        "Statement": "Patients must be able to undergo a PET scan to participate in the primary trial",
        "Label": "Entailment"
    },
    "0dcbaba7-bebf-457a-a915-2a2dba2c59ce": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00477464",
        "Statement": "substantially more doses of capecitabine than lapatinib are administered to the participants of the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "a3390ae6-d41d-4dc7-899e-de9534adfd6b"
        ]
    },
    "ac994a1a-d1eb-4454-8313-21056f8f4c92": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820222",
        "Statement": "in the primary clinical trial, the lapatinib plus capecitabine group had a greater percentage of patients with cns metastases compared to the trastuzumab plus capecitabine group.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "5de9caeb-9dd5-4535-8fe3-289450d9c626"
        ]
    },
    "075813ea-4efb-43c2-8e3c-bda8cad25d74": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02301988",
        "Statement": "ipatasertib is given specifically to patients in the first group of the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "faa65e54-aa04-4595-8dae-05cf00b4c887"
        ]
    },
    "67b346f8-72a3-4e08-966e-c6040add3008": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00450723",
        "Statement": "the primary clinical trial intervention involves multiple drugs administered intravenously and the secondary trial intervention is based on a simple fitness regime.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "f0e845f9-8991-45b5-a520-51e934756f7a"
        ]
    },
    "97fd111c-6969-43ab-93af-b3dff09960e5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00328783",
        "Statement": "The adverse events section in the primary trial is reports the incidence rate of 12 different Aes",
        "Label": "Contradiction"
    },
    "33385c87-b7da-435b-a6db-23e388a46067": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Secondary_id": "NCT00425854",
        "Statement": "the primary clinical trial and the secondary clinical trial both utilize the objective response tool to gauge intervention success, despite differing in their interpretation of what constitutes a complete response",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "8d9f94e3-871b-4fb4-a522-0a73d9d0ec3c"
        ]
    },
    "fc58f5e9-4e70-4baa-a51f-003e2c1d9ebf": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00733408",
        "Statement": "fainting was the most frequently reported adverse event in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "9d8b26d6-d574-4717-88b6-77458bc683f3"
        ]
    },
    "e344c1a0-c3ca-4840-adf4-6c8d0d04838e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "Patients must have no radiographically confirmed metastases to the brain in order to be eligible for the primary trial. fgfr4 gene amplification is a molecular genetic abnormality indicating the presence of multiple copies of the fgfr4 gene.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "a9bb6de9-c6f8-4c99-81cd-f101cbaab387"
        ]
    },
    "53b1a70f-3280-4600-b844-b453189ce384": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "the most common adverse event (ae) in the primary clinical trial was diarrhea, affecting over 15% of participants in cohort 1.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "2da13cd4-7189-4f85-be4d-5c1e213ae293"
        ]
    },
    "8e8d7895-dd22-420b-a3b9-edcdf55de7d1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00357110",
        "Statement": "physical examination sequence number is an identifier that describes the relative position of physical examination data within a series. there were 6 recorded deaths in cohort 1 of the primary trial and 7 in cohort 2.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "f114846e-79d8-4712-add0-bb34b65d418f"
        ]
    },
    "ecd9f728-5b87-4b48-a254-7afb151c89f1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "febrile neutropenia was an extremely rare adverse event, affecting a negligible number of participants in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "614d7ade-0fa7-4d77-bc19-1d3a2f2f48c2"
        ]
    },
    "2dad4fb6-3728-4be7-8617-2ff2cc6ada71": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274469",
        "Statement": "patients diagnosed with hormone receptor positive advanced breast cancer and who have previously undergone chemotherapy for this condition are qualified for the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "2e76c74a-b6dd-47d8-a674-c1e80b0a3a65"
        ]
    },
    "4cca1e9c-74fe-44db-9f65-8def84f9450a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01929395",
        "Statement": "Patients must have a palpable carcinoma to be included in the primary trial. agonist is an agent that has affinity for a receptor and intrinsic activity at that receptor.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "24b85b44-b9e6-4c28-b3aa-1bd97102b7f1"
        ]
    },
    "0d91fedb-25da-4993-82e1-0cf9cab13a6b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02340221",
        "Statement": "the primary clinical trial encourages patients who have been treated with either fulvestrant or a pi3k inhibitor",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "6b35bc10-f591-4b84-abac-40a74be949fa"
        ]
    },
    "3473ddab-e558-49e3-8915-92c3e8f74c75": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Statement": "movement is a change in location or position. neither of the cohorts in the primary trial are required to undergo surgery or receive any oral medication as part of the intervention.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "63a0a9fc-80b9-450f-b2c6-7aee37ce26a9"
        ]
    },
    "a774794f-9027-4f64-a02e-9ca320232335": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00331630",
        "Statement": "no cardiac or neural adverse events were recorded in the primary trial. exposure reference identifier is a character or string used to name, or characterize an exposure reference.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "c7dc582a-4a58-4cb5-b980-b2d2b6a128c3"
        ]
    },
    "87d79377-71b4-46fe-b1fc-24ee3b7664e9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00733408",
        "Statement": "in the primary clinical trial, the most common adverse events were allergic reactions",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "4dfff980-6a2b-4f01-9194-6ec831d6fed7"
        ]
    },
    "56cb82c5-316e-424c-bec6-7a53c1ec2662": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00570921",
        "Statement": "the primary clinical trial demands the administration of fulvestrant and everolimus both through oral ingestion",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "45ccd2c8-6e02-4f0f-a370-eed18d26e6dc"
        ]
    },
    "d76e452d-b88f-402d-aced-89382c3bae4b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00009945",
        "Statement": "none of the individual adverse events in the primary trial affect more than 100 patients, in total less than 30 patients suffer adverse events. life expectancy less than ten years is a response indicating that an individual expects to, or is expected to, live less than ten years.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "8648c7df-582a-42a9-9330-414b2430ac56"
        ]
    },
    "dad96d26-845f-495b-9b32-0925773b1e1a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01011946",
        "Secondary_id": "NCT00066573",
        "Statement": "unlike the secondary trial, which administers treatment orally, the primary trial administers both oral and topical medication to its participants.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "8ddf8b88-6e06-4c71-9e28-45f73a637af0"
        ]
    },
    "0c3248ef-6e06-4808-b141-ffe30be47fa4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00093795",
        "Statement": "ecchymosis indicator is an indication as to whether ecchymosis is present. the majority of participants in cohort 1 and 2 of the primary trial achieved Disease-free Survival for 5 years.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "2729a321-709b-4392-9604-dd7237bedb17"
        ]
    },
    "f3534e0a-e8b3-4fe9-8de5-20317d7149f7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01929395",
        "Statement": "Patients must have several visible carcinomas in the stomach and neck areas to be included in the primary trial. lung myolipoma is a benign tumor of the lung composed of mature adipocytes and smooth muscle cells.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "79ca2ee8-6c9c-40e6-a87c-925b50d3d3d2"
        ]
    },
    "49de43c3-87c1-4f71-96c6-369140fdd99d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01644890",
        "Statement": "a decrease of 1.4 months from average was observed in the shortest progression-free survival in the initial cohort of the primary clinical trial.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "8c6314f7-34f5-42a7-ba66-b95d050a6315"
        ]
    },
    "59785a7a-04bb-40cb-b5fa-59657dcd9744": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01581619",
        "Secondary_id": "NCT00106002",
        "Statement": "the results of the secondary trial and the primary trial are non-comparable. bicalutamide/degarelix regimen is a regimen consisting of bicalutamide and degarelix that can be used for the treatment of prostate cancer.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "0a6d1b4c-244e-44e2-a229-62e4cbdfa979"
        ]
    },
    "fe876bb0-7ce3-4197-81ad-920f1f77938e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00066573",
        "Statement": "there is a minimal difference between the results from the two the primary trial cohorts",
        "Label": "Entailment"
    },
    "831efc33-d45d-4d94-b49b-4aea62552441": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01929395",
        "Statement": "patients presenting visible carcinomas exclusively in the neck area are fit for participation in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "79ca2ee8-6c9c-40e6-a87c-925b50d3d3d2"
        ]
    },
    "6b35bc10-f591-4b84-abac-40a74be949fa": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02340221",
        "Statement": "Prior treatment with fulvestrant or with a phosphatidylinositol 3-kinase (PI3K) inhibitor is not admissible for the primary trial",
        "Label": "Entailment"
    },
    "3facad41-0221-42f8-834d-470e65c4aad5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00428922",
        "Statement": "the outcome measurement of the primary trial is The length of time during and after the treatment that a patient survives with the disease ",
        "Label": "Contradiction"
    },
    "e9e3a747-8ca5-4719-80ce-bc1783e3f074": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00450723",
        "Statement": "a drug taken orally serves as the intervention in the primary clinical trial, whereas for the secondary clinical trial, a medical procedure is the intervention.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "f0e845f9-8991-45b5-a520-51e934756f7a"
        ]
    },
    "d51f9090-e1eb-488f-96d5-7e8827262da9": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Statement": "Patients must have a Life expectancy of at least 1 year to enroll in the primary trial. non-host organism indicator is an indication as to whether the organism is one that is harbored or nourished by another organism.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "618a3ae1-b22c-4c35-86a6-190c1b5b5d21"
        ]
    },
    "c10eea1a-5768-442d-ae07-20b4f8f4b583": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02924883",
        "Statement": "Only patients with triple negative breast cancer are eligible for the primary trial",
        "Label": "Contradiction"
    },
    "1f15398d-f6fb-423a-acb3-bd63d9f3c8fb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00944047",
        "Statement": "under 0.6% of the primary trial patients in the intervention arm experienced pathologic complete response",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "9f7d476e-9db3-4c00-abe6-4c2f0160470a"
        ]
    },
    "d067c99c-135d-453f-9733-d70a3d3da4b1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005879",
        "Statement": "compared to cohort 1, a greater proportion of patients with slipped disks were observed in cohort 2 of the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "e4aeb013-7713-4b73-acbd-f8379cc6a494"
        ]
    },
    "959f9edf-65bb-4939-84e9-98af73a88a44": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00503750",
        "Secondary_id": "NCT00005879",
        "Statement": "the outcomes of primary clinical trial and secondary clinical trial are not comparable.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "dca4c9f7-bb2a-4f73-b390-93b7ced87c73"
        ]
    },
    "ad7039c3-1825-4ef6-887c-7461e3292002": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02131064",
        "Statement": "in cohort 1 of the primary trial there were 10 more cases of Left ventricular dysfunction than Abdominal pain. fairly sure is a subjective answer of agreement regarding the certainty of something.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "1329dec6-fb2c-4219-9db6-3fef9d94b316"
        ]
    },
    "8be1439d-b834-422d-859b-8ab6def8ef3c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00328783",
        "Statement": "part per trillion is a unit of proportion equal to 10e-12. The adverse events section in the primary trial is empty.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "fef5aedb-21c0-4130-b8a3-cb1df5017c7a"
        ]
    },
    "a505e763-c0ab-48ce-a0ea-5a07500c6777": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042938",
        "Statement": "the primary clinical trial omits data on the severity of dermatitis in radiation treatment site for the curcumin c3 complex cohort and the placebo cohort",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "4a15ec5e-4904-4f01-a0a2-c51e83c8c070"
        ]
    },
    "5cd8458b-c476-48a5-9d9b-30b71cfd27b6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Secondary_id": "NCT00876395",
        "Statement": "constipation is the most frequent adverse event in the primary clinical trial, while hypertension is the most common in the secondary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "324562e6-2b61-4a07-b937-86f99689f2d5"
        ]
    },
    "6499b181-7a23-4073-8459-ad46ff02b20f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00503906",
        "Statement": "Participants of the primary trial will receive the intervention for a total of 12 cycles (28 days)",
        "Label": "Contradiction"
    },
    "31cb7e0c-8240-4480-9c8d-220af752ec62": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01644890",
        "Statement": "The shortest PFS in cohort 1 of the primary trial was 1.4 months below average. grade 1 gynecomastia, ctcae is asymptomatic",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "8c6314f7-34f5-42a7-ba66-b95d050a6315"
        ]
    },
    "b9a0960b-8961-4698-a9fc-a2a62af1649c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00331630",
        "Statement": "the primary clinical trial did not document any cardiac or intestinal adverse events.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "553f00ea-5197-4233-b1e0-e5727856b599"
        ]
    },
    "1d436994-dd0e-4527-b040-e0cfc0d86307": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Secondary_id": "NCT00325234",
        "Statement": "the occurrence of holocraneal cephale and catheter-related infections are more frequent in the primary clinical trial compared to the secondary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "9c033072-5f94-4d79-af47-126d531f0d6e"
        ]
    },
    "c0161898-116c-4e7d-a79e-c3d8fb03fc01": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00915603",
        "Statement": "the shortest pfs in cohort 1 of the primary clinical trial exceeded the 7-month mark.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "0cef8c8e-7986-46c7-a597-c5733a9899c0"
        ]
    },
    "a805f174-2707-4302-a195-05153ea8523e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02186015",
        "Statement": "Only adults can take part in the primary trial",
        "Label": "Entailment"
    },
    "fb360514-14be-45ab-8b74-ea5a7eb181d7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01830933",
        "Statement": "the primary trial and the secondary trial do not report adverse events",
        "Label": "Entailment"
    },
    "838e7211-e1ba-44f1-b5ad-8c17b9b34072": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Statement": "the primary clinical trial requires patients to have a minimum expected lifespan of one year for enrollment",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "618a3ae1-b22c-4c35-86a6-190c1b5b5d21"
        ]
    },
    "d59ad80c-2f29-48cf-81ed-2aa5f26c1b48": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01118624",
        "Statement": "participants in the primary clinical trial receive pralatrexate doses calculated based on age rather than bodyweight.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "0ddb07ae-6e70-436d-8723-f609e59c57da"
        ]
    },
    "b0214345-3119-4a70-8861-dee190823231": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "lung myoepithelial carcinoma is a very rare malignant lung tumor with myoepithelial differentiation. All patients in cohort 1 of the primary trial had a PFS of over 7 months, with the highest PFS being just under 10 months.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "b8eaa8fd-61cf-4ca9-aaec-267d61c1fae3"
        ]
    },
    "d35f688d-d7a6-4e85-9b40-4942ea678e4d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00357110",
        "Statement": "there were no recorded deaths in the primary trial cohorts. non-neoplastic disorder is any disorder other than abnormal tissue growth resulting from uncontrolled cell proliferation.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "751fd763-89fa-4d52-8bda-f09b490a5e78"
        ]
    },
    "ee0385c0-d3c0-445f-8c29-5a69e2e162ce": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01224678",
        "Secondary_id": "NCT01042535",
        "Statement": "mental health disorders, pleuropericarditis, atrial thrombosis and anemia cases occurred in higher frequencies in the secondary clinical trial as opposed to the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "57b2ae97-0d1d-4d5d-bc4b-109e8e5acb32"
        ]
    },
    "872f51b1-872d-4941-ba34-ce1e0573aa23": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01644890",
        "Statement": "for cohort 1, the primary clinical trial registered minimal pfs durations of over a quarter-year.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "961a956e-fece-4baa-a2ad-d3a5320bd9d2"
        ]
    },
    "422abc1a-09fb-4f44-8971-f7ba0dde1f1d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00376597",
        "Statement": "the primary clinical trial does not permit the inclusion of patients diagnosed with stage 4 cancer",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "75a65913-5655-4377-b441-ecdd4dd75175"
        ]
    },
    "8dd79b8a-ca3d-47b0-b873-c8a40163f522": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01118624",
        "Statement": "in the primary clinical trial, participants receive pralatrexate doses adjusted according to their individual body weight",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "0ddb07ae-6e70-436d-8723-f609e59c57da"
        ]
    },
    "59160196-5456-41ae-b62f-ac6a4139b461": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01929395",
        "Statement": "to be eligible for the primary clinical trial, patients need to have several noticeable carcinomas in both the stomach and neck regions.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "79ca2ee8-6c9c-40e6-a87c-925b50d3d3d2"
        ]
    },
    "7a342a35-aa53-42b5-9d62-e143720b4e2c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00450723",
        "Statement": "The the primary trial intervention involves one drug taken orally and the secondary trial intervention is based on a medical procedure. neisseria gonorrhoeae, beta-lactamase positive is any bacterial species identified as neisseria gonorrhoeae that produces the enzyme beta-lactamase.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "d310ec4e-993e-4827-8dc5-9aca053972db"
        ]
    },
    "0e0a29a0-f029-4f58-922e-76a0893d5e8c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "dart device is a pointed missile which on contact with an animal delivers its medicinal content. All patients in cohort 1 of the primary trial had a PFS of over 8.8 months, with the highest PFS being just under 10 months.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "b9e29ea8-6847-40d4-b5c3-81c496101695"
        ]
    },
    "bd82826d-f8fb-42b1-96cc-e6b3d3cf5b83": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02186015",
        "Statement": "used medications or devices to aid or improve erections is a question about whether an individual uses or used medications or devices to aid or improve erections. Only adults can take part in the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "a805f174-2707-4302-a195-05153ea8523e"
        ]
    },
    "fbfa0f55-b037-43ed-a47d-7672935ce37b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Statement": "patients accepted into the primary clinical trial who are currently pregnant have never had a previous treatment for breast cancer",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "b1d28450-fc7d-496a-9c7c-bf711b28f8e4"
        ]
    },
    "1b232f4a-c724-44e3-b2fe-712ab8cb6fe4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Statement": "flucytosine therapy is restricted for individuals participating in the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "f10f3b84-e039-4a02-a98b-86d149d9a16f"
        ]
    },
    "3670d2eb-1a85-4fbe-8969-59915b1e1ded": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02419807",
        "Statement": "the primary clinical trial results section reports only one measurement",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "8b91cab9-d858-45f3-bf8d-3d6fc55b4818"
        ]
    },
    "490ce8de-cd39-4e74-9fa1-b6b1570e4ce9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00733408",
        "Statement": "appendix neuroendocrine tumor pm1a tnm finding v8 is appendix neuroendocrine tumor with metastasis confined to liver. (from ajcc 8th ed.) Infections were the most common adverse events recorded in the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "4dfff980-6a2b-4f01-9194-6ec831d6fed7"
        ]
    },
    "48f516ff-abb4-4312-9b00-02f53fb16218": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00944047",
        "Statement": "under a quater of the primary trial patients in the intervention arm experienced Pathologic Complete Response",
        "Label": "Contradiction"
    },
    "772b08d0-2a3b-4006-ab44-cd1b5063e2df": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02186015",
        "Statement": "just children may engage in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "2825d63b-8f22-4fb8-829f-9567845251c6"
        ]
    },
    "72b1eadb-7ff3-4dea-8bff-ffdd200b04b5": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01262027",
        "Secondary_id": "NCT02301988",
        "Statement": "the primary trial and the secondary trial use identical outcome measurements. secondary osteosarcoma is an osteosarcoma arising from a pre-existing lesion of the bone, usually paget disease, or due to radiation therapy.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "f2275929-7cfe-4bb1-a9f6-6bd0c4d5bf85"
        ]
    },
    "6decfdf8-f0a0-4a8f-a2a4-2a3ca99beace": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00066573",
        "Statement": "there is a slight disparity in the outcomes between the two cohorts of the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "fe876bb0-7ce3-4197-81ad-920f1f77938e"
        ]
    },
    "b90763b7-585b-4190-835d-799fdf776887": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02301988",
        "Statement": "primary clinical trial's cohort 1 patients are given more intense ipatasertib and placebo doses in contrast to patients in cohort 2",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "973f090a-8967-4d75-bb8e-6166c868337c"
        ]
    },
    "8d9f94e3-871b-4fb4-a522-0a73d9d0ec3c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Secondary_id": "NCT00425854",
        "Statement": "the secondary trial and the primary trial use Objective Response as the outcome measurement for their interventions, however they use different definitions of complete response ",
        "Label": "Contradiction"
    },
    "862530bf-a613-49dc-890e-fc6a5275ce4f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00425854",
        "Secondary_id": "NCT01224678",
        "Statement": "patients with significantly elevated ejection fraction are included in the primary trial, but can still be ineligible for the secondary trial if they are 85 years of age or over",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "6b9162d0-0816-46d4-81af-c60028dcc63b"
        ]
    },
    "245270f1-8bd2-426d-9fe3-06ce001b78bf": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Statement": "adverse events were experienced by only 6 out of 67 patients in cohort 1 of the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "29b2fa29-5a76-4877-95bb-1a8de7973d33"
        ]
    },
    "a61f2d3d-141c-40db-9032-be488c7fd52d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03012477",
        "Secondary_id": "NCT02419807",
        "Statement": "the primary and secondary clinical trials detail their outcomes as percentages, but they apply different units for measurement.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "0e609fad-9a28-4fb6-90b6-32a731e3b02c"
        ]
    },
    "f3eb153a-f262-4a5e-afc0-6fc515b96a7b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01307891",
        "Statement": "box is a square or rectangular vessel, usually made of cardboard or plastic. There was one case of  Neutropenia in both cohorts of the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "a9907a2e-254a-45ca-af50-3e44fd2f7af3"
        ]
    },
    "8e9611fc-89f8-44cb-af09-8d71a13ca082": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02915744",
        "Statement": "Cohort 1 and 2 of the primary trial do not receive the same intervention",
        "Label": "Entailment"
    },
    "8478198c-9320-4064-95e7-f7fbae65e0d2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02915744",
        "Statement": "in the primary clinical trial, cohorts 1 and 2 are not administered with nktr-102 through infusion",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "4309860d-042d-45a4-8a0a-a9fdd075247a"
        ]
    },
    "bdc0f8c2-3117-45b7-9910-c3bd900f30ad": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "in the primary clinical trial, the most prevalent ae was fatigue, reported by more than 10% of participants in cohort 1.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "2da13cd4-7189-4f85-be4d-5c1e213ae293"
        ]
    },
    "eb5d4efb-b0db-4afa-a84f-ad4591c80b8d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00570921",
        "Statement": "primary clinical trial participants are administered everolimus through iv infusion and fulvestrant as a subcutaneous injection.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "32361e21-ee57-4c34-9390-833ba5048a10"
        ]
    },
    "9ec12f7b-5473-47d0-83d4-4164b0ad7bb2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "all the patients in the primary clinical trial experienced a growth in their tumor size.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "7e5fd062-6ec3-480f-ab0e-e117eba2ffe7"
        ]
    },
    "265f801e-3c72-48f7-9164-c618ab17cf45": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Secondary_id": "NCT00325234",
        "Statement": "There are more cases of Urosepsis in the primary trial than in the secondary trial. confident am able to successfully handle life situations since having breast cancer is a question about whether an individual feels confident that they can successfully handle life situations since having breast cancer.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "7271e0db-bb82-423f-ad95-5ffa84fab97e"
        ]
    },
    "e6084278-3c40-4e14-a79f-b6ab817feb3a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02679755",
        "Statement": "none of the individual aes recorded in the primary trial affect more than 1/100th of the population.",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "c09fa61c-967a-40ae-96b0-c87b7cde237b"
        ]
    },
    "9b2f2560-5c85-4b10-bb20-7d082e6a87a2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00450723",
        "Statement": "the primary trial utilizes a single drug taken via iv and the intervention for the secondary trial entails administration of two oral drugs.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "d310ec4e-993e-4827-8dc5-9aca053972db"
        ]
    },
    "6436ac40-ec12-498a-81a9-72a39ddff8a8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00450723",
        "Statement": "have energy is a question about whether an individual has or had energy. The the primary trial intervention involves one drug taken orally and the secondary trial intervention is based on a medical procedure.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "f0e845f9-8991-45b5-a520-51e934756f7a"
        ]
    },
    "e9d93ff6-cc1b-45fe-bbf1-240e2dfd44d5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Statement": "have embarrassment due to problem with teeth, denture or mouth is a question about whether an individual has or had embarrassment due to problems with their teeth, denture or mouth. over 1/6 patients in cohort 1 of the primary trial suffered adverse events.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "8e91e404-086e-4063-8d54-83d1b8ebd969"
        ]
    },
    "4d09ccc6-21f4-4062-8100-fa4637388bc5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03098550",
        "Statement": "in the primary clinical trial, varying interventions are assigned to each of the study's cohorts",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "b0b61978-57db-4a1c-812c-509e8b05f2dc"
        ]
    },
    "09aa378e-9c0b-4e70-bdb3-822b8738cad6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "neither of the interventions in the primary trial resulted in an objective benefit for more than 60% of patients, in less than 1% of patients receiving the docetaxel then liposomal doxorubicin intervention suffered fatal complications",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "74e376d7-5713-43f3-93f1-9608059c9547"
        ]
    },
    "daf5eefd-90d8-45b8-8ad8-64544d6a82d3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "presence of hot flashes for 160 months prior to study registration is required for all patients that want to participate in the primary trial, but not necessary for entry to the secondary trial.",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "31105b43-832b-48bc-a78d-ee90c155ca44"
        ]
    },
    "4ba27afb-a2ef-4947-ad84-61b4c26c02e3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01042535",
        "Statement": "constipation was reported as the rarest side effect in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "16c29502-4683-4087-9410-ff1b786556f5"
        ]
    },
    "e1464641-f8bf-440a-80bc-0715c0462923": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00503906",
        "Statement": "the intervention for the participants of the primary clinical trial will not be limited to specific cycles but will proceed until the disease shows progression",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "59cd7909-00c3-4c23-9a08-a42dbc8eabdd"
        ]
    },
    "7c2f8f55-8cc0-421b-ace7-32542af9de0c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "the primary clinical trial documented that anemia, not febrile neutropenia, was the most prevalent adverse event",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "1842904b-5371-49ee-b6f4-8831b879098b"
        ]
    },
    "8648c7df-582a-42a9-9330-414b2430ac56": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00009945",
        "Statement": "none of the individual adverse events in the primary trial affect more than 100 patients, in total less than 30 patients suffer adverse events",
        "Label": "Contradiction"
    },
    "3b7f5f23-d787-4fb8-b509-deed9864c5c4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Secondary_id": "NCT01439945",
        "Statement": "in the secondary clinical trial, the occurrence of diarrhea has been reported in a single case, whereas no such cases have been reported in the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "bebfc78e-b35f-4677-8342-9567a7e795a1"
        ]
    },
    "0135db38-9d6e-4bec-b7e5-3f93b565955d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "to be eligible for the primary trial candidates must be over the age of 1.5 decades, have a severe disability and adequate hepatic, renal and heart functions aswell as adequate hematology levels.",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "f45ff82d-e0f5-456a-9d78-ddc2dc6ab929"
        ]
    },
    "b9532979-c6b7-4801-a3a5-740ee08ee798": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01307891",
        "Statement": "both cohorts of the primary clinical trial were completely free from any instances of neutropenia.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "734423d5-4b47-4448-ab98-811015d626f0"
        ]
    },
    "4e903870-0f82-4040-b559-11833188e8fc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00263588",
        "Statement": "patients with her2+ breast cancer can be included in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "215a5c4a-d90c-4500-8284-0679ce311734"
        ]
    },
    "6ea92ec3-cd44-476a-8159-f6e8a99ebabf": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01125566",
        "Statement": "active comparator arm is an arm describing the active comparator. ECOG score < 2 is necessary to be eligible for the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "7137dec6-5c98-4156-8035-7bbaaf0b649d"
        ]
    },
    "d477db90-ddde-4103-bbf6-f2926681ba6d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Secondary_id": "NCT00281697",
        "Statement": "most participants in the secondary trial and the primary trial did not suffer from Enterocolitis. progesterone receptor positive by immunohistochemistry 71-80 percent is an immunohistochemical staining finding indicating that 71-80 percent of the cells in a tissue sample are expressing progesterone receptor.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "2ef186d0-b4ab-44de-b785-a63e9e95851a"
        ]
    },
    "05d2cbee-a4b6-4861-af37-79e3258245da": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00066573",
        "Statement": "there is a minimal difference between the results from the two the primary trial cohorts. grade 2 bladder spasm, ctcae is antispasmodics indicated",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "fe876bb0-7ce3-4197-81ad-920f1f77938e"
        ]
    },
    "b95e34a1-9b7e-410f-802d-749eabc44168": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01929395",
        "Statement": "primary clinical trial accepts patients who do not have palpable tumors",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "24b85b44-b9e6-4c28-b3aa-1bd97102b7f1"
        ]
    },
    "d7c5e876-4a58-4936-ad8f-e0dbc3c81bac": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Secondary_id": "NCT00121992",
        "Statement": "urine output decreased, ctcae is a finding based on test results that indicate urine production is less relative to previous output. the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial reported 16.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "c100a7cd-e3a2-4901-a3e0-12336f769c7b"
        ]
    },
    "5c9cff55-63fb-4fe3-911a-3fd8d7b96fee": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "neither of the interventions in the primary trial resulted in an objective benefit for more than 1/10 patients.",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "75affd49-4905-4d43-9a5c-ef795281bac4"
        ]
    },
    "0046027c-5d00-4cfd-9dad-79f9d8889c3d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01644890",
        "Statement": "grow spiritually is a question about how often a person thought about growing spiritually. The shortest PFS in cohort 1 of the primary trial was less than 3 weeks.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "961a956e-fece-4baa-a2ad-d3a5320bd9d2"
        ]
    },
    "e4e693c9-5ab4-433f-a690-f85939681fd1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Secondary_id": "NCT01644890",
        "Statement": "the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures PFS. extracardiac rhabdomyoma is a benign mesenchymal neoplasm that shows mature skeletal muscle differentiation.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "794269ca-e7ec-4a65-ace5-b0f24a8cdc15"
        ]
    },
    "d1aacd05-348e-4bf7-9a04-6c23a52f5e16": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "anaplasia descriptor is a word or phrase that describes the type or extent of anaplasia found during a histopathologic exam. Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting most patients in the trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "614d7ade-0fa7-4d77-bc19-1d3a2f2f48c2"
        ]
    },
    "a7b21fab-0972-4063-9ed7-59b48a26fc54": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03098550",
        "Statement": "both cohorts of the primary trial receive identical interventions, the difference between the two cohorts is the types of cancer that the patients have. prostate cancer by whitmore-jewett stage is a term that refers to the staging of prostate carcinoma according to the whitmore-jewett staging system.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "b0b61978-57db-4a1c-812c-509e8b05f2dc"
        ]
    },
    "b389a17a-d61e-493e-8466-cc79cd20669e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02915744",
        "Statement": "the secondary clinical trial documents the overall survival (os) of patients in its researched groups.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "dc4c57b0-8c75-494e-81b0-3528df85ebff"
        ]
    },
    "b90aeda1-5ff3-4873-b945-a64037872b54": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "the primary trial intervention protocol lasts a total of 14 days. increased mitotic activity is an increase in the frequency of mitotic activity.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "236780db-9e59-4dc9-8da0-e786287011cf"
        ]
    },
    "4d6e984e-c572-4243-bdd3-17a64acbda53": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00593346",
        "Statement": "the primary trial does not report the PFS or objective response rate of its patient cohort, instead reporting the proportion of patients which experience dermatitis. smoothened antagonist is any agent that is an antagonist at the smoothened (smo) receptor.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "88668508-dfd4-4a39-91cd-cf1654a6dfc4"
        ]
    },
    "cd429536-2de4-4700-9e70-3161b512699a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01912612",
        "Statement": "several cases of congestive heart failure in the primary trial occurred in cohort 1, but none in cohort 2. several days is a subjective response indicating that something is true or present several days.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "d1b217ae-76f3-4ba6-958e-5b2558703ba4"
        ]
    },
    "700ae2b6-dad2-4f7e-a230-28e961ef6c2a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00606931",
        "Statement": "unit of tissue culture infective dose is a unit for measuring infectious activity of biologic product such as vaccine or pathogen defined in tissue culture assay. There is no adverse events section in the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "21611c2a-e6eb-4012-a209-9b6781e1f260"
        ]
    },
    "01c57dfa-a2e0-4ae9-9fb0-1db8e2352e9d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290758",
        "Secondary_id": "NCT02370238",
        "Statement": "procedure agents link group identifier is a sequence of characters used to link multiple procedure agents records to a single finding. Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "5d0ccb93-71ec-4079-92c6-d7cbf951a7bb"
        ]
    },
    "18c9f187-5d51-42d3-9e4a-f630b4c4ce87": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Statement": "anaplastic brain stem glioma is an anaplastic glioma that arises from the brain stem. all patients accepted into the primary trial have undergone Prior treatment for breast cancer with endocrine therapy.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "6d621974-c719-46df-8a50-d94e49583e33"
        ]
    },
    "3734c72c-0ff3-4e40-9c37-46cda9db3ef9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "no intervention in the primary clinical trial was able to deliver objective benefit to more than 40% of the patients.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "75affd49-4905-4d43-9a5c-ef795281bac4"
        ]
    },
    "b8eaa8fd-61cf-4ca9-aaec-267d61c1fae3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "All patients in cohort 1 of the primary trial had a PFS of over 7 months, with the highest PFS being just under 10 months",
        "Label": "Entailment"
    },
    "44dcf0bf-1ebb-4e7f-89d7-35a549e37093": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00357110",
        "Statement": "participant deaths were duly recorded within the primary clinical trial cohorts.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "751fd763-89fa-4d52-8bda-f09b490a5e78"
        ]
    },
    "f7de9b19-5ff1-4fb4-87c0-dd3b53d9e1b9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "the primary trial intervention protocol lasts a total of 3 weeks",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "236780db-9e59-4dc9-8da0-e786287011cf"
        ]
    },
    "02654706-3bcf-4b51-89d4-0b341eb858cf": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01118624",
        "Statement": "the primary trial participants recieve less than 0.3g/m^2 doses of pralatrexate",
        "Label": "Entailment",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "e9a4bd91-f58b-4234-9037-75e0699d1bbd"
        ]
    },
    "62be4676-099f-4c42-8029-773af8fde6f7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00572728",
        "Statement": "Patients must be bedbound or severaly disabled to participate in the primary trial",
        "Label": "Contradiction"
    },
    "3b4f95d3-fffc-4935-a1c1-e9b0c407ec61": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT00232505",
        "Statement": "the primary trial and the secondary trial participants do not receive any medication by IV. lead study agent is a primary medical product, practice, or application that is tested in a multi-agent clinical study.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "7edba90d-076d-4f55-b9d6-a1765ceb48bd"
        ]
    },
    "5d3cc9e5-0c31-4eca-b66d-f01ce68cbe7e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00944047",
        "Statement": "no patients in the intervention arm of the primary clinical trial experienced pathologic complete response",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "48f516ff-abb4-4312-9b00-02f53fb16218"
        ]
    },
    "1590679e-c5fd-48d4-9d3c-e7d75b6d52bc": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00900627",
        "Statement": "50% of cohort 2 patients in the primary trial suffered Keratitis. lapatinib/temozolomide regimen is a regimen consisting of lapatinib and temozolomide that can be used for the treatment of recurrent ependymoma.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "09fc4356-6154-427e-b710-ed5df6470aff"
        ]
    },
    "fc009915-ec76-4ecd-857f-61c1d8d083dc": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02679755",
        "Statement": "None of the individual Aes recorded in the primary trial affect more than 10% of the population. promis short form-social isolation-4a is a patient reported outcomes measure that assesses perceptions of being avoided, excluded, detached, disconnected from, or unknown by, others.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "c09fa61c-967a-40ae-96b0-c87b7cde237b"
        ]
    },
    "3e2a31c9-938c-4b20-a6a4-90ac9b98817f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00570921",
        "Statement": "the primary trial participants are administered Fulvestrant intramuscularly and Everolimus orally. regimen used to treat malignant peritoneal neoplasm is any regimen that can be used for the treatment of malignant peritoneal  neoplasm.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "45ccd2c8-6e02-4f0f-a370-eed18d26e6dc"
        ]
    },
    "458d4882-9369-420b-b1f1-3b7b312adb7e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00127933",
        "Statement": "32-year-old alex is not considered for the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "a792bbac-0e8a-4bf7-9cc5-56fad481e2fb"
        ]
    },
    "06fad978-1dc3-46f5-b45f-5ac6577f28b9": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Secondary_id": "NCT00274469",
        "Statement": "Patients must be female and have confirmed advanced colon cancer to be eligible for the secondary trial and the primary trial",
        "Label": "Contradiction"
    },
    "8c38b523-dc13-46e9-9567-13b8af78930d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02924883",
        "Statement": "oral gel dosage form is a gel intended for administration through the mouth. Only patients with HER2+ve breast cancer are eligible for the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "446f3c69-0de5-475c-a8e2-ff40ece90672"
        ]
    },
    "ab0138f6-cfcb-4c63-adb2-ecb6a120e33b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "candidates with an age over 18, a karnofsky score higher than 80, and suitable hepatic, renal, and cardiac functions, along with proper hematology levels are eligible for the primary clinical trial.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "7c7418d2-32d7-4517-874b-eb3db24ea16a"
        ]
    },
    "616bd76b-4502-4ee4-9580-aaf7c4cf553f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00357110",
        "Statement": "there were no recorded deaths in cohort 1 of the primary clinical trial and 10 in cohort 2.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "f114846e-79d8-4712-add0-bb34b65d418f"
        ]
    },
    "2c511a70-6d5a-4679-9668-320eac5a268a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290758",
        "Secondary_id": "NCT02370238",
        "Statement": "women undergoing endocrine therapy are eligible for the secondary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "5d0ccb93-71ec-4079-92c6-d7cbf951a7bb"
        ]
    },
    "bd9b1c5a-2c2f-410c-abd1-1d5ac995ebdc": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042938",
        "Statement": "the primary trial does not contain any information regarding the severity of dermatitis in radiation treatment site for both the curcumin c3 complex cohort and the placebo cohort",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "4a15ec5e-4904-4f01-a0a2-c51e83c8c070"
        ]
    },
    "57f53185-8bae-4e6e-8282-7c99a50bcae4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Secondary_id": "NCT01439945",
        "Statement": "There is only one case of Diarrhea in the secondary trial and over 14 different types of Aes recorded in the primary trial cohorts. spinal cord fissure is any of the grooves on in the spinal cord.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "4519d1cf-7f78-4aa8-85d6-ac94f7eb75a3"
        ]
    },
    "ea7e613c-39e7-4b58-bde5-fb5322c602d3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00357110",
        "Statement": "there were no recorded deaths in the primary trial cohorts. assessment of survivor concerns is a brief questionnaire designed to measure fears about recurrence and health in cancer survivors.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "751fd763-89fa-4d52-8bda-f09b490a5e78"
        ]
    },
    "4aa33f45-4b26-4327-a5eb-1ec51659341b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01596751",
        "Statement": "to participate in the primary clinical trial, patients must have evidence of progressing breast cancer",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "bc2024fc-5b39-4fa6-badf-f034d6fe8bb8"
        ]
    },
    "618b0ed2-7e40-4151-bc92-9fb4f24bfa18": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "atients wanting to take part in the primary trial must have a known and documented her2+ status and an lvef of at least 75 percent (%)",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "6b33b4ae-36f2-4a53-a954-6f246f6e023d"
        ]
    },
    "3d6d7f29-7648-4050-ba94-674644c581c0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Statement": "ongoing flucytosine treatments are necessary for all participants of the primary trial, treatments must have started at least 36 months before study entry",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "565d7982-aa9a-4c01-987c-1d67bc9c212d"
        ]
    },
    "c66bcac4-87e0-4a60-b775-28c8d54c9e21": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00333775",
        "Statement": "the two cohorts involved in the primary clinical trial are administered the same dosage of docetaxel. however, cohort 1 is also given 100 mg/m^2 of placebo.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "a5e388b9-da3c-437e-a6af-7ba76ad8bf1d"
        ]
    },
    "15dd723f-9f8a-4c1f-8ee4-88d5e25c7bf8": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT02340221",
        "Statement": "the metrics used to assess the outcomes of the primary and secondary clinical trials are different and cannot be directly compared",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "2a03c17f-3afe-40f1-a0db-4b876ee8c700"
        ]
    },
    "f7512adf-900e-4ce7-8225-bd20af939b60": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00900627",
        "Statement": "50% of cohort 2 patients in the primary trial suffered  Dose Limiting Toxicities . encounter due to occupational exposure to vibration is an icd encounter due to occupational exposure to vibration.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "1f6a14ae-e22b-4b40-b389-217570dbf38e"
        ]
    },
    "87a6f5eb-0c9e-47fc-8476-c2292f68635d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01042535",
        "Statement": "the primary clinical trial most commonly resulted in adverse events of blood clots",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "4f705481-5dd0-414c-b375-c56e8c235b42"
        ]
    },
    "b89c5116-25d8-4650-b623-077e1784e773": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00733408",
        "Statement": "the most prevalent adverse event reported in the primary clinical trial was dizziness",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "9d8b26d6-d574-4717-88b6-77458bc683f3"
        ]
    },
    "8f0501fc-9294-42a4-b785-560d1cb6d922": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00450723",
        "Secondary_id": "NCT00290758",
        "Statement": "whereas all instances of dyspnea were documented in cohort 1 of the secondary trial, the primary trial recorded no such cases",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "f04d9695-81b8-4d70-877b-59caddf901bd"
        ]
    },
    "6b9162d0-0816-46d4-81af-c60028dcc63b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00425854",
        "Secondary_id": "NCT01224678",
        "Statement": "Patients with significantly elevated ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or over",
        "Label": "Contradiction"
    },
    "f333104e-11f4-4d48-93d7-eb5b152e150c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "all participants within cohort 1 of the primary clinical trial showed a pfs that did not surpass 8.8 months, the maximum pfs capped at 8.7 months.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "b9e29ea8-6847-40d4-b5c3-81c496101695"
        ]
    },
    "470186be-c645-4e46-b531-a6236b285789": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274469",
        "Statement": "the primary clinical trial accepts patients diagnosed with hormone receptor positive advanced breast cancer, but without any prior chemotherapy treatment.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "2e76c74a-b6dd-47d8-a674-c1e80b0a3a65"
        ]
    },
    "38c15b50-04b0-42f5-aab3-e971b42b1327": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "a patient with a node positive t10 n4 m0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of 8cm",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "e6a4e9a6-56b8-4a30-9743-eb02688c090f"
        ]
    },
    "78f2300f-ef57-4ee6-9c57-45794f913b2b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Statement": "feel tired is a question about whether an individual feels or felt tired. ongoing flucytosine treatments are necessary for all participants of the primary trial, treatments must have started at least 6 months before study entry.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "565d7982-aa9a-4c01-987c-1d67bc9c212d"
        ]
    },
    "2e917273-a15e-4804-917f-d96b5b65aa4c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "the total count of adverse events (aes) was equal in both cohort 1 and cohort 2 of the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "1c4e3fe3-b5fe-4ea3-8d9e-0ce1502080e7"
        ]
    },
    "33e1ff47-d417-4b30-b3ee-b75281c2e548": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01307891",
        "Statement": "one instance of neutropenia was observed in both groups of the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "a9907a2e-254a-45ca-af50-3e44fd2f7af3"
        ]
    },
    "b3d019b0-76d3-4728-9191-af028ca4c4b3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00450723",
        "Secondary_id": "NCT00290758",
        "Statement": "there were no recorded cases of musculoskeletal adverse events in the secondary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "f3cb9150-32c6-4877-9a87-4fac45a24948"
        ]
    },
    "90cd3559-2fd4-4c61-a863-17fa756124e9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "in the primary clinical trial, 90% of patients that underwent interventions experienced marked improvement, with the docetaxel then liposomal doxorubicin intervention showing non-fatal complications.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "74e376d7-5713-43f3-93f1-9608059c9547"
        ]
    },
    "9c5d7931-ec1b-48cf-ab0a-5684c1a14743": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00022516",
        "Statement": "only t2, n1 or m1 patients are allowed to join the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "978d19fc-e7f6-485e-b8bd-cfcde06441ab"
        ]
    },
    "baee8562-5996-45e1-a697-bf7ec9e53af8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00022516",
        "Statement": "the primary clinical trial is available to patients who have been diagnosed as t1 n0 m0",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "978d19fc-e7f6-485e-b8bd-cfcde06441ab"
        ]
    },
    "4765c688-8462-4f06-9519-2d31cf18924e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00022516",
        "Statement": "t1 n0 m0 patients are eligible for the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "4a75574c-fa86-4e62-a210-81c7b98a3807"
        ]
    },
    "58181cdf-90d7-4783-b4f8-16e1e89bcfcf": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Secondary_id": "NCT01644890",
        "Statement": "the primary trial measures the overall quality of life of its cohorts, while the secondary trial assesses the duration of stable disease",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "794269ca-e7ec-4a65-ace5-b0f24a8cdc15"
        ]
    },
    "c0a62e1e-32c8-44cc-b845-42b9a307d634": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00856492",
        "Secondary_id": "NCT00009945",
        "Statement": "both the primary and secondary clinical trials assess the life quality and performance status of their patients, no reference is made to pcr or tumor diameter.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "70677d5f-7022-404c-8410-d1f89366d92f"
        ]
    },
    "66a98ab9-6c20-4c50-8f9b-a6e99aedc082": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "pediatric surgery is a surgical specialty that focuses on surgical treatment of diseases of children. Patients must have no radiographically confirmed metastases to the brain in order to be eligible for the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "a9bb6de9-c6f8-4c99-81cd-f101cbaab387"
        ]
    },
    "dcc15aa2-f5f5-46ad-929d-b594de755b35": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "the secondary clinical trial demands the presence of hot flashes for a minimum of 30 days before study registration, while the primary clinical trial doesn't have such a prerequisite.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "31105b43-832b-48bc-a78d-ee90c155ca44"
        ]
    },
    "13f47a0d-5e54-492e-8581-66d8108235bd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "every participant of the primary clinical trial resulted in the complete disappearance of target lesions, reduction by 30% or more in the sum of the longest diameter of target lesions, or stable disease condition.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "7e5fd062-6ec3-480f-ab0e-e117eba2ffe7"
        ]
    },
    "6f74c0bc-b66b-4473-abb6-74eaafdac976": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005879",
        "Statement": "there was a significantly higher percentage of patients with slipped disks in cohort 2 of the primary trial than in cohort 1. myocardial neoplasm is a benign or malignant neoplasm that affects the myocardium.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "ce8464bd-951e-44aa-97d9-10b917b055ce"
        ]
    },
    "8a441ea1-a1a6-43f7-bd22-9a2e7017b4c6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "a patient with a node positive t4 n0 m1 carcinoma of the prostate is eligible for the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "e6a4e9a6-56b8-4a30-9743-eb02688c090f"
        ]
    },
    "dc5b3afc-b776-4fe3-86c0-6eac1ecdb687": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Secondary_id": "NCT03098550",
        "Statement": "participants in the primary clinical trial are confirmed to have stage 3 invasive breast cancer cytologically, while the secondary clinical trial does not impose any particular cancer stage requirement.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "7f3fe97e-68ee-470f-b06e-21cdddb67aa8"
        ]
    },
    "833cd1aa-0a37-4be0-9d5a-4dc753f160bf": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02915744",
        "Statement": "Cohort 1 and 2 of the primary trial do not receive the same intervention. one activity hour is a response indicating that one hour (60 minutes) was spent on an activity.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "8e9611fc-89f8-44cb-af09-8d71a13ca082"
        ]
    },
    "9b6a82e2-3288-4641-8080-24cc894f31ce": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00376597",
        "Statement": "participants suffering from stage 4 cancer are barred from the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "75a65913-5655-4377-b441-ecdd4dd75175"
        ]
    },
    "e9bc190b-2751-46c3-a428-bf97e8c545b2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02915744",
        "Statement": "Cohort 1 and 2 of the primary trial do not receive NKTR-102 by infusion. 14q24 is a chromosome band present on 14q",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "4309860d-042d-45a4-8a0a-a9fdd075247a"
        ]
    },
    "9870ea6e-7a76-4999-b486-57549f0f7cfe": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting most patients in the trial. did you cough up blood is a question about whether an individual coughed up blood.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "614d7ade-0fa7-4d77-bc19-1d3a2f2f48c2"
        ]
    },
    "0e4e8e96-c11e-47e0-b2a4-83455e1a7756": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02679755",
        "Statement": "in the primary clinical trial, each recorded adverse event was experienced by no more than one patient",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "f46a7d27-a94f-4389-a1a0-4a8f5177b354"
        ]
    },
    "d1b7105d-0b7d-4b10-92a7-d63243ff0629": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00425854",
        "Secondary_id": "NCT01224678",
        "Statement": "Patients with significantly low ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or younger ",
        "Label": "Entailment"
    },
    "b42e4c6c-4e89-4b4a-9a82-7789039aac5e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00263588",
        "Statement": "taxonomy rank code is a coded value specifying the taxonomy rank. patients must have HER2- breast cancer to participate in the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "215a5c4a-d90c-4500-8284-0679ce311734"
        ]
    },
    "a53f7380-213c-49c2-83c2-53266cf73a6b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "the primary trial's interventions showed a clear objective benefit for at least 60% of the patients, predominantly for those prescribed docetaxel then liposomal doxorubicin.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "74e376d7-5713-43f3-93f1-9608059c9547"
        ]
    },
    "4a15ec5e-4904-4f01-a0a2-c51e83c8c070": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042938",
        "Statement": "the primary trial reports the Severity of Dermatitis in Radiation Treatment Site for the Curcumin C3 Complex cohort and the placebo cohort",
        "Label": "Entailment"
    },
    "1c72e2c4-987b-4f99-8100-21b1d1175976": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00944047",
        "Statement": "a majority of primary trial patients in the control arm exhibited pathologic complete response",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "48f516ff-abb4-4312-9b00-02f53fb16218"
        ]
    },
    "cffaf4d8-7e6b-4164-96cd-fffbd0fe0c0d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01307891",
        "Statement": "neutropenia affected a number of patients in both groups of the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "734423d5-4b47-4448-ab98-811015d626f0"
        ]
    },
    "47ba01d6-edc7-4acb-ab49-b0e86f4eeaf7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00915603",
        "Statement": "at least 2 participants of the primary trial, at least one from each cohort, had a Progression-Free Survival of 10.8 months",
        "Label": "Entailment"
    },
    "b5c039f2-c2df-4106-842b-04a40b0115a4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02301988",
        "Statement": "dosage of ipatasertib and placebo for cohort 1 patients in the primary clinical trial is identical to that of cohort 2 patients",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "973f090a-8967-4d75-bb8e-6166c868337c"
        ]
    },
    "b65cec4f-7a05-40b4-abe0-c701bbd053fe": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01042535",
        "Statement": "there were no reported cases of constipation as an adverse event in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "16c29502-4683-4087-9410-ff1b786556f5"
        ]
    },
    "69df54c1-7607-49b0-bfe5-ececa2e995eb": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01224678",
        "Secondary_id": "NCT01042535",
        "Statement": "the rate of occurrence for mental health conditions, pleuropericarditis, atrial thrombosis, and anemia was higher in the secondary clinical trial as compared to the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "57b2ae97-0d1d-4d5d-bc4b-109e8e5acb32"
        ]
    },
    "39792544-897b-4beb-a447-7519c0a11811": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00281697",
        "Statement": "medulloblastoma, not otherwise specified is a medulloblastoma which has not been further characterized. only patients with a HER2-positive status can take part in the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "43ee7645-ce1e-42d5-9a74-3e379f6f367b"
        ]
    },
    "ed76a80b-75b6-4d98-9219-84371ecbb389": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01830933",
        "Statement": "the primary clinical trial and the secondary clinical trial both document the same categories of adverse events.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "c7a953b0-ac96-4e0a-9c1d-98cf8af2861d"
        ]
    },
    "0e234405-b713-4e1d-a87d-4425e44153aa": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820222",
        "Statement": "the findings of the primary clinical trial indicate that the group treated with trastuzumab plus capecitabine had a greater number of patients with severe skin/subcutaneous or pulmonary toxicities than those treated with lapatinib plus capecitabine.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "566bdc2d-7c4a-4547-87da-ac81447ecca8"
        ]
    },
    "fbcb1c5e-aaf6-44b4-80d7-ecc255b7db1e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT03176238",
        "Statement": "in contrast to cohort 2 of the primary clinical trial, cohort 1 of the secondary clinical trial reported less instances of acute myocardial infarction, cardiopulmonary failure, and supraventricular tachycardia",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "080da381-b5dd-46d3-99c4-18112da153c1"
        ]
    },
    "1bb1520d-8e2b-4dd9-87d0-b8e6995fd265": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02419807",
        "Statement": "two varied measurements are outlined in the primary clinical trial's results part",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "8b91cab9-d858-45f3-bf8d-3d6fc55b4818"
        ]
    },
    "0d87b560-ddfe-4d7b-a6aa-8cdf94999b0a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Secondary_id": "NCT00274469",
        "Statement": "Patients must be female and have confirmed advanced breast cancer to be eligible for the secondary trial and the primary trial. difficult to open mouth wide is a question about whether an individual has or had difficulty opening their mouth wide.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "68379456-775b-463b-bfdb-d8aa42c9124b"
        ]
    },
    "b9f04c3e-1833-4ef0-b59a-80358a0ca207": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00281697",
        "Statement": "bothered by question is a question about whether an individual is bothered by something. only patients with a HER2-positive status can take part in the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "43ee7645-ce1e-42d5-9a74-3e379f6f367b"
        ]
    },
    "d2d2b060-43d3-4be3-bc8b-fb44b15e343b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00915603",
        "Statement": "at least 2 participants of the primary trial, at least one from each cohort, had a progression-free survival of 47 weeks",
        "Label": "Entailment",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "47ba01d6-edc7-4acb-ab49-b0e86f4eeaf7"
        ]
    },
    "77491149-0213-4408-8d1b-9354be49714e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Statement": "pain interferes with general activity is a question about whether a person's pain interferes or interfered with their general activities. Patients must have a Life expectancy of at least 1 year to enroll in the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "618a3ae1-b22c-4c35-86a6-190c1b5b5d21"
        ]
    },
    "a991b93c-959b-4e8e-a305-ad813a66e9e4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Secondary_id": "NCT00281697",
        "Statement": "in the primary and secondary clinical trials, most of the participants were not affected by enterocolitis",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "2ef186d0-b4ab-44de-b785-a63e9e95851a"
        ]
    },
    "60f8c47b-15dc-422c-b7e5-3bda50cf0224": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02924883",
        "Statement": "the primary clinical trial is exclusively for individuals diagnosed with triple negative breast cancer.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "c10eea1a-5768-442d-ae07-20b4f8f4b583"
        ]
    },
    "96376575-342e-400e-876b-02f4cc82b1e7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00820170",
        "Secondary_id": "NCT00263588",
        "Statement": "the secondary trial and the primary trial do not have the same inclusion and exclusion conditions. acfucy regimen is a chemotherapy regimen consisting of dactinomycin, 5-fluorouracil, and cyclophosphamide for the treatment of ovarian cancer.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "3a4003f6-ff1c-43d8-be48-f767266b2cf5"
        ]
    },
    "1b1ac392-b32d-45c2-8c82-8d54a17b9968": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00009945",
        "Statement": "how often have sexual thoughts or fantasies while awake is a question about how often an individual has or had sexual fantasies while awake. none of the individual adverse events in the primary trial affect more than 100 patients.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "1314146f-2869-4525-8034-7f732d238385"
        ]
    },
    "0eea67b6-d70f-4ac3-8375-23c7e066f228": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02419807",
        "Statement": "the primary clinical trial results section reports a single measurement for all 3 cohorts.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "d0b50aeb-aad8-4a8d-aae6-5c58a7d382c7"
        ]
    },
    "5b61478d-6862-4290-bb64-6cd5b368bc43": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572727",
        "Secondary_id": "NCT00328783",
        "Statement": "All patients in the primary trial receive higher doses of BKM120 than patients in the secondary trial. zeptometer is a metric unit of length equal to one sextillionth of a meter (10e-21 meter).",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "51be7c95-8da4-419c-950c-91ebdd2c3fe5"
        ]
    },
    "81c75cbe-5c77-4100-9145-6724d79855c6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Secondary_id": "NCT00325234",
        "Statement": "a greater number of urosepsis cases are found in the primary clinical trial than in the secondary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "7271e0db-bb82-423f-ad95-5ffa84fab97e"
        ]
    },
    "d7e36dd0-7d25-4c6a-a297-405725dd16bb": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00503750",
        "Secondary_id": "NCT00005879",
        "Statement": "the data sets of the primary clinical trial and the secondary clinical trial cannot be compared due to differing units of measurements, weeks in primary and quarters in secondary",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "7d52734c-0801-413d-9ae2-d190b972cde5"
        ]
    },
    "7f3fc2e4-dc31-4493-86b7-0c7ea1e744a3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00333775",
        "Statement": "all cohorts in the primary clinical trial receive varying dosages of docetaxel and cohort 1 is administered an active drug instead of a placebo.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "a5e388b9-da3c-437e-a6af-7ba76ad8bf1d"
        ]
    },
    "b982b62a-57fb-47e3-b150-cd89586fd990": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01905592",
        "Statement": "within the first cohort of the primary clinical trial, none of the patients were affected by the four adverse events that were identified.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "2655c892-216e-4b96-a8f2-6f64403215c5"
        ]
    },
    "01012cb0-0354-44e6-920b-11d0d11776e9": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "to be eligible for the primary trial candidates must be over the age of 6570 days, have a severe disability and adequate hepatic, renal and heart functions aswell as adequate hematology levels.",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "f45ff82d-e0f5-456a-9d78-ddc2dc6ab929"
        ]
    },
    "1ed66089-6bd6-4513-a15d-af93684d1fe3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT02340221",
        "Statement": "both the primary clinical trial and the secondary clinical trial determine the percent alteration in net influx constant (ki) by flt pet in their selected patient groups.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "49ba06b2-576d-4db2-80b6-51673416f2ba"
        ]
    },
    "87299573-90ec-481a-815d-3c3af024bb12": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00593346",
        "Statement": "the primary clinical trial does not provide the objective response rate or pfs of the cohort of patients",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "cc1f712a-2116-4e40-9810-f315e3fa5ff8"
        ]
    },
    "6c54bfed-fce2-443c-8ee7-8cd28e7465e1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Secondary_id": "NCT03098550",
        "Statement": "how has gynecologic cancer affected your desire for sexual contact is a question about how having gynecologic cancer has affected an individual's desire for sexual contact. all participants of the primary trial have stage 3 cytologically confirmed invasive breast cancer, there is no specific stage of cancer required for entry to the secondary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "7f3fe97e-68ee-470f-b06e-21cdddb67aa8"
        ]
    },
    "b8112e48-7e24-42b1-9d4a-80b3df80f97a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "the primary clinical trial includes patients with node positive t2 n2 m0 breast adenocarcinoma, and those with a node negative adenocarcinoma of the breast possessing a tumor diameter of more than 2cm",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "016943fa-57ea-4293-8131-03292ea1836c"
        ]
    },
    "fcdbbc7a-eca3-4225-86f4-750c03689ff0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00606931",
        "Statement": "an entire part of the primary clinical trial documentation is devoted to the identification and classification of adverse events.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "21611c2a-e6eb-4012-a209-9b6781e1f260"
        ]
    },
    "92328221-b9c1-4464-a580-31e223e3b128": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT00232505",
        "Statement": "the participants of both the primary clinical trial and the secondary clinical trial do not intake any medication orally",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "e7604382-09cd-43b4-998f-a51b33f25c5a"
        ]
    },
    "1adc970c-d433-44d0-aa09-d3834986f7a2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00066573",
        "Statement": "there is a 13.2% difference between the results from the two the primary trial cohorts",
        "Label": "Contradiction"
    },
    "d77bf47a-6b8a-4884-9295-ff7ff78c73a0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00376597",
        "Statement": "frontal bone is a bone of the skull forming the forehead, root of the nose and the roof of both orbits. Patients with stage 4 cancer are excluded from the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "75a65913-5655-4377-b441-ecdd4dd75175"
        ]
    },
    "1f6a3565-6aa7-4ecd-aee7-7872533597de": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00612560",
        "Secondary_id": "NCT01216176",
        "Statement": "flaxseed administration is not part of the regimen for primary trial participants, but it's a mandatory part of the secondary trial regimen",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "b0046821-ba27-4a90-8869-cb708b843aa4"
        ]
    },
    "a5afbe86-d274-4954-8f93-fee75aad1a5d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01998906",
        "Statement": "both cohorts of the primary trial undergo a total of 25 cycles, each lasting 5 weeks , patients receive the same types and dosages of medication throughout all 20 cycles",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "2a2c16a7-f427-4fdb-8153-94aac304e4b8"
        ]
    },
    "470a504c-ac0c-4d1b-81fc-748ef65ecfd8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820222",
        "Statement": "the findings of the primary clinical trial illustrate that the patient group treated with trastuzumab plus capecitabine exhibited a greater proportion of cns metastases, in comparison to those treated with lapatinib plus capecitabine.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "5de9caeb-9dd5-4535-8fe3-289450d9c626"
        ]
    },
    "0db28531-c77c-453c-b644-01cdcb9300a5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "in the primary clinical trial, all patients from the first cohort showed pfs exceeding 7 months, up to nearly 10 months",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "b8eaa8fd-61cf-4ca9-aaec-267d61c1fae3"
        ]
    },
    "25ce2260-e9cd-4016-9bb9-6086f785b8d2": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Secondary_id": "NCT01644890",
        "Statement": "the primary clinical trial focuses on evaluating the percentage of participants showing an objective response, while the secondary trial assesses the number of participants with disease progression or mortality.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "f42e1874-343a-43ed-bb0c-884509c4793c"
        ]
    },
    "26ee0b8d-a7aa-4bd4-a1ea-d88cd677d65b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "the primary clinical trial intervention protocol will be ceased before a patient achieves complete response or suffers from disease progression",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "1d1f57f8-85f7-448c-a4bb-15957da568fd"
        ]
    },
    "ad14ab21-cd9c-4de7-8cf0-d40ba3b601ec": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Secondary_id": "NCT01439945",
        "Statement": "There is one case of Diarrhea in the secondary trial and none in the primary trial. helicobacter pylori-related gastric adenocarcinoma is an adenocarcinoma that arises from the gastric mucosa and is caused by persistent infection with helicobacter pylori.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "bebfc78e-b35f-4677-8342-9567a7e795a1"
        ]
    },
    "9456f021-4c5f-437d-b930-cceac05b2a0c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01125566",
        "Statement": "an ecog score of less than 2 is a prerequisite for eligibility in the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "7137dec6-5c98-4156-8035-7bbaaf0b649d"
        ]
    },
    "2a2c16a7-f427-4fdb-8153-94aac304e4b8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01998906",
        "Statement": "Both cohorts of the primary trial undergo a total of 17 cycles, each lasting 3 weeks , patients receive the same types and dosages of medication throughout all 17 cycles",
        "Label": "Contradiction"
    },
    "978d19fc-e7f6-485e-b8bd-cfcde06441ab": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00022516",
        "Statement": "T1 N0 M0 patients are eligible for the primary trial",
        "Label": "Entailment"
    },
    "626c91e3-a674-458f-98b9-8f5fcc1bcef7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Secondary_id": "NCT00876395",
        "Statement": "the primary clinical trial and the secondary clinical trial most frequently report diarrhoea as an adverse event",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "eb1bfb08-eba0-4130-b328-00f56c0f84a6"
        ]
    },
    "c83f43ac-8339-4c8a-959e-d1f2238ff5e8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01042535",
        "Statement": "gingival hemangioma is a hemangioma arising from the gums. The most common adverse event in the primary trial was skin infection.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "4f705481-5dd0-414c-b375-c56e8c235b42"
        ]
    },
    "85a7a036-6e40-401a-9b7d-7ed1918bb419": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "patients wanting to take part in the primary trial must have a known and documented tnbc status and an lvef of at least 0.50",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "9abb10d7-496e-44fd-915d-d86aedf6c9b6"
        ]
    },
    "926c71f0-1a15-4dcd-9ed1-11702fc459a1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02679755",
        "Statement": "none of the adverse events encountered in the primary clinical trial have affected more than one individual",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "f46a7d27-a94f-4389-a1a0-4a8f5177b354"
        ]
    },
    "09bd6cbe-c17f-4184-9982-a075eee1a1b5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042938",
        "Statement": "the primary clinical trial indicates no variation in the severity of dermatitis in the radiation treatment site recorded for both the curcumin c3 complex group and the placebo group",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "e62f5a3f-0091-4980-9822-db8f4dc2502a"
        ]
    },
    "a7670418-ceb9-4aa6-af4d-6880877f2d8d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00263588",
        "Statement": "circuit breaker device is a device designed to open an electrical circuit when it becomes overloaded. patients must be able to receive medication orally to participate in the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "5c1e360c-fd93-4dd4-b855-71ba416d34cb"
        ]
    },
    "96337c16-7b47-4f57-8487-ee22cca7bd09": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01905592",
        "Statement": "despite the presence of two types of adverse events, no patients in cohort 1 of the primary clinical trial were affected",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "30483d7e-7703-459c-bd10-e2bd259c2a4f"
        ]
    },
    "f517874e-835a-4afb-9633-9ff79527b6c5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290758",
        "Secondary_id": "NCT02370238",
        "Statement": "primary clinical trial accepts women presently going through endocrine therapy",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "5d0ccb93-71ec-4079-92c6-d7cbf951a7bb"
        ]
    },
    "07042b0f-d422-49c3-8d53-81319927a4b3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Secondary_id": "NCT03098550",
        "Statement": "all participants of the primary trial have stage 2 or 3 histologically or cytologically confirmed invasive breast cancer, there is no specific stage of cancer required for entry to the secondary trial",
        "Label": "Entailment"
    },
    "e8d282ef-6c66-4547-8ab4-4fa9daa69041": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00593346",
        "Statement": "lung germ cell tumor is a germ cell tumor that arises from the lung. the primary trial does not report the PFS or objective response rate of its patient cohort.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "cc1f712a-2116-4e40-9810-f315e3fa5ff8"
        ]
    },
    "75cf4ec2-9f2b-4d5b-8772-af247eaca07b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232505",
        "Statement": "Patients with Histologically confirmed breast cancer stage I-III are not eligible for the primary trial",
        "Label": "Entailment"
    },
    "9f054b71-e893-4e55-aafb-e79d554cc5f2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00331630",
        "Statement": "both cardiac and neural adverse events were reported in the course of the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "c7dc582a-4a58-4cb5-b980-b2d2b6a128c3"
        ]
    },
    "9a424107-d39c-49f5-95fc-5e5079801cf6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "patients interested in the primary clinical trial must possess a recognized tnbc status and a minimum lvef of 50%",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "9abb10d7-496e-44fd-915d-d86aedf6c9b6"
        ]
    },
    "1cacad7c-7121-4578-9dc1-e9a38631ab28": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00944047",
        "Statement": "osseous component present is a morphologic finding indicating the presence of bone elements in a tissue sample. under a quater of the primary trial patients in the intervention arm experienced Pathologic Complete Response.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "48f516ff-abb4-4312-9b00-02f53fb16218"
        ]
    },
    "516f20e7-a264-4ec7-9317-21b135363acf": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT02340221",
        "Statement": "the outcome measurements of the primary clinical trial and the secondary clinical trial are not equivalent for their results",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "2a03c17f-3afe-40f1-a0db-4b876ee8c700"
        ]
    },
    "5f3e5269-5f7c-4e3d-908a-54e41f1e0c14": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00093795",
        "Statement": "the primary clinical trial demonstrated that 5 years of disease-free survival was not achieved by most of the participants belonging to cohorts 1 and 2.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "2729a321-709b-4392-9604-dd7237bedb17"
        ]
    },
    "5860816a-4f0e-4be7-b0ba-8d0c74ef402e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Statement": "to be considered for the primary clinical trial, patients should have a life expectancy of no less than one year",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "618a3ae1-b22c-4c35-86a6-190c1b5b5d21"
        ]
    },
    "427e3c01-6a1c-4bf9-bdd9-99aa409c89e0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00281697",
        "Statement": "only patients with a HER2-positive status can take part in the primary trial. target biospecimen is serum is a question regarding whether the target biospecimen is serum.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "43ee7645-ce1e-42d5-9a74-3e379f6f367b"
        ]
    },
    "780e7373-6e5d-4e6f-a848-99bdc3ab35cb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Statement": "Patients must have a Life expectancy of 75+ years to enroll in the primary trial. aortic valve annulus is a fibrous membrane that attaches to, and provides support for, the aortic valve leaflets.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "4b97a844-8d52-48bb-8eda-ca205268f016"
        ]
    },
    "7a1890ed-fad8-4c27-a586-03cee606f3ef": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00820170",
        "Secondary_id": "NCT00263588",
        "Statement": "rag2 gene mutation is a change in the nucleotide sequence of the rag2 gene. any patient eligible for the secondary trial will also be eligible for the primary trial .",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "a0065d58-e03b-4dd0-9c81-cbbf651a6d45"
        ]
    },
    "acd0943b-ba12-46de-8c44-55ab8a7b99f0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00357110",
        "Statement": "nominal scale is a scale that uses only categories, with no inherent order. (www.reference-wordsmith.com) there were no recorded deaths in the primary trial cohorts.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "751fd763-89fa-4d52-8bda-f09b490a5e78"
        ]
    },
    "719840af-d528-4d02-901e-6bd0d173e621": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042938",
        "Statement": "calcium is an element with atomic symbol ca, atomic number 20, and atomic weight 40.08. the primary trial reports the Severity of Dermatitis in Radiation Treatment Site for the Curcumin C3 Complex cohort and the placebo cohort, there is no difference in the results from these two cohorts.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "e62f5a3f-0091-4980-9822-db8f4dc2502a"
        ]
    },
    "bc0488ca-8279-4c18-98b5-89408d2b9534": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00093795",
        "Statement": "the primary clinical trial's first and second cohorts mostly recorded instances of disease relapse, contralateral breast cancer, second primary cancer, or death for reasons that are unrelated to the aforementioned medical conditions",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "0ea29bd5-20be-40ea-8ad7-705d283d1d48"
        ]
    },
    "c00ba8a2-38f9-4387-aeed-40d023639511": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00503750",
        "Secondary_id": "NCT00005879",
        "Statement": "the findings from primary clinical trial and secondary clinical trial cannot be compared directly.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "dca4c9f7-bb2a-4f73-b390-93b7ced87c73"
        ]
    },
    "8559c670-6c86-4c8c-9066-ad620862b470": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "only patients without extracranial metastases are eligible for the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "b9491012-49ba-4eb1-8230-1966f54ea012"
        ]
    },
    "68cc5657-6cc8-4653-b66f-47d673ea0006": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Statement": "the primary clinical trial reveals the proportion of patients who show no side effects when treated with neratinib in combination with paclitaxel",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "cdadcb0a-20c5-47f7-a63a-39f5c6f26ae2"
        ]
    },
    "679d1610-6303-406d-8454-ac12802e21c8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00066573",
        "Statement": "there is a 13.2% discrepancy in the results from the two cohorts involved in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "1adc970c-d433-44d0-aa09-d3834986f7a2"
        ]
    },
    "29d6932f-3fc9-4df4-b6f1-8273ab6dd5fd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00754325",
        "Statement": "a majority of participants in cohort 1 of the primary clinical trial experienced disease progression or death, compared to those in cohort 2",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "251a20d8-2555-4929-9d01-c02311bdc93f"
        ]
    },
    "e726eadb-62c0-436a-b841-3eb6a60b1253": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00281697",
        "Statement": "advanced anal carcinoma is anal carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment. a patient with a HER2-positive status can not take part in the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "00822101-fa21-4a26-bf45-3b1f535da005"
        ]
    },
    "44dab89f-12b7-4b79-ace8-61ba82ac304f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00900627",
        "Statement": "none of the cohort 2 patients in the primary clinical trial demonstrated symptoms of keratitis.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "09fc4356-6154-427e-b710-ed5df6470aff"
        ]
    },
    "2e8431f8-945b-44a1-9830-862606503090": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00240071",
        "Statement": "avastin, bevacizumab, and radiation treatment are included in the regimen of the primary clinical trial for participants",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "045ad91e-44fa-42cc-ac22-a7aab26a9009"
        ]
    },
    "6aae29c8-8e40-432a-92b0-9baac77b2b5a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01905592",
        "Statement": "the occurrence of a single type of adverse event resulted in the hospitalization of team 1 patients in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "30483d7e-7703-459c-bd10-e2bd259c2a4f"
        ]
    },
    "e6e4d626-0097-4bb8-a593-232c802f4599": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00022516",
        "Statement": "congenital respiratory system disorder is an abnormality of the respiratory system that is present at birth or detected in the neonatal period. T1 N0 M0 patients are eligible for the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "978d19fc-e7f6-485e-b8bd-cfcde06441ab"
        ]
    },
    "733d616f-e318-458c-9805-5ea621d5063b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Statement": "patients must have a life expectancy of at least 83 years to enroll in the primary trial",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "618a3ae1-b22c-4c35-86a6-190c1b5b5d21"
        ]
    },
    "6dd22da5-3cd5-41e4-833b-15750cf8f059": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00754325",
        "Statement": "a higher proportion of patients suffered Disease Progression or Death in cohort 2 of the primary trial than in cohort 1. health and quality of life rating score 1 is a subjective score of 1 on a scale that ranges from 1: very poor to 7: excellent.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "251a20d8-2555-4929-9d01-c02311bdc93f"
        ]
    },
    "c50d9c1e-9ae5-4aba-95a3-403531ce14cc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290758",
        "Secondary_id": "NCT02370238",
        "Statement": "micromole per liter per milligram per meter squared is a unit of concentration equal to micromoles per liter, divided by milligrams per meter squared. Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial, unless they are recieiving adjuvant therapy.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "4a41ac73-538a-43e5-b7ce-8c8e2d56286e"
        ]
    },
    "271983b8-925f-4b12-9534-704901468729": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00572728",
        "Statement": "Patients must be bedbound or severaly disabled to participate in the primary trial. powder is a solid substance in the form of tiny loose particles; a solid that has been pulverized.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "62be4676-099f-4c42-8029-773af8fde6f7"
        ]
    },
    "22befdee-a711-4bc9-b5c6-853152d99b9e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01596751",
        "Statement": "Breast cancer patients must have documented stable disease to participate in the primary trial. oliguria is abnormally low urine output.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "89f610a7-9e81-43a4-8c1e-5503233b2be1"
        ]
    },
    "b156b38c-7562-4cb2-902a-968edb52a2f2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02679755",
        "Statement": "none of the individual aes recorded in the primary trial affect more than 0.1 of the population.",
        "Label": "Entailment",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "c09fa61c-967a-40ae-96b0-c87b7cde237b"
        ]
    },
    "2b33afeb-137e-4e68-b641-a80145164372": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "all participants in the primary clinical trial experienced either total eradication of target lesions, a decrease of 30% or more in the combined length of the longest diameter of target lesions or a tumor that remained unchanged.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "7e5fd062-6ec3-480f-ab0e-e117eba2ffe7"
        ]
    },
    "835ca5d9-4da4-4750-8681-59538053ee6e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "eligibility for the primary clinical trial extends to patients with extracranial metastases",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "b9491012-49ba-4eb1-8230-1966f54ea012"
        ]
    },
    "319d7892-7755-42df-ad80-124ae454f817": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00066573",
        "Statement": "there is a 100% difference between the results from the two the primary trial cohorts",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "1adc970c-d433-44d0-aa09-d3834986f7a2"
        ]
    },
    "61ad9295-6b9c-4634-87ac-fae053ac1d5a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT03176238",
        "Statement": "in the first cohort of the secondary clinical trial, the occurrences of acute myocardial infarction, cardiopulmonary failure, and supraventricular tachycardia exceed those in the entire patient cohort of the primary clinical trial.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "5c975af8-6b7f-4a5d-b4a6-257c76763ce9"
        ]
    },
    "d51f022f-66c0-4fb3-8cfd-9e5082c96ce2": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00503750",
        "Secondary_id": "NCT00005879",
        "Statement": "the results from the primary clinical trial and the secondary clinical trial are incompatible due to differing units of measurement: hours and years",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "7d52734c-0801-413d-9ae2-d190b972cde5"
        ]
    },
    "a657401c-7908-441d-974c-9313ee09dbfa": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Secondary_id": "NCT01439945",
        "Statement": "don't take much care is a response indicating that an individual does not take as much care as they should. There is one case of Diarrhea in the secondary trial and none in the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "bebfc78e-b35f-4677-8342-9567a7e795a1"
        ]
    },
    "600a4f51-a42a-44a9-90a1-1c5be36f9626": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "neither of the interventions in the primary trial resulted in an objective benefit for more than 0.4 of patients.",
        "Label": "Entailment",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "75affd49-4905-4d43-9a5c-ef795281bac4"
        ]
    },
    "a2f6df3a-4d6c-4f69-9c38-26d298637c0d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00503906",
        "Statement": "the intervention in the primary clinical trial will be administered for a fixed number of treatment cycles, irrespective of disease progression.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "59cd7909-00c3-4c23-9a08-a42dbc8eabdd"
        ]
    },
    "2f76273e-07d4-4ee3-b944-13cb3d38c985": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01262027",
        "Secondary_id": "NCT02301988",
        "Statement": "the outcome measurements used in the primary clinical trial and secondary clinical trial greatly vary",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "0131ebe3-746b-45a5-ba60-fdd326974fec"
        ]
    },
    "ff8840d9-57d2-4338-b736-7840f92083aa": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02658734",
        "Statement": "the majority of participants in the primary clinical trial reported experiencing severe, grade 4 adverse effects, and reported a minimal incidence of mild, grade 1 events.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "878c09e7-3fd9-404e-921e-5b549e9578fb"
        ]
    },
    "5ccda3db-a533-48bd-9bad-eb9bb84af3a8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "presence of hot flashes for 1 month prior to study registration is required for all patients that want to participate in the primary trial, but not necessary for entry to the secondary trial.",
        "Label": "Entailment",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "31105b43-832b-48bc-a78d-ee90c155ca44"
        ]
    },
    "272000d8-e7cc-41ba-aca7-efd9c47814bb": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01307891",
        "Statement": "a single instance of neutropenia was detected within both cohorts of the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "a9907a2e-254a-45ca-af50-3e44fd2f7af3"
        ]
    },
    "f44c7478-a4fd-4034-b85b-1a5b8cfb5946": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01118624",
        "Statement": "the dose of pralatrexate given in the primary clinical trial is adjusted by the participant's height, not their weight.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "0ddb07ae-6e70-436d-8723-f609e59c57da"
        ]
    },
    "5a61b92b-b920-4d73-a75f-53720e597153": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Statement": "ongoing flucytosine treatments are necessary for all participants of the primary trial, treatments must have started at least 10 years before study entry",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "565d7982-aa9a-4c01-987c-1d67bc9c212d"
        ]
    },
    "40e0dc1a-8809-4ddf-b9b4-dca0e91f27c4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Secondary_id": "NCT00281697",
        "Statement": "most of the individuals involved in the secondary trial and the primary trial suffered from enterocolitis.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "2ef186d0-b4ab-44de-b785-a63e9e95851a"
        ]
    },
    "666f622d-7d7f-41a5-a3c5-9fc8733de228": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02679755",
        "Statement": "public identifier is a unique identifier for every administered component. None of the individual Aes recorded in the primary trial affect more than 10% of the population.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "c09fa61c-967a-40ae-96b0-c87b7cde237b"
        ]
    },
    "2da13cd4-7189-4f85-be4d-5c1e213ae293": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "The most common AE in the primary trial was Non-cardiac chest pain, which affected less than 5% of participants in cohort 1.",
        "Label": "Entailment"
    },
    "173089d5-260b-46dc-afc8-c4530480c43f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01125566",
        "Statement": "carcinosarcoma is a malignant tumor composed of a mixture of carcinomatous and sarcomatous elements. ECOG score > 2 is necessary to be eligible for the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "b2cdbcb8-de26-4a44-8a94-dd68c13f7e41"
        ]
    },
    "2093bebd-499b-4b9f-ae6c-55415ae95cb1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02419807",
        "Statement": "The the primary trial results section reports two different measurements, for all 3 cohorts. dad questionnaire question is a question associated with the dad questionnaire.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "d0b50aeb-aad8-4a8d-aae6-5c58a7d382c7"
        ]
    },
    "e9fd065c-342c-4dfb-9c1c-a4c0c44d0acd": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00612560",
        "Secondary_id": "NCT01216176",
        "Statement": "All the primary trial participants are administered Anastrazole in a pill form, but none of the secondary trial receive any Anastrazole",
        "Label": "Contradiction"
    },
    "4128b13a-112f-4032-8784-c50815e503da": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290758",
        "Secondary_id": "NCT02370238",
        "Statement": "patients undergoing endocrine therapy are eligible for both the primary clinical trial and the secondary clinical trial, irrespective of whether they are receiving adjuvant therapy or not.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "4a41ac73-538a-43e5-b7ce-8c8e2d56286e"
        ]
    },
    "5caeba5f-ecdc-43ab-af39-cf58040c6ae7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01644890",
        "Statement": "the shortest pfs in cohort 1 of the primary clinical trial was above average",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "8c6314f7-34f5-42a7-ba66-b95d050a6315"
        ]
    },
    "6a1b6f8c-caa4-407c-88b0-843db2e475a0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00450723",
        "Secondary_id": "NCT00290758",
        "Statement": "atlas - serum creatinine is atlas score (atlas) serum creatinine (as a measure of renal function). Between the secondary trial and the primary trial, all the recorded casesof Musculoskeletal adverse events occurred in cohort 2 of the secondary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "f3cb9150-32c6-4877-9a87-4fac45a24948"
        ]
    },
    "c7ed77c0-5331-499e-ba98-ce0fdf50bca0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00093795",
        "Statement": "lt webster 1932 is an inbred mouse strain developed by jt webster in 1932. the majority of participants in cohort 1 and 2 of the primary trial achieved Disease-free Survival for 5 years.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "2729a321-709b-4392-9604-dd7237bedb17"
        ]
    },
    "104c3ce8-8521-49b1-a1e6-60229a419cb9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00856492",
        "Secondary_id": "NCT00009945",
        "Statement": "the secondary trial and the primary trial do not both measure the pCR of their patient cohorts. skin papilloma, ctcae is a disorder characterized by the presence of one or more warts.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "42d1fcd3-8faa-4065-bbba-42cc90ab67fb"
        ]
    },
    "7d68a19c-bf16-4151-b506-b6c6ff2049e8": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT02340221",
        "Statement": "the outcome measurements of the primary clinical trial and the secondary clinical trial are exactly the same and are in line with standard clinical trial outcome measures.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "2a03c17f-3afe-40f1-a0db-4b876ee8c700"
        ]
    },
    "73d29798-6f80-4376-a91e-1a6f062b3e3f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232505",
        "Statement": "individuals diagnosed with histologically confirmed stage i-iv breast cancer cannot participate in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "3cb71095-8e01-40dc-bbf5-eeffed55f354"
        ]
    },
    "a764db1e-167e-4c76-9bae-27b374f8e1ac": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01307891",
        "Statement": "neutropenia was not observed in any patient within the two cohorts of the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "734423d5-4b47-4448-ab98-811015d626f0"
        ]
    },
    "64091fc1-8aa4-40a3-9557-d5a05d43b011": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Secondary_id": "NCT01644890",
        "Statement": "the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures Number of Participants With Disease Progression (PD) or Death. feel misunderstood by spouse or significant other is a question about whether an individual feels or felt misunderstood by their spouse or significant other.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "f42e1874-343a-43ed-bb0c-884509c4793c"
        ]
    },
    "91db79a8-f3a0-4633-82d5-0332a4e9f879": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00593346",
        "Statement": "the study report of the primary clinical trial does not disclose any incidence of dermatitis among its patient cohort",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "88668508-dfd4-4a39-91cd-cf1654a6dfc4"
        ]
    },
    "c5929ad9-d4b0-4c8c-9bc9-2733963339d6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00754325",
        "Statement": "a higher proportion of patients suffered Disease Progression or Death in cohort 2 of the primary trial than in cohort 1. rna virus is a virus whose genome consists of rna.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "251a20d8-2555-4929-9d01-c02311bdc93f"
        ]
    },
    "3e2d21cf-5c81-409f-93a5-397f799d9603": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "All the primary trial patients achieved either Disappearance of all target lesions, >=30% decrease in the sum of the longest diameter of target lesions or a tumor that is neither growing nor shrinking. adrenal gland angiosarcoma is a rare malignant soft tissue neoplasm arising from the vascular endothelium of the adrenal gland.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "7e5fd062-6ec3-480f-ab0e-e117eba2ffe7"
        ]
    },
    "d1f168dd-4f82-4f76-adae-5f0e883f9082": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Secondary_id": "NCT00274469",
        "Statement": "for inclusion in the primary clinical trial and the secondary clinical trial, patients must be female and diagnosed with advanced colon cancer",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "06fad978-1dc3-46f5-b45f-5ac6577f28b9"
        ]
    },
    "f9ebf53c-c5d7-4453-9c20-b8e483bd4493": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02419807",
        "Statement": "in the primary clinical trial, two distinct measurements are reported, covering all three cohorts, in the results section.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "d0b50aeb-aad8-4a8d-aae6-5c58a7d382c7"
        ]
    },
    "124e8a23-347b-44d4-9de3-c5018c9d9922": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02924883",
        "Statement": "individuals who have inflammatory breast cancer are eligible for the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "c10eea1a-5768-442d-ae07-20b4f8f4b583"
        ]
    },
    "7afcf1d6-b33d-4f02-93d1-0ad11d6e5214": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00503906",
        "Statement": "participants of the primary trial will receive the intervention for a total of 40 cycles (120 days)",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "6499b181-7a23-4073-8459-ad46ff02b20f"
        ]
    },
    "6431b510-80fc-4eb2-8933-59875c575572": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00063570",
        "Statement": "patients diagnosed with malignant brain tumour are accepted into the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "62e449ad-16b3-479d-94a5-ffc435b5e99c"
        ]
    },
    "b8f52597-4b3c-44a3-b4db-4d47b980f3d1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Secondary_id": "NCT03098550",
        "Statement": "participants in the primary clinical trial must have invasive breast cancer confirmed either cytologically or histologically at stage 2 or 3. no such specification regarding the cancer stage is required for participation in the secondary clinical trial.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "07042b0f-d422-49c3-8d53-81319927a4b3"
        ]
    },
    "8e6e1d2d-3803-40c4-a051-d78a690d5216": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00066573",
        "Statement": "the results of the two cohorts in the primary clinical trial differ by 13.2%.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "1adc970c-d433-44d0-aa09-d3834986f7a2"
        ]
    },
    "2491aba7-c566-42ca-8d24-e4a80f0612a4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01224678",
        "Secondary_id": "NCT01042535",
        "Statement": "there were more cases of mental health disorders, pleuropericarditis, atrial thrombosis and anemia in the primary clinical trial than in the secondary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "57b2ae97-0d1d-4d5d-bc4b-109e8e5acb32"
        ]
    },
    "d0b50aeb-aad8-4a8d-aae6-5c58a7d382c7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02419807",
        "Statement": "The the primary trial results section reports two different measurements, for all 3 cohorts.",
        "Label": "Contradiction"
    },
    "86b19b97-ca4d-48e7-8415-979dfdeb3c3e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT03176238",
        "Statement": "there are fewer instances of acute myocardial infarction, cardiopulmonary failure, and supraventricular tachycardia in cohort 1 of the secondary trial than in the total patient cohort of the primary trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "5c975af8-6b7f-4a5d-b4a6-257c76763ce9"
        ]
    },
    "302ce126-6ff5-4879-a43d-f6d952a86e8f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00900627",
        "Statement": "judeo-persian language is a group of jewish dialects spoken by the jews living in iran. 50% of cohort 2 patients in the primary trial suffered  Dose Limiting Toxicities .",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "1f6a14ae-e22b-4b40-b389-217570dbf38e"
        ]
    },
    "b2b16456-89c1-4fd3-a863-c5ee4a2b151e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "the primary clinical trial intervention protocol has a duration of 30 days",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "236780db-9e59-4dc9-8da0-e786287011cf"
        ]
    },
    "6402e13a-7cfb-4774-b7f9-80ecb79fda2a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01011946",
        "Secondary_id": "NCT00066573",
        "Statement": "the primary trial participants are not administered any oral medication whereas the secondary trial patients only receive treatment orally.",
        "Label": "Entailment"
    },
    "2a92a02b-9b16-4083-96a0-78daee0216e4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01912612",
        "Statement": "only one case of congestive heart failure was reported in the primary clinical trial, it belonged to cohort 1",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "9cbc00e9-3a2d-4471-a93e-72c95132fb6a"
        ]
    },
    "89665eb7-9a7c-417d-a81b-798faf972a65": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02915744",
        "Statement": "the interventions for cohort 1 and 2 in the primary clinical trial are not identical",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "8e9611fc-89f8-44cb-af09-8d71a13ca082"
        ]
    },
    "cbd95617-fc10-49d1-a311-32b961d5a23e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02186015",
        "Statement": "Only adults can take part in the primary trial. gelatinous specimen is a specimen that has a gelatinous consistency.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "a805f174-2707-4302-a195-05153ea8523e"
        ]
    },
    "e1a89aa8-c31a-4fc4-af7a-1c500585af4c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01307891",
        "Statement": "multiple cases of neutropenia were reported in both cohorts of the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "a9907a2e-254a-45ca-af50-3e44fd2f7af3"
        ]
    },
    "b4fbc393-4552-4cdf-a6b0-0274739ef541": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01912612",
        "Statement": "dsg3 antibody positive is an indication that antibodies that recognize desmoglein-3 (dsg3) have been detected in a sample. several cases of congestive heart failure in the primary trial occurred in cohort 1, but none in cohort 2.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "d1b217ae-76f3-4ba6-958e-5b2558703ba4"
        ]
    },
    "3de4b7d9-060f-4d99-8136-5a81ae6025ab": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005879",
        "Statement": "the primary clinical trial reported a higher rate of patients with slipped disks in cohort 2 than in cohort 1",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "e4aeb013-7713-4b73-acbd-f8379cc6a494"
        ]
    },
    "0ea29bd5-20be-40ea-8ad7-705d283d1d48": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00093795",
        "Statement": "the majority of participants in cohort 1 and 2 of the primary trial suffered some kind of disease Recurrence, Contralateral Breast Cancer, Second Primary Cancer, Death From Any Cause Prior to Recurrence or Second Primary Cancer",
        "Label": "Contradiction"
    },
    "c616ea43-1df6-4f0f-aa30-7c6f2379c613": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02658734",
        "Statement": "most patients in the primary clinical trial had grade 1 adverse events, with grade 4 being the least common severity.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "878c09e7-3fd9-404e-921e-5b549e9578fb"
        ]
    },
    "cf879596-3708-4102-a29e-4b30be8bb253": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01118624",
        "Statement": "the primary trial participants recieve less than 300mg/m^2 doses of Pralatrexate. human chorionic gonadotropin measurement is a laboratory test to detect the amount of human chorionic gonadotropin in a biospecimen.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "e9a4bd91-f58b-4234-9037-75e0699d1bbd"
        ]
    },
    "0bf7525d-a392-4256-9665-4f6049f39b23": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "in the primary clinical trial, neither interventions provided an objective benefit to over 40% of the patients.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "75affd49-4905-4d43-9a5c-ef795281bac4"
        ]
    },
    "9e8c6531-397d-4680-983f-74cf5bffeb07": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00606931",
        "Statement": "in the primary clinical trial, a section detailing possible adverse events is absent",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "21611c2a-e6eb-4012-a209-9b6781e1f260"
        ]
    },
    "d29256c0-777d-4a55-a89f-0d2425de22c0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT00852930",
        "Statement": "both the primary and secondary clinical trials report several instances related to cardiac failures and infections but they do not document any epilepsy adverse events",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "c2217d42-e90c-4ffe-b084-e653b9ace4d5"
        ]
    },
    "da188bea-fdad-4472-b3f3-0dcbd0aa28f1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Secondary_id": "NCT00325234",
        "Statement": "the secondary trial comprises more cases of urosepsis than the primary trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "7271e0db-bb82-423f-ad95-5ffa84fab97e"
        ]
    },
    "3296046c-8fd4-41d7-90dc-586f619533ca": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT00852930",
        "Statement": "the primary clinical trial and the secondary clinical trial do not document any cardiac or infection-related adverse events, but epilepsy instances are noted in both",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "c2217d42-e90c-4ffe-b084-e653b9ace4d5"
        ]
    },
    "0a508797-38ba-4677-82b5-8c8b1e9afb1e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03098550",
        "Statement": "cohort 1 in the primary clinical trial consists of her2 negative cancer patients, while cohort 2 consists of pr+ patients.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "3adcc8fc-b76b-407a-a006-729a13f571fb"
        ]
    },
    "48cdd681-f0fd-4a42-9232-e456524246d5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02340221",
        "Statement": "the primary clinical trial does not prohibit patients who have previously been treated with fulvestrant or a pi3k inhibitor from participating",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "904061c0-14fa-4f13-9118-9a41e24fa8eb"
        ]
    },
    "5a1e2268-2c1c-46bc-9299-aa6c221008c6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Secondary_id": "NCT00281697",
        "Statement": "chicken bursal lymphoma is a malignant lymphoma that arises in the bursa of fabricius in a chicken. a significant number of the participants in the secondary trial and the primary trial suffered from Enterocolitis.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f"
        ]
    },
    "d6164c66-5418-4373-a9bd-4ae4abca1dd6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT00232505",
        "Statement": "patients in both the primary clinical trial and the secondary clinical trial receive their medication exclusively through iv administration",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "7edba90d-076d-4f55-b9d6-a1765ceb48bd"
        ]
    },
    "d49d5c82-8d58-48b3-8c14-32656e2a78cc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00240071",
        "Statement": "the primary clinical trial's intervention strategy consists of the administration of avastin, bevacizumab and radiation therapy to the participants",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "045ad91e-44fa-42cc-ac22-a7aab26a9009"
        ]
    },
    "088cf8d1-31be-458b-a1e7-62480a3a70f1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "primary clinical trial requires eligible candidates to be over 18 years of age, possess a karnofsky score exceeding 80, have appropriate hepatic, renal, and cardiac functions, and maintain sufficient hematology levels.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "7c7418d2-32d7-4517-874b-eb3db24ea16a"
        ]
    },
    "cba0cb8e-69e9-498e-bc11-af3556c9eb04": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Statement": "the primary clinical trial indicates that there is no serious side effect reported in patients treated with neratinib in combination with paclitaxel to prevent an increase in dose or level of this treatment.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "17bbea92-8f92-41f3-9b9d-cf6e62cf6798"
        ]
    },
    "a33a5aef-f70f-4186-b50d-b672b0d0144f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03098550",
        "Statement": "both groups in the primary clinical trial are subjected to the same treatments, the difference lies in the kinds of cancer that the patients have.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "b0b61978-57db-4a1c-812c-509e8b05f2dc"
        ]
    },
    "96477fed-afd0-4360-b33a-30fd2016884f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Statement": "all the patients in cohort 1 of the primary clinical trial experienced adverse events",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "29b2fa29-5a76-4877-95bb-1a8de7973d33"
        ]
    },
    "ecefc90b-2d4c-4a69-9ecb-cd1518bfc24d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01224678",
        "Secondary_id": "NCT01042535",
        "Statement": "there were fewer reported cases of eye disorders, abdominal pain, febrile neutropenia and anemia in the secondary trial than the primary trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "b8322b23-a4f6-4cba-9761-be826b509de7"
        ]
    },
    "21effda4-23d9-4551-8e08-a5c48ef2eb10": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Statement": "the primary clinical trial discloses the proportion of patients administered with neratinib in combination with paclitaxel experiencing 1 or more side effects",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "cdadcb0a-20c5-47f7-a63a-39f5c6f26ae2"
        ]
    },
    "140d35b1-5016-4807-bec5-8cf0749e8334": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232505",
        "Statement": "those diagnosed with stage i-iii breast cancer, confirmed histologically, are disqualified from participating in the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "75cf4ec2-9f2b-4d5b-8772-af247eaca07b"
        ]
    },
    "b2b164be-69bc-4d6a-b142-059e7cd5bde2": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01581619",
        "Secondary_id": "NCT00106002",
        "Statement": "the results of the secondary trial and the primary trial are non-comparable. 2q33-q37 is a chromosome band present on 2q",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "0a6d1b4c-244e-44e2-a229-62e4cbdfa979"
        ]
    },
    "7641afea-8dcf-4ef9-b0c8-5fe407fcd218": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "all patients must have experienced hot flashes for a minimum of 4 months before registering for either the primary clinical trial or the secondary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "a5baab2c-9c32-4301-a574-4ba5a0c2eb00"
        ]
    },
    "869c7772-f086-4786-961e-5fb0e3bb51a5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005879",
        "Statement": "chromosome 1 satellite 2 is a satellite dna located in the large heterochromatin regions of chromosome 1. there was a significantly higher percentage of patients with slipped disks in cohort 2 of the primary trial than in cohort 1.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "ce8464bd-951e-44aa-97d9-10b917b055ce"
        ]
    },
    "26b2e268-8bd4-4a3f-9de5-66c6fa6956cc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00263588",
        "Statement": "only patients capable of receiving intravenous medication can participate in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "5c1e360c-fd93-4dd4-b855-71ba416d34cb"
        ]
    },
    "c7dc582a-4a58-4cb5-b980-b2d2b6a128c3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00331630",
        "Statement": "no cardiac or neural adverse events were recorded in the primary trial",
        "Label": "Entailment"
    },
    "eef02203-fca5-4162-a14a-e2a9bbc95066": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01262027",
        "Secondary_id": "NCT02301988",
        "Statement": "recurrent ebv infection is an epstein-barr virus infection that has recurred after a period of remission. the primary trial and the secondary trial use comparable outcome measurements.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "0131ebe3-746b-45a5-ba60-fdd326974fec"
        ]
    },
    "0560622d-3786-4370-bb3f-648de66dc243": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "patients with a node negative t1 n0 m0 adenocarcinoma of the breast are eligible for the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "016943fa-57ea-4293-8131-03292ea1836c"
        ]
    },
    "2cca4f01-255b-4862-b75b-0cec1cb69d15": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Statement": "the main adverse event in the first group of the primary trial was anaemia and tachycardia topped the list in the second group",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "ec1e269e-470d-43d9-8f23-8a19a5c96fcc"
        ]
    },
    "bf07cf20-7e95-4943-947a-d22a84d5b20c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00063570",
        "Statement": "patients who have been diagnosed with a malignant brain tumour are not eligible for the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "62e449ad-16b3-479d-94a5-ffc435b5e99c"
        ]
    },
    "2fc9a422-84b7-4b8c-939f-9e5ba8bc28a0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00357110",
        "Statement": "in the primary clinical trial, both cohort 1 and cohort 2 reported no fatality.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "f114846e-79d8-4712-add0-bb34b65d418f"
        ]
    },
    "6d415a51-fcae-4098-a379-20a8623bc843": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01011946",
        "Secondary_id": "NCT00066573",
        "Statement": "the primary trial participants are administered oral and topical medication, whereas the secondary trial patients only receive treatment orally. hepatitis g infection is a form of liver inflammation caused by the hepatitis g virus.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "8ddf8b88-6e06-4c71-9e28-45f73a637af0"
        ]
    },
    "1dd24409-2673-4f2f-b776-ae6c9774e236": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01262027",
        "Secondary_id": "NCT02301988",
        "Statement": "the outcome measurements utilized in both the primary and the secondary clinical trials are analogous",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "0131ebe3-746b-45a5-ba60-fdd326974fec"
        ]
    },
    "227f4a11-1e06-473a-ab68-87628d6361e6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00063570",
        "Statement": "patients with a Malignant brain tumour diagnosis are excluded from the primary trial. class code is a sequence of characters that represents a particular category of items.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "62e449ad-16b3-479d-94a5-ffc435b5e99c"
        ]
    },
    "b1dd7632-ed92-40a9-9293-bce68619c658": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00376597",
        "Statement": "Patients with stage 4 cancer are excluded from the primary trial, only patients with stage 2 and 3 cancer can be eligible",
        "Label": "Contradiction"
    },
    "c6bd5ca3-d544-4494-8fc4-6378af1ceace": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00477464",
        "Statement": "participants of primary clinical trial receive lapatinib more frequently than capecitabine",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "a52b2d4f-0b06-4960-a9c3-88cb92df0980"
        ]
    },
    "9fd82986-f7d2-461c-9642-ff848b30c3a9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03012477",
        "Secondary_id": "NCT02419807",
        "Statement": "both the primary clinical trial and the secondary clinical trial use the exact same unit of measure when reporting their outcomes",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "8460a212-8054-4bd2-b4e6-af1d137a2f79"
        ]
    },
    "cca72888-f5bc-418d-be35-d52f0185959a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "fulfilling the eligibility criteria for the primary clinical trial requires candidates to be older than 18, suffering from a serious disability, and maintaining sufficient hepatic, renal and cardiac functions in addition to adequate hematology levels.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "f45ff82d-e0f5-456a-9d78-ddc2dc6ab929"
        ]
    },
    "d8fa8db5-a85c-4411-b7aa-c4f2c0504c78": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00425854",
        "Secondary_id": "NCT01224678",
        "Statement": "pediatrician is a medical doctor with specialized training in the care of children. Patients with significantly low ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or younger .",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "d1b7105d-0b7d-4b10-92a7-d63243ff0629"
        ]
    },
    "9d507e77-88f8-42d0-b968-1c4c907aff31": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Statement": "more than half of the patients in cohort 1 of the primary clinical trial experienced adverse events",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "29b2fa29-5a76-4877-95bb-1a8de7973d33"
        ]
    },
    "80ebd7b7-0ad2-4ffd-abc6-670a9222800f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "febrile neutropenia was the most common adverse event recorded in the primary trial, affecting more than 5/6 of patients",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "1842904b-5371-49ee-b6f4-8831b879098b"
        ]
    },
    "ecd970dd-f01f-4321-8c53-6aa7637b9db6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01830933",
        "Statement": "the primary trial and the secondary trial do not report adverse events. oropharyngeal lymphoma is a lymphoma that arises from the oropharynx.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "fb360514-14be-45ab-8b74-ea5a7eb181d7"
        ]
    },
    "c59805d2-74a1-406e-ba4d-b63f7e54bedf": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00425854",
        "Secondary_id": "NCT01224678",
        "Statement": "Patients with significantly elevated ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or over. report nullification is action(s) undertaken to indicate that a previously transmitted report should be considered completely void (nullified).",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "6b9162d0-0816-46d4-81af-c60028dcc63b"
        ]
    },
    "ea650ded-4783-4f9e-b2b9-dc536c2c901b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042938",
        "Statement": "sequence is a serial arrangement in which things follow in logical order or a recurrent pattern. the primary trial reports the Severity of Dermatitis in Radiation Treatment Site for the Curcumin C3 Complex cohort and the placebo cohort.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "4a15ec5e-4904-4f01-a0a2-c51e83c8c070"
        ]
    },
    "c603d39c-a564-4da7-9dfa-e60c9e2bb555": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02915744",
        "Statement": "the primary clinical trial and the secondary clinical trial have discrepancies in the measurements recorded in their results.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "dd2f3c3d-fa95-4fca-a3f0-795fd4f3abf1"
        ]
    },
    "2b218375-2378-4b54-98e7-c0ce661413f3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00240071",
        "Statement": "during the primary clinical trial, the participants are subjected to more than a single medication type",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "82a3e542-f784-44d7-90f6-34d7e969283c"
        ]
    },
    "c740593c-ea18-49a0-a4de-e4f123e70c86": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "cd44 positive is an indication that cd44 expression has been detected in a sample. There were more total AEs in cohort 1 of  the primary trial than cohort 2.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "1c4e3fe3-b5fe-4ea3-8d9e-0ce1502080e7"
        ]
    },
    "b12b47c9-f163-45f6-a0b3-455ea011b45b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01011946",
        "Secondary_id": "NCT00066573",
        "Statement": "participants in the primary trial undergo treatment with oral medication, while patients in the secondary trial receive non-oral forms of treatment.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "6402e13a-7cfb-4774-b7f9-80ecb79fda2a"
        ]
    },
    "d3a99bb1-1405-4f8f-b8fa-31fd3ef5ff50": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Statement": "the primary clinical trial reported anaemia as the most frequent adverse occurrence in both the first and second cohorts",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "fbb62216-2cf2-4813-ad41-12a86940610f"
        ]
    },
    "6bb63168-d38c-45e2-b845-0777ec8df266": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "All the primary trial patients achieved either Disappearance of all target lesions, >=30% decrease in the sum of the longest diameter of target lesions or a tumor that is neither growing nor shrinking. cdisc adas-cog - naming objects and fingers: 11 is alzheimer's disease assessment scale-cognitive cdisc version (adas-cog cdisc version) naming task for object 11.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "7e5fd062-6ec3-480f-ab0e-e117eba2ffe7"
        ]
    },
    "48b4dbdb-f9cd-4eec-937e-4a2ffd3184da": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00856492",
        "Secondary_id": "NCT00009945",
        "Statement": "the pcr and tumor diameter metrics are measured in both the secondary and primary clinical trials among their respective patients.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "70677d5f-7022-404c-8410-d1f89366d92f"
        ]
    },
    "3f962fcd-ab9f-4560-a964-ffc1db9a4a22": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00606931",
        "Statement": "the primary clinical trial reports no patient instances of hypotension, hemorrhage or bradycardia throughout the duration of the trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "175044aa-72b1-405d-8506-30002f5098e4"
        ]
    },
    "7a2ff3e9-dc41-484c-9db3-7f7c370c5af3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Secondary_id": "NCT00274469",
        "Statement": "patients must be male and have a confirmed diagnosis of prostate cancer to participate in the primary clinical trial and secondary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "68379456-775b-463b-bfdb-d8aa42c9124b"
        ]
    },
    "76cee4f8-142a-43ef-ae86-ff7a9eadff92": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Secondary_id": "NCT00425854",
        "Statement": "the primary clinical trial and the secondary clinical trial incorporate objective response as the measure of intervention results, but their version of comprehensive response varies",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "8d9f94e3-871b-4fb4-a522-0a73d9d0ec3c"
        ]
    },
    "9087b7c7-798e-4429-a722-f14ddb6bd55b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02679755",
        "Statement": "every recorded ae in the primary clinical trial has an impact on at least 15% of the participants.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "c09fa61c-967a-40ae-96b0-c87b7cde237b"
        ]
    },
    "c4fd031f-0a1a-4ba8-9ccd-34d41524053d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "Presence of hot flashes for  30 days prior to study registration is required for all patients that want to participate in the primary trial, but not necessary for entry to the secondary trial. nf2 gene rearrangement is a molecular abnormality indicating rearrangement of the nf2 gene.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "31105b43-832b-48bc-a78d-ee90c155ca44"
        ]
    },
    "d5fa40f2-fafc-408f-9d7a-1d18bcac59c1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "All the primary trial patients achieved either Disappearance of all target lesions, >=30% decrease in the sum of the longest diameter of target lesions or a tumor that is neither growing nor shrinking. deleterious nbn gene mutation is a change in the nucleotide sequence of the nbn gene that is associated with increased risk of disease.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "7e5fd062-6ec3-480f-ab0e-e117eba2ffe7"
        ]
    },
    "79b26ab4-c007-4cfb-8a70-a789d399e138": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01581619",
        "Secondary_id": "NCT00106002",
        "Statement": "the findings from the primary clinical trial can be directly aligned with the results from the secondary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "0a6d1b4c-244e-44e2-a229-62e4cbdfa979"
        ]
    },
    "6cbfe577-5459-4ec2-9af4-c86ea295d446": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01905592",
        "Statement": "the two types of adverse events did not influence any of the cohort 1 patients in the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "30483d7e-7703-459c-bd10-e2bd259c2a4f"
        ]
    },
    "bebfc78e-b35f-4677-8342-9567a7e795a1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Secondary_id": "NCT01439945",
        "Statement": "There is one case of Diarrhea in the secondary trial and none in the primary trial",
        "Label": "Entailment"
    },
    "3fae6288-1ce4-476c-9766-ca55a018bb6d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "neither intervention in the primary clinical trial notably benefited more than 40% of the patients, correlatively, the docetaxel then liposomal doxorubicin-based intervention triggered fatal complications in more than 86% of individuals",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "74e376d7-5713-43f3-93f1-9608059c9547"
        ]
    },
    "e62f5a3f-0091-4980-9822-db8f4dc2502a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042938",
        "Statement": "the primary trial reports the Severity of Dermatitis in Radiation Treatment Site for the Curcumin C3 Complex cohort and the placebo cohort, there is no difference in the results from these two cohorts",
        "Label": "Contradiction"
    },
    "800e4b9c-bb45-4026-a5d4-07c9d37379bd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00263588",
        "Statement": "patients must have HER2- breast cancer to participate in the primary trial. how often turn away when undressing in front of partner is a question about how often an individual turns away when they have to undress in front of their partner.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "215a5c4a-d90c-4500-8284-0679ce311734"
        ]
    },
    "9f540456-9aa6-47ea-b249-7e2b19b87c2e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT00852930",
        "Statement": "both primary clinical trial and secondary clinical trial document incidences of cardiac adverse effects or infectious complications",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "06f798d1-2956-4903-83e9-58a41fa425f7"
        ]
    },
    "5cf4e6fc-d763-45df-9e8b-5dc0d11c2b47": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232505",
        "Statement": "dietary protein foods measurement is a determination of the protein-rich food in a nutritional product or meal, or a portion thereof. Patients with Histologically confirmed breast cancer stage I-IV are not eligible for the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "3cb71095-8e01-40dc-bbf5-eeffed55f354"
        ]
    },
    "107b4dce-d3ab-4fdf-8470-ae6a81c80e28": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02301988",
        "Statement": "cohort 1 patients of the primary clinical trial receive a lower dosage of ipatasertib and placebo than the cohort 2 patients",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "973f090a-8967-4d75-bb8e-6166c868337c"
        ]
    },
    "a41f907b-883f-4f1b-82fb-e0d0b088bf62": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00022516",
        "Statement": "T4 N2 M4 patients are eligible for the primary trial. somewhat of a problem is a subjective response indicating that something is a difficulty requiring resolution.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "4a75574c-fa86-4e62-a210-81c7b98a3807"
        ]
    },
    "bc7699c0-82f4-4a1b-9096-3b143c80532a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "individuals who are above 18 years old, have a severe disability, good hepatic, renal and cardiac functions and acceptable hematology levels are eligible to participate in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "f45ff82d-e0f5-456a-9d78-ddc2dc6ab929"
        ]
    },
    "fefebafe-80e9-4241-8c5a-f061403b5046": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "to be eligible for the primary trial candidates must be over the age of 18, have a Karnofsky score over 80 and Adequate hepatic, renal and heart functions aswell as Adequate hematology levels. dietary alpha tocopherol measurement is a determination of the alpha tocopherol in a nutritional product or meal, or a portion thereof.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "7c7418d2-32d7-4517-874b-eb3db24ea16a"
        ]
    },
    "acf7afe3-7619-4b19-8dc6-3849962d9f12": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Secondary_id": "NCT00121992",
        "Statement": "the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial did not report any. paternal relative is a person related by lineage through the father's side of the family.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "a5617ae4-05a3-42d0-9e14-141de5f8c010"
        ]
    },
    "fe3c546a-3bd6-4006-a6f0-05e88f53b6ed": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00093795",
        "Statement": "in the primary clinical trial, the bulk of cohort 1 and 2 participants demonstrated a five-year disease-free survival rate.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "2729a321-709b-4392-9604-dd7237bedb17"
        ]
    },
    "30851e32-5b6e-4a30-832f-42aadb1249de": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00754325",
        "Statement": "in the primary clinical trial, cohort 1 had a diminished rate of disease progression or death compared to cohort 2",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "251a20d8-2555-4929-9d01-c02311bdc93f"
        ]
    },
    "c22cc152-79b8-4a64-b70f-9710df38f683": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT03176238",
        "Statement": "acute myocardial infarction, cardiopulmonary failure, and supraventricular tachycardia are more prevalent in the first cohort of the secondary clinical trial than in the entire patient population of the primary clinical trial.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "5c975af8-6b7f-4a5d-b4a6-257c76763ce9"
        ]
    },
    "2a22e2de-0e80-4817-9239-478e6d0b4730": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00022516",
        "Statement": "patients diagnosed as t2 n1 m1 can join the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "4a75574c-fa86-4e62-a210-81c7b98a3807"
        ]
    },
    "96d50df8-2069-4eb1-9970-70593db8b115": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02131064",
        "Statement": "in cohort 1 of the primary trial there were more cases of Left ventricular dysfunction than Abdominal pain. venous angioleiomyoma is a morphologic variant of angioleiomyoma characterized by the presence of thick-walled veins.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "3a0c517d-9b9a-4497-9675-50ff12cd02b7"
        ]
    },
    "566bdc2d-7c4a-4547-87da-ac81447ecca8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820222",
        "Statement": "the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher precentage of patients with Grade 3 or 4 skin/subcutaneous or pulmonary toxicities, than the Lapatinib Plus Capecitabine group.",
        "Label": "Contradiction"
    },
    "d59294ed-600d-4f45-a82f-ec776384070f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Secondary_id": "NCT00274469",
        "Statement": "worry subscale is a subscale of the pediatric quality of life brain tumor module designed to assess issues associated with worry. Patients must be female and have confirmed advanced colon cancer to be eligible for the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "06fad978-1dc3-46f5-b45f-5ac6577f28b9"
        ]
    },
    "504ccf72-98c5-4a7c-8ce5-28566dfef0ed": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01581619",
        "Secondary_id": "NCT00106002",
        "Statement": "the outcomes of the secondary clinical trial are directly comparable with those of the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "0a6d1b4c-244e-44e2-a229-62e4cbdfa979"
        ]
    },
    "43a4677b-3fb1-4035-868d-683e7d5cf8d1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290758",
        "Secondary_id": "NCT02370238",
        "Statement": "women who are at present on endocrine therapy are barred from participating in the primary clinical trial and the secondary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "5d0ccb93-71ec-4079-92c6-d7cbf951a7bb"
        ]
    },
    "8c1401be-65be-4b50-973b-0b96a1470dfd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT00852930",
        "Statement": "the primary trial and the secondary trial do not record any cardiac or infection related adverse events. benign tongue neoplasm is a non-metastasizing neoplasm that arises from the tongue.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "06f798d1-2956-4903-83e9-58a41fa425f7"
        ]
    },
    "9f7d476e-9db3-4c00-abe6-4c2f0160470a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00944047",
        "Statement": "under 30% of the primary trial patients in the intervention arm experienced Pathologic Complete Response",
        "Label": "Entailment"
    },
    "0dfae12b-6eed-4450-83b8-7599ecc02c76": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "the procedure of the primary clinical trial will continue until either the patient completely recovers or the disease proceeds.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "1d1f57f8-85f7-448c-a4bb-15957da568fd"
        ]
    },
    "0bf8bd7b-6249-4e51-b614-fecba46b7692": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Statement": "certain cohorts in the primary clinical trial are mandated to undergo a surgical procedure as part of the study's protocol.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "0a079cca-abde-42cf-9cec-a76e7a380e14"
        ]
    },
    "4dfff980-6a2b-4f01-9194-6ec831d6fed7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00733408",
        "Statement": "Infections were the most common adverse events recorded in the primary trial",
        "Label": "Entailment"
    },
    "ca2dfaba-5d18-45e2-a086-1d8e22278518": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Secondary_id": "NCT00121992",
        "Statement": "conjunctivitis was reported in one patient in the secondary clinical trial, whereas sixteen instances were reported in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "c100a7cd-e3a2-4901-a3e0-12336f769c7b"
        ]
    },
    "5177a428-03f3-43e2-bf84-475b315fb17d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232505",
        "Statement": "patients with histologically confirmed breast cancer stage ii are eligible for the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "3cb71095-8e01-40dc-bbf5-eeffed55f354"
        ]
    },
    "3a0c31e5-981e-452a-a4ab-98cd9ac36089": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00374322",
        "Statement": " 3% of patients in the primary trial received a placebo intervention",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "e147796d-2edd-42d1-ac53-300fb8bd5eb6"
        ]
    },
    "f45ff82d-e0f5-456a-9d78-ddc2dc6ab929": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "to be eligible for the primary trial candidates must be over the age of 18, have a severe disability and Adequate hepatic, renal and heart functions aswell as Adequate hematology levels.",
        "Label": "Contradiction"
    },
    "b9e29ea8-6847-40d4-b5c3-81c496101695": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "All patients in cohort 1 of the primary trial had a PFS of over 8.8 months, with the highest PFS being just under 10 months",
        "Label": "Contradiction"
    },
    "b0ae9ca7-c364-452c-8139-af4e73fbc250": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01644890",
        "Statement": "the lowest recorded progression-free survival in cohort 1 of the primary clinical trial fell short of the average by 1.4 months.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "8c6314f7-34f5-42a7-ba66-b95d050a6315"
        ]
    },
    "09d359c2-33c8-4bf7-adee-58c586cf1909": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01596751",
        "Statement": "the primary clinical trial welcomes breast cancer patients, regardless of their disease status.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "89f610a7-9e81-43a4-8c1e-5503233b2be1"
        ]
    },
    "88668508-dfd4-4a39-91cd-cf1654a6dfc4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00593346",
        "Statement": "the primary trial does not report the PFS or objective response rate of its patient cohort, instead reporting the proportion of patients which experience dermatitis",
        "Label": "Contradiction"
    },
    "dda82880-3876-4081-8649-8a4fd1a655a4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00127933",
        "Statement": "both eliane, aged 56, and elizabeth, aged 32, meet the eligibility criteria for the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "f0273b8c-460d-46fe-9c52-8ff4b08e439b"
        ]
    },
    "fbb62216-2cf2-4813-ad41-12a86940610f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Statement": "Anaemia was the most common adverse event in cohort 1 and 2 of the primary trial",
        "Label": "Entailment"
    },
    "b1d28450-fc7d-496a-9c7c-bf711b28f8e4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Statement": "all pregnant patients accepted into the primary trial have undergone Prior treatment for breast cancer with endocrine therapy",
        "Label": "Contradiction"
    },
    "b6e240b7-42e4-4317-a953-1bdae3cd62b9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Secondary_id": "NCT01439945",
        "Statement": "a solitary case of diarrhea has been registered in the secondary clinical trial, contrasting with over 14 diverse types of aes found in the primary clinical trial cohorts.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "4519d1cf-7f78-4aa8-85d6-ac94f7eb75a3"
        ]
    },
    "997aa750-0e2f-4ebb-8300-55ccca21590d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01011946",
        "Secondary_id": "NCT00066573",
        "Statement": "while the secondary trial administers drugs orally to the patients, the primary trial includes both oral and topical treatment.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "8ddf8b88-6e06-4c71-9e28-45f73a637af0"
        ]
    },
    "59cd7909-00c3-4c23-9a08-a42dbc8eabdd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00503906",
        "Statement": "Participants of the primary trial will not receive the intervention for a set number of cycles, the cycles will continue until disease progression",
        "Label": "Entailment"
    },
    "90372e93-82a1-4eb2-9645-15c0f304eebe": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00477464",
        "Statement": "the primary trial participants receive significantly higher doses of Capecitabine than of Lapatinib. citrobacter freundii complex is a non taxonomic grouping of bacteria assigned to and including eight related species from the citrobacter genus.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "a3390ae6-d41d-4dc7-899e-de9534adfd6b"
        ]
    },
    "4f6129ea-5e51-46b3-9c0a-115fce74e594": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00022516",
        "Statement": "individuals having t4 n2 m4 can potentially participate in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "4a75574c-fa86-4e62-a210-81c7b98a3807"
        ]
    },
    "0585e11c-f424-458e-911c-ec98ac343009": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Statement": "all participants in both cohorts of the primary clinical trial are mandated to consume oral medication as part of the intervention protocol",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "63a0a9fc-80b9-450f-b2c6-7aee37ce26a9"
        ]
    },
    "0d51547e-12f6-4ec9-b20e-803c1f0b3f92": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00009945",
        "Statement": "no individual adverse event within the primary clinical trial influences more than 100 patients.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "1314146f-2869-4525-8034-7f732d238385"
        ]
    },
    "4a8b6b3d-e7eb-4e32-9545-d755d94a7ef0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01998906",
        "Statement": "Both cohorts of the primary trial undergo a total of 17 cycles, each lasting 3 weeks , patients receive the same types and dosages of medication throughout all 17 cycles. device is an object contrived for a specific purpose.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "2a2c16a7-f427-4fdb-8153-94aac304e4b8"
        ]
    },
    "fc06eba7-608b-4bd3-8e60-830190089bfc": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00900627",
        "Statement": "keratitis affected half of the cohort 2 patients participating in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "09fc4356-6154-427e-b710-ed5df6470aff"
        ]
    },
    "21611c2a-e6eb-4012-a209-9b6781e1f260": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00606931",
        "Statement": "There is no adverse events section in the primary trial",
        "Label": "Entailment"
    },
    "faa65e54-aa04-4595-8dae-05cf00b4c887": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02301988",
        "Statement": "Only cohort 1 patients of the primary trial are administered Ipatasertib",
        "Label": "Entailment"
    },
    "1673792d-7e2b-484c-8a43-a76ad459d5b3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290758",
        "Secondary_id": "NCT02370238",
        "Statement": "women who are presently on endocrine treatment are not allowed to participate in either the primary or secondary clinical trial, unless they are undergoing adjuvant therapy.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "4a41ac73-538a-43e5-b7ce-8c8e2d56286e"
        ]
    },
    "77686b92-7f16-4e2a-a3c1-96e5bdfe577f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00333775",
        "Statement": "one cohort in the primary clinical trial receives a higher dose of docetaxel than the other.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "9bcc31df-c1f6-4785-9235-f673213acf3a"
        ]
    },
    "e158fa81-c2a7-403c-918a-c646210b8a1c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00063570",
        "Statement": "ecg evaluator blinding parameters is a description of the parameters to which the ecg assessors were blinded to within the study. patients with a Malignant brain tumour or colon cancer diagnosis are eligible for the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "015dd869-db90-45a9-a951-9dc7dc2b2e01"
        ]
    },
    "a25c26ec-50ac-42e3-8467-01b0ac4bbd46": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Statement": "patients currently receiving flucytosine therapy can enter the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "f10f3b84-e039-4a02-a98b-86d149d9a16f"
        ]
    },
    "1dbf33fc-70ca-4aa9-8a23-55f0037c2512": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT00232505",
        "Statement": "in both the primary and the secondary clinical trials, drug administration is not performed intravenously",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "7edba90d-076d-4f55-b9d6-a1765ceb48bd"
        ]
    },
    "ced57c60-ca18-4943-9fd1-1cda1c7b10d5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00240071",
        "Statement": "the primary clinical trial employs a pure immunotherapy approach, discarding avastin, bevacizumab and radiotherapy from the treatment strategy",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "045ad91e-44fa-42cc-ac22-a7aab26a9009"
        ]
    },
    "811acf93-7e7e-4f3e-a9d5-954ed8e8b446": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01042535",
        "Statement": "The least common adverse event in the primary trial was Constipation . recurrent esophageal carcinoma is an esophageal carcinoma which has reappeared after a period of remission or after presumed treatment.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "16c29502-4683-4087-9410-ff1b786556f5"
        ]
    },
    "1c32759c-ba00-4663-adc1-e71dc0ac4302": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00357110",
        "Statement": "the primary clinical trial cohorts included a number of recorded deaths.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "751fd763-89fa-4d52-8bda-f09b490a5e78"
        ]
    },
    "80b8d8cd-0d4a-48c2-a271-e6b45695a216": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00240071",
        "Statement": "in the primary clinical trial, patients are not given multiple types of medication as part of the study.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "82a3e542-f784-44d7-90f6-34d7e969283c"
        ]
    },
    "ba76fdb5-2060-4644-8660-bc996fd6b9bd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "neither of the interventions in the primary trial resulted in an objective benefit for more than 40%, in fact over 80% of patients receiving the docetaxel then liposomal doxorubicin intervention suffered fatal complications",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "74e376d7-5713-43f3-93f1-9608059c9547"
        ]
    },
    "5707d009-71f6-468e-97fc-a37a4b22b80d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01262027",
        "Secondary_id": "NCT02301988",
        "Statement": "the primary clinical trial uses a distinct set of outcome measures compared to the secondary trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "f2275929-7cfe-4bb1-a9f6-6bd0c4d5bf85"
        ]
    },
    "3bd29da3-3bfb-4699-b223-6c00de36801b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02679755",
        "Statement": "serotonin antagonist is any agent that binds to and blocks serotonin receptors. None of the individual Aes recorded in the primary trial affect more than than one patient.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "f46a7d27-a94f-4389-a1a0-4a8f5177b354"
        ]
    },
    "7064225a-1e96-4a50-b0d8-bb324b4dd15e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01998906",
        "Statement": "Both cohorts of the primary trial undergo a total of 17 cycles, each lasting 3 weeks . coefficient of fat absorption measurement is a measurement of the coefficient of fat absorption in a biological specimen.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "43ce26e5-03fa-4e9d-b0eb-6ea356295753"
        ]
    },
    "4f705481-5dd0-414c-b375-c56e8c235b42": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01042535",
        "Statement": "The most common adverse event in the primary trial was skin infection",
        "Label": "Entailment"
    },
    "d310ec4e-993e-4827-8dc5-9aca053972db": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00450723",
        "Statement": "The the primary trial intervention involves one drug taken orally and the secondary trial intervention is based on a medical procedure.",
        "Label": "Contradiction"
    },
    "29fe6365-950f-474f-97a3-f043fbe6c59b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "in the primary clinical trial, enrolment is open to patients who have an unidentified her2+ status and whose lvef does not exceed 40%",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "6b33b4ae-36f2-4a53-a954-6f246f6e023d"
        ]
    },
    "3b131e04-e97a-43a7-9f79-ce1cb0ed5bb1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00503906",
        "Statement": "optic chiasm is an anatomic structure formed by the crossing of the two optic nerves under the hypothalamus. Participants of the primary trial will not receive the intervention for a set number of cycles, the cycles will continue until disease progression.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "59cd7909-00c3-4c23-9a08-a42dbc8eabdd"
        ]
    },
    "d721e21d-f8ba-48f3-829d-2d4b12e484cf": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "no prior experience of hot flashes is required for patients to be included in the primary clinical trial, however, the secondary clinical trial necessitates patients to have had hot flashes for the last 30 days at least.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "31105b43-832b-48bc-a78d-ee90c155ca44"
        ]
    },
    "81726dc8-37c1-48a5-b26e-6ee00b8e716f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01042535",
        "Statement": "the primary clinical trial reported skin infection as the most common adverse event",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "4f705481-5dd0-414c-b375-c56e8c235b42"
        ]
    },
    "0c0e9449-3636-425f-9a9f-ef174af64fe9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00900627",
        "Statement": "liter per kilogram is a dose calculation unit expressed in liter(s) per kilogram. 50% of cohort 2 patients in the primary trial suffered  Dose Limiting Toxicities .",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "1f6a14ae-e22b-4b40-b389-217570dbf38e"
        ]
    },
    "79224fe5-8550-4edd-a461-3aaf6733518f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "patients wanting to take part in the primary trial must have a known and documented tnbc status and an lvef of at least 1/2",
        "Label": "Contradiction",
        "Intervention": "Numerical_paraphrase",
        "Causal_type": [
            "Preserving",
            "9abb10d7-496e-44fd-915d-d86aedf6c9b6"
        ]
    },
    "1c4e3fe3-b5fe-4ea3-8d9e-0ce1502080e7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "There were more total AEs in cohort 1 of  the primary trial than cohort 2",
        "Label": "Contradiction"
    },
    "73434f41-5981-4477-8448-ba6135018cfd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00503906",
        "Statement": "Participants of the primary trial will not receive the intervention for a set number of cycles, the cycles will continue until disease progression. seal device is a device designed to prevent passage of some material through a joint or opening.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "59cd7909-00c3-4c23-9a08-a42dbc8eabdd"
        ]
    },
    "ec305800-7cb3-4365-a50b-1a8b4463d55b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01224678",
        "Secondary_id": "NCT01042535",
        "Statement": "abdominal pain, eye disorders, febrile neutropenia and anemia were less common in the secondary trial compared to the primary trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "b8322b23-a4f6-4cba-9761-be826b509de7"
        ]
    },
    "8d25cb08-1893-49ad-8499-8d30ba5b6377": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00944047",
        "Statement": "under 30% of the primary trial patients in the intervention arm experienced Pathologic Complete Response. mouth sensitivity at its worst is a question about an individual's mouth sensitivity at its worst.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "9f7d476e-9db3-4c00-abe6-4c2f0160470a"
        ]
    },
    "564053bd-1b8e-4c93-a970-5e51829a5d7f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Statement": "patients with a life expectancy of less than 12 months can participate in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "618a3ae1-b22c-4c35-86a6-190c1b5b5d21"
        ]
    },
    "2729a321-709b-4392-9604-dd7237bedb17": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00093795",
        "Statement": "the majority of participants in cohort 1 and 2 of the primary trial achieved Disease-free Survival for 5 years.",
        "Label": "Entailment"
    },
    "61291247-3aba-4ce4-92b9-0fbbb583e068": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00376597",
        "Statement": "in the context of the primary clinical trial, patients having stage 2 or 3 cancer are allowed, while stage 4 patients are not eligible",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "b1dd7632-ed92-40a9-9293-bce68619c658"
        ]
    },
    "cd76b8d4-f0c6-4000-b6e6-4aec5bfc6671": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02915744",
        "Statement": "the primary clinical trial does not administer nktr-102 by infusion to its first and second cohorts",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "4309860d-042d-45a4-8a0a-a9fdd075247a"
        ]
    },
    "de7ed7bb-74ec-44c2-9376-32dd65a8112e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "every participant in the first cohort of the primary clinical trial demonstrated a pfs of less than 8.8 months, the longest reaching around 8.5 months.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "b9e29ea8-6847-40d4-b5c3-81c496101695"
        ]
    },
    "7271e0db-bb82-423f-ad95-5ffa84fab97e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Secondary_id": "NCT00325234",
        "Statement": "There are more cases of Urosepsis in the primary trial than in the secondary trial",
        "Label": "Entailment"
    },
    "c63cce82-7ee7-4fef-a5de-c698d3ae44dd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00333775",
        "Statement": "the dosage of docetaxel in the primary clinical trial varies between cohorts.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "9bcc31df-c1f6-4785-9235-f673213acf3a"
        ]
    },
    "210b2568-7fe7-4b6c-a140-c7c30f71bc11": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00477464",
        "Statement": "in the primary clinical trial, the doses of capecitabine provided to the participants surpass those of lapatinib significantly",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "a3390ae6-d41d-4dc7-899e-de9534adfd6b"
        ]
    },
    "63a0a9fc-80b9-450f-b2c6-7aee37ce26a9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Statement": "neither of the cohorts in the primary trial are required to undergo surgery or receive any oral medication as part of the intervention",
        "Label": "Contradiction"
    },
    "d6ed64f5-c77b-4652-8fce-09763cbe2c9d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT02340221",
        "Statement": "orbit cavernous hemangioma is a cavernous hemangioma arising from the orbit. the primary trial and the secondary trial measure the Percent Change in Net Influx Constant (Ki) by FLT PET in their patient cohorts.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "49ba06b2-576d-4db2-80b6-51673416f2ba"
        ]
    },
    "3c8185bb-8fdd-4a18-80d2-601f5e31a3f8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00733408",
        "Statement": "nausea was identified as the most common side effect in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "9d8b26d6-d574-4717-88b6-77458bc683f3"
        ]
    },
    "17473a62-73f6-4370-994f-9f65afa7a660": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "A patient with a node positive T2 N2 M0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of over 2cm. glottic laryngeal tumor with subglottic extension is a finding of glottic involvement from a laryngeal tumor with extension of the tumor into the subglottis.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "016943fa-57ea-4293-8131-03292ea1836c"
        ]
    },
    "d01fda83-5dc8-4ad5-92b8-7553dabd7046": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00428922",
        "Statement": "the outcome measurement of the primary trial is The length of time during and after the treatment, that a patient lives with the disease but it does not get worse",
        "Label": "Entailment"
    },
    "538cd6b7-c491-4453-8967-f724019affbe": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02924883",
        "Statement": "colo 205 is an adenocarcinoma cell line established from the ascites fluid of a 70 year old caucasian male with colon carcinoma. Only patients with triple negative breast cancer are eligible for the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "c10eea1a-5768-442d-ae07-20b4f8f4b583"
        ]
    },
    "5de9caeb-9dd5-4535-8fe3-289450d9c626": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820222",
        "Statement": "the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher precentage of patients with CNS Metastases than the Lapatinib Plus Capecitabine group.",
        "Label": "Entailment"
    },
    "0a079cca-abde-42cf-9cec-a76e7a380e14": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Statement": "neither of the cohorts in the primary trial are required to undergo surgery as part of the intervention",
        "Label": "Entailment"
    },
    "2a12b970-8776-41e9-9f89-dfadd1ac2bcb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00333775",
        "Statement": "all groups participating in the primary clinical trial are given equivalent dosages of docetaxel",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "9bcc31df-c1f6-4785-9235-f673213acf3a"
        ]
    },
    "d23cbbf0-43bf-46fd-a69e-db668da19210": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "mode is a particular functioning condition or arrangement. neither of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients, in fact over 86% of patients receiving the Docetaxel Then Liposomal Doxorubicin intervention suffered fatal complications.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "74e376d7-5713-43f3-93f1-9608059c9547"
        ]
    },
    "b31c2994-14fc-4c49-b2c2-bb3d7b5d2922": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00066573",
        "Statement": "there is a 13.2% difference between the results from the two the primary trial cohorts. electrolyte secretion alteration is a finding indicating a deficiency or excess in secretion of one or more electrolytes.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "1adc970c-d433-44d0-aa09-d3834986f7a2"
        ]
    },
    "09548209-181e-49fe-a3fb-24fee8924e5e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Statement": "the primary clinical trial revealed anaemia as the most frequent negative occurrence in cohort 1, while tachycardia dominated in cohort 2",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "ec1e269e-470d-43d9-8f23-8a19a5c96fcc"
        ]
    },
    "5da91516-eb2a-4650-a344-8f086946bca9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Statement": "Only 6/67 patients in cohort 1 of the primary trial suffered adverse events. bone marrow stem cell is a hematopoietic stem cell found in the bone marrow.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "29b2fa29-5a76-4877-95bb-1a8de7973d33"
        ]
    },
    "81c128a4-90d4-4808-aff5-84839b289415": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01307891",
        "Statement": "There were multiple patients which suffered Neutropenia in both cohorts of the primary trial. aortic angiosarcoma is a malignant vascular neoplasm arising from the aorta.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "734423d5-4b47-4448-ab98-811015d626f0"
        ]
    },
    "0de136cc-288d-431c-954e-7c2a31d45d80": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00503906",
        "Statement": "participants of the primary trial will receive the intervention for a total of 2 cycles (7 days)",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Preserving",
            "6499b181-7a23-4073-8459-ad46ff02b20f"
        ]
    },
    "2a0b664d-24dd-4a74-99e3-c645493f9e41": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572727",
        "Secondary_id": "NCT00328783",
        "Statement": "patients in the secondary clinical trial receive higher doses of paclitaxel than patients in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "3ba42f68-a643-4d10-afd0-cbb358d05a6f"
        ]
    },
    "b87d2d1f-43f8-4c5e-8e22-59702a7a805c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005879",
        "Statement": "the proportion of patients with slipped disks in cohort 2 of the primary clinical trial was equal to the proportion in cohort 1",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "ce8464bd-951e-44aa-97d9-10b917b055ce"
        ]
    },
    "9a435dc2-53dc-4c63-b301-4a5020b4dca5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00376597",
        "Statement": "Patients with stage 4 cancer are excluded from the primary trial, only patients with stage 2 and 3 cancer can be eligible. col18a1 gene product is a protein encoded by the col18a1 gene.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "b1dd7632-ed92-40a9-9293-bce68619c658"
        ]
    },
    "a917dfee-13e9-458d-923b-ac7ab6e58cde": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02131064",
        "Statement": "in cohort 1 of the primary trial there were more cases of Left ventricular dysfunction than Abdominal pain. lipoadenoma is an adenoma in which the neoplastic epithelial cells are admixed with adipose tissue cells.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "3a0c517d-9b9a-4497-9675-50ff12cd02b7"
        ]
    },
    "a1e79b3c-056e-46df-a188-ef79db4cec80": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03098550",
        "Statement": "in the primary clinical trial, despite receiving the same treatments, the two cohorts differ based on the cancer types of the patients. cohort 1 includes all those diagnosed with her2 positive cancer, whereas cohort 2 consists of pr- patients.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "3adcc8fc-b76b-407a-a006-729a13f571fb"
        ]
    },
    "5051733e-bea0-4908-87a1-17ac6c878ed5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00376597",
        "Statement": "patients possessing a diagnosis of stage 4 cancer cannot be included in the primary clinical trial, eligibility is limited to those with stage 2 and 3 cancer only",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "b1dd7632-ed92-40a9-9293-bce68619c658"
        ]
    },
    "975d9b28-972d-4607-a088-27d01b9ea802": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00240071",
        "Statement": "multiple types of drugs are administered to the participants throughout the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "82a3e542-f784-44d7-90f6-34d7e969283c"
        ]
    },
    "c2a81a5d-9cdc-4949-ae97-85b5f49664ce": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "a patient with a node positive t5 n5 m0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of 134cm",
        "Label": "Contradiction",
        "Intervention": "Numerical_contradiction",
        "Causal_type": [
            "Altering",
            "e6a4e9a6-56b8-4a30-9743-eb02688c090f"
        ]
    },
    "f0c3733a-0438-4f43-abe5-a7fa9c9b8cfd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00593346",
        "Statement": "the primary clinical trial provides detailed reports on both the pfs and objective response rates of its study participants.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "cc1f712a-2116-4e40-9810-f315e3fa5ff8"
        ]
    },
    "599f1785-1f8f-4eae-aaa1-65fcc829c7af": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00593346",
        "Statement": "the primary clinical trial doesn't provide information about its patient cohort's pfs or objective response rate but rather the percentage of patients suffering from dermatitis",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "88668508-dfd4-4a39-91cd-cf1654a6dfc4"
        ]
    },
    "0b5ff5d9-353f-4afe-a074-fc9b2a58db9e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "all members of the first cohort in the primary clinical trial had a progression-free survival period of more than seven months, with the longest nearing ten months",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "b8eaa8fd-61cf-4ca9-aaec-267d61c1fae3"
        ]
    },
    "a0bf7e19-fab9-46d0-b82c-c7450bb66165": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01416389",
        "Statement": "the primary clinical trial has no interest in tracking the number of lesion fluctuations within its cohorts.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "812bd63c-4bfb-49cb-8fa9-baa3f8f6dabe"
        ]
    },
    "20098648-edf0-4b21-afa8-1e5bc9b658b7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Statement": "fda memorandum of understanding is a formal document outlining an agreement between the us food and drug administration and another entity. over 1/6 patients in cohort 1 of the primary trial suffered adverse events.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "8e91e404-086e-4063-8d54-83d1b8ebd969"
        ]
    },
    "a9ea2595-1216-489f-b042-89ff18063061": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00331630",
        "Statement": "no cardiac or bowel-related adverse events were recorded in the primary trial. gain of chromosome 2p is a cytogenetic abnormality that refers to the duplication of all or part of the short arm of chromosome 2.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "553f00ea-5197-4233-b1e0-e5727856b599"
        ]
    },
    "a3ce07dc-aa0b-453a-8f07-565eaf783796": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00820170",
        "Secondary_id": "NCT00263588",
        "Statement": "patient eligibility is unique for the primary trial and does not necessarily align with the criteria for the secondary trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "a0065d58-e03b-4dd0-9c81-cbbf651a6d45"
        ]
    },
    "ad793739-109f-4229-949a-7dda18138a31": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02915744",
        "Statement": "different interventions are conducted for cohort 1 and 2 in the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "8e9611fc-89f8-44cb-af09-8d71a13ca082"
        ]
    },
    "09fc4356-6154-427e-b710-ed5df6470aff": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00900627",
        "Statement": "50% of cohort 2 patients in the primary trial suffered Keratitis",
        "Label": "Contradiction"
    },
    "33424381-2f0f-4c76-9493-d5df394f724f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01416389",
        "Statement": "the primary clinical trial documents the variation in lesion count for the patients under examination.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "812bd63c-4bfb-49cb-8fa9-baa3f8f6dabe"
        ]
    },
    "4852dc90-bf27-4008-b506-4d19d21f2528": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00009945",
        "Statement": "over 100 patients suffer from individual adverse events in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "8648c7df-582a-42a9-9330-414b2430ac56"
        ]
    },
    "4314d306-8cc0-4c84-94a9-9e424635f62b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01224678",
        "Secondary_id": "NCT01042535",
        "Statement": "the secondary clinical trial yielded more cases of eye disorders, abdominal pain, febrile neutropenia, and anemia compared to the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "b8322b23-a4f6-4cba-9761-be826b509de7"
        ]
    },
    "64199a98-74ab-430a-995b-7bbb1e32adfa": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02340221",
        "Statement": "having taken a phosphatidylinositol 3-kinase (pi3k) inhibitor disqualifies a patient from the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "904061c0-14fa-4f13-9118-9a41e24fa8eb"
        ]
    },
    "d6a5fa39-0481-49e0-aba8-9b36debf83a4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "another adverse event, not febrile neutropenia, was the most prevalent during the duration of the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "614d7ade-0fa7-4d77-bc19-1d3a2f2f48c2"
        ]
    },
    "34bc34d6-5390-403e-a8fd-53b952578abd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232505",
        "Statement": "Patients with Histologically confirmed breast cancer stage I-III are not eligible for the primary trial. metastatic esophageal adenocarcinoma is an adenocarcinoma that arises from the esophagus and has metastasized to another anatomic site.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "75cf4ec2-9f2b-4d5b-8772-af247eaca07b"
        ]
    },
    "c0bd76a6-547e-499f-a985-756f8505ce65": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01224678",
        "Secondary_id": "NCT01042535",
        "Statement": "aldosterone synthase deficiency type 2 is aldosterone synthase deficiency characterized by decreased conversion of 18-hydroxycorticosterone to aldosterone. There were more cases of Eye disorders, Abdominal pain, Febrile neutropenia and Anemia in the secondary trial than in the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "b8322b23-a4f6-4cba-9761-be826b509de7"
        ]
    },
    "f173983d-7cda-4887-8708-6e9280c008be": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "Presence of hot flashes for at least 4 month prior to study registration is required for all patients that want to participate in the primary trial or the secondary trial. acute physiology and chronic health evaluation ii apch115 standardized character result 2 is acute physiology and chronic health evaluation ii apch115 standardized character result 2 - for elective postoperative patients.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "a5baab2c-9c32-4301-a574-4ba5a0c2eb00"
        ]
    },
    "751fd763-89fa-4d52-8bda-f09b490a5e78": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00357110",
        "Statement": "there were no recorded deaths in the primary trial cohorts.",
        "Label": "Entailment"
    },
    "8e171fee-cab7-4b09-a3d9-ec1810acce76": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274469",
        "Statement": "hormone receptor negative breast cancer patients who have undergone two rounds of previous treatments can participate in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "b1219e71-fbf5-4bba-8a93-a27ae444e3e1"
        ]
    },
    "93365224-2a44-4680-8e17-7f6ead8ed568": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00066573",
        "Statement": "17q21.3 is a chromosome band present on 17q there is a 13.2% difference between the results from the two the primary trial cohorts.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "1adc970c-d433-44d0-aa09-d3834986f7a2"
        ]
    },
    "73a0effc-6eb8-44fc-b6cf-a0efb45531fa": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00263588",
        "Statement": "patients must be able to receive medication orally to participate in the primary trial. congenital leukocyte abnormality is an abnormality of leukocytes, the cause of which is present from birth.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "5c1e360c-fd93-4dd4-b855-71ba416d34cb"
        ]
    },
    "b03b1ee1-6b51-4455-ac97-ae9bb4c527eb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "All patients in cohort 1 of the primary trial had a PFS of over 7 months, with the highest PFS being just under 10 months. go-source is a property representing the organization that is the supplier or owner of each go annotation associated with a concept.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "b8eaa8fd-61cf-4ca9-aaec-267d61c1fae3"
        ]
    },
    "07e09e6d-561e-495d-95f8-50a48cf96d71": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Secondary_id": "NCT00281697",
        "Statement": "enterocolitis was a common condition among participants in both the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "2ef186d0-b4ab-44de-b785-a63e9e95851a"
        ]
    },
    "5d4f2a05-3b7f-4afd-b0e6-2fc08955ee2b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00357110",
        "Statement": "in the cohorts of the primary clinical trial, no incidents of death were reported.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "751fd763-89fa-4d52-8bda-f09b490a5e78"
        ]
    },
    "8c341824-5ff8-4ba8-814b-2a6f355f407a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Statement": "patients with a predicted survival of at least one year are qualified to participate in the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "618a3ae1-b22c-4c35-86a6-190c1b5b5d21"
        ]
    },
    "0098e4a2-0bce-4771-aaf8-0da68473c856": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00900627",
        "Statement": "dose limiting toxicities were suffered by 50% of cohort 2 patients in the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "1f6a14ae-e22b-4b40-b389-217570dbf38e"
        ]
    },
    "23ee1600-272b-451c-b6cd-7055b7157c0b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02924883",
        "Statement": "only those diagnosed with her2-positive breast cancer can participate in the primary clinical trial",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "446f3c69-0de5-475c-a8e2-ff40ece90672"
        ]
    },
    "66677ffc-2ef4-4045-a1d5-d8c87ef5e03e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00063570",
        "Statement": "a malignant brain tumour diagnosis qualifies a patient for inclusion in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "62e449ad-16b3-479d-94a5-ffc435b5e99c"
        ]
    },
    "0379da85-a0a9-4452-be13-e9e092d4a91a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00093795",
        "Statement": "most participants in the first and second cohort of the primary clinical trial failed to attain 5 years of disease-free survival.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "2729a321-709b-4392-9604-dd7237bedb17"
        ]
    },
    "ae6006b7-b615-4626-8756-1be4281acd04": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00570921",
        "Statement": "everolimus is given intramuscularly (to the deltoid) and fulvestrant orally in the context of the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "32361e21-ee57-4c34-9390-833ba5048a10"
        ]
    },
    "126a303b-bb9d-4951-9ad2-40fe2aa4adbe": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00820170",
        "Secondary_id": "NCT00263588",
        "Statement": "if an individual is qualified to participate in the secondary clinical trial, they will also be qualified for the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "a0065d58-e03b-4dd0-9c81-cbbf651a6d45"
        ]
    },
    "41629c0b-3dda-41db-b841-1d297b613065": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "absence of radiographically confirmed metastases to the brain is a prerequisite for eligibility in the primary clinical trial.",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "a9bb6de9-c6f8-4c99-81cd-f101cbaab387"
        ]
    },
    "fcc8aafb-5234-4ea1-8a7f-8e91b5a6e335": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00450723",
        "Secondary_id": "NCT00290758",
        "Statement": "the incidence of recorded musculoskeletal adverse events was distributed evenly between the two cohorts of the secondary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "f3cb9150-32c6-4877-9a87-4fac45a24948"
        ]
    },
    "c12e10fd-e984-4139-9582-9c528c50f384": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01912612",
        "Statement": "the only case of congestive heart failure in the primary clinical trial emerged in cohort 2.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "9cbc00e9-3a2d-4471-a93e-72c95132fb6a"
        ]
    },
    "c7d08b65-ffcf-458a-a902-26ff4da731be": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00450723",
        "Statement": "vaginal cream dosage form is a cream intended for administration in or around the vagina. The the primary trial intervention involves one drug taken orally and the secondary trial intervention is based on a medical procedure.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "d310ec4e-993e-4827-8dc5-9aca053972db"
        ]
    },
    "1c684d1f-44ba-4bd4-a235-1c6bb07ca07a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "participants who wish to join the primary clinical trial should have a confirmed tnbc status and an lvef rate of 50% or greater",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "9abb10d7-496e-44fd-915d-d86aedf6c9b6"
        ]
    },
    "52fa7575-98d8-48b3-b66b-51ee875c92ec": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00066573",
        "Statement": "posterior tibial artery branch is any artery arising from the posterior tibial artery. there is a minimal difference between the results from the two the primary trial cohorts.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "fe876bb0-7ce3-4197-81ad-920f1f77938e"
        ]
    },
    "0e609fad-9a28-4fb6-90b6-32a731e3b02c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03012477",
        "Secondary_id": "NCT02419807",
        "Statement": "the primary trial and the secondary trial report their results as perecentages but use different units of measure.",
        "Label": "Contradiction"
    },
    "7d52734c-0801-413d-9ae2-d190b972cde5": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00503750",
        "Secondary_id": "NCT00005879",
        "Statement": "The results from the secondary trial and the primary trial can be compared by changing the units from days to months",
        "Label": "Contradiction"
    },
    "bf3ce7ca-44c4-451c-ada3-5e6c0de7d442": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01929395",
        "Statement": "to be accepted into the primary clinical trial, patients need to have a tangible carcinoma",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "24b85b44-b9e6-4c28-b3aa-1bd97102b7f1"
        ]
    },
    "e6005004-5a30-4194-90ed-929a0c8a4980": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00066573",
        "Statement": "kbtbd4 small in-frame insertion mutation is an in-frame nucleotide insertion affecting six codons or less in the kbtbd4 gene. there is a 13.2% difference between the results from the two the primary trial cohorts.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "1adc970c-d433-44d0-aa09-d3834986f7a2"
        ]
    },
    "29ff421c-c9c0-4a97-a6d0-16e59b8f57db": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Secondary_id": "NCT01439945",
        "Statement": "no diarrhea was identified among the patients of the secondary trial, whereas multiple instances were detected among the participants of the primary trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "4519d1cf-7f78-4aa8-85d6-ac94f7eb75a3"
        ]
    },
    "543dbdce-24b4-4cc5-86cf-9581d4dda1bc": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02658734",
        "Statement": "22q12.2 is a chromosome band present on 22q Most patients in the primary trial experienced a grade 1 adverse events, the least common severity was grade 4.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "878c09e7-3fd9-404e-921e-5b549e9578fb"
        ]
    },
    "8bbedcf5-cbaa-45f4-b67d-73e06a0d8e1f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00428922",
        "Statement": "the outcome measurement of the primary clinical trial is the rate of patients' response to the treatment",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "d01fda83-5dc8-4ad5-92b8-7553dabd7046"
        ]
    },
    "e055e769-39a4-44b3-b7a1-79ae72545c75": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "occurrence of hot flashes is not a prerequisite for patient participation in the primary or secondary clinical trials.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "a5baab2c-9c32-4301-a574-4ba5a0c2eb00"
        ]
    },
    "c3b6337c-855a-4ba0-99bd-1e6ab8f1b0e2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Statement": "either surgical procedures or oral medication treatments are necessary components for participation in the primary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "63a0a9fc-80b9-450f-b2c6-7aee37ce26a9"
        ]
    },
    "60e609fe-c70e-4916-93b8-b5446ac8a937": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01011946",
        "Secondary_id": "NCT00066573",
        "Statement": "the primary trial involves administering medication through nasal and rectal routes, whereas the secondary trial delivers treatment via transdermal patches.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Preserving",
            "8ddf8b88-6e06-4c71-9e28-45f73a637af0"
        ]
    },
    "2493db03-313e-4b42-899a-e5ca75fc18af": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Secondary_id": "NCT00274469",
        "Statement": "only female patients diagnosed with advanced colon cancer are considered eligible candidates for the primary clinical trial and the secondary clinical trial",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "06fad978-1dc3-46f5-b45f-5ac6577f28b9"
        ]
    },
    "cc44edf7-d4ea-4fdd-a56c-788847264dfd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01644890",
        "Statement": "the least progression free survival(pfs) observed in cohort 1 of the primary clinical trial was lesser than 3 weeks",
        "Label": "Contradiction",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "961a956e-fece-4baa-a2ad-d3a5320bd9d2"
        ]
    },
    "20be555f-6041-4a0b-98ca-4881e814a18a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Statement": "the primary trial reports the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer side effects that are serious enough to prevent an increase in dose or level of that treatment. cerebral blood flow assessment is an evaluation of the perfusion of blood through the brain.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "17bbea92-8f92-41f3-9b9d-cf6e62cf6798"
        ]
    },
    "a752c207-1f38-479d-a318-531b0bee5582": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00374322",
        "Statement": "a patient group involved in the primary clinical trial underwent a placebo treatment",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "c40fdf91-9f81-454a-bba9-ec5c950cef6e"
        ]
    },
    "19e110af-a2cd-4f49-a97b-57d5ef932bb2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00127933",
        "Statement": "glucose urine excretion rate is a determination of the amount of glucose being excreted in urine over a defined period of time. eliane is a 56 year old woman, and alex is a 32 year old man, both eliane and alex can both be eligible for the primary trial.",
        "Label": "Contradiction",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "a792bbac-0e8a-4bf7-9cc5-56fad481e2fb"
        ]
    },
    "d284b8b2-b2bb-4f1f-a622-9aab2b91e122": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01912612",
        "Statement": "ability to participate in sexual activities is a question about an individual's ability to participate in sexual activities. The only case of congestive heart failure in the primary trial occurred in cohort 1.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "9cbc00e9-3a2d-4471-a93e-72c95132fb6a"
        ]
    },
    "083c95d7-258e-46f8-94fa-d65a243e911e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "candidates under the age of 18 are eligible for the primary clinical trial, even if their karnofsky score is below 80.",
        "Label": "Contradiction",
        "Intervention": "Contradiction",
        "Causal_type": [
            "Altering",
            "7c7418d2-32d7-4517-874b-eb3db24ea16a"
        ]
    },
    "65cd1454-3297-4ede-bbfe-7bdcf089e40b": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00503750",
        "Secondary_id": "NCT00005879",
        "Statement": "the conclusions drawn from the primary clinical trial and secondary clinical trial are not equivalent or comparable.",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "dca4c9f7-bb2a-4f73-b390-93b7ced87c73"
        ]
    },
    "413a1496-e87b-46c0-abd6-5cef0f23352f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290758",
        "Secondary_id": "NCT02370238",
        "Statement": "the primary clinical trial and the secondary clinical trial do not admit women currently under endocrine therapy",
        "Label": "Entailment",
        "Intervention": "Paraphrase",
        "Causal_type": [
            "Preserving",
            "5d0ccb93-71ec-4079-92c6-d7cbf951a7bb"
        ]
    },
    "5af9eb3b-a5ef-4223-b6fa-6a4bf340cbd2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00572728",
        "Statement": "grade 3b follicular lymphoma is a grade 3 follicular lymphoma composed of solid sheets of centroblasts. Patients must be able to undergo a PET scan to participate in the primary trial.",
        "Label": "Entailment",
        "Intervention": "Text_appended",
        "Causal_type": [
            "Preserving",
            "32ed503c-1cfd-44f6-b8bb-23d9d175d73d"
        ]
    },
    "812bd63c-4bfb-49cb-8fa9-baa3f8f6dabe": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01416389",
        "Statement": "the primary trial reports the changes in the number of lesions for patients in its cohorts.",
        "Label": "Contradiction"
    }
}